---
document_datetime: 2023-09-21 21:17:17
document_pages: 142
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/pepaxti-epar-public-assessment-report_en.pdf
document_name: pepaxti-epar-public-assessment-report_en.pdf
version: success
processing_time: 150.7036895
conversion_datetime: 2025-12-23 04:39:39.883686
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 June 2022 EMA/638305/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Pepaxti

International non-proprietary name: melphalan flufenamide

Procedure No. EMEA/H/C/005681/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................6                                                          |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6        |                                                                                                          |
| 1.2. Legal basis and dossier content..............................................................................6          |                                                                                                          |
| 1.3. Information on Paediatric requirements...................................................................6              |                                                                                                          |
| 1.4. Information relating to orphan market exclusivity.....................................................6                 |                                                                                                          |
| 1.4.1. Similarity..........................................................................................................6 |                                                                                                          |
| 1.5. Applicant's request(s) for consideration...................................................................7            |                                                                                                          |
| 1.5.1. Conditional marketing authorisation.....................................................................7             |                                                                                                          |
| 1.5.2. New active substance status                                                                                           | ...............................................................................7                         |
| 1.6. Protocol assistance                                                                                                     | ...............................................................................................7         |
| 1.7. Steps taken for the assessment of the product.........................................................7                 |                                                                                                          |
| 2. Scientific discussion                                                                                                     | ................................................................................9                        |
| 2.1. Problem statement                                                                                                       | ...............................................................................................9         |
| 2.1.1. Disease or condition...........................................................................................9      |                                                                                                          |
| 2.1.2. Epidemiology                                                                                                          | ....................................................................................................9    |
| 2.1.3. Aetiology and pathogenesis                                                                                            | ................................................................................9                        |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                  | ..............................................9                                                          |
| 2.1.5. Management...................................................................................................10       |                                                                                                          |
| 2.2. About the product                                                                                                       | ..............................................................................................11         |
| 2.3. Type of Application and aspects on development....................................................11                    |                                                                                                          |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................12     |
| 2.4.1. Introduction....................................................................................................12    |                                                                                                          |
| 2.4.2. Active Substance.............................................................................................12       |                                                                                                          |
| 2.4.3. Finished Medicinal Product                                                                                            | ................................................................................16                       |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects............................................20                      |                                                                                                          |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................20                                                                                 |
| 2.4.6. Recommendation(s) for future quality development.............................................20                       |                                                                                                          |
| 2.5. Non-clinical aspects                                                                                                    | ............................................................................................20           |
| 2.5.1. Introduction....................................................................................................20    |                                                                                                          |
| 2.5.2. Pharmacology                                                                                                          | .................................................................................................20      |
| 2.5.3. Pharmacokinetics.............................................................................................24       |                                                                                                          |
| 2.5.4. Toxicology                                                                                                            | ......................................................................................................27 |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                             | .........................................................32                                              |
| 2.5.6. Discussion on non-clinical aspects......................................................................32            |                                                                                                          |
| 2.6. Clinical aspects                                                                                                        | ..................................................................................................37     |
| 2.6.1. Introduction....................................................................................................37    |                                                                                                          |
| 2.6.2. Clinical pharmacology                                                                                                 | ......................................................................................38                 |
| 2.6.3. Discussion on clinical pharmacology...................................................................52              |                                                                                                          |
| 2.6.4. Conclusions on clinical pharmacology.................................................................55               |                                                                                                          |
| 2.6.5. Clinical efficacy                                                                                                     | ...............................................................................................55        |
| 2.6.6. Discussion on clinical efficacy............................................................................96         |                                                                                                          |
| 2.6.7. Conclusions on the clinical efficacy...................................................................               | 102                                                                                                      |
| 2.6.8. Clinical safety................................................................................................       | 102                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 2.6.9. Discussion on clinical safety ............................................................................      | 125                                                                                                       |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 2.6.10. Conclusions on the clinical safety...................................................................          | 130                                                                                                       |
| 2.7. Risk Management Plan ......................................................................................       | 130                                                                                                       |
| 2.7.1. Safety concerns.............................................................................................    | 130                                                                                                       |
| 2.7.2. Pharmacovigilance plan ..................................................................................       | 130                                                                                                       |
| 2.7.3. Risk minimisation measures............................................................................          | 131                                                                                                       |
| 2.7.4. Conclusion....................................................................................................  | 131                                                                                                       |
| 2.8. Pharmacovigilance............................................................................................     | 131                                                                                                       |
| 2.8.1. Pharmacovigilance system..............................................................................          | 131                                                                                                       |
| 2.8.2. Periodic Safety Update Reports submission requirements                                                          | ................................... 132                                                                   |
| 2.9. Product information ..........................................................................................    | 132                                                                                                       |
| 2.9.1. User consultation...........................................................................................    | 132                                                                                                       |
| 3. Benefit-Risk Balance............................................................................132                 |                                                                                                           |
| 3.1. Therapeutic Context .........................................................................................     | 132                                                                                                       |
| 3.1.1. Disease or condition.......................................................................................     | 132                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                 | 132                                                                                                       |
| 3.1.3. Main clinical studies .......................................................................................   | 133                                                                                                       |
| 3.2. Favourable effects ............................................................................................   | 134                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                 | 134                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................     | 135                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects .......................................                  | 136                                                                                                       |
| 3.6. Effects Table.................................................................................................... | 137                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................             | 139                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                   | 139                                                                                                       |
| 3.7.2. Balance of benefits and risks...........................................................................        | 141                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance .........................................                 | 141                                                                                                       |
| 3.8. Conclusions                                                                                                       | ..................................................................................................... 141 |
| 4. Recommendations...............................................................................141                   |                                                                                                           |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

Adverse drug reaction

AE

Adverse event

AESI

Adverse event of special interest

AML

Acute myeloid leukaemia

AUC

Area under the curve

AUCinf

Area under the curve extrapolated to

infinity

BMI

Body mass index

BSA

Body surface area

BUN

Blood urea nitrogen

CL

CBR

Clearance

Clinical benefit rate

CMA

Conditional Marketing Authorization

Cmax

Maximum concentration

CR

Complete response

CrCl

DOCB

Creatinine clearance

Duration of clinical benefit

DOR

Duration of response

ECG

Electrocardiogram

ECOG

Eastern Cooperative Oncology Group

eGFR

Estimated glomerular filtration rate

EMA

European Medicines Agency

EMD

Extramedullary disease

HRQoL

Health-related quality of life

IC50

Half maximal inhibitory concentration

IMiD

Immunomodulatory drug

IMWG

International Myeloma Working Group

IRC

Independent Review Committee

ISS

Integrated Summary of Safety or

International Staging System

IV

Intravenous

M-protein

Monoclonal protein spike

MAA

Marketing Authorisation Application

mAb

Monoclonal antibody

MDS

Myelodysplastic syndrome

MedDRA

Medical Dictionary for Regulatory Activities

MM

Multiple myeloma

MR

Minimal response

NCCN

National Comprehensive Cancer Network

NE

Not estimable

ORR

Overall response rate

OS

Overall survival

PD

Progressive disease

PFS

Progression-free survival

PI

Proteasome inhibitor

PK

Pharmacokinetics

PO

Oral (per os)

PR

Partial response

PT

Preferred term

QoL

Quality of life

RRMM

Relapsed-refractory multiple myeloma

SAE

Serious adverse event

sCR

SCS

Stringent complete response

Summary of Clinical safety

SD

Stable disease

SmPC

Summary of Product Characteristics

SMQ

Standardized MedDRA query

SOC

System organ class

SPM

Second primary malignancy

TCR

Triple-class refractory

TEAE

Treatment-emergent adverse event

<div style=\"page-break-after: always\"></div>

TFI TSP TTP TTR URC VGPR WBC WRO

Treatment-free interval Targeted Safety Population Time to progression Time to response Uniform Response Criteria Very good partial response White blood cell Written Response Only

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Oncopeptides AB submitted on 15 April 2021 an application for marketing authorisation to the European Medicines Agency (EMA) for Pepaxti, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 June 2020.

Pepaxti, was designated as an orphan medicinal product EMA/OD/293/14 on 19 March 2015 in the following condition: Treatment of plasma cell myeloma.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Pepaxti as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the Orphan designation withdrawal assessment report published under the 'Assessment history' tab on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/pepaxti.

The applicant applied for the following indication:

Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody.

## 1.2. Legal basis and dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/0001/2015 on the granting of a class waiver.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## 1.5. Applicant's request(s) for consideration

## 1.5.1. Conditional marketing authorisation

The applicant requested consideration of its application for a Conditional marketing authorisation in accordance with Article 14-a of the above-mentioned Regulation.

## 1.5.2. New active substance status

The applicant requested the active substance melphalan flufenamide contained in the above medicinal product to be considered as a new active substance, as the applicant claimed that it was not a constituent of a medicinal product previously authorised within the European Union.

During the procedure, the applicant withdrew the new active substance claim.

## 1.6. Protocol assistance

The applicant did not seek Protocol assistance from the CHMP.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Paula Boudewina van Hennik

Co-Rapporteur:  Elita Poplavska

| The application was received by the EMA on                                                                                                                     | 15 April 2021     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| The procedure started on                                                                                                                                       | 20 May 2021       |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                   | 5 August 2021     |
| The CHMP Co-Rapporteur's critique was circulated to all CHMP and PRAC members on                                                                               | 23 August 2021    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                   | 23 August 2021    |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                        | 16 September 2021 |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                            | 16 December 2021  |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on | 2 March 2022      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                       | 10 March 2022     |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                        | 24 March 2022     |

<div style=\"page-break-after: always\"></div>

| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 13 April 2022   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 3 May 2022      |
| SAG-Oncology experts were convened to address questions raised by the CHMP on The CHMP considered the views of the SAG-Oncology as presented in the minutes of this meeting.            | 11 May 2022     |
| The CHMP agreed on a 2 nd list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                            | 19 May 2022     |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 24 May 2022     |
| The CHMP Rapporteur circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 8 June 2022     |
| The outstanding issues were addressed by the applicant during an oral explanation before the CHMP during the meeting on                                                                 | N/A             |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Pepaxti on | 23 June 2022    |
| The CHMP adopted a report on similarity of Pepaxti with Blenrep, Darzalex, Farydak, Imnovid, Kyprolis, Ninlaro, Abecma and Carvykti on                                                  | 23 June 2022    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Multiple myeloma (MM) is an incurable malignant plasma cell disorder. It is characterised by clonal proliferation of plasma cells in the bone marrow and the production of excessive amounts of a monoclonal immunoglobulin protein (Ig; usually of the IgG or IgA type or free light chain [paraprotein, monoclonal protein spike (M-protein), or M-component]). MM predominantly affects the older patient, with a median age at onset of 72 years in Europe (Palumbo and Anderson 2011).

The most common criteria used in diagnosis of symptomatic MM are the presence of neoplastic plasma cells comprising greater than 10% of BM cells or presence of a plasmacytoma; paraprotein (M protein) in the serum and/or urine; and evidence of related organ or tissue impairment due to plasma cell disorder.

According to the International Myeloma Working Group (IMWG) criteria (Rajkumar et al. 2011), relapsed-refractory multiple myeloma (RRMM) is defined as disease that is nonresponsive while on salvage therapy, or progresses within 60 days of last therapy in patients who have achieved minimal response (MR) or better at some point previously, before then progressing in their disease course.

## 2.1.2. Epidemiology

MM is the second most common haematologic malignancy, and accounts for approximately 1-2% of all new cancer cases, with a global incidence rate of 1.7 per 100,000 and an age-standardised incidence rate of 2.1-3.4 per 100,000 in France, Germany, Italy, Spain and the UK. An estimated 35,842 patients were diagnosed in the EU27 during 2020, with an estimated 23,275 deaths due to the disease (ECIS 2020). Multiple myeloma is more common in men than women (ECIS 2020) and in the US, twice as common in African Americans than in other races and ethnicities (SEER 2019).

## 2.1.3. Aetiology and pathogenesis

The initiating event driving malignant development is either the acquisition of hyperdiploidy or a translocation involving the immunoglobulin heavy chain gene locus. Such clonal events can occur in almost all cells, and are present in the precursor conditions monoclonal gammopathy of undetermined significance (MGUS) and smouldering multiple myeloma.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Sometimes patients are asymptomatic and identified with routine blood testing, although most patients with MM experience symptoms leading to significant decrement to quality of life, including bone pain, bone fractures, fatigue, anaemia, infections, hypercalcemia, hyperviscosity of the blood, and renal insufficiency.

Patients with MM may have symptom-free periods, but the disease always relapses, and patients may become refractory to all available treatment options due to mutations and/or clonal evolution of the tumour cells.

<div style=\"page-break-after: always\"></div>

Clinical outcomes for patients with multiple myeloma depend on several factors, including intrinsic tumour cell characteristics (cytogenetic abnormalities, gene expression profile, extramedullary growth, lactate dehydrogenase levels), tumour burden (β2 - microglobulin [B2M], low platelet count), and patient features (age, comorbidities, frailty). Outcomes also depend on depth of response to therapy. Models combining patient and disease characteristics have been created, because individual prognostic factors do not capture the full heterogeneity in outcome. The original multiple myeloma International Staging System, based on serum albumin and B2M concentrations, reflects tumour burden and patient condition. This staging system has been updated as the Revised International Staging System, which includes information on the presence of high-risk genetic lesions-t(4;14), t(14;16), or del(17p), either alone or in combination-or increased lactate dehydrogenase concentration.

While the advent of novel treatment regimens has translated into improvements in outcomes over the past 15 years (Sonneveld 2017), the disease is ultimately fatal, with a 5-year survival around 50% (Seer 2019). Patients who develop disease refractory to immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and CD38- targeting monoclonal antibodies (mAbs), i.e., are triple-class refractory (TCR), have an overall survival of only a few months. Although patients with relapsed disease can achieve responses to subsequent anti-myeloma regimens, the duration of response typically decreases with successive relapses until resistant disease develops.

## 2.1.5. Management

The management of patients with relapsed/refractory disease represents a clinical challenge, as these patients suffer from continuing symptoms, complications of the disease (including renal failure, blood cytopenia or recurrent infections) and decreased quality of life. These patients typically receive salvage therapy until the next relapse, progression or the development of intolerable toxicity and then go onto the next salvage option. Current treatment strategies in pre-treated RRMM patients focus on controlling disease progression and prolonging survival. These strategies include glucocorticoids (dexamethasone, prednisolone, methylprednisolone), chemotherapy, PIs (e.g. bortezomib, carfilzomib and ixazomib), IMiDs (e.g. thalidomide, lenalidomide and pomalidomide), mAbs (e.g. daratumumab, isatuximab and elotuzumab) and the histone deacetylase inhibitor panobinostat. However, none of the newly approved medicinal products (mainly combinations) has provided a cure. Ultimately patients relapse and treatment options are exhausted.

With the approval of daratumumab and its wide use in combinations in earlier lines of MM treatment, a new population of patients is created who have become refractory to all available agents (including daratumumab). Triple class refractory (TCR) patients have generally been exposed to all 5 drugs that have demonstrated single-agent effect (with or without glucocorticoids), including bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. Most of these patients have already received alkylating agent therapy, other anti-MM drugs, as well as multiple courses of glucocorticoids. Frequently, they also have numerous comorbidities and consequently receive multiple concomitant medications.

Recently, 3 new classes of products have received a conditional approval for use in patients with similar characteristics as the TCR subpopulation of pivotal clinical Study OP-106. Blenrep (belantamab mafodotin) is a BCMA-targeted mAb approved for the treatment of MM in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one PI, one IMiD, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy. It induced an overall response in approximately a third of the pivotal study population. Nexpovio (selinexor) is a Selective Inhibitor of Nuclear Export (SINE) compound, recently approved in combination with dexamethasone, for the treatment of MM in adult patients who have received at least four prior therapies and whose disease is refractory to at least two PIs, two IMiDs and an anti-CD38 mAb, and

<div style=\"page-break-after: always\"></div>

who have demonstrated disease progression on the last therapy. Selinexor has shown to be active in about a quarter of the pivotal study population. Abecma (idecabtagene vicleucel) is an anti-BCMA CART cell therapy for the treatment of RRMM patients who have received at least three prior therapies, including an IMiD, a PI and an anti-CD38 mAb and have demonstrated disease progression on the last therapy. It induced an ORR in 67.1% of enrolled patients with a CR rate of 28.6% and median duration of response of 11 months.

Patients who have been heavily pretreated might also benefit from retreatment, which can be considered after long-lasting remission, because previously used drugs can be given in different combinations. Novel agents can also be combined with traditional cytotoxic agents, such as cyclophosphamide, anthracyclines, or bendamustine. Alternatively, patients with advanced disease can be enrolled in clinical studies evaluating new agents with novel mechanisms of action.

## 2.2. About the product

Melphalan flufenamide (melflufen) is a lipophilic peptide conjugated alkylating drug designed for targeted delivery of alkylating moieties to tumour cells. The drug is composed of a di-peptide and an alkylating moiety of the bischloroethylamine group. It shares the bis (2 -chloroethyl)amino alkylating group with the marketed compounds cyclophosphamide, bendamustine, chloroambucil and melphalan. Although melphalan is one of the metabolites of melflufen, melflufen has the intrinsic capacity to act as an alkylator without any activating step. The lipophilic characteristics of melflufen allow for a faster cellular uptake whereas the peptide hydrolysis mediated by aminopeptidases (like aminopeptidase N (APN)), allows for a potentiated effect in APN-rich environments, resulting in accumulation of alkylating moieties in cancer cells. According to the applicant, this is expected to result in improved efficacy without an increase in toxicity compared to melphalan. Similar to other nitrogen mustard drugs, crosslinking of DNA is involved in the anti-tumour activity of melphalan flufenamide. In cellular assays, melphalan flufenamide inhibited proliferation and induced apoptosis of haematopoietic and solid tumour cells. Retained cytotoxic activity was demonstrated in multiple myeloma cells with absent or impaired p53 functionality. Melphalan flufenamide showed synergistic cytotoxicity with dexamethasone in melphalan resistant and non-resistant multiple myeloma cell lines.

## 2.3. Type of Application and aspects on development

At the time of submission, the applicant requested consideration of its application for a Conditional Marketing Authorisation in accordance with Article 14-a of the above-mentioned Regulation, based on the following criteria:

- The benefit-risk balance is positive (according to the applicant).
- It is likely that the applicant will be able to provide comprehensive data. The applicant states its intention to provide the following data as specific obligation:
- o Results from study OP-103 (OCEAN), an ongoing randomized, controlled trial, comparing melflufen and dexamethasone to pomalidomide and dexamethasone in relapsed-refractory MM. Although the patients can be enrolled to this study in an earlier stage of disease (2-4 prior lines of treatment and refractory to both the last line and to lenalidomide), there will be a substantial number of patients who are triple class refractory patients. This study will provide controlled efficacy and safety data in the indicated patient population.
- Unmet medical need will be addressed, as there are few available therapies for these patients and survival at this stage of the disease is limited. Melflufen offers a new treatment option with

<div style=\"page-break-after: always\"></div>

an alternative mechanism of action which shows efficacy and a different, manageable safety profile.

- The benefits to public health of the immediate availability outweigh the risks inherent in the fact that additional data are still required. Melflufen is intended for a subset of MM patients with a dismal prognosis and limited approved treatment options. Based on the positive benefit: risk demonstrated in study OP-106, immediate availability of melflufen would provide these patients with a novel therapeutic option with meaningful response durability and a manageable safety profile. Additional data are being generated to confirm safety and efficacy of melflufen in a randomised phase 3 study (OP-103).

During the procedure, in response to the List of Questions, the applicant presented the full clinical study report of confirmatory Study OP-103, indicating that no additional results were planned to be submitted as confirmatory data. Hence, the applicant applied for a Full Marketing Authorisation not subject to any specific obligations.

## 2.4. Quality aspects

## 2.4.1. Introduction

The  finished  product  is  presented  as  powder  for  concentrate  for  solution  for  infusion  containing  20 mg/vial of melphalan flufenamide (as hydrochloride) as active substance.

Other ingredients are sucrose. The product is available in 50 mL Type 1 glass vial sealed with chlorobutyl rubber stopper and aluminium overseal with a plastic removable cap containing 20 mg powder.

## 2.4.2. Active Substance

## 2.4.2.1. General information

The chemical name  of melphalan flufenamide hydrochloride is 4-[Bis-(2-chloroethyl)amino]-Lphenylalanine-4-fluoro-L-phenylalanine  ethyl  ester  hydrochloride  corresponding  to  the  molecular formula C24H31Cl3FN3O3. It has a relative molecular mass of 534.9 g/mol and the following structure:

<div style=\"page-break-after: always\"></div>

Figure 1 active substance structure

<!-- image -->

The active substance is a non hygroscopic, white to slightly yellowish powder. It is poorly soluble and susceptible  to  hydrolysis  in  water-based  solutions.  It  is  soluble  in  different  solvents  (e.g.  ethanol, methanol).

The chemical structure of Melphalan flufenamide (also referred to as Melflufen) was elucidated by a combination of nuclear magnetic resonance spectroscopy (NMR), liquid chromatography-mass spectrometry (LC-MS and LC-MS/MS) and fourier transform infrared spectroscopy (FTIR).

The solid state properties of the active substance were measured by 2D-NMR studies for assignment of the 1H-and 13C-NMR spectra were performed as well as a polymorph screening study and determination of  the  absolute  stereochemistry  of  melflufen  hydrochloride  by  single  crystal  X-ray  crystallographic methods. The active substance is highly crystalline and it consists of one crystalline modification.

The active substance includes two stereochemical centers in the S,S configuration. Stereoisomerism has been observed and is routinely control in the specifications.

## 2.4.2.2. Manufacture, characterisation and process controls

The active substance has been manufactured by one manufacturing site: Magle Chemoswed AB (Magle Chemoswed).

Melphalan  flufenamide  is  synthesized  in  four  main  steps  using  well  defined  starting  materials  with acceptable specifications. A schematic flow chart of the active substance synthesis and a description of the manufacturing process including information on in-process controls for each step is provided.

The synthetic route for melflufen hydrochloride consists of four linear chemical steps, which are referred to as Reaction Step 1, 2, 3 and 4, respectively: amide coupling, catalytic hydrogenation, reductive bischloroethyl alkylation and Boc-deprotection/salt formation. No class 1 solvents are used. Pd is used as catalyst.

The  reprocessing  method  is  clearly  described  and  the  criteria  for  deciding  when  re-processing  is performed is provided. Typical batch size is given with 3.4 kg.

<div style=\"page-break-after: always\"></div>

The proposed starting materials are p-fluoro-L-phenylalanine ethyl ester hydrochloride and Boc-p-nitroL-phenylalanine. Chloroacetic acid and sodium chloroacetate also contribute to the structure of melflufen hydrochloride. They are used to form a simple moiety (bis-ethyl chloride amine) of the structure of the intermediate Boc-melflufen and are not considered regulatory starting materials.

During the procedure a major objection was raised on the choice of p-fluoro-L-phenylalanine ethyl ester hydrochloride and Boc-p-nitro-L-phenylalanine as starting materials. The applicant provided additional scientific justification and data to support their choice and updated the active substance control strategy accordingly.

The synthetic routes from both starting materials and from the used starting material manufacturers are provided,  including  information  on used  solvents,  reagents  and  potential  catalysts.  According  to  the information given no class 1 solvents and class 1 catalysts are used in the manufacture of both starting materials. The active substance includes two stereochemical centres in the S,S configuration which are derived from the two proposed starting materials. Batch data of the starting materials from all used SM manufacturers are given and comply with the proposed SM specifications. ICH Q7, Q11 and Q11 Q&amp;A document has been followed by the applicant. Based on this the MO was satisfactorily resolved.

Materials used in the manufacture of the active substance (solvents, reagents, catalysts and auxiliary material) are listed including information where each material is used, which parameters are tested and which in-house acceptance criteria are set.

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products (Melflufen aminodipeptide and melflufen nitrodipeptide), starting materials and reagents have been presented.

The manufacturing process of melflufen hydrochloride is a standard manufacturing process and does not involve aseptic processing or sterilization. The analysis results for the batches obtained in the process validation are presented and comply with the proposed acceptance criteria.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development program. An overview of the manufacturing process development, including information on used manufacturers, starting materials, intermediate formed in the penultimate reaction step and reagents used in the final reaction step was provided. Batch analysis data for active substance batches from the different synthetic routes are given. The batch data comply with the specification in place at time at the time of analysis. Purging of potential impurities is discussed. The used methods are described and suitable for their intended use. The quality of the active substance used in the various phases of the development is considered to be comparable with that produced by the proposed commercial process. Process parameter criticality has been assigned based on Design of Experiments (DoEs) which were carried out for process steps 1 - 4. Proven Acceptable Ranges (PARs) have been investigated as a part of  the  process  understanding  and  development  but  are  not  included  in  the  description  of  the manufacturing  process  in  3.2.S.2.2.  Normal  Operating  Range  (NOR)  are  stated  and  are  considered acceptable. No design space is claimed.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

Potential  process  impurities  and  drug-related  impurities  (this  includes  also  reagents,  solvents  and catalysts)  are  discussed  and  summarized  including  information  on  control  strategy  and  acceptance criteria. No discussion on potential genotoxic impurities is given. According to the given information from the applicant in the non-clinical overview melflufen is indicated for anticancer treatment in patients with few  treatment  options  and  the  molecule  has  identical  alkylating  functions  as  cyclophosphamide, bendamustine, chloroambucil and melphalan, compounds with documented carcinogenic and teratogenic

<div style=\"page-break-after: always\"></div>

activity. ICH M7 does not apply to active substances and finished products intended for advanced cancer indications as defined in the scope of ICH S9 (Ref. 4).  This was considered acceptable.

The active substance is packaged in LDPE bags which complies with the EC directive 2002/72/EC and EC 10/2011  as  amended  and  are  commonly  used  for  active  substance  packaging.  The  specification  is appropriate and the suitability of the LDPE bags with respect to stability and compatibility with the active substance is confirmed by the results obtained from stability studies.

## 2.4.2.3. Specification

The  active  substance  specification  includes  tests  for  appearance  (for  powder  and  solution  in  1% methanol, visual), identification (by FTIR and HPLC by RT), assay (HPLC), total purity (HPLC), related substances (HPLC), chiral purity (HPLC), residual solvents (GC), water content (Ph. Eur.), sulphated ash (Ph. Eur.), chloride content (titration), microbial limits (Ph. Eur.) and bacterial endotoxins (Ph. Eur.).

The  performed  tests  and  acceptance  criteria  are  discussed  and  justified.  Tests  for  identification, regioisomer, chiral purity, residual solvents, sulphated ash, chloride content and bacterial endotoxins are performed at release of active substance only which is accepted as these tests are not considered stability indicating.

The  analytical  methods  used  have  been  adequately  described  and  (non-compendial  methods) appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data (n=5, full scale) of the active substance are provided. The results are within the specifications and consistent from batch to batch.

## 2.4.2.4. Stability

Stability data from three process validation batches stored at stored at long-term (5°C) for up 36 months and  accelerated  storage  conditions  (25°C)  for  up  to  6  months  according  to  the  corresponding  ICH guideline were provided. Furthermore, additional supportive stability data were submitted.

The following parameters were tested: appearance of powder, appearance of solution, assay, total purity, related substances, water content, microbial limits. The analytical methods used were the same as for release and were stability indicating.

No significant changes in any of the test results (stability indicating parameters) were observed in the long-term testing and accelerated testing.

Forced  stress  stability  studies  (including  heat,  artificial  light,  acidic  and  alkaline  environment)  were performed.  The  active  substance  is  unstable  under  acidic  and  basic  conditions.  Results  for  forced degradation study and mass balance were provided. Photo-stability testing was performed according to ICH Q1B. Significant degradation is observed after exposure to light equivalent to 2 times the exposure level recommended in ICH Q1B.

The analytical  procedures  used  are  the  same  as  the  ones  used  for  routine  control  and  are  stability indicating. Only stability indicating parameters have been tested, which is acceptable as outlined above.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  supplier  is sufficiently stable. The stability results justify the proposed retest period of 36 months, when stored at 5 ± 3°C in the proposed container.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

The finished product is a powder for concentrate for solution for infusion. Lyophilised white to off-white powder. The qualitative and quantitative composition are outlined in Table 1.

Table 1 Composition of finished product

| Naine of Ingredient     | Quality Standard   | Function          | Quantity (mg/vial)   |
|-------------------------|--------------------|-------------------|----------------------|
| Melflufen hydrochloride | In-house           | Active ingredient | 21.48                |
| Sucrose                 | Ph. Eur.           | Bulking agent     | 1,000                |
| tert-Butanol            | In-house           | Co-solvent        | N/Ab                 |
| WaterforInjections      | Ph. Eur.           | Solvent           | N/Ab                 |
| Nitrogen                | Ph. Eur.           | Inert gas         | N/Ac                 |
| Total                   |                    |                   | 1,021.48             |

Coresponding to 20 mg melflufen free base

Removed duing the lyophilisationprocess

The exact amoumt of nihrogen per vial cannot be determined as the vials are backfilled with nitrogen at the end of the lyo process.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards. In addition sucrose complies an in-house acceptance criterion for bacterial endotoxins NMT 0.07 EU/mg, thus with a stricter limit than Ph. Eur., which is acceptable. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC and in  paragraph 2.4.1 of this report. Tert-butanol is used as a co-solvent which is removed during the lyophilization process (also WFI is removed). Tert-butanol is controlled according to in-house standards which is acceptable.

Melflufen is reconstituted with 40 ml 5% glucose solution and then further diluted with 0.9% sodium chloride  -  the  amount  of  sodium  chloride  used  to  dilute  o  final  volume  is  depending  on  the  dose (40/30/20/15  mg  active  substance,  resulting  in  final  concentrations  of  0.16/0.13/0.10/0.08  mg/ml respectively). Detailed instructions for reconstitution and dilution are presented in the SmPC section 6.6. The standard dose is 40 mg; the total amount of the reconstituted solution from two vials.

Formulation development is adequately described. Early development was based on a concentrate for solution  for  infusion  (DMA  formulation).  Subsequently  the  development  was  aimed  towards  a  new formulation  replacing  the  DMA  formulation  with  improved  long-term  stability,  i.e.    a  powder  for concentrate  for  solution  for  infusion  (lyophilized  formulation).  Initially,  ethanol/water  mixtures  were used,  but  after  various  tries,  the  final  excipients  have  been  found  leading  to  a  bulk  solution  for lyophilisation which is stable and a lyophilisate cake which is easy to reconstitute. Clinical formulations are described. Sugar concentration in the pharmaceutical form has been studied during the development of the production process. No overage is used. The proposed target fill weight is 18.8 g/vial.

Detailed  information  on  manufacturing  development  history  is  presented.  The  dosage  form  is manufactured according to non-standard manufacturing processes according to Annex II of EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1,  Corr.1  as  the  respective  manufacturing  processes include aseptic processing. Manufacturing of the powder additionally includes a lyophilisation step. The applicant states that compounding and filling procedures were established at an early stage, with only minor improvements implemented during the continued development. Separate data on compounding and filling process development are provided.

<div style=\"page-break-after: always\"></div>

The selected sterilisation method (0.22 µm filtration) is in general justified. Further provided justification regarding  thermal  stability  was  provided.  Selection  of  the  container  closure  system  is  sufficiently justified. Primary packaging materials comply with respective Ph. Eur. requirements (i.e. Ph. Eur. 3.2.1 and Ph. Eur. 3.2.9).

The product is packaged in type 1 clear glass vials (50 ml vials, 20 mm) which comply with respective Ph. Eur. monograph 3.2.1, closed with chlorobutyl stoppers (20 mm grey), which comply with respective Ph. Eur. monograph 3.2.9 and closed with a flip-off cap (20 mm Alu unlined w/Flip-off; not in direct contact with the drug product). Technical drawings for all three parts of the immediate packaging are provided.  Detailed  descriptions  and  respective  specifications  are  included  (including  appearance  and dimensions).  As  secondary  packaging,  card  boxes  are  used.  The  choice  of  the  container  closure  is therefore regarded as justified.

Considering  the  dosage  form  (solid;  reconstituted  product  has  short  contact  time  at  moderate temperature) and compendial quality of primary packaging materials, it is acceptable that the intended CCS (container closure system) compatibility testing study is not included in the dossier. Extractables/leachables  (E/L)  deriving  from  the  container  closure  system  (vials  and  stoppers)  were investigated. Toxicological assessment of the extractables detected above the AET level concluded that their estimated daily intakes are below the permitted daily exposure (PDE) values, thus E/L content is acceptable. The analytical principles of the applied analytical methods are appropriate for the intended use. Analytical methods are sufficiently discussed.

Container  closure  is  confirmed  to  be  verified  applying  compendial  methods;  accepted.  Further,  a container closure integrity test has been performed (and validated). CCIT is specified accordingly. Bulk solution  compatibility  with  process  materials  have  been  investigated.  E/L  profile  investigations  are acceptable. Study design is appropriate and includes positive control (extraction with isopropanol).

The compatibility of melflufen finished product with the proposed reconstitution/dilution solution (5% glucose  solution:  0.9%  sodium  chloride  solution  (8:17  v/v))  was  investigated  and  confirmed,  with acceptable assay results.

An extractables study has been performed regarding infusion components/materials. Study design is appropriate for in-use conditions and includes standard dose and lowest dose controls. Found amounts of  extractables  are  toxicologically  negligible.  In  conclusion,  no  significant  difference  is  observed depending on which configuration of infusion materials were used, thus melflufen is compatible with commonly used infusion materials and no restrictions are required.

## 2.4.3.2. Manufacture of the product and process controls

The manufacturing process consists of seven main steps: preparation of excipient solutions, preparation of  melflufen  bulk  solution,  sterile  filtration of  bulk  solution,  vial  filling,  lyophilisation  and  stoppering, capping and sealing, and bulk packaging. The process is considered to be a non-standard manufacturing process.

Batch quantity is defined based on the theoretical amount of bulk solution and number of filled vials. Tert-butanol and water for injections are removed by freeze-drying.

The control  strategy  regarding  critical  manufacturing  steps  is  accepted.  The  in-process  controls  are adequate for  this  type  of  manufacturing  process  and  pharmaceutical  form.  Process  parameters  and details regarding sterile filtration and aseptic processing including filter integrity and control of bioburden are provided. The bulk solution is tested immediately prior to sterile filtration for microbiological purity with the acceptable IPC limit of NMT 10 CFU/100 ml.

<div style=\"page-break-after: always\"></div>

Major steps of the manufacturing process have been validated by a number of studies. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. Data on three production scale batches are submitted covering the batch size 112.8 kg. All process parameters were taken into account. Compliance of critical process parameters is demonstrated by means of batch data. Analytical data of IPCs and intermediate controls are provided. Out of Specifications (OOS) were found for manufacture overall yield (NLT 90%) however these were accepted as being due to high amount of sampling.

## 2.4.3.3. Product specification

The finished product specifications include appropriate tests for this kind of dosage form; appearance (visual), identification (HPLC), assay (HPLC), related substances (HPLC), water content (KF), residual solvents (GC), content uniformity(Ph. Eur.), particulate contamination (visible and subvisible particles) (Ph. Eur.), sterility (Ph. Eur.), bacterial endotoxins (Ph. Eur.), crystalline content (XRPD) and container closure integrity test (UV-blue dye).

The specification for the reconstituted solution (product reconstituted in 40 ml of 5% glucose) contains tests for: reconstitution time, completeness of solution, clarity and degree of opalescence (Ph. Eur.), degree of coloration (Ph. Eur.), pH (Ph. Eur.) and osmolality (Ph. Eur.).

Parameters included in specification complies with requirements of ICH Q6A and Ph. Eur. monograph for parenteral  preparations.  All  set  specification  parameters  and  respective  limits  are  justified  by  the applicant. Regarding limit of TBA, following can be said from a nonclinical point of view: the calculated PDE for tert-butanol is 35 mg/day based upon the LOEL (lowest observed effect level) for nephropathy in females 333 from a 2-year rat carcinogenicity study. One vial of melflufen contains 1021.48 mg of which  3.5%  would  equate  to  35.75  mg  tert-butanol.  This  would  be  considered  comparable  to  the proposed PDE from a non-clinical perspective, particularly so since a second scenario calculates a PDE of 42.5 mg/kg base on a mouse carcinogenicity study where follicular hyperplasia was observed in the thyroid of female animals.

Five degradation products are briefly discussed in respective dossier section: three actual (and specified) impurities, namely dechlorohydroxy melflufen, dechloroethyl melflufen and 5-hydroxymethyl furfural. All three actual degradants have been identified by a suitable reference standard. Further, two potential impurities, namely melflufen carboxylic acid and dechloroethyl-ethylcarboxy-melflufen are stated. Both have been found in early development batches below the ICH Q3B identification threshold. Thus, they are controlled as unspecified impurities which is acceptable.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

The potential presence of elemental impurities in the finished product has been assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. The applicant investigated the risk of elemental impurities in three batches stored at 2-8°C for 11, 24 and 33 months respectively. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed (as requested) considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article  5(3)  of  Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation

<div style=\"page-break-after: always\"></div>

EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided, it  is  accepted that  there  is  no  risk  of  nitrosamine  impurities  in  the  active substance or the related finished product. Therefore, no specific control measures are deemed necessary.

Batch data from six batches (commercial batch size, 6000 vials) are provided. All results comply with respective specification limits except for one batch which had an OOS with parameter sterility, however the root cause has been identified and is not related to the process performance. Batch data for the same six batches are provided for the reconstituted drug product.

## 2.4.3.4. Stability of the product

Stability data from three, full scale batches of finished product stored for up to 24 months under long term conditions (5±3°C) and for up to 12 months under accelerated conditions (25±2°C) according to the ICH guidelines were provided. The batches are identical to those proposed for marketing and were packed  in  the  primary  packaging  proposed  for  marketing.  Supportive  stability  data  from  additional batches used for clinical supply were also provided.

Samples were tested for appearance, assay, related substances, water content, particulate contamination, sterility and bacterial endotoxins, crystalline content and container closure integrity. The analytical procedures used are stability indicating.

Forced degradation studies have been conducted (hydrolysis, acidic environment, alkali environment, oxidative  environment,  heat  exposure  and  artificial  light  irradiation  exposure).  It  is  stated  that degradation occurred (greater than 2.5%) at the hydrolysis, acidic, alkaline, oxidative and thermal forced degradation conditions. A decrease in assay of 8.4% could be found when the finished product was treated  with  light  irradiation.  Thus,  melflufen  is  not  regarded  as  stable  under  forced  degradation conditions  but  the  HPLC  method  is  regarded  as  stability-indicating.  Mass  balance  is  regarded  as acceptable.

Performed photostability study according to ICH Q1B (option 2) showed that the finished product is photolabile  if  not  adequately  protected  from  light.  Thus,  the  finished  product  should  be  kept  in  the secondary packaging to avoid any degradation.

Since OOS are observed at accelerated storage conditions, storage in refrigerator is justified as well. In the SmPC it is stated that the finished product should not be frozen. This is acceptable as freeze-thaw studies have not been conducted and stability after freezing is thus unclear. Confirmation is given that the start of shelf-life is calculated according to CPMP/QWP/072/96.

In-use stability  studies  are  performed  with  two  batches.  The  in-use  study  was  conducted  using  the proposed analytical procedures, with the exception of the HPLC methods that were adjusted with regards to sample preparation and sample concentration to enable testing of the admixtures. An in-use stability specification is provided. The post-approval stability protocol and stability commitment is accepted.

Based on available stability data, the proposed shelf-life of 24 months and storage conditions (Store in a refrigerator (2°C to 8°C). Do not freeze. Store in the original package in order to protect from light.) as stated in the SmPC (section 6.3) are acceptable.

## 2.4.3.5. Adventitious agents

No excipients derived from animal or human origin have been used.

<div style=\"page-break-after: always\"></div>

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. During the procedure a major objection was raised on the choice of active substance starting materials. The applicant provided additional scientific justification and data to support their choice and updated the active substance control strategy accordingly. The MO was satisfactorily resolved. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.6. Recommendation(s) for future quality development

Not applicable.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

## 2.5.2. Pharmacology

A range of in vitro and in vivo pharmacology studies have been performed to assess the efficacy of melflufen. These data have been published or are in manuscript form. The activity of melflufen has been examined using multiple myeloma (MM) cell lines and patient samples and in vivo using rodent xenograft or hollow fiber models.

Melflufen flufenamide (4-[Bis-(2-chloroethyl)amino]-L-phenylalanine-4-fluoro-L-phenylalanine ethyl ester hydrochloride), abbreviated melflufen and previously called J1, is an ethyl ester of a di-amino acid consisting of the amino acid derivative of melphalan (mustard-L-phenylalanine) and para-fluoro-Lphenylalanine. Melphalan has been in clinical use as an antitumor agent for more than 60 years and has the classical bis-(2-chloroethyl) amino alkylating function identical to that in the other marketed cytotoxic compounds cyclophosphamide, chloroambucil and bendamustine. Melflufen has, due to the extra para-fluoro-L-phenylalanine group as compared to melphalan, an increased lipophilicity (logD 2.3), leading to an easier passage of the cell membrane.

## 2.5.2.1. Primary pharmacodynamic studies

Primary pharmacodynamics in vitro

Nitrogen-based alkylating agents like melphalan exert their cytotoxic action through covalent interaction with intracellular nucleophiles, especially DNA, as a result of the spontaneous formation of reactive cyclic aziridinium ion intermediates. Bifunctional agents (such as melphalan, cyclophosphamide, chlorambucil and bendamustine) are able to crosslink a DNA strand within a double helix (intrastrand), between two strands (interstrand) or between DNA and proteins and are more

<div style=\"page-break-after: always\"></div>

active than monofunctional agents. Cross-linking of DNA is probably the most important factor for the cytotoxic effect, resulting in inhibitory effects on DNA replication and transcription, which subsequently triggers cell death.

In vitro studies in multiple myeloma RPMI 8226 cells showed that melflufen (1 µM) easily crosses the cell membrane and was subsequently rapidly and extensively hydrolysed, forming desethyl-melflufen and, by peptidases, mainly melphalan. Intracellular concentration of melflufen was quantifiable for 30 min. In contrast, melphalan was detectable for up to 2 h having a 27-fold higher intracellular melphalan than melflufen exposure. When melflufen treatment of RPMI-8226 multiple myeloma cells was compared with melphalan, it was found that treatment with 5 μM of melflufen loads the cells with about 2.5fold more melphalan than can be achieved with 100 μM of melphalan. In this case melflufen functions as a prodrug, loading the cell with a ~50-fold higher amount of intracellular melphalan than when exposing to melphalan.

Aminopeptidases such as LAP3, LTA4H, RNPEP and aminopeptidase N (APN) have shown similar capability to form melphalan out of melflufen. Moreover, cell lines with high hydrolytic activity also display a larger difference between melflufen and melphalan activity, suggesting a role of these enzymes in the activation of melflufen. If a peptidase inhibitor is added, the cytotoxic activity is decreased. Moreover, if the peptide bond in melflufen is chemically modified to be non-hydrolysable, the cytotoxic activity is significantly impaired.

The cytotoxic activity of melflufen has been examined in a range of Multiple Myeloma (MM) cell lines and in patient-derived MM samples and melflufen showed cytotoxicity in the MM cell line RPMI8226, and the melphalan-resistant 8226/LR5 and doxorubicin-resistant sublines. In the MM cell lines, the IC50 of melflufen varied from 0.4 - 1.7 µM and was 10-fold lower than of melphalan. Another in vitro study on the potency of melflufen in bortezomib-resistant MM cells showed that melflufen was significantly more potent in the bortezomib-adapted (to develop resistance) derivatives of AMO-1, RPMI-8226 and ARH-77 cell lines than in the corresponding unadapted cells. The ability of melflufen to exert activity in drug resistant MM cells was further documented in a study on carfilzomib-resistant subline of AMO-1 cells subjected to CRISPR/Cas knock-out of the ABCB1 gene.

When the cytotoxic effect was determined in primary cultures of 3 human myeloma cells, melflufen showed a mean IC50 that was approximately 0.2 μM. A similar cytotoxic activity of melflufen (IC50 ~0.5 μM) was observed when tested in MM patient tumour cells, puri fied by using CD138+ antibody enrichment. In a study investigating the cytotoxicity of melflufen in CD138+CD38+ bone marrow cells from MM patients (15 samples from 14 patients) a median IC50 of 0.9 nM was observed but with a high variability in response.

Additional in vitro studies to evaluate cytotoxicity were conducted with melflufen in a panel of different human tumour cell lines, including patient-derived tumour samples. The average half maximal inhibitory concentration (IC50) of melflufen in 23 cell lines derived from haematologic cells (acute leukaemia, lymphoma, and myeloma) was 0.20 μM compared to 6.9 μM for melphalan, a 35 -fold difference. The average IC50 of melflufen in the 24 cell lines derived from solid tumour cells (neuroblastoma, lung cancer, ovarian cancer, and renal cell cancer) was 0.41 μM compared to 18 μM for melphalan, a 44-fold difference. Melflufen was shown to be more potent in haematologic malignancies than in solid tumours.

Combining melflufen with the commonly used myeloma drugs lenalidomide (immunomodulatory), bortezomib (proteasome inhibitor), or dexamethasone (glucocorticoid) triggered synergistic antimyeloma activity in cell lines RPMI LR5 (melphalan resistant) and MM.1S.

In addition to the increased cytotoxicity of melflufen, as compared to melphalan, melflufen showed cytotoxic activity in cells with dysfunctional p53, suggesting that a functional p53 is not needed for

<div style=\"page-break-after: always\"></div>

melflufen-induced cytotoxicity. In line with this melflufen also showed cytotoxic activity in CD138+CD38+ plasma cells, isolated from primary bone marrow samples from MM patients with confirmed chromosome 17p deletion or TP53 mutations.

In vitro and in vivo studies found an anti-angiogenic effect, an inhibition of vessel formation, which is in line with highly expressed APN in vascular endothelial cells leading to a higher melphalan formation intracellularly. The relevance of different peptidase expression in other tissues on melflufen activity in humans is unclear. Melflufen showed a similar high sensitivity on immature human umbilical cord blood CD34+ progenitor cells (FMCA-GM7) and a more differentiated CD34+ derived cell population (FMCAGM14) but melphalan was 68- and 23-fold less sensitive to GM7 and GM14 cells, respectively. In addition, cytotoxic effects were demonstrated on osteoclasts precursors and on osteoclastogenesis, possibly linked to lower tumour-induced bone resorption.

The mechanism of action for the cytotoxicity of melflufen is suggested to be the bis-(2-chloroethyl) amino alkylating function inducing cross-linking of DNA leading to inhibitory effects on DNA replication and transcription. In this respect melflufen was found to increase dose- and timedependently γ -H2AX, a DNA damage response protein, and induces apoptosis (annexin V, caspase-3), which was found in vitro and in vivo. A flow cytometry study showed cell cycle arrest in the G2/M phase, which is in line with a higher sensitivity of rapidly dividing cells. Melflufen-induced DNA damage, as indicated by the proteins γ -H2AX, ATR and CHK1, was found to be more rapid and robust than with melphalan, and washout experiments showed that a 2 hour exposure of MM cells to melflufen was sufficient to initiate irreversible DNA damage and cytotoxicity.

In conclusion, from the presented in vitro PD data, it is not clear whether melflufen itself exhibits cytotoxicity as the ~50-fold increase in melphalan intracellularly with melflufen treatment is also in line with the increase in cytotoxicity, seen in most cell lines with melflufen as compared to melphalan. In addition, if a peptidase inhibitor is added, the cytotoxic activity is decreased. Moreover, if the peptide bond in melflufen is chemically modified to be non-hydrolysable, the cytotoxic activity is significantly impaired.

## Primary pharmacodynamics in vivo

The in vivo efficacy of melflufen has been investigated in mice and in rats using the implanted hollow fiber method (fibers containing T-cell leukaemia, small cell lung cancer, renal adenocarcinoma ACHN and MM cells) as well as in subcutaneous tumour xenografts in nude rats and nude or SCID mice using tumour cells of different origin (neuroblastoma, ovarian carcinoma, B-cell lymphoma and MM).

The hollow fiber method consists of subcutaneously implanted fibers, in rodents and provides a robust model that reports modest sensitivity to several standard cytotoxic drugs. The read-out is a percentage net growth over 5 days of subcutaneous placement (SD or QD treatment). Three cell lines (T-cell leukaemia CCRF-CEM, small cell lung cancer NCI-H69, and renal adenocarcinoma ACHN) and two primary cultures of human tumour cells (from patients with CLL or ovarian carcinoma) were used as tumour models in the NMRI mouse. Both melflufen and an equal dose of melphalan inhibited growth of all three tumour cell lines and melflufen, but not melphalan, inhibited one (ovarian carcinoma) of the two primary tumour cells.

The effect of melflufen and of an equimolar dose of melphalan (4 µmol/kg) was also assessed in MM (MM.IS cell, sc) xenografts in SCID mice (2 mg/kg melflufen IV BIW for 3 weeks). At an equimolar dose, melflufen but not melphalan significantly inhibited tumour growth and time to survival. In addition to an effect on multiple myeloma, subcutaneous xenograft studies using other tumors types in nude (neuroblastoma SH-SY5Y) or SCID mice (ovarian carcinoma A2780) also showed significantly better antitumoral effects with melflufen than melphalan at equimolar doses.

<div style=\"page-break-after: always\"></div>

In another SCID mouse xenograft leukaemia model, AML primary sample (AML-ps) tumour cells from bone marrow blasts of AML patient were used. Both melflufen and melphalan decreased the amount of circulating leukaemia cells by &gt;99% and increased survival from 34 days to &gt;104 days. Melflufen treatment (8 mg/kg) showed a higher proportion of leukemic free animals than that observed with equimolar melphalan treatment.

The Vk*MYC transgenic mouse with spontaneous occurring myeloma tumours has been suggested as an alternative model to predict single-agent drug activity. Both melflufen (4 mg/kg, IP, BIW) and melphalan were shown to be active in this model (&gt;50% response).

Melflufen inhibited tumour growth in xenografted nude rats using the very resistant SK-N-BE(2) or sensitive SH-SY5Y neuroblastoma cell lines and also showed significant increase in caspase-3 positive cells and decrease in cell proliferation.

Using the hollow fiber method in the Sprague Dawley rat as tumour model, two cell lines (T-cell leukaemia CCRF-CEM and MM RPMI8226) were evaluated. Melflufen (I V, single dose 1.33 μmol/kg, i.e. 0.66 mg/kg) inhibited cell growth of the CCRF-CEM cell but not of the MM RPMI8226 cell line, while melphalan at an equimolar dose, was inactive in both models.

In conclusion, despite the, in contrast to human, instantaneous de-esterification of melflufen in rodent plasma upon administration, the xenograft and hollow fiber methods using nude/SCID mice or nude rats showed a higher efficacy on tumour cell growth inhibition with melflufen than with an equimolar melphalan dose in five of the seven xenograft models and three of the five hollow fiber models.

## 2.5.2.2. Secondary pharmacodynamic studies

Given the general cytotoxic, alkylating activity of melflufen, its rapid conversion to melphalan, the intended indication and the large clinical experience with melphalan, it is agreed that no secondary pharmacodynamic screening panel data have been provided.

## 2.5.2.3. Safety pharmacology programme

Safety pharmacology comprised of an in vitro study on the effect on hERG tail current amplitude and GLP-compliant studies in the rat and dog using a standardized observation battery study (rat), respiratory/cardiovascular study (rat), a cardiovascular telemetry study (dog) and holter monitoring studies (dog). No stand-alone safety pharmacology studies have been performed concerning the potential effects of melflufen to affect renal function/urinary parameters, but this is evaluated in the general toxicity studies.

In a combined telemetry / plethysmography study, a single dose 30-min intravenous (IV) infusion of melflufen (9.17 mg/kg) to male Wistar rats (n=6), resulted in a short-lasting (&lt;15 min) but statistically significant stimulatory action on respiration and heart rate. This might be explained as a stress response related to local irritation and pain, effects commonly associated with high dose chemotherapeutic regimens. There was no effect on tidal volume, blood pressure, temperature or locomotor activity.

In a GLP-compliant, 2-cycle IV infusion study in the rat, clinical signs were monitored using a standardized observation battery that included assessment of motor activity, mood/awareness, motor incoordination, and muscle tone. No signs of any CNS toxicity were observed at the low and mid doses of 3.3 and 6.6 mg/kg (Q3W), respectively, while high-dose animals (9.2 mg/kg) had mainly statistically significant incidences of piloerection, slowed body movements and occasional reduced spontaneous locomotor activity.

<div style=\"page-break-after: always\"></div>

While melphalan did not show an inhibitory effect at 100 µM, melflufen showed a concentrationdependent inhibition of the human ether-a-go-go related gene (hERG) current in CHO cells yielding an IC50 of 1.63.1 μM (0.8 -1.55 μg/mL), which is about 5.4 - 10.4 times higher than the anticipated Cmax of melflufen (148 ng/mL) at the proposed human dose of 40 mg. Therefore, hERG-related effects on QT interval cannot be completely excluded in humans. Although the in vitro hERG study was performed as non-GLP-compliant, the data of the study are considered adequate given the quality of the presented study data.

The multiple dose effect of melflufen on ventricular repolarization was investigated in vivo in two male and two female Beagle dogs upon IV administration (30 min infusion, 0.9 mg/kg, every three weeks for three cycles). No treatment related abnormalities in rhythm or in complex morphology were recorded in any animal at any time point. No relevant changes were observed in any measured or computed parameters, including repolarization parameters, i.e. QT or QTc interval corrected for heart rate. Using 24 hrs holter monitoring in male and female Beagle dogs, a single dose 30-minute IV melflufen infusion (2.5 mg/kg, n=6 and 8.75 mg/kg, n=1) revealed no evidence of any QT prolongation or other rhythm disorders. The ECG data from the 17.5 mg/kg study are not considered as, due to a human error, post dose ECG recordings up to 30 hrs are not available and two out of three animals died. The 2.5 mg/kg dose level is almost 4-fold the clinical dose but this corresponds to a 2fold lower melflufen concentration than the clinical Cmax at 40 mg. These in vivo observations with high doses thus suggest that melflufen is devoid of significant effects on the heart but it should be noted that clinical Cmax concentrations were not reached and the melflufen plasma concentrations quickly declined to BLQ after the infusion. The effect of melflufen on ventricular polarization was also investigated in the clinic but, the available data are limited, may also raise a concern (see clinical AR).

In conclusion, in contrast to melphalan, melflufen induced a concentration-dependent inhibition of the hERG channel current, leading to an 30- to 60-fold lower IC50 than melphalan, which is about 5-10 times higher than the anticipated clinical melflufen Cmax. The in vivo studies did not reveal reasons of concern but it should be noted that clinical Cmax concentrations were not reached. Currently, the possible mechanism of this difference with melphalan and the clinical relevance of this finding is unclear.

## 2.5.2.4. Pharmacodynamic drug interactions

It is agreed that no pharmacodynamic drug interaction studies with melflufen are needed as it is quickly transformed into melphalan and there is ample clinical experience with melphalan.

## 2.5.3. Pharmacokinetics

## Methods of analysis

Concentrations of melflufen, desethyl-melflufen and melphalan in plasma of rats, rabbits and dogs were measured with LC-MS/MS methods. Melphalan is a known antitumour agent. Melphalan flufenamide (melflufen) is a derivative of melphalan, which is hypothesised to lead to higher concentrations of melphalan in the tumour cells compared to melphalan treatment because melflufen is rapidly taken up into cells followed by a rapid enzymatic hydrolysis of the molecule to the active metabolite melphalan.

In toxicokinetic studies in dogs, validated methods were used. The validation was adequate regarding calibration, accuracy, precision, matrix effect and stability. Long-term stability was long enough to cover the maximum storage period of the samples. Dilution integrity in dogs was determined up to 3000 ng/mL.

<div style=\"page-break-after: always\"></div>

In rats, no toxicokinetic studies were performed. Pharmacokinetic studies were performed in rats, separately from the toxicology studies but with similar doses as in the toxicology studies. In rat PK study 20050055TRB, a validated method was used. The method was validated for the measurement of melflufen and melphalan in rats, but not for desethyl-melflufen. In rat study 20050535TRB, it is not clear whether the method which was used, was the same as in study 20050055TRB. In rat PK study AB19-70-02, a method was used which was validated for use in dogs but not in rats.

The method used in rabbits was not validated for use in rabbit plasma. Rabbits were however not used in the toxicology studies.

Methods used in the other pharmacokinetic studies were fit for purpose.

## Absorption

Studies were performed in rats, rabbits and dogs, with IV administration by 30-minute infusion.

After administration of melflufen to rats, melflufen was not detectable in plasma because it was degraded very quickly already in plasma (see further under 'Metabolism'). Tmax of melphalan occurred at 0.58 h after the start of infusion (5 minutes after the end of infusion) and melphalan Cmax and AUClast increased approximately dose-proportionally at doses 3.3 to 9.2 mg/kg of meflufen. After comparing equimolar doses of melflufen and melphalan (9.2 mg/kg melflufen vs 4.9 mg/kg melphalan and 3.3 mg/kg melflufen vs 2.0 mg/kg melphalan), AUClast of melphalan was higher after administration of melflufen than after administration of melphalan. Cmax of melphalan after administration of melflufen was higher than after melphalan administration in one study, but slightly lower in another study. Elimination half-life of melphalan was 0.74 - 1.17 h. Volume of distribution of melphalan was 407 mL/kg (distribution slightly more than intracellular fluid) and clearance of melphalan was 379 mL/h/kg.

Also in rabbits, melflufen was degraded very quickly.  Measurable concentrations of melflufen in plasma were only found during infusion, and also in one sample at 10 minutes after the end of infusion. Tmax of melphalan occurred at 0.42 h after the start of infusion. When equimolar doses of melflufen and melphalan were compared, Cmax and AUClast were lower (35% and 24% respectively) after administration of melflufen than after administration of melphalan. Elimination half-life of melphalan was 0.63 - 0.66 h. Volume of distribution of melphalan was 1024 mL/kg (approximately similar to total body water) and clearance of melphalan was 1131 mL/h/kg.

In dogs, low levels of melflufen were found, with Tmax at 0.28 - 0.50 h after the start of infusion. Tmax of melphalan occurred at 0.50 - 0.75 h after the start of infusion. Exposure to melphalan increased approximately dose-proportionally after administration of melflufen (from 0.45 to 0.90 mg/kg and from 8.75 to 17.5 mg/kg). After comparing equimolar doses of melflufen and melphalan (0.9 mg/kg vs 0.55 mg/kg [day 1] and 17.5 mg/kg vs 10 mg/kg), Cmax and AUClast were lower (4652% and 0.7-20%) after administration of melflufen than after administration of melphalan, although in study 2014-0252, there was only a minor difference in AUC. Elimination half-life was 0.04 - 0.07 h for melflufen and 0.61 - 0.79 h for melphalan. Volume of distribution was 780 - 2400 mL/kg for melflufen and 1310 - 1430 mL/kg for melphalan (both beyond total body water). Clearance was 15330 - 25020 mL/h/kg for melflufen and 1160 - 1460 mL/h/kg for melphalan. No consistent gender effect was observed. Only in study 0373-2012, at 0.90 mg/kg exposure was slightly higher in females, but the difference with males was less than two-fold and was therefore not clinically relevant.

In rabbits and dogs the administration of 0.9 mg/kg of melflufen or an equimolar dose of melphalan, showed that melflufen administration was associated with an approximately 25% lower AUCinf than that observed after melphalan administration. It was justified with more alkylator being retained in the tissues after melflufen administration.

<div style=\"page-break-after: always\"></div>

Gender differences on melflufen absorption were investigated only in dogs and specific differences were not noted. Human and dog pharmacokinetic data were compared, and it was concluded that from a pharmacokinetic point of view dog can be considered as a suitable species for safety testing of melflufen, therefore it is considered sufficient to demonstrate gender differences only in this species.

In an experiment by Nygren (2009), melflufen was added to human blood. Melphalan peaked in the red blood cell compartment at 10 minutes, whereas in the plasma compartment it was still increasing at 45 minutes. Desethyl-melflufen was low in both compartments. This indicates that in human, melflufen is converted into melphalan faster in the blood cell compartment than in plasma.

## Distribution

After in vitro incubation of melflufen in whole blood of rats, melflufen was mainly converted into desethyl-melflufen in the plasma fraction. Melphalan was low in both plasma and red blood cell fraction. In human blood, melflufen distributed quickly to blood cells (Tmax of melflufen in blood cell fraction 1 min) and melphalan in the blood cell fraction gradually increased with Tmax of 6 min. In human blood, melphalan formation was considerably higher in the red blood cell fraction than in plasma. In dog blood, the pattern was comparable to human blood, but the formation of melphalan was somewhat slower (Tmax of melphalan in blood cell fraction was 60 min). These results indicate preferential formation of melphalan in blood cells in dogs and humans. A comparable pattern was found in a human multiple myeloma cell line.

In a study in female CB17 SCID mice xenografted with MM.S1 cells (multiple myeloma cells), the highest concentrations of melflufen and melphalan at 15 min after injection were found in pancreas, kidneys, liver, heart and lung. At 4 hours post dose the concentrations were 4 to 10-fold lower than at 15 minutes. Melflufen and melphalan were also found in the tumours. The amounts in tumour appear limited.

In rats, covalent binding of melphalan-related radioactivity was found in all investigated tissues.

Protein binding of melphalan was 86% in plasma of rats at concentrations of 101 - 2747 ng/mL (0.33 - 9.0 nmol/mL). Protein binding of melphalan in plasma of healthy humans was 80 - 92% at concentrations of 92 - 10072 ng/mL (0.3 - 33 nmol/mL). Melphalan was primarily bound to albumin. In plasma from cancer patients, protein binding varied 54 - 94%.

Melanin binding was not studied.

Placental transfer and excretion into milk were not studied. As an alkylating anticancer agent, melphalan is expected to be teratogenic and because it is a genotoxic compound, women treated with melflufen should not breast-feed.

## Metabolism

In vitro studies in mouse and rat blood showed that melflufen is degraded quickly, mainly into desethyl-melflufen by esterases (elimination half-life of melflufen 9 and 15 seconds in mouse and rat blood respectively). Subsequently, in rat plasma, desethyl-melflufen is slowly converted into melphalan. The amount of melphalan was low after incubation of melflufen in whole blood of rats. In an in vitro study in rat liver microsomes, the formation of monoglutathionyl and diglutathionyl melphalan derivatives has been observed. These conjugates have not been observed in vivo.

After incubation of melflufen in dog and human whole blood, melflufen was converted into melphalan in the red blood cell fraction (elimination half-life of melflufen 7.0 and 4.4 min in dog and human blood respectively). When melflufen was incubated in dog plasma, there was no appreciable formation of melphalan. Experiments in dog and human blood support a rapid inflow of melflufen to cells, formation

<div style=\"page-break-after: always\"></div>

of melphalan in the cells and then a slow out-transport of melphalan. The metabolism of melflufen is in humans more comparable to dogs than to rats.

Experiments in human multiple myeloma cell line RPMI 8226/S showed an intracellular rapid formation of melphalan, a short plateau and then a gradual decrease of intracellular melphalan. At 1 µM, intracellular melphalan could be quantified up to 120 min.

In vivo in rats, melflufen was metabolized so quickly into desethyl-melflufen that melflufen was not detected. High levels of desethyl-melflufen were observed during infusion, which decreased thereafter. In rabbits, melflufen was converted quickly into melphalan. In dogs, melflufen was detectable, but was quickly metabolized, mainly into melphalan.

## Excretion

Melphalan-related radioactivity was excreted in both urine (44%) and faeces (25%) of dogs within 11 days after IV dosing. A total of 8% of melphalan-related radioactivity was excreted as intact melphalan in urine. In bile, 86% of melphalan-related radioactivity consisted of intact melphalan at 30 min after dosing and 72% at 4 hours after dosing.

## Pharmacokinetic drug interactions

Pharmacokinetic drug interactions have not been studied for melflufen.

## 2.5.4. Toxicology

## 2.5.4.1. Single dose toxicity

The acute toxicity of a single dose of melflufen was evaluated in mice, rats, dogs and minipigs. Melflufen was administered intravenously (IV) via a bolus injection (rodents) or a 30-minute infusion (dogs and minipigs) followed by a follow-up period. In the non-GLP minipig study and in one non-GLP dog study (2014-0252), melflufen was compared with melphalan. In the other studies described, only the safety of melflufen was evaluated.

In GLP rodent studies, mortality was evident at the high dose of melflufen (46.7 mg/kg in mice, 11.7 mg/kg in rats) and was associated with haemorrhagic intestinal tract and red lungs preceded by several clinical signs. Tonic seizures have been reported in mice shortly after administration at ≥ 23.3 mg/kg. These have not been observed in any other species tested or in repeated-dose mice studies administered doses up to 23.3 mg/kg.

In the non-GLP minipig study (1 animal per group), the animal given 2.4 mg/kg melflufen was terminated earlier (Day 5) due to severe clinical signs. An equimolar dose of melphalan was better tolerated based on clinical signs. In both animals, a severe decrease in WBC counts, with a more rapid decline in the melflufen-treated animal, was observed and marked histologic changes were seen in the gastro-intestinal tract, bone marrow, spleen, and testicular tubular epithelium. The melflufen-treated animal appeared to show slightly more severe histologic changes compared to the melphalan-treated animal.

Three single-dose studies were performed in Beagle dogs. In non-GLP dog study 2014-0252, melphalan was included at an equimolar dose of 17.5 mg/kg melflufen. In non-GLP studies 0253-2021 and 2014-0252, mortality occurred at the high doses (1.25 and 17.5 mg/kg). In GLP study 2018-0158, no mortality occurred, but the follow-up period was restricted to six days. Effects of melflufen and melphalan were observed on the gastro-intestinal tract and the haemolymphopoietic system as main target organs. The haemolymphopoietic system was mostly affected by lymphoid depletion and severe

<div style=\"page-break-after: always\"></div>

drops in WBC populations. The gastro-intestinal and haematological effects, as well as the damage to the testicular epithelium seen in study 2018-0158, are probably related to the mode of action of an alkylating compound on rapidly replicating cell populations.

## 2.5.4.2. Repeat dose toxicity

The safety of melflufen was evaluated in a pivotal two-cycle mouse study, a pivotal two-cycle rat study and a pivotal three-cycle dog study. Melphalan was not included in these studies. Animals were given a dose of melflufen once per cycle, and the cycle duration was three weeks. Melflufen was administered via intravenous (IV) infusion over 30 minutes via the caudal vein in rodents and via the jugular vein in dogs. The animals were followed for 14 days (rodents) or 11/12 days (dogs) following the final infusion. For comparing the toxicity of melflufen for the different species tested, it is important to note that based on the pharmacokinetics of melflufen, results from dogs are likely to be more relevant for humans than rodents.

## Mice

Swiss mice were administered with 5.8 - 23.3 mg/kg/cycle melflufen. Main adverse effects regarding haematology included dose-related reductions in white blood cells (WBCs), lymphocytes, red blood cells (RBCs), starting from the low dose, and reductions in haemoglobin, haematocrit and thrombocytes at the high-dose. All these findings resolved in the recovery period. The main histopathological treatment-related findings included bone marrow toxicity, effects on secondary lymphoid tissues and testicular toxicity. These findings included hyperplastic myelopoiesis in the sternum bone marrow and extramedullary haemopoiesis in the spleen and liver, of which the latter are probably compensative effects for the loss of blood cells. Testicular toxicity was apparent as observed by germinal epithelium degeneration in the testicles accompanied by hypospermia in the epididymides. Correlating with the histopathological findings, there were weight reductions of the testes and increases in spleen weight. The No Observed Adverse Effect Level (NOAEL) was not determined, as effects on haematology were apparent at all dose levels. The lowest observed adverse effect level (LOAEL) was 5.8 mg/kg. No toxicokinetics evaluation was performed.

## Rats

Sprague-Dawley rats were treated with melflufen at doses of 3.3 - 9.2 mg/kg/cycle. The peptidase cleavage product para-fluorophenylalanine ethyl ester was administered to a separate group of rats at a dose equimolar to the high dose of melflufen. No major treatment-related effects were observed in this group.

For melflufen-treated animals, the main dose-related haematological effects starting from the lowest dose included reductions in WBCs, consisting of neutrophils, lymphocytes and eosinophils. Levels of RBCs, haematocrit, haemoglobin and thrombocytes were dose-dependently reduced starting from the mid-dose. With exception of lymphocytes and RBCs, all findings (partially) resolved in the recovery period. The main histopathological treatment-related findings included lymphoid depletion of secondary lymphoid tissues and testicular toxicity. Secondary lymphoid tissue toxicity with dose-related incidence consisted of lymphoid atrophy in the mesenteric and submaxillary lymph nodes and spleen starting from the lowest dose. Peyer's patch lymphoid degeneration and lymphoid atrophy of the thymus occurred with dose-related incidence as well as severity starting from the low-dose. Similar as in mice, extramedullary haemopoiesis in the spleen and liver was observed from the low dose onwards. Testicular toxicity was apparent in the mid-dose groups and higher with dose-related incidence and severity of germinal epithelium degeneration in the testicles. Correlating with these histopathological findings, there were weight reductions of the testis and thymus and an increased spleen weight. Other treatment-related histopathological changes included siderophages in the mesenteric lymph nodes and

<div style=\"page-break-after: always\"></div>

plasma cell hyperplasia in the submaxillary lymph nodes. Perivascular mononuclear cell infiltration and alveolar macrophage aggregates were found in the lungs with a dose-related incidence and severity. The NOAEL was not reached, as effects on haematology and histopathology were apparent at all dose levels. The LOAEL is considered to be 3.3 mg/kg. No toxicokinetics evaluation was performed.

## Dogs

Beagle dogs were treated with melflufen at doses of 0.45 or 0.9 mg/kg/cycle. The main haematological effects starting from the lowest dose included dose-related reductions in neutrophils, lymphocytes, platelets, monocytes and eosinophils. RBCs, haematocrit and haemoglobin levels were less affected in dogs compared to rodents. In dogs, the decreases were only observed after the final dose in high-dose animals. The levels of thrombocytes were not affected in dogs. With exception of eosinophil levels, all findings (partially) resolved in the recovery period. Treatment-related histopathological findings associated with bone marrow toxicity included reduced cellularity in two high-dose dogs, while one high-dose dog showed increased cellularity. A dose-related increase in severity and incidence of lymphoid depletion in the spleen was observed. In addition, treatment-related extramedullary haematopoiesis in the spleen was seen, which was, similar as the increased bone marrow cellularity, probably a compensatory effect. Treatment-related testicular toxicity was apparent in high-dose animals that consisted of germ cell depletion in the testes and oligospermia of the epididymides. Correlating with this finding, there was a weight reduction of the testes. The NOAEL was not established, as effects on haematology and histopathology were apparent at both dose levels. At both dose levels, the exposure to melflufen and its quickly formed metabolite melphalan were below the human therapeutic exposure. The exposure multiples based on AUC0-inf were ranging from 0.2 (for both melflufen and its metabolite melphalan at 0.45 mg/kg) to 0.3 - 0.9 (for melflufen 0.5 and 0.9 for males and females at and its metabolite melphalan 0.3 and 0.4 for males and females, at 0.9 mg/kg). All observed effects must therefore be considered as clinically relevant.

Overall, adverse histopathological findings that were common for both rodents and non-rodents were bone marrow toxicity, lymphoid depletion of secondary lymphoid tissues, and testicular toxicity. Significant effects were seen on the male reproductive organs in mice, rats and dogs. Degeneration of the testicular epithelium accompanied by hypospermia in epididymides were observed at the highest melfufen dose of 23 mg/kg in mice and at the highest melflufen dose of 0.9 mg/kg in dogs. Doserelated weight reductions of the testis and epididymides in the mid- and high-dose groups were also observed. The effects on the male reproductive organs were not reversible. No abnormality in organ weights, in macroscopic and microscopic observation were seen in females' reproductive organs in the pivotal repeat-dose toxicity mice, rat and dog studies. Female fertility was not further investigated. In rats, it appeared that was slightly more toxicity of secondary lymphoid tissues compared to dogs, which might be related to the fact that melflufen remained longer in plasma before it was metabolised, allowing for more systemic distribution and toxicity. In dogs, which are pharmacokinetically a more translatable model for humans compared to rats, adverse effects occurred below clinical exposures. The main targets of toxicity, bone marrow, lymphoid organs and testes, are suggestive of the pharmacological mode of action of an alkylating compound on rapidly replicating cell populations. The changes in the repeated dose toxicity studies were consistent with what was reported in single dose studies except that less gastro-intestinal toxicity was observed. This might be related to the higher doses administered in the single dose studies or due to a longer follow-up period, allowing for recovery from potential damage.

## Interspecies comparison

Melphalan increased approximately dose-proportionally in rats, dogs and humans. Effect of gender was investigated only in dogs and humans. No consistent gender effect was observed in dogs. In humans, no gender effect was observed for melphalan. For melflufen data were too limited to draw a conclusion

<div style=\"page-break-after: always\"></div>

on gender effect, this was however not a problem because it was cleared very quickly. Protein binding was 86% in rats, 80 - 92% in healthy humans and 54 - 94% in cancer patients. Volume of distribution of melphalan was 407 mL/kg in rats (slightly more than intracellular fluid), 1024 mL/kg in rabbits (approximately total body water), and 1310 - 1430 mL/kg in dogs (more than total body water). Volume of distribution of melflufen in dogs was 780 - 2400 mL/kg (could not be determined in rats and rabbits). A more extensive distribution of melphalan in dogs than in rats is consistent with formation of melphalan in cells in dogs, whereas in rats, melphalan is mostly formed in plasma. In humans, volume of distribution was 35 L for melflufen and 76 L for melphalan after a single dose (beyond total body water for melphalan). In mice and rats, melflufen remains primarily in plasma and is converted there primarily into desethyl-melflufen and for a minor part into melphalan. In dogs and humans, melflufen was distributed quickly into red blood cells and was converted there into melphalan and desethylmelflufen. Desethyl-melflufen was also converted into melphalan and melphalan was then slowly transported out of the cells. The metabolism of melflufen in humans is more comparable to dogs than to rats. Elimination half-life of melphalan was 0.74 - 1.17 h in rats, 0.63 - 0.66 h in rabbits, and 0.61 - 0.79 h in dogs. For melflufen, elimination half-life could only be determined in dogs (0.04 - 0.07 h). In humans, elimination half-life was 2 min for melflufen and 70-80 min for melphalan. Melphalanrelated radioactivity was excreted in both urine (44%) and faeces (25%) of dogs. No human data regarding excretion in urine and faeces were provided.

## 2.5.4.3. Genotoxicity

In line with ICH S9, no standard genotoxicity studies have been performed with melflufen. Melflufen is an alkylating agent is a genotoxic substance by definition. Furthermore, it has been reported in literature that mutagenicity is induced by melphalan.

## 2.5.4.4. Carcinogenicity

No carcinogenicity studies were conducted for melflufen, which is in line with ICH S1 and S9. The mechanism of action of melflufen suggests that, similarly with all alkylating agents including the hydrolysis product melphalan, there is a risk for genetic damage and potentially carcinogenicity.

## 2.5.4.5. Reproductive and developmental toxicity

No standard reproductive and developmental toxicity studies have been conducted with melflufen. Based on its mechanism of action as an alkylating anticancer agent and literature, melflufen is suspected to induce testicular suppression and suppression of ovarian function. In addition, melphalan caused foetal harm when administered to rats, including teratogenicity and/or embryo-foetal lethality, as shown in reproductive studies conducted for melphalan. This has been reflected in section 4.6 of the SmPC. In line with ICH S9, it is accepted that embryo-foetal toxicity studies are not considered essential for the purpose of marketing applications for pharmaceuticals that are genotoxic and target rapidly dividing cells in general toxicity studies, or belong to a class that has been well characterized as causing developmental toxicity. Melflufen is not intended for use in a pediatric population; juvenile toxicity studies in animals were not conducted. This position is consistent with the ICH S9 guidance document.

## 2.5.4.6. Toxicokinetic data

Concentrations in control samples were below the lower limit of quantification (LLOQ). No toxicokinetic data were collected in studies in mice and rats. Also no pharmacokinetic studies were performed in

<div style=\"page-break-after: always\"></div>

mice. In pharmacokinetic studies in male rats, AUClast of melphalan at 9.2 mg/kg melflufen (which was the maximal dose in the pivotal rat study 20040837TR) was 6400 ng.h/mL (study 20050055TRB) or 8720 ng.h/mL (study 20050535TRB), corresponding to exposure multiples of 5.9 - 8.1 compared to human AUCinf, indicating sufficient exposure in the rat.

In dog studies 0373-2012 and 2018-0158, exposure to melflufen and melphalan was below the human therapeutic exposure. In study 2014-0252, exposure was sufficiently high (up to 11x and 7.5x human exposure for melflufen and melphalan respectively, after IV administration of melflufen). No consistent gender effect was observed in dogs.

## 2.5.4.7. Local Tolerance

The applicant has provided information on the local tolerance of melflufen infusions based on repeateddose toxicity studies in mice, rats and dogs as well as on a combined PK and local tolerability study in dogs and a comparative local tolerance study in mice.

Local irritancy has been observed at (in dogs) and above (rodents) clinical concentrations when melflufen was administered via peripheral vein injections. When administered via the intended central vein infusion, clinically relevant concentrations did not cause local tissue irritancy in dogs.

## 2.5.4.8. Other toxicity studies

No specific studies were conducted with melflufen to investigate antigenicity.

No data on immunotoxicity are discussed. Melflufen is indicated and intended for myelosuppression and non-clinical data clearly suggest bone marrow- and haematologic toxicity.

No specific studies were conducted with melflufen to investigate dependence as melflufen is not a CNS active drug.

No dedicated studies on metabolites were conducted because there are no major metabolites in humans which were not formed in the animal studies.

Studies on impurities

The applicant has indicated the presence of impurities in the drug substance (DS) and drug product

(DP) that concern five drug-related substances and a sucrose degradation product, 5- hydroxymethylfurfural (HMF), with specification limits above the qualification thresholds. The applicant indicated that the related substances are likely either as genotoxic as melflufen as they have identical alkylating functions as melflufen or are considered less genotoxic since they have lost alkylating functions that are present in melflufen. Hence, the genotoxic potential of these impurities have been sufficiently addressed.

An assessment of toxicity that is not linked to the genotoxic activity of the related substances was provided since the DS specification limits and the DP specification limit for dechloro-hydroxy-melflufen are all above the ICH Q3A(R2) qualification threshold of 0.15%. The impurity levels in non-clinical and clinical batches are low or unknown. Hence, the applicant has provided justifications for each impurity to discuss that they have been toxicologically qualified.

From a non-clinical point of view, it is agreed that melflufen carboxylic acid (desethyl melflufen), dechloro-hydroxy-melflufen,,  HMF, 3(N)-,4(F)-melflufen, dechloroethyl-melflufen and dechloroethyl-4hydroxy-1-methylbutyl melflufen have been sufficiently toxicologically qualified.

Phototoxicity

<div style=\"page-break-after: always\"></div>

Potential phototoxic activity of melflufen or melphalan was evaluated in a GLP-compliant in vitro 3T3 Neutral Red Uptake phototoxicity assay according to the validated BALB 3T3-NRU method (OECD 432) and demonstrated that melflufen nor melphalan are phototoxic.

## 2.5.5. Ecotoxicity/environmental risk assessment

Melphalan flufenamide PEC surfacewater value is below the action limit of 0.01 µg/L and is not a PBT substance as log Kow does not exceed 4.5. The compound is not considered as PBT nor vPvB.

Therefore melphalan flufenamide is not expected to pose a risk to the environment.

Table 1. Summary of main study results

| Substance (INN/Invented Name): melphalan flufenamide   | Substance (INN/Invented Name): melphalan flufenamide   | Substance (INN/Invented Name): melphalan flufenamide                                                                             | Substance (INN/Invented Name): melphalan flufenamide   |
|--------------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| CAS-number (if available): 380449-51-4                 | CAS-number (if available): 380449-51-4                 | CAS-number (if available): 380449-51-4                                                                                           | CAS-number (if available): 380449-51-4                 |
| PBT screening                                          |                                                        | Result                                                                                                                           | Conclusion                                             |
| Bioaccumulation potential- log K ow                    | non-guideline shake flask                              | Log K ow = 4.36 at pH 10 Log D ow = 1.78 at pH 1.5 Log D ow = 1.91 at pH 5.0 Log D ow = 2.29 at pH 6.5 Log D ow = 2.29 at pH 7.4 | Potential PBT (N)                                      |

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

Melflufen, i.e. melphalan flufenamide, is hydrolysed by peptidases forming melphalan. Melphalan has been in clinical use as an antitumor agent for more than 60 years. Nitrogen-based alkylating agents like melphalan exert their cytotoxic action through covalent interaction with intracellular nucleophiles, in particular DNA. Bifunctional agents, like melphalan are able to crosslink a DNA strand within a double helix, between two strands or between DNA and proteins. Cross-linking of DNA is probably the most important factor for the cytotoxic effect.

In vitro studies to evaluate cytotoxicity were conducted with melflufen in a panel of different human tumour cell lines, including patient-derived tumour myeloma samples. The average half maximal inhibitory concentration (IC50) of melflufen in 23 cell lines from haematologic origin (acute leukaemia, lymphoma, and myeloma) was 0.20 μM compared to 6.9 μM for melphalan, a 35 -fold difference. The average IC50 of melflufen in the 24 cell lines derived from solid tumour cells (neuroblastoma, lung cancer, ovarian cancer, and renal cell cancer) was 0.41 μM compared to 18 μM for melphalan, a 44 -fold difference. Melflufen was thus shown to be more potent in haematologic malignancies than in solid tumours.

In vitro studies in human multiple myeloma RPMI 8226 cells showed that melflufen easily crosses the cell membrane and that it was subsequently rapidly and extensively hydrolysed to desethyl-melflufen and, by peptidases, mainly to melphalan. Intracellular concentration of melflufen was low and only quantifiable for 30 min, while melphalan was detectable for up to 2 h and having a 27-fold higher intracellular exposure. When melflufen treatment of RPMI-8226 multiple myeloma cells was compared

<div style=\"page-break-after: always\"></div>

with melphalan, it was found that treatment with melflufen loads the cells with about 50-fold more melphalan than can be achieved with melphalan treatment. In this case melflufen functions as a prodrug, the in vitro cytotoxic activity (IC50) of melflufen, however, was only 10-fold lower, as compared to melphalan. Therefore, from the presented in vitro PD data, it is not clear whether melflufen itself exhibits cytotoxicity as the increase in melphalan intracellularly with melflufen treatment is also in line with the increase in cytotoxicity, seen in most cell lines with melflufen as compared to melphalan. In addition, if a peptidase inhibitor is added, the cytotoxic activity is decreased. Moreover, if the peptide bond in melflufen is chemically modified to be non-hydrolysable, the cytotoxic activity is significantly impaired.

As reviewed by the applicant, aminopeptidase N (APN) has previously been shown to efficiently hydrolyse the peptide bond of melflufen (Wickstrom, Viktorsson et al. 2010) but recent experiments have demonstrated that other aminopeptidases such as LAP3, LTA4H and RNPEP have the same capability (Schepsky, Traustadottir et al. 2020; Miettinen, Kumari et al. 2021). The increased aminopeptidase expression in tumour cells has been suggested as one of the major drivers of the selectivity for the cytotoxic activity of melflufen. It was also demonstrated that melflufen exhibits antiangiogenic properties due to the high expression of aminopeptidases in human vascular endothelial cells. In this context, the applicant was invited to further elaborate the possible effect of melflufen considering the level of aminopeptidase expression/activity in various human tissues (supposedly in the form of metanalyses) to provide additional valuable information regarding the activity of melflufen in humans. This is important also considering the limited availability of data on melflufen distribution in vivo . The applicant has provided the summary of different aminopeptidase expression in various human tissues in a scientifically sound way and shortly commented on the impact of it with regards to the melflufen activity in different normal tissues. It is acceptable to acknowledge that the aminopeptidase expression levels cannot be directly correlated with melflufen activity in human body.

By using MM cell lines, Chauhan, Ray et al. (2013) have demonstrated that melflufen shows synergistic cytotoxicity with dexamethasone in melphalan-resistant and non-resistant multiple myeloma (MM) cell lines. The applicant, based on recent scientific literature, has provided a discussion on the mechanism of action with regards to the synergy especially because the medicinal product is designated as an orphan medicinal product for the indication: Treatment of multiple myeloma (MM) in combination with dexamethasone. Justification of pharmaceutical combinations is suggested by ICH guideline S9 on nonclinical evaluation for anticancer pharmaceuticals. The applicant acknowledges that the exact mechanism (mode of action) of the synergism has not been confirmed so far; however, it is highly plausible that it relies on the convergence of several of the above-mentioned pathways.

In vivo, despite the, in contrast to human, instantaneous de-esterification of melflufen in rodent plasma upon administration, the xenograft and hollow fiber methods using nude- or SCID mice or nude rats showed a higher efficacy on tumour cell growth inhibition with melflufen than with an equimolar melphalan dose in five of the seven xenograft models and three of the five hollow fiber models.

In contrast to melphalan, melflufen induced a concentration-dependent inhibition of the hERG channel current, leading to an 30- to 60-fold lower IC50 than melphalan, which is about 5-10 times higher than the anticipated clinical melflufen Cmax. The in vivo studies did not reveal reasons of concern but it should be noted that clinical Cmax concentrations were not reached. However, no QTc signals have been seen with melphalan previously and in the clinical studies most QTc prolongation signals were not considered related to melflufen.

## Pharmacokinetics

Dilution integrity in dog was determined up to 3000 ng/mL. For concentrations exceeding 3000 ng/mL, i.e. for the highest concentrations in study 2014-0252, formally it is not certain how reliable the data are. This is however not expected to have a relevant effect on the conclusions.

<div style=\"page-break-after: always\"></div>

In rat PK study 20050055TRB, a validated method was used. The method was validated for the measurement of melflufen and melphalan in rats, but not for desethyl-melflufen. Regarding the measurement of desethyl-melflufen in rats, it is therefore not certain how reliable the values are. It is however clear that desethyl-melflufen formation is high in rats and that this is not representative for humans, because in humans melflufen is mainly metabolised into melphalan, and only for a minor part into desethyl-melflufen. Furthermore, the validation of the method used in the rat was not complete (back calculated concentrations of the calibration standards are not given and carry-over and freeze/thaw stability were not investigated) and there was a substantial matrix effect for melphalan in rat plasma. The matrix effect is one of the reasons that measured concentrations in rats may be less reliable. Because dogs are the most relevant species and rats are less relevant based on the comparability of the metabolism of melflufen with humans, this issue is not further pursued. In the method used in rat study 20050535TRB, changes were introduced in plasma handling, extraction and storage compared to the validated method used in study 20050055TRB, in order to investigate whether melflufen could be detected in plasma of rats. The method was not validated after these changes. This is however not expected to have influenced conclusions to a relevant extent, considering that dogs, and not rats were the most relevant species compared to humans. In rat PK study AB19-7002, a method was used which was validated for use in dogs but not in rats. Overall, it is not clear how reliable the measured concentrations in rats are.

The hypothesis that melflufen is distributed to the cells quickly, after which it is converted to melphalan which then remains in the cells, would be supported by a lower melphalan exposure after melflufen administration than after melphalan administration. This is the case for the rabbit and the dog, though in dog the effect on AUC was only minor in one of the two comparative studies, while it converted before melflufen reaches the cells. This is supported by results from an in vitro study described by Nygren (2009). In this study, the half-life of melflufen in blood of rats was 15 seconds and it was mainly converted into desethyl-melflufen, whereas it was 7 minutes in dog blood and 4.4 minutes in human blood. In dog and in humans melflufen was converted mainly into melphalan.

It was noted that a statistically higher concentration of radioactivity was observed in the brain of melflufen-treated mice comparing to melphalan treated mice 4h post administration. Higher concentrations after melflufen treatment than after melphalan treatment were also found in a low.

was not the case in rat. In rats, melflufen is converted into melphalan so quickly, that most likely it is Both in dog and human red blood cells as in human multiple myeloma cells, it was observed that melphalan, after having been formed intracellularly, is gradually transported out of the cell into the plasma. Since melphalan is transported out of the cell following intracellular formation, the amount of time that melphalan is available for its action inside the cell appears limited. In an in vitro study in human myeloma cells, melphalan was detectable intracellularly up to 2 h after the start of incubation of melflufen (at 1 µM), with a peak at around 20 minutes. In a study in female CB17 SCID mice xenografted with MM.S1 cells (multiple myeloma cells), the highest concentrations of melflufen and melphalan at 15 min after injection were found in pancreas, kidneys, liver, heart and lung. At 4 hours post dose the concentrations were 4 to 10-fold lower than at 15 minutes. Melflufen and melphalan were also found in the tumours. The amounts in tumour appear limited. This can be explained by the angiogenesis in xenografted tumour tissue, which is less pronounced and takes several days to develop, in combination with the rapid degradation of melflufen by esterases in mice. Melflufen will be largely degraded before it is distributed to the tumour and converted into melphalan there.  A distribution study in rabbits was provided. Melphalan- and melflufen-derived radioactivity levels were high in kidneys, lungs and myocardium compared to plasma. In this study, the levels can however not be compared with levels in tumours. distribution study in rabbits (2.6 - 2.8 times higher). Absolute concentrations in brain were, however,

<div style=\"page-break-after: always\"></div>

In a published melphalan distribution study in rats (Ahmed, Hsu et al. 1982) a slower rate of melphalan elimination has been reported from skin and eyes. Melanin binding of melflufen metabolites melphalan and desethyl-melflufen has not been studied nor discussed by the applicant. Melflufen due to its rapid metabolism should not possess a risk. However the possible interaction of melfulfen metabolites with melanin remains questionable. The applicant has conducted a QWB study in Dutch Belted rabbits to study melflufen and melphalan tissue distribution. Melflufen related radioactivity was equally distributed in pigmented and non-pigmented skin and radioactivity in the uveal tract/retina was similar to that observed in the brain indicating that melflufen does not specifically bind to melanin. The provided data in rabbits also suggest that melphalan, which is the main metabolite of melflufen, binds to melanin. Despite the fact that the provided data are very limited, strong binding of melphalan to melanin containing tissue was not observed and therefore should not be considered as a risk factor.

Applicant emphasizes that a dog from a pharmacokinetic point of view is considered to be the most relevant species for melflufen testing, however tissue distribution data in dogs have not been demonstrated nor discussed. Therefore, it is unclear how reliable the extrapolation of tissue distribution data from rodents to humans are, taking into consideration differences in the metabolism between species. Applicant was requested to provide literature data on the tissue distribution of melflufen and its metabolites in dogs or a justification that would support extrapolation of tissue distribution data from rodents to humans, taking into consideration that metabolism of melflufen in rodents differs from that observed in humans. Applicant claims that there are no literature data available on tissue distribution of melflufen in dogs but has performed a QWBA tissue distribution study in rabbits with radiolabelled melflufen and melphalan. Taking into consideration that melflufen has a higher lipophilicity, a more extensive tissue distribution than in melphalan dosed group was expected, and a higher concentration of radioactivity was found in 37 out of 52 investigated tissues of melflufen dosed animals. Differences between melflufen and melphalan covalently bound radioactivity in plasma, kidney cortex, kidney medulla, liver, lung and small intestinal wall was not observed. Rabbit, due to similarities in metabolism to humans and dogs, can be considered as a relevant species for tissue distribution studies.

The fate of melphalan was addressed only briefly and is not clearly described. It was described in an in vitro study in rat liver microsomes, that the formation of monoglutathionyl and diglutathionyl melphalan derivatives has been observed, but that these conjugates have not been observed in vivo. Also it was described that melphalan was found to be hydrolysed into mono- and dihydroxyderivatives in cancer patients. Overall it appears that in animals, additional metabolites may be formed besides mono- and dihydroxymelphalan, but that in humans melphalan is mainly converted into mono- and dihydroxymelpyhalan. It appears that monohydroxy-melphalan has cytotoxic activity and dihydroxymelphalan has not. The information provided regarding excretion of melphalan is very limited. Melphalan-related radioactivity was excreted in both urine (44%) and faeces (25%) of dogs within 11 days after IV dosing. Hence, in 11 days after dosing, only 69% of total radioactivity was excreted. This recovery is, however, in line with the recovery found in other mass balance studies with alkylating agents. According to Dubbelman et al (2013), incomplete recovery is not uncommon for an alkylating agent. Part of this may possibly be explained by irreversible binding to tissue components. enzymes is involved in the degradation of melflufen or melphalan, and no transporters are involved in

Pharmacokinetic drug interactions have not been studied for melflufen. The potential for pharmacokinetic drug-drug interactions is however expected to be low, since no metabolism by CYP the cellular uptake of melflufen.

## Toxicology

<div style=\"page-break-after: always\"></div>

The safety of melflufen was evaluated in three non-GLP single dose toxicity studies (dogs and minipigs), three non-GLP single dose toxicity studies (mice, rats and dogs) and in three GLP repeated dose toxicity studies (mice, rats and dogs). According to the ICH S9 guidance on nonclinical evaluation for anticancer pharmaceuticals (EMEA/CHMP/ICH/646107/2008), nonclinical studies of 3 months duration in both rodent and non-rodent species are required before marketing of anti-cancer pharmaceuticals. Melflufen has been tested for 35 days in mice and rats and 43 days in dogs. A rationale for not conducting appropriate duration toxicity studies for anticancer pharmaceutical is based on the toxicity profile of alkylating products. Furthermore, melflufen was used longer than 3 months in patients in clinical trials and haematological toxicity was the major and dose limiting toxicity for melflufen observed in these studies. Therefore, no new information was expected from the toxicity studies.

The observed melflufen-related findings in the pivotal repeated dose toxicity studies were likely related to its pharmacological action as an alkylating agent on rapidly dividing cells, and included severe effects on the bone marrow, lymphoid organs, testes and the haemolymphopoietic system.

In two single dose studies, in the non-GLP minipig study and in one non-GLP dog study, melphalan was included as comparator. It should be noted that acute single dose toxicity studies as currently performed using very high doses of a compound are not considered relevant to compare the toxicity of melflufen with melphalan (also see 'Questions and answers on the withdrawal of the 'Note for guidance on single dose toxicity'' (EMA/CHMP/SWP/81714/2010)). In addition, there are several methodological issues: In the minipig study, the histologic comparison was performed on different days for each animal. Due to the lack of a recovery period for the earlier terminated minipig, the comparison of the histopathological findings between melflufen and melphalan is of limited relevance. In addition, the number of test subjects in the study was as low as one animal per group, which severely limits the interpretation of the study. In the comparative non-GLP dog study, the follow-up period was restricted to four days, due to expected severe effects of high doses. It should be noted that a limited number of animals per group were used, and that severe toxic effects, but also potential recovery, that could occur at a later timepoint, are most likely missed due to the short follow-up period. Together, the limitations of these studies prevent to conclude that the safety profile of melflufen is really different compared to that of melphalan.

Regarding the repeated-dose toxicity mice study, it should be noted that histopathology was only performed for animals in the high dose group. Possible treatment-related histopathological effects at lower doses were not reported. The NOAEL was not determined in this study. As no toxicokinetic data were available for mice, the safety margin compared to the clinical exposure is uncertain.

In the rat study, toxicokinetics were also not evaluated. Pharmacokinetics studies that used similar doses indicated a possible exposure multiple at the LOAEL of 2.4 based on an AUClast of 2570 ng.h/mL (study 20050055TRB) or 5.6 based on an AUClast of 6032 ng.h/mL (study AB19-70-02), indicating that the effects seen in rats are likely to be clinically relevant. However, it is not certain how reliable the measured concentrations are, as the used method was not validated in rats (study AB19-70-02) and a substantial matrix effect was observed in rat plasma (study 20050055TRB).  In addition, it should be noted that based on the pharmacokinetics of melflufen, humans are more comparable to dogs than to rodents: in mice and rats, melflufen remained mainly in plasma where it was converted primarily into desethyl-melflufen and for a minor part into melphalan. In dogs and humans, melflufen was distributed quickly into red blood cells, where it was converted into melphalan and desethylmelflufen. Desethyl-melflufen was also converted into melphalan and melphalan was then slowly transported out of the cells. Hence, the dog is considered the most relevant laboratory species for the human situation from a metabolic point of view.

<div style=\"page-break-after: always\"></div>

Several impurities were reported in the drug substance (DS) and drug product (DP). These concern five drug-related substances and a sucrose degradation product, 5-hydroxymethylfurfural (HMF). For all of these impurities, specification limits are above the qualification thresholds. It is agreed that melflufen carboxylic acid (desethyl melflufen), dechloro-hydroxy-melflufen and HMF have been sufficiently toxicologically qualified. These substances have either been present in non-clinical/clinical studies due to being a major metabolite, a hydrolysis product of melflufen, or a sucrose degradation product with a known safety profile, respectively. The provided justifications for the toxicologically qualification of 3(N)-,4(F)-melflufen, dechloroethyl-melflufen and dechloroethyl-4-hydroxy-1methylbutyl melflufen are also considered adequate. It should be noted that it would have been preferable if the applicant had investigated the impurity levels in non-clinical batches which would enable comparison between batches. Stating that these substances should have been present to some degree in batches used for pivotal toxicity studies without providing data is wholly inadequate. However, based on the provided literature and the fact that these impurities have either lost one alkylating function (dechloroethyl-melflufen and dechloroethyl-4-hydroxy-1-methylbutyl melflufen) compared to melflufen or are of a similar structure as melflufen (3(N)-,4(F)-melflufen), it is presumable that these impurities are either less toxic or as toxic as melflufen itself. It can be agreed that ICH S9 should be taken into account (melflufen is a bifunctional alkylator with a distinct toxicity profile linked to this activity, indicated as last line treatment of multiple myeloma). Overall, there are no safety concerns expected from these impurities from a non-clinical point of view.

## 2.6. Clinical aspects

a marketing authorisation for melphalan flufenamide can be approvable from a non-clinical point of view.

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 2 Pharmacokinetic analyses in melflufen clinical studies

| Study No.   | Patient Population     | Melflufen Dose Range (mg)   |   N with PK Data | Compound Analyzed                       | Sampling   | Study Status   |
|-------------|------------------------|-----------------------------|------------------|-----------------------------------------|------------|----------------|
| O-05-001    | Solid tumor patients   | 25 to 130                   |               29 | Melflufen Melphalan                     | Rich       | Completed      |
| O-12-M1     | RRMM                   | 15 to 55                    |               12 | Melflufen Melphalan Desethyl- melflufen | Rich       | Completed      |
| OP-103      | RRMM                   | 30 to 40                    |               96 | Melphalan                               | Sparse     | Ongoing        |
| OP-104      | RRMM                   | 30 to 40                    |               11 | Melphalan                               | Sparse     | Ongoing        |
| OP-107      | RRMM and renal failure | 40                          |                7 | Melphalan                               | Sparse     | Ongoing        |

Abbreviations: N=number of patients; No=number; PK=pharmacokinetics; RRMM=relapsed/refractory multiple myeloma

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

Clinical pharmacokinetic (PK) and pharmacodynamic (PD) properties of melflufen and melphalan as well as exposure-response relationships of melphalan have been evaluated in studies in patients with solid tumours or multiple myeloma ( Error! Reference source not found. ).

Treatment with melflufen is hypothesised to lead to higher concentrations of melphalan in the tumour cells compared to melphalan treatment because melflufen is rapidly taken up into cells followed by a rapid enzymatic hydrolysis of the molecule to the active metabolite melphalan.

The recommended dose of melflufen is 40 mg administered intravenously over 30 minutes on Day 1 of each 28 day treatment cycle.

Specifically, PK information for melflufen is available from Study O-05-001 in patients with solid tumours and Study O-12-M1 in patients with multiple myeloma. Due to the very short disappearance half-life of melflufen from plasma, reflecting distribution, only the metabolite melphalan was measured in subsequent clinical studies. Melphalan PK parameters in patients with RRMM and impaired renal function are being assessed in the ongoing Study OP-107. In addition to the pharmacokinetics of melphalan studied in the melflufen clinical program, literature data have been used to complement pharmacokinetics of melphalan.

<div style=\"page-break-after: always\"></div>

## Bioanalytical methods

Samples with lithium or sodium heparin as anti-coagulant were centrifuged at +4°C in a pre-chilled centrifuge within 5 minutes after the sample was obtained. The tubes with plasma were frozen within 10 minutes to ensure that the degradation of the compounds was minimal.

Following protein precipitation, melflufen (or J1), desethyl-melflufen (or des-J1) and melphalan in human plasma were determined by UPLC-MS/MS. Melflufen-D8 hydrochloride and melphalan-D8 were used as internal standards. In general validation of bioanalytical method used in studies OP-103, OP104, OP-107 have been performed in accordance with the requirements stated in the guideline EMEA/CHMP/EWP/192217/2009  Rev.  1 Corr.  2**, however, approximately 20% of the plasma samples were analysed outside the long term stability period established. It was demonstrated by sensitivity analysis that this did not affect the popPK analysis to a relevant extent.

The bioanalytical method in study O-05-001 was suboptimal and does not meet current standards. Given these issues the PK data of study O-05-001 cannot be used for multi-study analyses. Since the in study performance of the quality controls and standards was acceptable and reproducible, the PK results of this study can be used for within study comparison but should be considered cautiously.

## PopPK analysis

The population PK analysis was conducted via nonlinear mixed-effects modeling with a qualified installation of the NONMEM® software. The stochastic approximation expectation maximization (SAEM) method followed by Monte Carlo importance sampling (IMP) was employed for all model runs.

Data were pooled from studies O-12-M1, OP-103, OP107, and OP-109 for the development of the population PK model. The full PK analysis dataset included 294 patients, contributing a total of 2177 observations. Of these, 2155 samples had quantifiable melphalan concentrations, and 22 samples were BLQ (1.0%).

Approximately two-thirds (n=207, 70.4%) of patients had received less than four prior therapies when enrolled, 70 (23.8%) patients had received four to five and 17 (5.8%) patients had received 6 or more prior therapies. Patient's multiple myeloma was classed as triple class refractory if it was resistant to all three classes of standard myeloma therapies (i.e., proteasome inhibitors, immunomodulatory agents and monoclonal antibodies). This pooled population included 56 (19.0%) triple class refractory patients. The ISS classification and ECOG status are both measures of how a patient's disease is progressing. Most patients had an ISS disease classification of stage I or II (41.2 and 40.5%, respectively) and 17% of patients were classified as stage III. The ISS classification was missing for 4 patients (1.4%). Patients were similarly distributed among ECOG grades 0, 1 and 2 (37.4%, 52.7% and 9.9%, respectively). EMD is a rare but recognized manifestation of multiple myeloma in which the multiple myeloma cells form tumours outside of the bone marrow: 34 (11.6%) patients had EMD reported in this pooled population. There are multiple types of myelomas, here, patients were categorized according to whether they had an IgG or non-IgG myeloma: 180 (61.2%) patients had IgG myelomas and 114 (38.8%) had non-IgG myelomas.

The final model was a three-compartment model with melflufen dosing into a peripheral compartment and linear clearance. The final model included fixed effects of time-varying weight on clearance and volume terms. The effects of time-varying eGFR, baseline total protein, race (White versus Black/Asian/Other or Not Specified), baseline age, baseline AST and baseline BILI were estimated on CL. Additionally, the effects of baseline age, baseline AST and baseline BILI were estimated on V1.

Parameter estimates from the final SAEM-IMP run, and the median and 95% CIs of the bootstrap runs on sampled datasets are presented in Table 3 and Table 4. Compared to the base model, IIV on CL decreased from 42.8% to 33.4% and IIV on V1 decreased from 60.8% to 56.3%. Residual random

<div style=\"page-break-after: always\"></div>

effects were described with a proportional (CV% = 23.2) error model. Fixed and random effects parameters were estimated with reasonable precision, but shrinkage was high for V1 and V3. Linear and log-linear pcVPC plots indicated that the pharmacokinetics of melphalan are reasonably well predicted by the popPK model. Melphalan exposure increased modestly with lower body weight and there was a clear increase in melphalan exposure with decreasing renal function with CrCL &lt; 60 ml/min.

There were no obvious trends evident in the plots of NPDE or inter-individual random effects versus continuous or categorical covariates, may be some bias at early time points during the 30-minute infusion. Because of the high shrinkage on volume of distribution, PK metric parameters which are mostly influenced by clearance such as AUC (Cave) are preferred over Cmax values for exposureresponse analyses.

Table 3 PK Final Model: Summary of population PK fixed effects parameter estimates.

|                             |                             |                                                                 | Non-parametric bootstrap   | Non-parametric bootstrap   |
|-----------------------------|-----------------------------|-----------------------------------------------------------------|----------------------------|----------------------------|
|                             |                             | Estimate                                                        | Median                     | 95% CI                     |
| Structural model parameters | Structural model parameters |                                                                 |                            |                            |
| CL (L/h)                    | exp(0)                      | Clearance                                                       | 22.7 23.0                  | 21.1, 25.0                 |
| V1 (L)                      | exp(02)                     | Apparent central volume                                         | 2.94 2.74                  | 2.00, 3.56                 |
| Q2 (L/h)                    | exp(03)                     | Intercompartmental clearance to peripheral                      | 0.227 0.239                | 0.142,0.483                |
| Q3 (L/h)                    | exp(04)                     | Intercompartmental clearance to deep tissues                    | 13.6 12.8                  | 10.1, 18.7                 |
| V3 (L)                      | exp(05)                     | Deep tissues volume                                             | 45.8 44.8                  | 29.9, 67.4                 |
| V2/Q2 (/h)                  | 06                          | Proportional relationship between peripheral volume (V2) and Q2 | 1.16 1.19                  | 0.927, 1.29                |
| Covariate effect parameters | Covariate effect parameters |                                                                 |                            |                            |
| CLeGFR                      | 0g                          | eGFR effect on CL                                               | 0.315 0.324                | 0.158, 0.502               |
| CLpROT                      | 010                         | Total protein effect on CL                                      | 0.710 0.749                | 0.481,1.03                 |
| CLRACE                      | 011                         | Race effect on CL                                               | 0.199 0.163                | 0.0493, 0.276              |
| CLAGE                       | 012                         | Age effect on CL                                                | -0.000982 -0.0294          | -0.311, 0.236              |
| VIAGE                       | 013                         | Age effect on V1                                                | 2.01 2.03                  | 0.794, 3.68                |
| CLAST                       | 014                         | AST effect on CL                                                | 0.0181 0.0320              | -0.0867,0.152              |
| VlAST                       | 015                         | AST effect onV1                                                 | 0.142 0.172                | -0.452, 0.637              |
| CLBILI                      | 016                         | Bilirubin effect on CL                                          | 0.0681 0.0751              | -0.0135, 0.161             |
| VlBILI                      | 017                         | Bilirubin effect onV1                                           | -0.249 -0.328              | -0.658, 0.0719             |

Parameters estimated in the log-domain were back-transformed for clarity

The confidence interval was determined from the 2.5th and 97.5th percentiles of the non-parametric bootstrap (n=500) estimates.

Abbreviations: CI = confidence interval; eGFR = estimated glomular filtration rate

Source code: pk-model-table-final.R

Source file: pk-param-boot-fixed.tex

<div style=\"page-break-after: always\"></div>

Table 4 PK Final Model: Summary of population PK random effects parameter estimates.

|                                     |                                     | Final Model                         | Final Model                         | Non-parametric bootstrap            | Non-parametric bootstrap            |
|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                     |                                     | Estimate                            | Shrinkage (%)                       | Median                              | 95% CI                              |
| Interindividual variance parameters | Interindividual variance parameters | Interindividual variance parameters | Interindividual variance parameters | Interindividual variance parameters | Interindividual variance parameters |
| IIV-CL                              | 2(1,1)                              | 0.106 [CV%=33.4]                    | 7.43                                | 0.100                               | 0.0707,0.139                        |
| IIV-V1                              | S2(2,2)                             | 0.275 [CV%=56.3]                    | 57.8                                | 0.297                               | 0.151, 0.775                        |
| IIV-Q2                              | 2(3,3)                              | 0.210 [CV%=48.4]                    | 93.6                                | 0.161                               | 0.0100,0.548                        |
| IIV-Q3                              | S2(4,4)                             | 0.230 [CV%=50.9]                    | 25.4                                | 0.237                               | 0.0990,0.381                        |
| IIV-V3                              | S2(5,5)                             | 0.0250 [CV%=15.9]                   | 76.0                                | 0.0250                              | FIXED                               |
| Residual variance                   | Residual variance                   | Residual variance                   | Residual variance                   | Residual variance                   | Residual variance                   |
| Proportional                        | Z(1,1)                              | 0.0537 [CV%=23.2]                   | 11.6                                | 0.0535                              | 0.0438, 0.0631                      |

## Exposure-response analysis (report ONC0101F)

Data from studies O-12-M1 (N=76 with 12 PK), OP-103 (N=228 with 225 PK) and OP-107 (N=32 with 31 PK) were pooled for the development of the E-R efficacy models.

Logistic regression was used to develop an exposure-efficacy model of ORR using melphalan average concentration (Cavg) in Cycle 1 as the exposure. Cavg was calculated as the cumulative area under the concentration time curve (AUC) for Cycle 1 divided by the duration of Cycle 1. Since elimination half-life of melphalan is short 70 min, and the dosing interval is 28 days, the calculated Cavg is very low but Cavg, as used in exposure-response analysis, is actually a measure for AUC during the first cycle. Least absolute shrinkage and selection operator (LASSO) was implemented to identify predictive covariates of ORR. Patient data used in the covariate selection analysis were age, sex, race, body weight, body surface area, time since diagnosis, renal function, and hepatic function, triple refractory status, International Staging System (ISS) status, presence of extramedullary disease (EMD), Eastern Cooperative Oncology Group (ECOG) status, type of myeloma (IgG vs non-IgG), number of prior lines of therapy, prior autologous stem-cell transplantation (ASCT) transplant, time since prior ASCT transplant, and cytogenetic risk status. Main effects of these covariates as well as interactions with exposure were explored to develop a predictive model. Models were compared using model selection criteria, e.g., Akaike information criterion (AIC) and Bayesian information criterion (BIC), and were diagnosed and evaluated using randomized quantile residuals and visual predictive checks. The final predictive model was used to compute predictions of the probability of ORR at average exposures of different renal impairment populations (i.e., normal, mild, moderate, and severe).

## Exposure-safety analysis were conducted for:

- multiple AEs, dose modifications etc.  by logistic regression models or
- exposure-myelosuppression AEs relationships by semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models for the time course of thrombocyte and neutrophil counts in relapsed refractory multiple myeloma (RRMM) patients receiving PEPAXTI and
- exploring the potential influence of ASCT on the pharmacodynamic (PD) parameters describing the time course of neutropenia and thrombocytopenia.

<div style=\"page-break-after: always\"></div>

Pooled data from Studies O-12-M1, OP-103 and OP-107 were used.

The time-course of neutrophil and thrombocyte response to melphalan concentration were described using a semi-mechanistic PK/PD model of myelosuppression. The model was comprised of eight compartments (see Figure 2). The first 3 compartments represent the kinetics of melphalan; compartment 4 represents a proliferation compartment; compartments 5 to 7 are maturation compartments; and compartment 8 represents the blood stream with circulating neutrophils and thrombocytes from which PD samples were taken over time. All analyses were conducted via nonlinear mixed effects modeling with a qualified installation of NONMEM ®  version 7.4 (ICON Development Solutions, Dublin, Ireland).

Figure 2: PD model schematic.

<!-- image -->

The final thrombocytopenia model expanded the base model to include covariate effects. As with the base model, the final model included an estimated effect of TPO-RA treatment (i.e. romiplostim or eltrombopag with or without a blood or platelet infusion) if patients required treatment (and fixed it to 0 if they did not). Additionally, the effect of eGFR, EMD and hepatic impairment category (normal versus mild impairment) were estimated on EC50. The effect of ISS classification, EMD, and hepatic impairment category (normal versus mild impairment) were estimated on CIR.

## Absorption

Melflufen is administered intravenously and therefore, no bioavailability (BA) or bioequivalence (BE) studies have been performed.

In study O-12-M1, PK of melflufen and the metabolites desethyl-melflufen and melphalan were assessed in a subset of patients with relapsed/refractory multiple myeloma during the first treatment cycle. Melflufen PK is characterized by low plasma concentrations during the IV infusion and a very rapid disappearance after the end of infusion with a half-life of less than 5 minutes (Figure 3). Plasma concentrations of melphalan, the main active metabolite, increased rapidly and melphalan plasma concentrations exceed those of melflufen within 15 minutes after the start of the 30-minute melflufen infusion. Peak plasma concentrations of melphalan appear with a Tmax of 34-45 min, a delay by 5 to 15 minutes after the end of the melflufen infusion. Melphalan Cmax was approximately 3 to 4-fold higher than the Cmax of melfufen and AUC of melphalan was almost 20-fold higher than the AUC of

<div style=\"page-break-after: always\"></div>

melflufen (see Table 5 Descriptive statistics for PK parameters by compound in patients receiving the melflufen dose of 40 mg (study O-12-M1: N=8 melphalan and desethylmelflufen, N=7 for mellufen, updated Table D120 response). ).

Plasma concentrations of the metabolite desethyl-melflufen remained very low during and after melflufen administration. Because of the low plasma concentrations and hence low impact on the efficacy and safety, desethyl-melflufen was not measured in the other studies.

Figure 3 Mean plasma concentration-time profiles for melflufen, melphalan, and desethyl-melflufen after infusion of melflufen over 30 minutes at the 40 mg dose level (study O-12-M1, N=7)

<!-- image -->

PK parameters for melflufen and the metabolites desethyl-melflufen and melphalan following 40 mg melflufen IV dosing are summarised in Table 5.

<div style=\"page-break-after: always\"></div>

Table 5 Descriptive statistics for PK parameters by compound in patients receiving the melflufen dose of 40 mg (study O-12-M1: N=8 melphalan and desethylmelflufen, N=7 for mellufen, updated Table D120 response).

| PK parameter      | Compound           | Mean (SD)       | Geometric mean (CV%)   | Median   | Min    | Max    |
|-------------------|--------------------|-----------------|------------------------|----------|--------|--------|
| Tmax min          | Melflufen          | 21.3 (4.82)     | 20.8 (24.8)            | 25       | 15     | 25     |
| Tmax min          | Desethyl melflufen | 27.8 (3.06)     | 27.6 (11.0)            | 27       | 25     | 32     |
| Tmax min          | Melphalan          | 39.3 (3.92)     | 39.1 (9.95)            | 38.5     | 34     | 45     |
| Cmax ng/mL        | Melflufen          | 159 (63.4)      | 148 (42.6)             | 160      | 87     | 255    |
| Cmax ng/mL        | Desethyl melflufen | 16.8 (7.67)     | 15.4 (45.7)            | 13.5     | 9.1    | 30.7   |
| Cmax ng/mL        | Melphalan          | 519 (71.6)      | 515 (13.8)             | 516      | 403    | 660    |
| AUC0-t ng/mL*min  | Melflufen          | 3406 (1501)     | 3124 (47.6)            | 2636     | 1772   | 5218   |
| AUC0-t ng/mL*min  | Desethyl melflufen | 315 (126)       | 293 (43.4)             | 283      | 166    | 508    |
| AUC0-t ng/mL*min  | Melphalan          | 7034 (1266)     | 6930 (19.0)            | 6943     | 4745   | 9264   |
| AUCinf ng/mL*min  | Melflufen          | 3787 (1691)     | 3465 (48.4)            | 3009     | 1873   | 5983   |
| AUCinf ng/mL*min  | Desethyl melflufen | 632 (354)       | 543 (66.3)             | 524      | 224    | 1125   |
| AUCinf ng/mL*min  | Melphalan          | 64,828 (14,416) | 63,419 (22.8)          | 63,429   | 48,911 | 81,335 |
| AUClast ng/mL*min | Melflufen          | 3762 (1695)     | 3437 (49)              | 2966     | 1854   | 5959   |
| AUClast ng/mL*min | Desethyl melflufen | 547 (311)       | 470 (65)               | 444      | 201    | 1048   |
| AUClast ng/mL*min | Melphalan          | 55,943 (12,101) | 54,801 (22)            | 55,118   | 42,573 | 71,536 |
| T%2 min           | Melflufen          | 2.18 (0.604)    | 2.09 (34.3)            | 2.27     | 1.07   | 2.80   |
|                   | Desethyl melflufen | 13.2 (7.33)     | 11.2 (71.5)            | 12.0     | 3.82   | 24.3   |
|                   | Melphalan          | 80.0 (9.55)     | 79.4 (12.0)            | 78.2     | 66.1   | 92.8   |
|                   | Melflufen          | 756 (334)       | 692 (48.5)             | 797      | 401    | 1282   |
| CL L/h            | Desethyl melflufen | NC              | NC                     | NC       | NC     | NC     |
| CL L/h            | Melphalan          | 23.8 (5.26)     | 23.3 (22.7)            | 23.8     | 18.1   | 30.2   |

NC Not calculated

Melflufen and melphalan Cmax and AUC increased in approximate relation to dose over melflufen dose range 25-130 mg (study O-05-001). There is no accumulation with a monthly dosing interval. Intersubject variability of melflufen exposures is considerably higher than the intersubject variability of melphalan. Across studies, the intersubject variability of melphalan pharmacokinetics is modest 2030% and the intrasubject variability is lower.

In most clinical studies, only pharmacokinetics of melphalan was evaluated. Descriptive statistics for melphalan PK parameters for cycle 1 for patients with RRMM from the ongoing studies OP-103, OP104, and OP107 are shown in Table 6.

<div style=\"page-break-after: always\"></div>

Table 6 Melphalan PK parameters in patients with RRMM for Cycle 1 in studies OP-103, OP-104 and OP-107 at the melfufen dose of 40 mg (Interim PK report)

| Variable (Unit)      |   N | Mean   | Min-Max          | Geometric Mean   |   Geometric Mean CV% |
|----------------------|-----|--------|------------------|------------------|----------------------|
| C max (ng/mL)        | 104 | 461    | 158-988          | 441              |                 30.3 |
| AUCast (ng/mL*min)   | 104 | 44,604 | 15,698 - 108,934 | 42,268           |                 33   |
| AUCo.inf (ng/mL*min) | 104 | 56,425 | 24,085 - 116,049 | 53,931           |                 30.5 |
| ty (min)             | 104 | 71.2   | 47.5 -123        | 69.7             |                 20.6 |

## Distribution

In vitro studies were conducted to support that the formation of melphalan is not spontaneously but is formed in cells studies (Nygren 2009, Recipharm 2019). When melflufen was added to whole human blood at 37°C, the distribution to erythrocytes was very rapid with peak concentrations observed within one minute. The melflufen disappearance half-life from plasma and erythrocytes was approximately 4-5 minutes. However, when melflufen was added to human plasma, the disappearance half-life was 2-5 hours and there is no appreciable formation of melphalan.

In human plasma, protein binding of melphalan was 80 - 92% at concentrations from 0.3 - 33 nmol/mL (Greig, Sweeney et al. 1987). The plasma protein binding in cancer patients treated with melphalan has been reported to vary between 54-94% (Reece, Hill et al. 1988).

The mean (CV%) volume of distribution was 35 L (71%) for melphalan flufenamide (study O-12-M1) and the mean apparent volume of distribution is 76 L (32%) for the metabolite melphalan after a single dose of melphalan flufenamide (study OP-103).

## Elimination

Total melflufen plasma CL in humans is very high with values ranging from 400 to 1280 L/h (study O12-M1) with mean 692 L/h (CV 49%). Apparent clearance of melphalan was 23.3 L/h (CV=23%).

Elimination half-life of melflufen and melphalan is approximately 2 min and 60-80 min, respectively.

Excretion of melflufen in urine and faces was not evaluated.

Melflufen is readily metabolized by intracellular peptidases into melphalan or by esterases into hydrophilic desethyl-melflufen. Melphalan is eliminated primarily by spontaneous hydrolysis to monohydroxymelphalan and melphalan is to some extent excreted unchanged in the urine (Evans et al. 1982, Reece et al. 1988).

## Special populations

The relationship between demographic factors and the melphalan PK parameters Cmax and AUC for the melflufen dose 40 mg was evaluated by popPK analysis.

Patient race was predominantly reported as White (269 patients, 91.5%) with the other 8.5% of patients categorized as Black or African American, Asian and other or not specified (3.1%, 2%, and 3.4%, respectively). Patient age ranged from 41 to 91 years with a median of 68 years; 110 patients

<div style=\"page-break-after: always\"></div>

were &lt;65 years, 129 patients were 65-74 years, 50 patients were 75-84 and 5 patients were ≥ 85 years. Body weight ranged from 40.0 to 140 kg with a median of 75.4 kg, and body surface area (BSA) ranged from 1.26 to 2.71 m 2  with a median of 1.88m 2 . The pooled dataset included 65 patients (22.1%) with normal renal function, 139 patients (47.3%) with mild renal impairment, 84 patients (28.6%) with moderate renal impairment and six patients (2.0%) with severe renal impairment. Estimated glomerular filtration rate (eGFR) ranged from 27.2 to 121 with a median of 72.6 mL/min/1.73m 2 . CRCL ranged from 29.2 to 160 mL/min with a median of 72.2 mL/min across all patients.

The Forest plot (Figure 4 PK Final Model: Effects of weight, race, renal function, chronic kidney disease (CKD), total protein, hepatic function and age on the melphalan maximum concentration in the 28 day dosing interval (AUC (top), Cmax (bottom))) shows the effects of the covariates on AUC and Cmax of melphalan following administration of 40 mg melfufen. Body weight and renal function were the demographic factors affecting melphalan exposure. Total protein, albumin, race, age, sex, aspartate transaminase, bilirubin, ECOG status, type of myeloma, presence of extramedullary disease, ISS disease classification, number of prior lines of therapy, and refractory status are not expected to result in clinically relevant differences (within 20% of mean) melphalan exposure.

<div style=\"page-break-after: always\"></div>

Figure 4 PK Final Model: Effects of weight, race, renal function, chronic kidney disease (CKD), total protein, hepatic function and age on the melphalan maximum concentration in the 28 day dosing interval (AUC (top), Cmax (bottom)).

Thegrey shaded areaisthereferencerangewith alowerbound of0.8 and anupperboundof1.25.Thereference subjectwas a68yearold,70kg, White patient with mild renal impairment (eGFR=76 mL/min), normalhepatic function (AST=20.0 U/L, BILI=8.6 umol/L), and total protein level c 76g/L.MildhepaticimpairmentwassimulatedusingAST=38.4U/L andBILI=11.1umol/L.RenalimpairmentforCKDstage1,3,and4was simulated usingthe medianeGFR(102,47.3 and 28.0 mL/min,respectively)for eachoftherenal impairment categories assigned based oneGFR (mL/min)intheobserveddataset.

<!-- image -->

Source code:forest-plots.R Source graphic: 64-forest-plot-cmax-auc.pdf page: 3

## Cmax (nM)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 7 Age distribution among patients included in PK analyses across studies

|           | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| PK Trials | 127/288                                           | 49/288                                            | 5/288                                           |

## Pharmacokinetic interaction studies

Pharmacokinetic drug interactions have not been studied for melflufen.

Melflufen is rapidly metabolized intracellularly to melphalan. Systemic exposure to melflufen occurs only during the 30-minute infusion and for a few minutes after the end of infusion. Therefore, drugdrug interactions by competition for drug metabolic enzymes are highly unlikely for melflufen.

Melphalan is eliminated from plasma primarily by spontaneous hydrolysis to non-alkylating metabolites and with a contribution of direct renal elimination. There is no appreciable active metabolism of melphalan. Drug-drug interactions with melphalan caused by inhibition of drug metabolic enzymes are therefore unlikely.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Melphalan flufenamide (melflufen) is an optimized derivative of the classical nitrogen based alkylating agent melphalan. Owing to its high lipophilicity, melflufen freely and rapidly traverse the cell membrane. The rapid inflow of melflufen into cells is followed by rapid enzymatic hydrolysis of the ester/peptide bond leading to molecular trapping and high local concentration of primarily melphalan.

Nitrogen-based alkylating agents like melflufen exert their cytotoxic action through covalent interaction with intracellular nucleophiles, especially DNA, as a result of the spontaneous formation of reactive cyclic aziridinium ion intermediates. Cross-linking of DNA is probably the most important factor for the cytotoxic effect, resulting in inhibitory effects on DNA replication and transcription which subsequently triggers cell death.

## Primary and Secondary pharmacology

Melphalan flufenamide (melflufen) is an optimized derivative of the classical nitrogen based alkylating agent melphalan. Melphalan has been in clinical use as an antitumor agent for more than 60 years. Owing to its high lipophilicity, melflufen freely and rapidly traverses the cell membrane. The rapid inflow of melflufen into cells is followed by rapid enzymatic hydrolysis of the ester/peptide bond leading to molecular trapping and high local concentration of primarily melphalan.

Nitrogen-based alkylating agents like melflufen exert their cytotoxic action through covalent interaction with intracellular nucleophiles, especially DNA, as a result of the spontaneous formation of reactive cyclic aziridinium ion intermediates. Cross-linking of DNA is probably the most important factor for the cytotoxic effect, resulting in inhibitory effects on DNA replication and transcription which subsequently triggers cell death. The proof of concept for efficacy of melflufen was shown through non-clinical in vitro and in vivo experiments, and thereby the mode of action is sufficiently demonstrated.

## Effect on corrected QT interval (QTc)

The effect of melflufen on ventricular repolarization was studied in a phase I/IIa study in patients with relapsed and or relapsed-refractory multiple myeloma (study O-12-M1). The primary objective of the

<div style=\"page-break-after: always\"></div>

Phase 1 part of the study was to determine the maximum tolerated dose (MTD) of the combination of melflufen and dexamethasone (15 to 55 mg melflufen). Within phase II, additional patients were to be enrolled and treated at the MTD. Holter ECG data were collected in 23 patients, whereof 11 patients in the 40 mg melflufen plus dexamethasone cohort (i.e. the MTD in phase 1, selected as the clinical dose for phase 2), and from 2 to 4 patients in the remaining dose groups.

On Day 1 in Cycle 1, the mean change-from-baseline QTcF (DQTcF) was overall small and did not exceed 3.5 msec in the 40 mg melflufen+dexamethasone group. In the highest dose group (55 mg melflufen+dexamethasone) with only 2 observations on subsequent days, mean ∆ QTcF was substantially higher on Day 1 in Cycle 2: mean ∆ QTcF was 22.7 msec at the pre-dose time point and up to 35.7 msec post-start of dosing, representing a mean increase of 13 msec. In the 40 mg melflufen+dexamethasone group, mean ∆ QTcF did not exceed 1.7 msec and 4.1 msec on Day 1 in Cycle 2 and Cycle 3, respectively. There were no subjects with QTcF &gt; 480 msec and no subjects with ∆ QTcF &gt; 60 msec. Melflufen with dexamethasone at the studied dose did not show notable changes on cardiac conduction (the PR and QRS intervals) or heart rate.

## Exposure-efficacy analyses

The ORR for Studies O-12-M1, OP-103 and OP-107 was 18.7%, 34.6%, and 54.8%, respectively, with an overall ORR estimate of 32.9% in the pooled relapsed refractory multiple myeloma (RRMM) population. Melphalan exposure did not affect ORR. Type of myeloma, prior autologous stem cell transplant, EMD status, and ECOG status were the main factors influencing ORR. Model predictions of overall response rate of melphalan Cavg in Cycle 1 at population average exposures of normal, mild, moderate, and severe renal function, showed comparable overall response rate after accounting for other factors (Figure 5 ). Sensitivity analyses using melphalan maximum concentration in the dosing interval (Cmax) in Cycle 1 exposure showed similar melphalan exposure effects on ORR.

<div style=\"page-break-after: always\"></div>

Figure 5 ORR model: Predictions of ORR at typical Cavg in Cycle 1 values for different renal impairment function populations The shaded region represents the 95% CI for predicted ORR of the reference patient, who has melphalan Cavg in Cycle 1 of 4.31 (nanomoles (nM)), ECOG status 0, IgG myeloma, no prior autologous stem cell transplant, no extramedullary disease, and baseline age of 68 years. Melphalan Cavg in Cycle 1 exposures of 3.77, 4.31, 5.10, and 6.42 corresponded to average melphalan exposures for patients with normal, mild, moderate, and severe renal impairment.

<!-- image -->

## Exposure-safety analyses

An interim analysis of the relationship between melphalan AUCinf and nadir levels of neutrophils and thrombocytes during the first melflufen treatment cycle for the completed Study O-12-M1 and the ongoing studies OP-103, OP-104, and OP-107, showed a clear increase in incidence of Grade 3 and Grade 4 neutropenia with increasing AUCinf values (Table 8).

<div style=\"page-break-after: always\"></div>

Table 8 Incidence of Grade 3 and Grade 4 neutropenia and thrombocytopenia at Nadir in Cycle 1 by melphalan AUCinf Range (Interim analysis of studies OP-103, O-12-M1, OP-104, OP-107).

|              | Melphalan AUCinf (ng/mL *min)   | Melphalan AUCinf (ng/mL *min)   | Melphalan AUCinf (ng/mL *min)   |
|--------------|---------------------------------|---------------------------------|---------------------------------|
|              | <45,000                         | 45,000-65,000                   | >65,000                         |
| Neutrophils  |                                 |                                 |                                 |
| Grade 3      | 3/32 (9%)a                      | 13/51 (25%)                     | 15/33 (45%)                     |
| Grade 4      | 3/32 (9%)                       | 7/51 (14%)                      | 5/33 (15%)                      |
| Grade 3+4    | 6/32 (19%)                      | 20/51 (39%)                     | 20/33 (61%)                     |
| Thrombocytes |                                 |                                 |                                 |
| Grade 3      | 7/32 (22%)                      | 10/51 (20%)                     | 4/33 (12%)                      |
| Grade 4      | 2/32 (6%)                       | 5/51 (10%)                      | 9/33 (27%)                      |
| Grade 3+4    | 9/32 (28%)                      | 15/51 (29%)                     | 13/33 (39%)                     |

Neutropenia and Thrombocytopenia assessed by Laboratory Values

Abbreviations: AUCinf = area under the concentration-time curve extrapolated to infinity.

- a Incidence n/N (%)

Exposure-safety analysis were conducted for multiple AEs, dose modifications by logistic regression models (ONC0101F-BriefComm-AE-v1.0-Final, 2021-08-02) using pooled data from studies OP-103, O12-M1, OP-104, OP-107. Cycle 1 exposure metrics were used because the use of cumulative metrics was hindered by the variable follow-up lengths and dose modification patterns. Since many AEs and dose modifications occurred soon after start of treatment, the use of cycle 1 exposures is acceptable to evaluate exposure-AEs relationships during the first two cycles. The strongest trends between melphalan exposure and dose modifications at least grade 3 AEs, and leukopenia events of at least grade 3.

Exposure-myelosuppression AEs relationships were evaluated further by semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) models for the time course of thrombocyte and neutrophil counts in relapsed refractory multiple myeloma (RRMM) patients receiving PEPAXTO (ONC0101FReport-v1.0-Draft 2021-08-10) and exploring the potential influence of ASCT on the pharmacodynamic (PD) parameters describing the time course of neutropenia and thrombocytopenia (ONC0101FBriefComm-PKPD-ASCT-v1.0-Final 2021-10-08) using pooled data from studies OP-103, O-12-M1, OP104, OP-107.

The PKPD models showed that thrombocyte and neutrophil count decreased with increasing melphalan exposures. Patients with moderate to severe renal impairment were less sensitive to thrombocytopenia and had higher baseline neutrophil counts than patients with normal or mild renal function. This may suggest that proliferation/maturation/circulation of neutrophils and thrombocytes may be different in patients with moderate and severe renal impairment.

EMD, mild hepatic impairment, and prior ASCT have an effect on the concentration resulting in 50% of the maximal effect relative to the reference patient, reducing EC50 value approximately 65%, 42%, and 60%, respectively. ISS and ASCT have an effect on the estimated baseline thrombocytes relative to the reference patient reducing the value approximately 30% and 34%, respectively. Including ASCT in the PKPD model for thrombocytopenia resulted in differences between the model parameter estimates for EMD and ASCT on EC50 and estimates from non-parametric bootstrap indicating that the

<div style=\"page-break-after: always\"></div>

model was less robust including ASCT. The other covariates were not influenced by inclusion of prior ASCT.

Higher melphalan concentrations caused more neutropenia in patients with an Eastern Cooperative Oncology Group (ECOG) status &gt;0 relative to patients with an ECOG status of 0. The lower the patients' body weight, a higher incidence of thrombocytopenia and neutropenia could be observed, as seen in the safety data base (N=491).

Table 9 Neutropenia and Thrombocytopenia based on the safety data base (N=491)

<!-- image -->

| Body weight   | Neutropenia   | Thrombocytopenia   |
|---------------|---------------|--------------------|
| <60kg n=57    | 71,9%         | 80,7%              |
| 60-75kg n=191 | 59,2%         | 70,2%              |
| 75-95kg n=177 | 53,7%         | 62,1%              |
| >95kg n=64    | 46,9%         | 64,1%              |

Source: Table 18.3.4.

## 2.6.3. Discussion on clinical pharmacology

Clinical pharmacokinetic and pharmacodynamic properties of melflufen and its active metabolite melphalan as well as melphalan exposure-response relationships have been evaluated in 5 studies in patients with solid tumours or multiple myeloma. Pharmacokinetics were not evaluated in study OP106, but were evaluated in study OP-103. Three of these studies are still ongoing and the data lock was May 2019. A population PK and exposure-response evaluation of melphalan plasma concentration data across melflufen studies will be performed when all data from the ongoing Study OP-103 are available. This analysis will further investigate the relationship between PK parameters and intrinsic and extrinsic factors, and the exposure-response relationship for safety and efficacy variables. With the response to the answers to the questions, the applicant has submitted the popPK report, an exposureefficacy report and 3 reports on exposure-safety analyses.

Melflufen is a lipophilic peptide conjugated alkylating drug designed to increase cellular melphalan concentrations. Due to its high lipophilicity, the cellular uptake of melflufen is very rapid. Inside the cells the peptide bond is hydrolysed and melphalan is formed, resulting in a different disposition / higher cellular concentrations of melphalan. This is hypothesised to result in improved efficacy without increase in toxicity compared to melphalan.

Indeed, melflufen PK is characterized by a very rapid disappearance from plasma after the end of infusion with a half-life of less than 5 minutes. Melphalan, the main active metabolite, is rapidly formed with peak plasma concentrations of melphalan 5 to 15 minutes after the end of the melflufen infusion and melphalan plasma concentrations exceeded melflufen plasma concentrations halfway the infusion. Melphalan Cmax was approximately 3 to 4-fold higher than the Cmax of melfufen and AUC of melphalan was almost 20-fold higher than the AUC of melflufen. The plasma concentrations of the active metabolite desethyl-melflufen is in contrast to several animal species very low in humans.

No direct comparison of the pharmacokinetics of melphalan following equimolar doses of melflufen and melphalan in human were submitted to support the different disposition of melphalan following melflufen and melphalan administration. In dogs, such a comparison was made (study OP-2019-002): melphalan mean Cmax was 40% lower and the mean AUC ∞ 2% in melflufen administered dogs compared to in melphalan administered dogs (see non-clinical AR). The lower melphalan Cmax may

<div style=\"page-break-after: always\"></div>

support a different distribution of melphalan following infusion of melflufen compared to melphalan infusion. Further, support for the hypothesis that melflufen is rapidly taken up into cells followed by a rapid enzymatic hydrolysis of the molecule, leading to high intracellular exposure to the more hydrophilic metabolites desethyl-melflufen and melphalan, is mainly supported by in vitro data. In vitro data showed that melflufen is stable in plasma at 37°C (half-life 2-5 hours) while melflufen was rapidly cleared form blood (half-life &lt; 5min) and taken up by blood cells. These data indicate that melphalan is not spontaneously formed from melflufen in plasma but is formed in cells. This was further supported by a 50-fold higher accumulation of melphalan in cell lines when administered as melflufen compared to melphalan (see non-clinical part). It is doubtful that the increase in cellular melphalan concentrations is specific for tumour cells since melflulfen is rapidly widely distributed (animal tissue distribution) and enters cells by passive transport. Further, already 15 min after start of infusion melphalan plasma concentrations exceed melflufen plasma concentrations. This does not indicate a tumour specific response. In vitro data confirmed that melflufen, melphalan and desethyl melflufen exhibit alkylating activities and could contribute to the efficacy and toxicity in vivo. However, there are no data from MM patients treated with melflufen to indicate occurrence of similar distinct time profiles for cellular exposure to melflufen, desethyl-melflufen, and melphalan and their DNA adducts in vivo as was shown in vitro and it is not possible to estimate this contribution quantitatively in relation to the activity of melphalan without a direct comparison with melphalan. Therefore, the claim of an improved benefit-risk of melflufen treatment compared to melphalan treatment due to altered disposition of melphalan cannot be concluded without a direct comparison. Pharmacokinetics of melflufen has only been evaluated in two studies. This is considered acceptable because melflufen can be considered a derivate of melphalan, designed to increase melphalan concentrations in the tumour cells. Melflufen and melphalan Cmax and AUC increased in approximate relation to dose over melflufen dose range 25-130 mg. No studies were conducted to evaluate the excretion of melflufen or melphalan, effect of hepatic impairment and no pharmacokinetics interaction studies have been performed. Melflufen is not metabolised by CYP enzymes but by cellular esterases and aminopeptidases to desethylmelflufen and melphalan, respectively. Given the short plasma elimination half-life of melfufen, and the much higher melphalan exposure compared to melflufen indicating that melphalan is the main moiety responsible for efficacy and safety, absence of excretion, hepatic impairment and drug interaction studies for melflufen is considered acceptable. Melphalan is eliminated primarily by spontaneous hydrolysis to monohydroxymelphalan and melphalan is partly excreted unchanged in the urine. Hence, the interaction potential of melphalan is low. During the evaluation procedure, reports on popPK and melphalan exposure-response analyses were provided. The reporting and model evaluation of the popPK and exposure-response modelling was well described and in agreement with EMA guidelines (CHMP/EWP/185990/06). The popPK model seems to describe the pharmacokinetics of melphalan adequately, and seems fit for use in exposure-response analyses but some additional plots are requested for better evaluation. Body weight, renal function and total protein but not gender or age were co-variates on melphalan exposure. The applicant proposes a lower starting dose of 30 mg for subjects &lt;60 kg and for subjects with renal function eGFR 30-45 mL/min/1.73 m2 (see dosing below). Melphalan is partly excreted unchanged in the urine. At day 120 responses, the applicant has included results from study OP-107 in the popPK and the exposure-response analyses, this study included 24 subjects with moderate and 6 subjects with severe renal impairment. The subjects were classified as having severe renal impairment the lowest eGFR was 27.2 ml/min/1.73m2 which is borderline severe renal impairment. Based on popPK modelling, melphalan exposure was 29% and 51% higher in subjects with moderate and severe renal impairment compared to subjects with normal renal function. A lower starting dose of 30 mg of Pepaxti has been proposed for patients with eGFR 30-45

<div style=\"page-break-after: always\"></div>

mL/min/1.73 m2 because melphalan exposure was on average 30% higher in these subjects and melflufen was worse tolerated in the group started on 40 mg melflufen compared to the group started on 30 mg melflufen. Therefore, the reduced starting dose for subject with eGFR 30-45 mL/min/1.73 This has sufficiently described in sections 4.2 and 5.2 of the SmPC. Data from 4 subjects with severe renal impairment enrolled in cohort 2a of study OP-107 and treated with 20 mg melflufen will be submitted when the study report is finalised (expected Q3-Q4 2022).

Sound rationale for the selected flat dosing regimen has not been provided. According to the with a BSA 1.6 m2 compared to subjects with a BSA of 2.2 m2. This does not support a flat dosing strategy. Melphalan is usually dosed based on body weight or based on body surface area. Higher m2 is considered acceptable. Treatment of subjects with severe renal impairment is not recommended. Logistic regression was used to develop an exposure-response model of ORR and a parametric time-toevent model was used to develop an exposure-response model of OS and PFS. For the exposureefficacy relationships, melphalan Cave in the first cycle was used as exposure parameter. Use of AUC (Cave) over Cmax is supported because of the high shrinkage for volume of distribution. Since response is rather rapidly achieved for ORR, melphalan Cave in the first cycle is considered an acceptable exposure metric. Time to event exposure-PFS and exposure-OS analyses were hampered by the many dose reductions, which resulted in a decreasing melphalan exposure over time, and the lowest average exposures were associated with patients remaining under observation for the longest durations. This resulted in an inverse exposure-response relationship when KM curves were stratified by cumulative (and duration normalized) metrics of melphalan exposure. Therefore, for exposureefficacy relationships, the exposure-ORR relationship is considered most informative. There was no correlation between plasma melphalan exposure Cave and ORR. Since almost all patients started on 40 mg melflufen, the exposure range of melphalan in the first cycle is limited and this may hamper extrapolation to other dosing regimen. Disease related factors such as type of myeloma, prior autologous stem cell transplant, EMD status, and ECOG status were the main factors influencing ORR. Exposure safety analyses focussed on thrombocytopenia and neutropenia. The choice of the thrombocyte and neutrophil nadir as the PD endpoint is in general considered acceptable for an alkylating agent. PKPD modelling showed that higher melphalan concentrations caused more thrombocytopenia and neutropenia ≥ grade 3. In addition to melphalan exposure, was ECOG status a covariate in the model: higher melphalan concentrations caused more neutropenia in patients with an ECOG status &gt;0 relative to patients with an ECOG status of 0. EMD, mild hepatic impairment, and prior ASCT have an effect on the concentration resulting in 50% of the maximal effect relative to the reference patient, reducing EC50 value approximately 65%, 42%, and 60%, respectively. ISS and ASCT have an effect on the estimated baseline thrombocytes relative to the reference patient reducing the value approximately 30% and 34%, respectively. The semi-mechanistic PKPD models for the time course of thrombocyte and neutrophil counts overestimated the variability, which renders simulations somewhat more uncertain. Nevertheless, simulations suggested that dose reduction after recovery from the first Grade 3 neutropenia event was likely to mitigate the overall risk of developing subsequent episodes of Grade 3 neutropenia. The recommended dosage modifications for adverse reactions of Pepaxti for haematologic adverse reaction accordingly. While this changed dosing recommendations may mitigate subsequent neutropenia grade 3 episodes, it is not estimated to reduce the risk of developing episodes grade 3 thrombocytopenia. The rate of Grade 3 thrombocytopenia events is more affected by a lower melflufen starting dose. Since the proposed dose modification may contribute to lower some AEs as simulated for neutropenia, the proposed change can be accepted. Starting Dose pharmacokinetic data presented, melphalan exposure (Cmax and AUC) are ~50% higher in subjects

<div style=\"page-break-after: always\"></div>

melphalan exposures were associated with an increased incidence of grade 3+4 haematologic AEs. Thrombocytopenia was a major reason for premature discontinuation of melflufen treatment.

In response to request for justification of the flat dosing, the applicant proposes a lower melflufen starting dose of 30 mg instead of 40 mg for patients with bodyweight &lt; 60 kg. The rationale is that there is a clear increase in thrombocytopenia and neutropenia with increasing melphalan exposure, while there was no correlation between melphalan exposure in the first cycle and ORR. The reduced starting dose for subjects with low body-weight was further substantiated by PK simulations indicating that the 30 mg starting dose in subjects weighing &lt;60 kg is expected to result in a comparable melphalan exposure to subjects weighing 70-80 kg. In study OP-103, the overall incidence of AE leading to discontinuation was 32% in patients with a body weight &lt;60 kg and 26% in patients with a body weight ≥ 60 kg, but the percentage of patients without dose reduction was 52% vs 47%, respectively. In the safety data base (N=491), a higher incidence of thrombocytopenia and neutropenia could be observed in subjects with lower body weight (Table 6). Therefore, the reduced starting dose for subjects with low body-weight is considered acceptable.

Though data are limited, melflufen in combination with dexamethasone did not result in a clinically relevant QTc prolongation in patients with MM. The absence of an effect on QTc prolongation is supported by what is known for melphalan.

## 2.6.4. Conclusions on clinical pharmacology

Pharmacology of melflufen has only been evaluated in two studies. This is considered acceptable because melflufen can be considered a derivate of melphalan, designed to increase melphalan concentrations in (the tumour) cells. Melphalan has been in clinical use as an antitumor agent for more than 60 years.

Overall, clinical pharmacology has been characterized.

## 2.6.5. Clinical efficacy

Main clinical efficacy data is derived from Phase 2 single arm trial OP-106 (HORIZON) investigating melflufen in combination with dexamethasone in relapsed refractory multiple myeloma (RRMM) patients (Table 6). Supportive data is derived from Phase 1/2 dose finding study O-12-M1. In response to the Day 120 List of Questions, results of recently conducted Phase 3 randomized controlled trial OP103 (OCEAN) were submitted as confirmatory data.

<div style=\"page-break-after: always\"></div>

Table 10. Overview of Clinical Studies Supporting Efficacy

<!-- image -->

| Study No./ Study Sites (No.) County)/Lead Investigator                                          | Study Desigu. Population                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Treatiment Regimen: Total Daily Dose, Route of Adninistration                                                                                                                                                                                                                   | StudyEnrollment                                                                                                                                             | Efficacy Endpoints                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pivotal                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                 |                                                                                                                                                             |                                                                                                                                                                                                                |
| OP-106 (17 sites*, France, Italy, Spain, US) Global lead inveshigator: Richardson               | A single-am, open-label Phase 2 multicenter study to evaluate efficacy and safety ofpatients with RRMMwhoarerefiactoryto pomalidomide and/or an anti-CD38 mAb PatientswitlhprogressiveMMwho havereceivedat least2priorlines of therapy, including an IMhD and a Pl, and arerefiactory to pomalidomide and/or an anthi-CD38 mAb, demonshating relapse while on therapy or within 60 days of completion of the last dose of pomalidomide and/or an anthi-CD3S mAb in any line, | 40 mgQ4W melflufen + LD dexamethasone Patientsreceiveda40-mgIV doseof mellufenonDay 1 of each 28-day cycle and40 mg of PO dexamethasone on Days 1, 8,15,and22 ofeach cycle. Patients>75years ofage received areduced starting dose of dexamethasone(20 mg)on the same schedule. | Overall: N=157 Tnple-class refactory subpopulation: N=119                                                                                                   | ORR, DOR PFS, OS,CBRTINT,TTNT or death, TTR TTP, duationof SD,duation of disease stabilization, duation of clinical benefit,fiunctional status and well-being Response was assessed according to IMWG critenia |
| 0-12-M1 (7 sites; Denmark, Italy, Netheriands, Sweden, US) Global lead investigator: Richardson | regardless ofresponse An open-label Phase 1/2a multicenterstudy toidentifythe MTD, followed by efficacy, and safetyofmelflufenaloneandin combinahion with dexamethasone PatientswithRRMMwhoreceived at least 2 or more pnior lines of therapy including lenalidomide and bortezomb                                                                                                                                                                                           | Phase 1: 15, 25,40, or55 mg Q3Wmelflufen+LD dexamethasone Phase2:40mgQ3W→Q4W melflufen + LD dexamethasone PatientsreceivedanIVdose of melflufenonDaylofeach cycle and PO dexamethasone onDays 1,8,15,and 22 of each 21/28-day cycle                                             | Total: N=75 Melflufen + dexamethasone: Phase 2: N=45 (including Phase 1: N=23 6patients treatedwith 40 mg in Phave 1) Single-agent melflufen: Phase 2: N=13 | ORR DOR,OS,PFS TTP, TIR time to first subsequent treatment Respon5e Wa5 a5se5sed according to IMWG cnitenia                                                                                                    |

Twenty-two sites Were open for eurollment, 20 sites screened patients, and 17 sites eurolled patients.

Abbreviations:CSR=clinical shudy reportDOR=duration ofresponseIiD=inmumomodulatory dng,IMWG=Intermational MyelomeWorkingGroup;IRC=Independent Review Committee; IV = intravenous; LD = low dose,mAb = monoclonal annbody, MTD =mxinmm tolerated dose; NA =not applicable; ORR =overall response rate; OS = overall suvival;PFS=progression-free survival;PI=proteasome inhibitor,PO=by mouth;Q3W=every 3weeks;Q4W=etery 4weeks;RP2D=reconmended Phese2 dose; RRMM=relapsed and refractory multiple myeloms; SD = stable disease, TTNT = time to next treemment TTp = time to progression; TTR = time to response; US =Umited States.

## 2.6.5.1. Dose response study(ies)

## Study O-12-M1

Open-label, Phase 1/2a Study O-12-M1 was designed to determine the maximum tolerated dose (MTD) of melflufen + dexamethasone (dex) in patients with RRMM and subsequently the efficacy and safety in patients treated at the MTD.

The standard 3 + 3 Phase I design was followed, with 3 to 6 patients to be tested at each dose level, depending on the dose limiting toxicities (DLTs) observed. Meflufen dose levels tested were 15, 25, 40 or 55mg at Day 1 of each 21-day Cycle, all in combination with 40 mg dex at days 1, 8 and 15 of each 21 day Cycle.

Eligible patients were adults with RRMM that had at least 2 or more prior lines of therapy, including lenalidomide and bortezomib and had demonstrated disease progression on or within 60 days of completion of last therapy.

In Phase 1 of the study, the MTD was determined at 40 mg melflufen Day 1 of each cycle in combination with 40 mg dexamethasone weekly, based on a total of 4 (66.7%) patients that experienced at least one DLT in the 55 mg cohort.

An additional 45 patients received meflufen + dex at the MTD in Phase 2a of the study. The proportion of triple class refractory (TCR) patients was 6%. The treatment cycle was 21 days, until the cycle length was increased to 28 days due to delayed haematologic recovery. The overall ORR (&gt;PR) was

<div style=\"page-break-after: always\"></div>

31.1% (n=14) in the combination cohort. For an additional cohort of ≥ 20 patients that received singleagent melflufen, ORR was only 7.7% (n=1) and low dose dex was added back to the treatment regimen.

## 2.6.5.2. Main study

## Study OP-106 - HORIZON

Single arm, open-label Phase 2 study of melflufen in combination with dexamethasone (dex) in patients with RRMM who are refractory to Pomalidomide and/or an anti-CD38 mAb.

## Methods

## · Study Participants

Key inclusion criteria

- -Male or female, age 18 years or older.
- -A prior diagnosis of multiple myeloma with documented disease progression in need of treatment at time of screening.
- -Measurable disease defined as any of the following:
- o Serum monoclonal protein ≥ 0.5 g/dL ( ≥ 5 g/L) by serum protein electrophoresis (SPEP);
- o ≥ 200 mg/24 hours of monoclonal protein in the urine on 24-hour urine protein electrophoresis (UPEP);
- o Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL ( ≥ 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio.
- -A minimum of 2 prior lines of therapy, including an IMiD and a PI, and was refractory to pomalidomide and/or an anti-CD38 mAb. (Refractory status included patients who relapsed while on therapy or within 60 days of last dose of pomalidomide and/or an anti-CD38 mAb in any line, regardless of response).
- -Life expectancy of ≥ 6 months.
- -ECOG performance status ≤ 2 (patients with worse performance status based solely on bone pain secondary to multiple myeloma may have been eligible following consultation and approval of the medical monitor).
- -12-lead electrocardiogram (ECG) with Fridericia's formula for the interval of time from the start of the Q wave to the end of the T wave, correcte d for heart rate (QTcF) interval of ≤470 msec
- -The following laboratory results must have been met during screening (within 21 days) and also prior to study drug administration on Cycle 1 Day 1:
- o Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109/L)
- o Platelet count ≥ 75,000 cells/mm3 (75 x 109/L)
- o Haemoglobin ≥ 8.0 g/dl
- o Total Bilirubin ≤ 1.5 x upper limit of normal (ULN); or higher value in patients diagnosed with Gilberts syndrome after review and approval by the medical monitor

<div style=\"page-break-after: always\"></div>

- o Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 x ULN
- o Renal function: Estimated creatinine clearance by Cockcroft-Gault formula ≥ 45 mL/min.

## Key exclusion criteria

- -Evidence of mucosal or internal bleeding and/or was platelet transfusion refractory.
- -Any medical conditions that, in the Investigator's opinion, would have imposed excessive risk to the patient or would have adversely affected his/her participating in this study. Examples of such conditions are: a significant history of cardiovascular disease (e.g., myocardial infarction (MI), significant conduction system abnormalities, uncontrolled hypertension, ≥ Grade 3 thromboembolic event in the last 6 months).
- -Active infection, treated with parenteral anti-infectives within 14 days, or oral anti-infectives within 7 days, prior to initiation of treatment
- -Primary refractory (never responded ( ≥ minimal response [MR]) to any prior therapy).
- -Other malignancy diagnosed or requiring treatment within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix or breast, and very-low and low risk prostate cancer patients in active surveillance as defined in NCCN Version 3, 2016.
- -Known human immunodeficiency virus (HIV) or active hepatitis B or C viral infection.
- -Concurrent symptomatic amyloidosis or plasma cell leukaemia.
- -POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes].
- -Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to initiation of therapy. Immunomodulatory drugs, PIs, and/or corticosteroids within 2 weeks prior to initiation of therapy. Prednisone up to but no more than 10 mg orally q.d. or its equivalent for symptom management of comorbid conditions was permitted but dose should have been stable for at least 7 days prior to initiation of therapy. Other investigational therapies and monoclonal antibodies or live vaccines within 4 weeks prior to initiation of therapy (other washout times may have been considered following consultation with the medical monitor).
- -Residual side effects to previous therapy &gt; Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 2 without pain were permitted).
- -Prior autologous or allogeneic stem cell transplant within 12 weeks of initiation of therapy.
- -Prior allogeneic stem cell transplant with active graft-versus-host-disease (GVHD).
- -Prior major surgical procedure or radiation therapy within 4 weeks of the initiation of therapy (this did not include limited course of radiation used for management of bone pain within 7 days of initiation of therapy).
- -Known intolerance to steroid therapy.

## · Treatments

Melflufen 40 mg was administered as a 30-minute central IV infusion on Day 1 of every 28-day cycle.

<div style=\"page-break-after: always\"></div>

Dexamethasone 40 mg was administered orally on Days 1, 8, 15 and 22 of each 28-day cycle (once weekly [q1w]). Patients ≥ 75 years of age received 20 mg of dexamethasone on the same schedule. Dexamethasone could be continued weekly at the Investigator's discretion in the event of a cycle prolongation with delayed administration of melflufen.

Treatment continued until disease progression (PD), unacceptable toxicity, or the patient/treating physician determined it was not in the patient's best interest to continue.

## · Objectives

The primary objective of this Phase 2 study was to evaluate the efficacy of melflufen treatment in RRMM patients.

The key secondary objectives of this study were to evaluate safety and tolerability of melflufen as well as duration of response (DOR).

## · Outcomes/endpoints

The primary endpoint was overall response rate (ORR), defined as the proportion of patients for whom the best overall confirmed response is stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

The key secondary efficacy endpoint was DoR defined for patients who achieved a PR or better as the duration in months from first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause.

Main other secondary endpoints were:

- -Progression free survival (PFS), defined as the duration in months from start of treatment until first evidence of confirmed disease progression. Disease progression was defined according to IMWG-URC as PD or death due to any cause, whichever occurred first.
- -Overall survival (OS), defined as the time in months from the date of the first dose of study drug to date of death due to any cause.
- -Clinical benefit rate (CBR), defined as the proportion of patients with the best overall confirmed response of minimal response (MR) or better.
- -Time to response (TTR), defined for patients with confirmed responses of PR or better as the duration in months from the study treatment start to the first occurrence of a confirmed response of PR or better.
- -Time to next treatment (TTNT), time (months) from the study treatment start to the start of first post study myeloma therapy (excluding radiotherapy). A second definition was used including death.
- -Patient reported outcomes (PRO) change from baseline in QLQ-C30 and Eq-5D-3L.

## · Randomisation and Blinding (masking)

No randomisation or blinding was performed considering the single arm trial design. An independent review committee (IRC) sensitivity analyses was included for response assessment.

## · Statistical methods

The Full analysis set (FAS) was defined as all patients who fulfil all eligibility criteria at screening and prior to initiation of therapy and according to intention-to-treat principle as per ICH E9.

<div style=\"page-break-after: always\"></div>

Patients that are triple-class refractory, defined as refractory to at least one PI, at least one IMiD, and at least one Anti-CD38 mAb, were specified as the primary subgroup of interest. This subgroup constitutes the majority of patients and will be used for all analyses of efficacy and safety.

Efficacy analysis The primary endpoint, ORR, was to be considered met if the lower bound of the 95% confidence interval for actual ORR among triple-class refractory patients is higher than 15%.

Multiplicity control No inferential statistical comparisons using p-values are planned as part of the statistical analysis plan (SAP). Confidence intervals will be provided for descriptive purposes, and the increasing probability of type I error by number of statistical conclusions should be considered when interpreting the results. The efficacy endpoints are listed by order of relevance.

Sample size For the initial sample size estimation, inclusion of ~39 pomalidomide refractory patients and ~39 daratumumab refractory patients were to be enrolled. The sample size was adjusted during the study to ~150 patients. The updated sample size was precision-based, with an assumed observed ORR of 30%, and an exact 95% confidence interval from 22.3% to 38.7%, given a sample size of 130 patients. Sample size calculation has been based on the overall study population rather than the currently proposed target population of TCR MM patients.

Interim analysis An interim analysis for futility was conducted after 19 patients had been enrolled in each (original) group and were evaluable for response. The response rates were 5/19 in the pomalidomide refractory group and 3/19 in the daratumumab refractory group based on which it was recommended to proceed the study without changes or limitations.

Handling of missing values/censoring/discontinuations Secondary endpoint PFS was right-censored according to the conventions described in Table 11.

Table 11. Conventions for Censoring of PFS

| Situation                                                                    | Date of Progression or Censoring                                                       | Outcome    |
|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------|
| No post baseline response assessments                                        | Dateoffirstdose                                                                        | Censored   |
| Non-protocolsystemicanticancer therapystartedbefore documentationofPDordeath | Date of last response assessment priortostartofnewanticancer therapy                   | Censored   |
| DeathorPDaftermorethan1 consecutivelymissedresponse assessment               | Dateof lastresponseassessment withoutdocumentationofPDthatis beforethefirstmissedvisit | Censored   |
| UnconfirmedPDasthefinal responseassessment                                   | Dateof latestPDassessment                                                              | Progressed |
| AliveandwithoutPDdocumentation                                               | Date of lastresponse assessment                                                        | Censored   |
| Death or PD between scheduled responseassessments                            | Dateof death orpreceding response assessment showing PD, whicheveroccursfirst          | Progressed |
| Deathbeforefirstresponse assessment                                          | Dateof death                                                                           | Progressed |

For secondary endpoints DOR and duration of clinical benefit the SAP defined that disease progression, and dates of progression and censoring, were to be determined as described for the analysis of PFS. For OS, patients who are alive will be censored at the last follow up visit or data cut-off date for patients still on-study.

## Results

## · Participant flow

Out of 215 patients that signed the Informed Consent Form, 58 never received any study treatment. Out of the 58 patients, 50 failed to meet one of the study specific eligibility criteria; 36 failed one of

<div style=\"page-break-after: always\"></div>

the criteria set forth in inclusion criterion #10 related to laboratory values and another 14 failed various eligibility criteria. Eight patients met all eligibility criteria but were never treated due to various reasons.

A total of 119 patients (75.8%) were TCR, with generally consistent disposition compared to the overall FAS.

Allocation

Analysis

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 12. Patient disposition (FAS)

| Variable, n (%)                                 | Triple-class Refractory   | AI1        |
|-------------------------------------------------|---------------------------|------------|
| Number of enrolled'treated patients             | 119                       | 157        |
| Completed treatment                             |                           |            |
| sa1                                             | 102 (85.7)                | 131 (83.4) |
| Ongoing                                         | 17 (14.3)                 | 26 (16.6)  |
| Primary reason for discontinuation of treatment |                           |            |
| Progressive disease                             | 71 (59.7)                 | 88 (56.1)  |
| Adverse event                                   | 16 (13.4)                 | 26 (16.6)  |
| Lack of efficacy                                | 5 (4.2)                   | 5 (3.2)    |
| Physician decision                              | 4(3.4)                    | 5 (3.2)    |
| Withdrawal by patient                           | 6(5.0)                    | 7(4.5)     |
| Patients in PFS follow-up                       | 2 (1.7)                   | 5 (3.2)    |
| Patients in Os follow-up                        | 26 (21.8)                 | 35 (22.3)  |
| Completed study                                 |                           |            |
|                                                 | 74 (62.2)                 | 91 (58.0)  |
| Ongoing                                         | 45 (37.8)                 | 66 (42.0)  |
| Primary reason forstudy discontinuation         |                           |            |
| Death                                           | 71 (59.7)                 | 87 (55.4)  |
| Lost to follow-up                               | 1 (0.8)                   | 2 (1.3)    |
| Withdrawal of patient                           | 1 (0.8)                   | 1 (0.6)    |

Abbreviatious: n = number of patients in each category; OS = overall survival; PFS = progression-fee suvival.

## · Conduct of the study

The original protocol was approved on 04 May 2016. There were 6 protocol amendments. Key changes to the protocol and SAP pertain to the population of interest (eventually TCR patients), related increase in sample size as well as the introduction of an independent review committee (IRC) and quality of life endpoints. A total of 27 protocol deviations were observed in 20 patients. Most deviations were related to study drug administration (15 deviations out of a total of 669 cycles) and missed laboratory assessments (6 deviations). Eleven patients did not meet eligibility criteria and were granted waivers.

## · Baseline data

Median age at enrolment was 65 years in the overall population and TCR subpopulation (Table 13). Almost 60% of patients were male and most patients were Caucasian (~85%) in both study populations.

<div style=\"page-break-after: always\"></div>

Table 13. Baseline Demographic Characteristics (FAS)

| Variable                            | Triple-class Refractory N=119   | All N=157   |
|-------------------------------------|---------------------------------|-------------|
| Age (years), n                      | 119                             | 157         |
| Mean (SD)                           | 64.7 (9.46)                     | 64.7 (9.36) |
| Median                              | 65.0                            | 65.0        |
| Min, max                            | 35,86                           | 35,86       |
| Age category (years),n (%)          |                                 |             |
| <65                                 | 59 (49.6)                       | 78 (49.7)   |
| ≥65 to ≤75                          | 41 (34.5)                       | 54 (34.4)   |
| >75                                 | 19 (16.0)                       | 25 (15.9)   |
| Sex, n (%)                          |                                 |             |
| Male                                | 70 (58.8)                       | 89 (56.7)   |
| Female                              | 49 (41.2)                       | 68 (43.3)   |
| Race, n (%)                         |                                 |             |
| Asian                               | 1 (0.8)                         | 1 (0.6)     |
| BlackorAfricanAmerican              | 8 (6.8)                         | 11 (7.1)    |
| Caucasian                           | 100 (84.7)                      | 135 (86.5)  |
| NativeHawaiian/OtherPacificIslander | 1 (0.8)                         | 1 (0.6)     |
| Other                               | 8 (6.8)                         | 8 (5.1)     |
| Not reported                        | 1                               | 1           |
| Ethnicity, n (%)                    |                                 |             |
| Hispanic or Latino                  | 4 (3.7)                         | 5 (3.5)     |
| NotHispanic or Latino               | 103 (96.3)                      | 139 (96.5)  |
| Not reported                        | 12                              | 13          |

Abbreviations: max = maximum; min = minimum; n = number of patients in each category; N = total number of patients in the relevant analysisset;SD =standard deviation.

MM disease characteristics at baseline are summarized in Table 14. Median time since initial diagnosis was 6.2 years among TCR patients, and similar for the overall study population. As expected in this advanced patient population, patients with ISS stage III disease, extramedullary disease, and high-risk cytogenetic features were well represented.

<div style=\"page-break-after: always\"></div>

Table 14. Baseline disease characteristics (FAS)

| Category                                            | Triple-class Refractory N-119   | AlI N-157          |
|-----------------------------------------------------|---------------------------------|--------------------|
| Time since initial dingnosis (years), n             | 611                             | 157                |
| Mean (SD)                                           | 6.7(3.38)                       | 7.0 (3.46)         |
| Median                                              | 6.2                             | 6.5                |
| Min, max                                            | 0.7.24.6                        | 0.7,24.6           |
| ISS category, n (96)                                |                                 |                    |
| ShageI                                              | 41 (35.0)                       | 63 (40.6)          |
| Shge                                                | 36 (30.8)                       | 49 (31.0)          |
| Stage II                                            | 36 (30.8)                       | 39 (25.2)          |
| Unknown                                             | 4(3.4)                          | 4(2.6)             |
| Missing                                             | 2                               | 2                  |
| ECOG performance status, n (%6)                     |                                 |                    |
| Grade 0                                             | 26 (21.8)                       | 39 (24.8)          |
| Gade 1                                              | 75 (63.0)                       | 93 (59.2)          |
| Gnde 2                                              | 18(15.1)                        | 25 (15.9)          |
| Serum p2-mieroglobulin (mg/L),n                     | 113                             | 151                |
| Mean (SD)                                           | 5.0 (5.63)                      | 4.6 (4.98)         |
| Median                                              | 3.8                             | 3.5                |
| Min, max                                            | 0.0.57.0                        | 0.0.57.0           |
| Heavy chain at study enhy, n (%6)                   |                                 |                    |
| IgA.                                                | 26 (21.8)                       | 30 (19.1)          |
| IgD                                                 | 2(1.7)                          | 2(1.3)             |
| IgG                                                 | 63 (22.9)                       | 88 (50.1)          |
| IgM                                                 | 2(1.7)                          | 2(1.3)             |
| Mulliple                                            | 2(1.7)                          | 2(1.3)             |
| None                                                | 23 (19.3)                       | 32 (20.4)          |
| Unknown                                             | 1(0.8)                          | 1(0.0)             |
| Light chain at study entry, n (96)                  |                                 |                    |
| Kappa                                               | 75 (63.0)                       | 100 (63.7)         |
| Lamda                                               | 44 (37.0)                       | 57(36.3)           |
| Heavy-light chain combination at study entry,n (%o) |                                 |                    |
| IgA kappa                                           | 17 (14.3)                       | 18(11.5)           |
| IgA lambda                                          | 9 (7.6)                         | 12 (7.0)           |
| IgD kappa                                           | 1 (0.8)                         | 1(0.0)             |
| IgD lambda                                          | 1 (0.8)                         | 1(0.6)             |
| IgG kappa IgG lambda                                | 39 (32.8) 24 (20.2)             | 57(36.3) 31 (19.7) |
| IgM kappa                                           | 2(1.7)                          | 2(1.3)             |
| Multiple kappa                                      | 2(1.7)                          | 2(1.3)             |
| None kappa                                          | 13 (10.9)                       | 19 (12.1)          |
| None lambda                                         | 10 (8.4)                        | 13 (8.3)           |
| Unknown kappa                                       | 1 (0.8)                         | 1(0.0)             |
| Maxinum baseline plasma cell involvement in         | 103                             | 137                |
| bone marrowbr (%o),. n                              |                                 |                    |
| Mean (SD)                                           | 29.0 (30.81)                    | 29.6 (29.14)       |
| Median                                              | 18.0                            | 20.0               |
| Min, max                                            | 0.0.97.0                        | 0.0,97.0           |
| Extramedullary disease, n (96)                      |                                 |                    |
|                                                     | 50 (42.0)                       | 55 (35.0)          |
| No                                                  | 69(58.0)                        | 102 (65.0)         |
| Baseline disease risk status category, n (96)       |                                 |                    |
| Highd                                               | 41 (34.5)                       | 59 (37.0)          |
| Standard                                            | 52 (43.7)                       | 67 (42.7)          |
| Unknown                                             | 26 (21.8)                       | 31(19.7)           |

number of patients in each category: N - total mumber of patents in the relevant analysis set; SD = standard deviation, .

Baseline laboratory tests were defined as the most recent assessment before administation of the first dose of study drug.

Time since initial diagnosis was ealeulated relhative to finst dose of shudy drug.

Bone mamow aspirate or biopsy.

d Patients who had the genetie subtype t(4; 14), t(14:16), deletion 17p. gain 1q (+1q), t(14,20) were high risk.

Patients had received a median of 5 (range 2-12) prior therapies, and 119 (~76%) were TCR (

Table 15; Table 16). Approximately 16% of the TCR population was Melphalan refractory. The majority of patients (n=97/119, 81.5%) was also at least quad-refractory and 47% of patients was penta-

<div style=\"page-break-after: always\"></div>

refractory (n=56/119). In total 117/119 TCR patients had received 3 prior lines of therapy, in line with the newly proposed target population.

Table 15. Lines of Prior Therapy (FAS)

| Variable                                                               | Triple-class Refractory N=119   | All N=157   |
|------------------------------------------------------------------------|---------------------------------|-------------|
| Number of lines of prior therapy, n                                    | 119                             | 157         |
| Mean (SD)                                                              | 5.5 (1.87)                      | 5.2 (1.84)  |
| Median                                                                 | 5.0                             | 5.0         |
| Min, max                                                               | 2,12                            | 2,12        |
| Number of prior regimens, n (%)                                        |                                 |             |
| 2                                                                      | 2 (1.7)                         | 5 (3.2)     |
| 3                                                                      | 15 (12.6)                       | 24 (15.3)   |
| 4                                                                      | 14 (11.8)                       | 23 (14.6)   |
| 5                                                                      | 36 (30.3)                       | 46 (29.3)   |
| 6                                                                      | 23 (19.3)                       | 28 (17.8)   |
| 7                                                                      | 14 (11.8)                       | 15 (9.6)    |
| 8                                                                      | 5 (4.2)                         | 6 (3.8)     |
| 9                                                                      | 6 (5.0)                         | 6 (3.8)     |
| 10                                                                     | 2 (1.7)                         | 2 (1.3)     |
| 11                                                                     | 1 (0.8)                         | 1 (0.6)     |
| 12                                                                     | 1 (0.8)                         | 1 (0.6)     |
| Patients with a prior autologous transplant, n (%)                     |                                 |             |
| Yes                                                                    | 81 (68.1)                       | 108 (68.8)  |
| No                                                                     | 38 (31.9)                       | 49 (31.2)   |
| Best disease response to most recent prior regimen, n (%)              |                                 |             |
| Stringent complete response (sCR)                                      | 0                               | 1 (0.6)     |
| Complete response (CR)                                                 | 0                               | 2 (1.3)     |
| Very good partial response (VGPR)                                      | 7 (5.9)                         | 13 (8.3)    |
| Partial response (PR)                                                  | 29 (24.4)                       | 35 (22.3)   |
| Minimal response (MR)                                                  | 8 (6.7)                         | 9 (5.7)     |
| Stable disease (SD)                                                    | 23 (19.3)                       | 33 (21.0)   |
| Progressive disease (PD)                                               | 22 (18.5)                       | 30 (19.1)   |
| Unknown                                                                | 30 (25.2)                       | 34 (21.7)   |
| Refractory to at least 1 component of most recent prior regimen, n (%) |                                 |             |
| Yes                                                                    | 117 (98.3)                      | 154 (98.1)  |
| No                                                                     | 2 (1.7)                         | 3 (1.9)     |
| Refractory to most recent prior regimen, n (%)                         |                                 |             |
| Alkylator class                                                        | 29 (24.4)                       | 35 (22.3)   |
| Cyclophosphamide                                                       | 22 (18.5)                       | 28 (17.8)   |
| Bendamustine                                                           | 5 (4.2)                         | 5 (3.2)     |

Table continued next page

<div style=\"page-break-after: always\"></div>

| Variable                                       | Triple-class Refractory N=119   | AII N=157       |
|------------------------------------------------|---------------------------------|-----------------|
| Melphalan                                      | 2 (1.7)                         | 2(1.3)          |
| Anti-CD38 mAb class                            | 59 (49.6)                       | 63 (40.1)       |
| Daratmumab                                     | 56 (47.1)                       | 59 (37.6)       |
| Isahiximab                                     | 3(2.5)                          | 4(2.5)          |
| IMiD class                                     | 49 (41.2)                       | 74 (47.1)       |
| Pomalidomide                                   | 37 (31.1)                       | 60 (38.2)       |
| Thalidomide                                    | 7 (5.9)                         | 7 (4.5)         |
| Lenalidomide                                   | 3 (2.5)                         | 4 (2.5)         |
| Miscellaneious IMiD                            | 2 (1.7)                         | 3 (1.9)         |
| Other mAb class                                | 12 (10.1)                       | 16 (10.2)       |
| Miscellaneous other monoclonal antbodies       | 8 (6.7)                         | 12 (7.6)        |
| Elotuzumab                                     | 4(3.4)                          | 5 (3.2)         |
| PI class                                       | 44 (37.0)                       | 57 (36.3)       |
| Carfilzomib                                    | 23 (19.3)                       | 27 (17.2)       |
| Bortezomib                                     | 18 (15.1)                       | 25 (15.9)       |
| Ixazomib                                       | 3(2.5                           | 5(3.2)          |
| Refractory to at least 1 prior regimen, n (%6) |                                 |                 |
| Alkylator class                                | 76 (63.9)                       | 92 (58.6)       |
| Alkylators miscellaneous                       | 1 (0.8)                         | 1 (0.6)         |
| Bendamustine                                   | 13 (10.9)                       | 14 (8.9)        |
| Camustine                                      | 6 (5.0)                         | 6 (3.8)         |
| Cyclophosphamide                               | 65 (54.6)                       | 80 (51.0)       |
| High-dose melphalan                            | 2 (1.7)                         | 3(1.9)          |
| Melphalan                                      | 19 (16.0)                       | 21 (13.4)       |
| Anti-CD38 mAb class                            | 119 (100)                       | 125 (79.6)      |
| Daratumuumab                                   | 112 (94.1)                      | 117 (74.5)      |
| Isahuximab                                     | 9 (7.6)                         | 10 (6.4)        |
| IMiD class                                     | 116 (97.5)                      | 153 (97.5)      |
| IMiD miscellaneous                             | 4(3.4)                          | 5 (3.2)         |
| Lenalidomide                                   | 108 (90.8)                      | 140 (89.2)      |
| Pomalidomide                                   | 104 (87.4)                      | 140 (89.2)      |
| Thalidomide                                    | 25 (21.0)                       | 34 (21.7)       |
| Other class                                    | 119 (100)                       | 155 (98.7)      |
| Doxorubicin                                    | 19 (16.0)                       | 22 (14.0)       |
| Other miscellaneous                            | 119 (100)                       | 155 (98.7)      |
| Other mAb class                                | 27 (22.7)                       | 33 (21.0)       |
| Elotuzumab                                     | 13 (10.9)                       | 15 (9.6)        |
| Other mAb miscellaneous                        | 15 (12.6)                       | 21 (13.4)       |
| PI class                                       | 115 (96.6)                      | 145 (92.4)      |
| Bortezomib                                     | 80 (67.2)                       | 101 (64.3)      |
| Carfilzomib                                    | 72 (60.5)                       | 86 (54.8)       |
| Ixazomib                                       | 19 (16.0)                       | 22 (14.0)       |
| Oprozomib PI miscellaneous                     | 1 (0.8) 1 (0.8)                 | 1 (0.6) 1 (0.6) |
| Received an IMfiD,PI,and anti-CD38 mAb         |                                 |                 |
| (hiple-class exposed), n (96)                  | 119 (100)                       | 125 (79.6)      |
| ON                                             | 0                               | 32 (20.4)       |
| Double-class refractory only, n (%6)           |                                 |                 |
| BL                                             | 0                               | 30 (19.1)       |
| No                                             | 119 (100)                       | 127 (80.9)      |

Abbreviations: IMiD = immumomodulatory dhug: mAb = monoclonal antibody; n =mumber of patient in each category: N = total number of patients in therelevsnt snalysis set; PI = proteasome inhibitor, SD = gtundard deviation.

a\"Other miscellaneous\"includes dexamethasone.

<div style=\"page-break-after: always\"></div>

Table 16. Refractory status

| Refractory Status                                                                | Triple-dlass Reractory (N-119) n (4)   | Ovenll (N-157) n(9)   |
|----------------------------------------------------------------------------------|----------------------------------------|-----------------------|
| Refiactory to most recent prior regimen                                          | 117 (98.390)                           | 01 86 151             |
| Refiactory to prior allyhator                                                    | 76 (63.996)                            | 92 (55.690)           |
| Refaetory to prior darabmrumab                                                   | 112 (94.1%)                            | 117 (74.5%)           |
| Refractory to pnor pomalidomide                                                  | 104 ($7.4%)                            | 140 ($9.2%)           |
| Rehaetory to pier daranumumab and pomlkomide                                     | 97 (81.594)                            | 100 (63.7%4)          |
| Reffactory andor intolerant to prior IMD                                         | 119 (100%)                             | 156 (99.4%)           |
| Refuxctory to pnor IMD                                                           | 116 (97.59)                            | 153 (97.598)          |
| Intolerant to prior IMiD                                                         | 9 (7.6%)                               | 10 (6.40)             |
| Refiactory andor intolerant to prior PI                                          | 119 (100.%)                            | 06106H1               |
| Refaetory to pnorPI                                                              | 115 (96.690)                           | 145 (92.4)            |
| Intolerant to prior PI                                                           | 9 (07.64)                              | 10 (6.49)             |
| Refhaclory andor intolerant wo pnor ant-CD3s mAb                                 | 119 (100.4)                            | 125 (79.694)          |
| Refnctory to pnor anti-CD3S mAb                                                  | 119 (100)                              | 125 (79.6%)           |
| Intolerant to prior mti-CD38 mAb                                                 |                                        | 2(1.394)              |
| Received an IMiD and PI only but not anti-CD38 mAb (double-class exposed)        | 0                                      | 32(20.490)            |
| Refastery to pior PI and IMD only, md not anti-CDIs mAb (double-dlaw refractory) |                                        | 30 (19.19)            |
| Received an IMD, Pl, and Anti-CD3S mAb (miple-claw exposed)                      | 119 (100.4)                            | 125 (79.694)          |
| Patientsrefiaclory to at leat 1 comiponent of most recent pnior regimen          | 117 (98.99)                            | 154 (98.19)           |

Tnplcb ectory was dfiod refctory or intolent to st kost oe proteeo hibior, at least Q0 imemunouodubaiory drug, and at least one anti-CD3s monocloral anhbody.

FAS =Full Anlis Sat, IMAD mmuoodibioy dg, mAbmcoocloa snnbody, Pl pousoow uhiior

## · Numbers analysed

A total of 157 patients overall were treated in the study and included in the FAS. The TCR subpopulation consisted of 119 patients. The HRQoL analysis set comprised 64 of the 72 patients who enrolled on or after protocol version 5.0, and was used for analysis of PROs of the functional status and well-being endpoints.

## · Outcomes and estimation

## Primary endpoint - ORR

Based on Investigator assessment, a total of 46 patients out of 157 had a best response of PR or better for an overall confirmed response rate of 29.3% (95% CI: 22.32%, 37.08%) in the overall study population (Table 17; data cut-off 14 Jan 2020). One sCR was reported and no complete responses. A sensitivity analysis based on IRC assessment indicated similar results for the ORR (29.9% [95% CI: 22.9, 37.8]).

The overall confirmed response rate was 26.1% (95% CI: 18.44%, 34.89%) for the triple-class refractory subpopulation based on Investigator and IRC assessment.

Exploratory updated results with 1.5 years additional follow up (data cut-off 12 Aug 2021) suggest an ORR of 33.8% (95% CI: 26.4%, 41.7%) for the overall population and 29.1% (95% CI: 21.0%, 38.2%) for the applicant's proposed indication population (N=117).

<div style=\"page-break-after: always\"></div>

Table 17. ORR based on Investigator and IRC Assessment (FAS)

|                                                  | Investigator Assessment             | Investigator Assessment   | IRC Assessment                      | IRC Assessment    |
|--------------------------------------------------|-------------------------------------|---------------------------|-------------------------------------|-------------------|
| Variable                                         | Triple-class Refractory N=119 n (%) | All N=157 n (%)           | Triple-class Refractory N=119 n (%) | All N=157 n (%)   |
| ORR: SCR + CR +VGPR + PR, % (95% CI)             | 26.1 (18.4, 34.9)                   | 29.3 (22.3, 37.1)         | 26.1 (18.4, 34.9)                   | 29.9 (22.9, 37.8) |
| CBR: SCR + CR + VGPR + PR + MR, % (95% CI)       | 39.5 (30.7, 48.9)                   | 45.2 (37.3, 53.4)         | 37.8 (29.1, 47.2)                   | 43.9 (36.1, 52.1) |
| DSR: sCR + CR + VGPR + PR + MIR + SD, % (95% CI) | 64.7 (55.4, 73.2)                   | 68.8 (60.9, 75.9)         | 63.9 (54.6, 72.5)                   | 68.2 (60.3, 75.4) |
| Best overall response, n (%)                     |                                     |                           |                                     |                   |
| Stringent complete response (sCR)                | 0                                   | 1 (0.6)                   | 0                                   | 1 (0.6)           |
| Complete response (CR)                           | 0                                   | 0                         | 0                                   | 0                 |
| Very good partial response (VGPR)                | 13 (10.9)                           | 17 (10.8)                 | 14 (11.8)                           | 19 (12.1)         |
| Partial response (PR)                            | 18 (15.1)                           | 28 (17.8)                 | 17 (14.3)                           | 27 (17.2)         |
| Minimal response (MR)                            | 16 (13.4)                           | 25 (15.9)                 | 14 (11.8)                           | 22 (14.0)         |
| Stable disease (SD)                              | 30 (25.2)                           | 37 (23.6)                 | 31 (26.1)                           | 38 (24.2)         |
| Progressive disease (PD)                         | 35 (29.4)                           | 42 (26.8)                 | 30 (25.2)                           | 36 (22.9)         |
| Not evaluablea                                   | 7 (5.9)                             | 7 (4.5)                   | 13 (10.9)                           | 14 (8.9)          |

Abbreviations: CBR = clinical benefit rate; DSR = disease stabilization rate; IRC =Independent Review Committee; n =number of patients in each category; N = total number of patients in the relevant analysis set; ORR = overall response rate.

aNot evaluable due tonopostbaseline or only1 postbaseline assessment before data cutoff, or nopostbaseline assessment due to other reasons.

## Key secondary endpoint - Duration of Response

At the time of the data cutoff (14 Jan 2020), 46 patients (30 patients with events and 16 censored patients) achieved PR or better; the median DOR in the overall study population was 5.5 months (95% CI: 3.9, 7.6) based on investigator assessment (Table 18). Of the 30 patients with events, 27 patients (17.2%) progressed and 3 patients died (1.9%). The reason for censoring was patients without documented progression at the time of the data cut-off (16 patients [10.2%]).

By Investigator assessment, median DOR in the TCR subgroup was 4.4 months (95% CI: 3.4, 7.6) . DOR was measured for 31/119 (26.1%) of patients in this subgroup; 20 patients (16.8%) had an event and 11 were censored patients (patients without documented disease progression at the time of the data cut-off: 9.2%).

Assessment by the IRC yielded slightly longer median DORs compared with Investigator-assessed DORs in both the overall study population (6.7 months) and TCR subgroup (5.5 months).

The DOR at the updated data-cut of 12 Aug 2021 was 6.70 months (95% CI: 4.40, 8.11) for the overall population and 6.97 months (95% CI: 3.88, 9.79) for the applicant's proposed indication population (N=117).

<div style=\"page-break-after: always\"></div>

Table 18. Duration of Response (PR or better) Based on Investigator and IRC Assessment (FAS)

|                                             | InvestigatorAssessment        | InvestigatorAssessment   | IRCAssessment                 | IRCAssessment   |
|---------------------------------------------|-------------------------------|--------------------------|-------------------------------|-----------------|
| Variable                                    | Triple-class Refractory N=119 | All N=157                | Triple-class Refractory N=119 | All N=157       |
| OR (≥ PR), n (%)                            | 31 (26.1)                     | 46 (29.3)                | 31 (26.1)                     | 47 (29.9)       |
| Patients with events,n (%)                  | 20 (16.8)                     | 30 (19.1)                | 21 (17.6)                     | 31 (19.7)       |
| Patients censored, n (%)                    | 11 (9.2)                      | 16 (10.2)                | 10 (8.4)                      | 16 (10.2)       |
| Responseduration(months)Quartiles (95% CI)a |                               |                          |                               |                 |
| P25                                         | 3.1 (2.4, 3.9)                | 3.7 (3.0, 4.0)           | 3.4 (2.4, 4.6)                | 3.8 (3.0, 4.4)  |
| Median                                      | 4.4 (3.4, 7.6)                | 5.5 (3.9, 7.6)           | 5.5 (4.2, 8.1)                | 6.7 (4.2, 8.1)  |
| P75                                         | 8.1 (7.4, NE)                 | 11.2 (7.4, NE)           | 9.4 (7.5, NE)                 | 12.2 (7.5, NE)  |

Abbreviations:BOR =best overall response; n =number of patients in each category; N = total number of patients in the relevant analysis set; NE = not evaluable; P25 = 25th percentile; P75 = 75th percentile; PR = partial response.

Notes: Only patients whose BOR of PR or better, as determined by the Investigator, are included.

aKaplan-Meier product-limit estimates.

## Other secondary endpoints

## PFS

Median PFS in the overall study population was 4.24 months (95% CI: 3.42, 4.86;

Table 19; Figure 6) based on Investigator assessment and after a median follow up of 10.18 months. Based on IRC assessment, median PFS was similar: 4.37 months (95% CI: 3.42, 4.83).

Median PFS in the TCR subpopulation was 3.94 months (95% CI: 3.02, 4.63) based on Investigator assessment and 3.98 months (95% CI: 3.02, 4.53) based on IRC.

Table 19. PFS Based on Investigator and IRC Assessment (FAS)

|                                          | InvestigatorAssessment        | InvestigatorAssessment   | IRCAssessment                 | IRCAssessment   |
|------------------------------------------|-------------------------------|--------------------------|-------------------------------|-----------------|
| Variable                                 | Triple-class Refractory N=119 | All N=157                | Triple-class Refractory N=119 | All N=157       |
| Patients with events, n (%)              | 94 (79.0)                     | 121 (77.1)               | 93 (78.2)                     | 118 (75.2)      |
| Patients censored, n (%o)                | 25 (21.0)                     | 36 (22.9)                | 26 (21.8)                     | 39 (24.8)       |
| PFSDuration (months) Quartiles (95% CI)* |                               |                          |                               |                 |
| P25                                      | 1.9 (1.6, 2.3)                | 2.0 (1.8, 2.5)           | 2.1 (1.8, 2.4)                | 2.3 (1.9, 2.8)  |
| Median                                   | 3.9 (3.0, 4.6)                | 4.2 (3.4, 4.9)           | 4.0 (3.0, 4.5)                | 4.4 (3.4, 4.8)  |
| P75                                      | 6.5 (5.3, 9.3)                | 7.8 (6.4, 10.5)          | 6.3 (5.2, 9.4)                | 7.8 (5.8, 10.3) |

Abbreviation: CI = confidence interval; IRC = independent review committee; n = number of patients in each category; N = total number of patients in the relevant analysis set; P25 = 25th percentile; P75 = 75th percentile.

aKaplan-Meier product-limit estimates.

<div style=\"page-break-after: always\"></div>

Figure 6. PFS Based on Investigator Assessment in overall study population and TCR subgroup (FAS)

<!-- image -->

OS

The median OS was 11.63 months (95% CI: 9.30, 15.41) for the overall study population after a median OS follow-up of 14.00 months (95% CI: 10.78, 18.69; Table 20, Figure 7).

In the TCR population, median OS was 11.24 months (95% CI: 7.66, 13.17).

Table 20. Overall Survival (FAS)

|                                                  | EMD a (N=55)        | Triple-class refractory b (N=119)   | Overall (N=157)      |
|--------------------------------------------------|---------------------|-------------------------------------|----------------------|
| Number (%) of patients with events               | 40 (72.7%)          | 72 (60.5%)                          | 88 (56.1%)           |
| Number (%) of patients censored                  | 15 (27.3%)          | 47 (39.5%)                          | 69 (43.9%)           |
| Alive:Study discontinuation                      | 0                   | 2 (1.7%)                            | 3 (1.9%)             |
| Alive: Ongoing                                   | 15 (27.3%)          | 45 (37.8%)                          | 66 (42.0%)           |
| Survival duration (months) potential follow-up ( | 16.76 (9.72, 29.27) | 14.00 (10.81, 17.41)                | 14.00 (10.78, 18.69) |
| Survival duration (months) quartiles (95% C1) d  |                     |                                     |                      |
| 25t Percentile                                   | 3.42 (2.10, 5.13)   | 5.06 (3.88, 5.82)                   | 5.26 (4.24, 6.41)    |
| Median                                           | 6.47 (5.13, 9.66)   | 11.24 (7.66, 13.17)                 | 11.63 (9.30, 15.41)  |
| 75th Percentile                                  | 18.46 (9.30, 24.44) | 18.46 (14.49, 28.85)                | 21.13 (17.64, NE)    |

- CI = confidence interval; EMD = extramedullary disease; FAS = Full Analysis Set; NE = not estimable

a Extramedullary disease was defined as myeloma disease either originating in, but extending beyond, the cortical bone or as a separate soft tissue mass.

c Calculated using the reverse Kaplan-Meier method where the censoring variable is inverted.

b Triple-class refractory was defined as refractory or intolerant to at least one proteasome inhibitor, at least one immunomodulatory drug, and at least one anti-CD38 monoclonal antibody.

dKaplan-Meier product limit estimates.

<div style=\"page-break-after: always\"></div>

Figure 7. Overall Survival in overall study population and TCR subgroup(FAS)

<!-- image -->

## CBR

The clinical benefit rate (MR or higher) was 45.2% (95% CI: 37.3, 53.4) based on investigator assessment in the overall study population and 39.5% (95% CI: 30.7, 48.9) in the TCR subpopulation. Similar results were obtained based on IRC assessment.

## Time to response

In the overall and TCR study population, the median time to response was 1.9 months (Inv based). Based on IRC assessment, the TTR was 1.2 months and 1.5 months, respectively.

## TTP

By Investigator assessment, median TTP in the overall study population was 4.4 months (95% CI: 3.8, 5.3) and among TCR patients 4.1 months (95% CI: 3.1, 4.9).

## TTNT

Median time to next treatment or death was 5.8 months in the overall study population (95% CI: 4.8, 7.1) and 5.3 months (95% CI: 4.5, 6.3) in the TCR population. Median time to next treatment (without death as event) was 8.21 months (7.16, 10.84) in the overall study population, and 7.89 months (6.93, 10.87) in the TCR population.

## Duration of stable disease

The median duration of SD was 3.8 months (95% CI: 3, 4.6) in both the overall study population as well as the TCR subgroup.

## Duration of disease stabilization

For the overall study population, median duration of disease stabilization was 5.6 months (95% CI: 4.9, 6.8) and in the TCR subgroup 5.3 months (95% CI: 4.6, 6.5).

## Duration of clinical benefit

<div style=\"page-break-after: always\"></div>

Of the 71 patients with investigator-assessed response of MR or better in the overall study population, median duration of clinical benefit was 6.7 months (95% CI: 4.3, 7.5). Median duration of clinical benefit was 4.6 months (95% CI: 3.9, 7.5) in the 47 patients of the TCR subgroup with an Investigator-assessed response of MR or better.

## Change from Baseline in levels of serum and urine M-protein spike

The majority of patients (118, 81.4%) achieved a decrease of M-protein levels.

## Change from Baseline in QLQ-C30 assessment

A total of 36 patients of the HRQoL Analysis set met the criteria for having evaluable PROs at Cycle 4. In the EORTC-QLQ-C30, the mean change from baseline of the Global Health Status/QoL score to Cycle 4 was 2.8 (95% CI: -4.8, 10.4), the mean change from baseline in symptom score for Fatigue was 3.7 (95% CI: -3.0, 10.4), and the mean change from baseline in symptom score for Pain was 0.9 (95% CI: -7.8, 9.7). (Of note: For GHS/QoL positive values indicate improvement while for Pain and Fatigue negative values indicate improvement.) For the 27 evaluable TCR patients, similar results were presented.

## Change from Baseline in EQ-5D-3L assessment

While small mean changes were observed, the EQ-5D-3L health utility index and VAS mean scores were generally stable over time by cycle for the overall and TCR study population.

## Change from Baseline in levels of serum and urine M-protein spike

The median relative reduction from baseline to best response was -36.8% in 108 TCR patients evaluable for response. Greater reductions were seen in patients achieving responses (PR or VGPR); median reduction was 78.9% and 98.6%  in patients with PR and VGPR as best response, respectively.

## · Ancillary analyses

Subgroup analyses of efficacy endpoints of Study OP-106 and O-12-M1 were performed by demographic and disease characteristics. Responses seem to increase with age and were slightly higher in females vs. males. Responses were shorter with increasing ISS Stage at baseline and with higher cytogenetic risk status. In patients that received ≥6 prior lines of therapy, responses were lower (19.2%) vs patients with &lt;4 (29.4 %) or ≥4 -≤5 prior lines (32%) in the TCR population. Patients refractory to an alkylator had lower response rates (18.4%) vs. patients not refractory to an alkylator (39.5%). Of note: there was no formal hypothesis testing set up in this single-arm, open-label study and relatively small numbers of patients were included per subgroup.

Efficacy results for patients previously exposed to melphalan in Study OP-106 are presented in Table 21.

Table 21. Efficacy results in melphalan exposed patients

Efficacy results within subpopulations in OP-106-original CSRefficacy Jan-2020

|                                           | N   | ORR,eVs (%6)[95%C1]   | DOR (95% CI)     | PFS (95% CI)     | OS (95% CI)        |
|-------------------------------------------|-----|-----------------------|------------------|------------------|--------------------|
| Mlelphalan(high or standard dose) exposed | 88  | 21 (23.9) [15.4-34.1] | 4.24 (3.22-8.11) | 3.81 (3.09-4.53) | 8.74 (6.05-11.53)  |
| HD melphalan exposed                      | 73  | 18 (24.7) [15.3-36.1] | 4.24 (3.22-8.11) | 4.01 (3.09-4.67) | 10.12 (6.47-13.24) |
| Melphalan (standard dose only) exposed 15 |     | 3 (20.0)[4.3-48.1]    | 6.36 (3.02-NA)   | 2.40 (1.12-5.06) | 5.06 (1.77-7.20)   |
| HD melphalanrefractory                    | 8   | 1 (12.5) [0.3-52.7]   | 3.22 (NA-NA)     | 3.98 (1.31-NA)   | 4.24 (2.23-9.66)   |
| Melphalanrefractory(standard dose only)   | 12  | 1 (8.3) [0.2-38.5]    | 3.42 (NA-NA)     | 3.32 (1.77-5.26) | 5.78 (2.00-24.44)  |

<div style=\"page-break-after: always\"></div>

In response to D195 list of outstanding issues, the applicant presented post-hoc subgroup results for the 3L+ TCR study population by time to progression since stem cell transplantation (Table 22). This is based on exploratory analyses in study OP-103 (see supportive study below). The response rate as well as median DoR was numerically higher in patients without prior autologous stem cell transplantation (ASCT) or time to progression (TTP) ≥3 years compared to patients with more recent transplantation with TTP &lt;36 months.

Table 22. Efficacy results in TCR 3L+ patients and with no prior ASCT or who have progressed more than 36 months from an ASCT and patient who have progressed within 36 months from an ASCT in OP-106 HORIZON study

| Population                                         | TCR3L+ (n=110)           | NoASCTorprogressed >=36months(n=52)   | ASCTprogressed<36 months (n=58)   |
|----------------------------------------------------|--------------------------|---------------------------------------|-----------------------------------|
| Overall response rate (ORR), 95% CI (%)            | 28 (25.5) [17.6%, 34.6%] | 15 (28.8) [17.1, 43.1]                | 13 (22.4) [12.5, 35.3]            |
| Median duration of response (DoR), 95% CI (months) | 5.4 (3.5-8.1)            | 7.6 (3.0-12.3)                        |                                   |
| Median time tofirstresponse(range)                 | 2.1 (1.0-15.3)           |                                       | 3.9 (3.1-7.4)                     |
|                                                    |                          | 2.3 (1.0-10.5)                        | 1.9 (1.0-15.3)                    |
| MedianPFS,95%CI(months)                            | 3.7 (2.8-4.4)            | 4.2 (2.1-5.4)                         | 3.4 (2.8-4.2)                     |
| MedianOS,95%CI(months)                             | 9.5 (6.4-12.0)           | 11.2 (6.4-12.7)                       | 8.6 (5.6-13.2)                    |

## · Summary of main efficacy results

The following table summarises the efficacy results from the main study supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 23 Summary of efficacy for trial OP-106 (HORIZON)

Title: A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory Pomalidomide and/or an antiCD38 Monoclonal Antibody

| Study identifier   | Sponsor ID: OP-106 (HORIZON) EudraCT number: 2016-000865-21                                                                                                                                                                                                         | Sponsor ID: OP-106 (HORIZON) EudraCT number: 2016-000865-21                                                                                                                                                                                                         |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design             | NCT number: NCT02963493 Phase 2 single-arm, open-label, multi-centre study of melphalan flufenamide in combination with dexamethasone (DEX) in patients with RRMM who are refractory to pomalidomide (POM) and/or daratumumab (DARA)/anti-CD38 monoclonal antibody. | NCT number: NCT02963493 Phase 2 single-arm, open-label, multi-centre study of melphalan flufenamide in combination with dexamethasone (DEX) in patients with RRMM who are refractory to pomalidomide (POM) and/or daratumumab (DARA)/anti-CD38 monoclonal antibody. |
|                    | Duration of treatment phase as defined in protocol: until progressive disease (PD) or unacceptable toxicity. Duration of Run-in phase: N/A. Duration of Follow-up phase as defined in protocol: until death, or subsequent therapy, or for 24 months after PD.      | Duration of treatment phase as defined in protocol: until progressive disease (PD) or unacceptable toxicity. Duration of Run-in phase: N/A. Duration of Follow-up phase as defined in protocol: until death, or subsequent therapy, or for 24 months after PD.      |
| Hypothesis         | An ORR of at least 15% would represent a clinically meaningful treatment effect, according to protocol.                                                                                                                                                             | An ORR of at least 15% would represent a clinically meaningful treatment effect, according to protocol.                                                                                                                                                             |
| Treatments groups  | Overall study population                                                                                                                                                                                                                                            | N=157. All treated patients.                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                                                    | Triple class refractory (TCR) subpopulation                                                                                                                                     | Triple class refractory (TCR) subpopulation                                                                                                                                     | N=119. Refractory or intolerant to at least one PI, at least one IMiD, and at least one anti-CD38 monoclonal                                                                                    | N=119. Refractory or intolerant to at least one PI, at least one IMiD, and at least one anti-CD38 monoclonal                                                                                    |
|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                          | Primary endpoint                                                                                                                                                                | Overall Response Rate (ORR)                                                                                                                                                     | Proportion of patients for whom the best overall confirmed response is stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).  | Proportion of patients for whom the best overall confirmed response is stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).  |
| Endpoints and definitions                          | Key secondary endpoint                                                                                                                                                          | Duration of response (DOR)                                                                                                                                                      | For patients who achieved a PR or better; the duration in months from first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause. | For patients who achieved a PR or better; the duration in months from first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause. |
| Endpoints and definitions                          | Other secondary endpoint                                                                                                                                                        | Progression free survival (PFS)                                                                                                                                                 | The time in months from start of treatment until first evidence of confirmed disease progression or death due to any cause, whichever occurred first.                                           | The time in months from start of treatment until first evidence of confirmed disease progression or death due to any cause, whichever occurred first.                                           |
| Endpoints and definitions                          | Other secondary endpoint                                                                                                                                                        | Overall survival (OS)                                                                                                                                                           | The time in months from the date of the first dose of study drug to date of death due to any cause.                                                                                             | The time in months from the date of the first dose of study drug to date of death due to any cause.                                                                                             |
| Database lock 2020-03-28 (data cut-off 2020-01-14) | Database lock 2020-03-28 (data cut-off 2020-01-14)                                                                                                                              | Database lock 2020-03-28 (data cut-off 2020-01-14)                                                                                                                              | Database lock 2020-03-28 (data cut-off 2020-01-14)                                                                                                                                              | Database lock 2020-03-28 (data cut-off 2020-01-14)                                                                                                                                              |
| Results and Analysis*                              | Results and Analysis*                                                                                                                                                           | Results and Analysis*                                                                                                                                                           | Results and Analysis*                                                                                                                                                                           | Results and Analysis*                                                                                                                                                                           |
| Analysis description                               | Primary Analysis                                                                                                                                                                | Primary Analysis                                                                                                                                                                | Primary Analysis                                                                                                                                                                                | Primary Analysis                                                                                                                                                                                |
| Analysis population and time point description     | Full analysis set (FAS), defined as all subjects who received at least one dose of melflufen. Best confirmed response measured during treatment until progressive disease (PD). | Full analysis set (FAS), defined as all subjects who received at least one dose of melflufen. Best confirmed response measured during treatment until progressive disease (PD). | Full analysis set (FAS), defined as all subjects who received at least one dose of melflufen. Best confirmed response measured during treatment until progressive disease (PD).                 | Full analysis set (FAS), defined as all subjects who received at least one dose of melflufen. Best confirmed response measured during treatment until progressive disease (PD).                 |
| Descriptive statistics and estimate variability    | Treatment group                                                                                                                                                                 | Treatment group                                                                                                                                                                 | Overall study population                                                                                                                                                                        | TCR subpopulation                                                                                                                                                                               |
| Descriptive statistics and estimate variability    | Number of                                                                                                                                                                       | Number of                                                                                                                                                                       | n=157                                                                                                                                                                                           | N=119                                                                                                                                                                                           |
| Descriptive statistics and estimate variability    | subject ORR                                                                                                                                                                     | subject ORR                                                                                                                                                                     | 29.3%                                                                                                                                                                                           | 26.1%                                                                                                                                                                                           |
| Descriptive statistics and estimate variability    | 95% CI                                                                                                                                                                          | 95% CI                                                                                                                                                                          | (22.32; 37.08)                                                                                                                                                                                  | (18.44; 34.89)                                                                                                                                                                                  |
| Descriptive statistics and estimate variability    | Median DoR**                                                                                                                                                                    | Median DoR**                                                                                                                                                                    | 5.49 months                                                                                                                                                                                     | 4.40 months                                                                                                                                                                                     |
| Descriptive statistics and estimate variability    | 95% CI                                                                                                                                                                          | 95% CI                                                                                                                                                                          | (3.88; 7.59)                                                                                                                                                                                    | (3.42; 7.59)                                                                                                                                                                                    |
| Descriptive statistics and estimate variability    | Median PFS                                                                                                                                                                      | Median PFS                                                                                                                                                                      | 4.24 months                                                                                                                                                                                     | 3.94 months                                                                                                                                                                                     |
| Descriptive statistics and estimate variability    | 95% CI                                                                                                                                                                          | 95% CI                                                                                                                                                                          | (3.42; 4.86)                                                                                                                                                                                    | (3.02; 4.63)                                                                                                                                                                                    |
| Descriptive statistics and estimate variability    | Median OS                                                                                                                                                                       | Median OS                                                                                                                                                                       | 11.63 months                                                                                                                                                                                    | 11.24 months                                                                                                                                                                                    |
| Descriptive statistics and estimate variability    | 95% CI                                                                                                                                                                          | 95% CI                                                                                                                                                                          | (9.30; 15.41)                                                                                                                                                                                   | (7.66; 13.17)                                                                                                                                                                                   |
| Notes                                              | *Presented results are based on Investigator assessment. **For the calculation of DoR, patients who achieved a PR or better were                                                | *Presented results are based on Investigator assessment. **For the calculation of DoR, patients who achieved a PR or better were                                                | *Presented results are based on Investigator assessment. **For the calculation of DoR, patients who achieved a PR or better were                                                                | *Presented results are based on Investigator assessment. **For the calculation of DoR, patients who achieved a PR or better were                                                                |

<div style=\"page-break-after: always\"></div>

## 2.6.5.3. Clinical studies in special populations

Clinical efficacy has not been investigated for special populations in separate clinical studies.

Subgroup analyses by age (&lt;65, ≥ 65-≤ 75 and &gt;75) have been presented for the pivotal trial, suggesting increasing efficacy with age.

No separate efficacy data were presented for included patients with mild to moderate renal- or mild hepatic impairment. Patients with an estimated GFR below 45 mL/min/1.73 m2 or moderate to severe hepatic impairment have not been studied.

Table 24 Age distribution among patients included in efficacy analyses

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 113/246                                           | 33/246                                            | 4/246                                           |
| Non Controlled Trials | 54/157                                            | 24/157                                            | 1/157                                           |

## 2.6.5.4. In vitro biomarker test for patient selection for efficacy

N/A

## 2.6.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

N/A

## 2.6.5.6. Supportive study

## Study OP-103 - OCEAN

Randomized, controlled, open-label Phase 3 Study OP-103 investigated melflufen + dex with pomalidomide + dex in patients with relapsed refractory MM who were refractory to lenalidomide.

## Methods

## Study Participants

## Key inclusion criteria

- -Male or female, age 18 years or older
- -Prior diagnosis of multiple myeloma with documented disease progression in need of treatment at time of screening
- -Measurable disease defined as any of the following:
- o Serum monoclonal protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP)

<div style=\"page-break-after: always\"></div>

- o ≥ 200 mg/24 hours of monoclonal protein in the urine on 24-hour urine electrophoresis (UPEP)
- o Serum free light chain (SFLC) ≥ 10 mg/dL AND abnormal serum kappa to lambda free light chain ratio
- -Received 2 to 4 prior lines of therapy including lenalidomide and a PI, either sequential or in the same line, and was refractory (relapsed and refractory or refractory) to both the last line of therapy and to lenalidomide ( ≥ 10 mg) administered within 18 months prior to randomization (refractory to lenalidomide included patients who relapsed while on lenalidomide therapy or within 60 days of last dose following at least 2 cycles of lenalidomide with at least 14 doses of lenalidomide per cycle)
- -Life expectancy of ≥ 6 months
- -ECOG performance status ≤ 2
- -Females of childbearing potential had a negative pregnancy test or pomalidomide pregnancy prevention plan completed within 10 to 14 days prior to planned start of treatment. All patients had to agree to either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control.
- -12-lead electrocardiogram (ECG) with corrected QT (QTc) interval calculated by Fridericia Formula (QTcF) interval of ≤ 470 msec
- -The following laboratory results must have been met during screening (within 21 days) and also immediately before study drug administration on C1D1 ( 'inclusion criterion 10' ):
- o Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 (1.0 x 109/L) (growth factors could not be used within 10 days prior to first drug administration)
- o Platelet count ≥ 75,000 cells/mm3 (75 x 109/L) (without required transfusions during the 10 days prior to first drug administration)
- o Hemoglobin ≥ 8.0 g/dl (red blood cell [RBC] transfusions were permitted)
- o Total bilirubin ≤ 1.5 x upper limit of normal (ULN), or patients diagnosed with Gilberts syndrome, that were reviewed and approved by the medical monitor
- o Aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 3.0 x ULN
- o Renal function: Estimated creatinine clearance by Cockcroft-Gault formula ≥ 45 mL/min (Appendix G of the protocol [Appendix 16.1.1])
- -Must be able to take antithrombotic prophylaxis

## Key exclusion criteria

- -Primary refractory disease (i.e., never responded with ≥ MR) to any prior therapy)
- -Evidence of mucosal or internal bleeding and/or were platelet transfusion refractory (i.e., platelet count failed to increase by &gt; 10,000 cells/mm3 after transfusion of an appropriate dose of platelets)
- -Any medical conditions that, in the Investigator's opinion, would have imposed excessive risk to the patient or would have adversely affected his/her participating in this study.
- -Prior exposure to pomalidomide

<div style=\"page-break-after: always\"></div>

- -Known intolerance to IMiDs ( ≥ Grade 3 hypersensitivity reaction or at the Investigator ' s discretion)
- -Known active infection requiring parenteral or oral anti-infective treatment within 14 days of randomization
- -Other malignancy diagnosed or requiring treatment within the past three years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma insitu of the cervix or breast or very low and low risk prostate cancer in active surveillance
- -Pregnant or breast-feeding females
- -Serious psychiatric illness, active alcoholism, or drug addiction that may have hindered or confused compliance or follow-up evaluation
- -Known human immunodeficiency virus or active hepatitis C viral infection
- -Active hepatitis B viral infection
- -Concurrent symptomatic amyloidosis or plasma cell leukemia
- -POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein [M-protein], and skin changes)
- -Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to randomization. The use of live vaccines within 30 days before randomization. IMiDs, PIs, or corticosteroids within 2 weeks prior to randomization. Other investigational therapies and monoclonal antibodies within 4 weeks of randomization. Prednisone up to but no more than 10 mg orally once daily or its equivalent for symptom management of comorbid conditions was permitted but dose should have been stable for at least 7 days prior to randomization
- -Residual side effects to previous therapy &gt; Grade 1 prior to randomization (alopecia any grade and/or neuropathy Grade 2 without pain were permitted)
- -Prior peripheral stem cell transplant within 12 weeks of randomization
- -Prior allogeneic stem cell transplantation with active graft-versus-host-disease
- -Prior major surgical procedure or radiation therapy within 4 weeks of randomization
- -Known intolerance to steroid therapy

## Treatments

Patients were randomized to receive:

- -Melflufen 40 mg IV on Day 1 of every 28-Day cycle, or
- -Pomalidomide (POM) 4 mg capsules orally on Days 1 to 21 in each 28-Day cycle.

Both treatment arms were administered 40 mg dex orally once weekly on Days 1, 8, 15 and 22 of each 28-Day cycle for patients &lt;75 years of age or 20 mg for patients ≥75 years.

Dose modifications, including reductions, and delays for both melflufen and dexamethasone were implemented based on patient tolerance.

<div style=\"page-break-after: always\"></div>

Patients received treatment until there was documented PD (confirmed on two consecutive assessments), unacceptable toxicity or the patient/treating physician determined it was not in the patient's best interest to continue.

## Objectives

The primary objective of this Phase 3 trial was to compare PFS between both treatment arms as assessed by IRC according to IMWG-URC response criteria.

Key secondary objectives were to assess and compare ORR, OS, safety and tolerability in both treatment arms.

## Outcomes/endpoints

The primary endpoint was PFS, defined as time (months) from date of randomization to the earlier of confirmed disease progression or death due to any cause. Progression dates were assessed by the IRC using the IMWG-URC.

The key secondary endpoints were:

- -ORR, defined as the proportion of patients achieving a best confirmed response of sCR, CR, VGPR, or PR using local laboratory evaluation.
- -OS, defined as time (months) from date of randomization to death due to any cause. Patients still alive at end of study, or lost to follow up, were censored at last day known alive.

Other secondary efficacy endpoints were:

Unless stated otherwise, response and progression status were to be assessed by the IRC using the IMWG-URC.

- -DOR defined as the time from the first evidence of confirmed assessment of sCR, CR, VGPR, or PR to first confirmed disease progression, or to death due to any cause. Duration of response was defined only for patients with a confirmed PR or better.
- -Clinical benefit rate (CBR), i.e., ≥ MR: is the rate of response evaluable patients that achieved a confirmed MR or better.
- -TTR defined as the time from the date of randomization to the date of the first documented confirmed response in a patient that had responded with ≥ PR.
- -TTP defined as the time from the date of randomization to the date of the first documented confirmed PD.
- -Duration of clinical benefit (DOCB) defined as the time from the first evidence of confirmed assessment of sCR, CR, VGPR, PR, or MR to first confirmed disease progression, or to death due to any cause. DOCB was defined only for patients with a confirmed MR or better.
- -Best response during the study (sCR, CR, VGPR, PR, MR, SD, or PD) using the IMWG-URC.
- -Primary and secondary endpoints as assessed by investigators.

<div style=\"page-break-after: always\"></div>

## Randomisation and blinding (masking)

Patients were 1:1 randomized and stratified by age ( ≥ 75 years of age versus &lt; 75 years of age), number of lines of prior therapy (2 versus 3 to 4 prior lines) and international staging system (ISS) Score (1 versus ≥ 2).

The study was unblinded.

## Statistical methods

Analysis sets The Full analysis set (FAS) was defined as all subjects who were randomized. The Per Protocol (PP) analysis set was defined as all patients who received at least one dose of melflufen, pomalidomide, or dexamethasone, and had a baseline assessment of disease status and at least 1 post-baseline assessment for disease response. Patients who had major protocol deviations, related to critical eligibility criteria, the assessment of efficacy or the safety of the patient that could have significantly impacted the interpretation of study results, were excluded from the Per Protocol analysis set.

Efficacy analysis The primary analysis of PFS was performed using a log-rank test stratified by the randomization stratification factors to compare treatment group survival distributions based on the FAS. Superiority of melflufen+dex over pomalidomide+dex with respect to the primary endpoints was claimed if the 2-sided p-value was &lt;0.05 favoring melflufen+dex. In addition to a significant p-value for the treatment comparison based on the log-rank test, the superiority of melflufen+dexamethasone versus pomalidomide+dexamethasone was demonstrated if the upper limit of the 95% CI for the hazard ratio was &lt; 1.0.

Non-inferiority of melflufen+dex versus POM + dex was demonstrated if the upper limit of the 95% CI for the HR was &lt; 1.2.

Multiplicity control Superiority testing of melflufen+dex over pomalidomide+dex with respect to the key secondary endpoints performed using a gatekeeping procedure based on a closed fixed-sequence test, provided the primary efficacy endpoint comparison was statistically significant at an alpha level 0.05. In case of statistical superiority on the primary endpoint then ORR was tested for statistical superiority. In case of statistical superiority on ORR, then overall survival was tested for statistical superiority.

Sample size The planned sample size was 450 patients based on 90% power with 0.05 two-sided significance level and HR of 0.70 (melflufen + dex/POM+dex), an accrual time of 24 months, ~15% early censor rate and a median PFS of POM+ dex of 3.6 months.

Interim analysis No interim analysis were performed. Based on sample size assumptions, the final analysis was to take place when 339 patients had experienced PFS events.

Handling of missing values/censoring/discontinuations Unconfirmed PD as the final response assessment for PFS was also assessed as confirmed PD and, therefore, an event. PFS was rightcensored according to the conventions described in Table 25.

<div style=\"page-break-after: always\"></div>

Table 25. Conventions for Censoring of PFS

| Situation                                                                            | Date of Progression or Censoring                                                                   | Outcome    |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|------------|
| No post baseline response assessments                                                | Date of randomization                                                                              | Censored   |
| Non-protocol systemic anticancer therapy started before documentation of PD or death | Date of last response assessment prior to start of new anticancer therapy                          | Censored   |
| Death or PD after more than 1 consecutively missed response assessment               | Date of last response assessment without documentation of PD that is before the first missed visit | Censored   |
| Unconfirmed PD as the final response assessment                                      | Date of latest PD assessment                                                                       | Progressed |
| Alive and without PD documentation                                                   | Date of last response assessment                                                                   | Censored   |
| Death or PD between scheduled response assessments                                   | Date of death or preceding response assessment showing PD, whichever occurs first                  | Progressed |
| Death before first response assessment                                               | Date of death                                                                                      | Progressed |

PD = disease progression; PFS = progression-free survival

## Results

## Participant flow

A total of 495 patients were randomized in the study. Of these, 21 patients were randomized, but not treated;18 patients randomized to melflufen+dex and 3 patients randomized to pom + dex. The most common reasons were low laboratory values in both treatment arms (Table 26, Figure 8).

Approximately 18% of patients were still receiving treatment as of the data cut-off (3 Feb 2021).

The most common reason for treatment discontinuation was progressive disease (n=257, 54.2%), followed by adverse event (n=73, 15.4%).

<div style=\"page-break-after: always\"></div>

Table 26. Summary of Patient Disposition

|                                                               | Melflufen+Dexamethasone N=246 n(%)   | Pomalidomide+Dexamethasone N=249 n(%)   | Overall N=495 n (%)   |
|---------------------------------------------------------------|--------------------------------------|-----------------------------------------|-----------------------|
| Number of screenedpatients in theEnrolledAnalysisSet          | 一                                    | 一                                       | 644                   |
| Number of screen failures                                     | 一                                    | 一                                       | 149                   |
| Number of randomized patients in the Full Analysis Set b      | 246                                  | 249                                     | 495                   |
| Number of patients randomized not treated                     | 18                                   | 3                                       | 21                    |
| NumberoftreatedpatientsintheSafetyAnalysisSete                | 228 (92.7%)                          | 246 (98.8%)                             | 474 (95.8%)           |
| Number of treated patients in the Per Protocol Analysis Set d | 218 (88.6%)                          | 236 (94.8%)                             | 454 (91.7%)           |
| Number of treated patients in the PRO Analysis Set e          | 77 (31.3%)                           | 81 (32.5%)                              | 158 (31.9%)           |
| Number of treated patients in the PK Analysis Set f           | 224 (91.1%)                          | 一                                       | 224 (45.3%)           |
| Treatment Status                                              |                                      |                                         |                       |
| Ongoing                                                       | 42 (18.4%)                           | 46 (18.7%)                              | 88 (18.6%)            |
| Discontinued                                                  | 186 (81.6%)                          | 200 (81.3%)                             | 386 (81.4%)           |
| Primaryreasonfortreatmentdiscontinuation                      |                                      |                                         |                       |
| Progressive disease                                           | 116 (50.9%)                          | 141 (57.3%)                             | 257 (54.2%)           |
| Adverse event                                                 | 38 (16.7%)                           | 35 (14.2%)                              | 73 (15.4%)            |
| Lack of efficacy                                              | 6 (2.6%)                             | 8 (3.3%)                                | 14 (3.0%)             |
| Physician decision                                            | 17 (7.5%)                            | 9 (3.7%)                                | 26 (5.5%)             |
| Withdrawal by patient                                         | 9 (3.9%)                             | 6 (2.4%)                                | 15 (3.2%)             |
| Lost to follow up                                             | 0                                    | 1 (0.4%)                                | 1 (0.2%)              |
| Number of treated patients in PFS follow-up                   | 10 (4.4%)                            | 1 (0.4%)                                | 11 (2.3%)             |
| Number of treated patients in OS follow-up ?                  | 70 (30.7%)                           | 82 (33.3%)                              | 152 (32.1%)           |
| Study Staus                                                   |                                      |                                         |                       |
| Ongoing                                                       | 126 (51.2%)                          | 129 (51.8%)                             | 255 (51.5%)           |
| Discontinued                                                  | 120 (48.8%)                          | 120 (48.2%)                             | 240 (48.5%)           |
| Primaryreasonforstudydiscontinuation                          |                                      |                                         |                       |
| Death                                                         | 116 (47.2%)                          | 108 (43.4%)                             | 224 (45.3%)           |
| Lost to follow-up                                             | 1 (0.4%)                             | 2 (0.8%)                                | 3 (0.6%)              |
| Withdrawal by patient                                         | 3 (1.2%)                             | 10 (4.0%)                               | 13 (2.6%)             |

OS = overall survival; PFS = progression-free survival; PK = pharmacokinetic; PRO = patient-reported outcomes.

(signing of consent).

The Safety Analysis Set was defined as all patients who received at least one dose of melflufen,pomalidomide, or dexamethasone.

The Full Analysis Set was defined as all randomized patients.

d The Per Protocol Analysis Set was defined as all patients who received at least one dose of melflufen, pomalidomide, or dexamethasone, and had a baseline assessment of disease status and atleast one post-baseline assessment for diseaseresponse.Patients with majorprotocol deviations,related to critical eligibility criteria, the assessment of efficacy orthesafetythat couldsignificantly impact theinterpretationof studyresults,were excludedfromthePerProtocolAnalysisSet.

f The PK Analysis Set was defined as all patients in the Full Analysis Set who feceived at least 1 dose of melflufen and had 3 samples with measurable concentrations in at leastone treatment cycle.

The PRO Analysis Set was defined as all patients who enrolled on or after protocol version 4.1 and had completed the same PRO questionnaire at baseline and post-baseline.

Percentage calculations used theSafetyAnalysisSet as denominator.

hPatients reporting more than one screen failure reason were counted more than once.

<div style=\"page-break-after: always\"></div>

Figure 8. Study OP-103 - Patient Disposition

<!-- image -->

## Conduct of study

The original protocol (version 1.1) was approved on 07 Dec 2016. There were 5 protocol amendments. Key changes pertained to a change of inclusion criteria 4 to allow patients that received lenalidomide and a proteasome inhibitor during the first line of therapy and were refractory to lenalidomide in the first line to potentially enroll in the study to improve accrual; addition of PRO as exploratory endpoint; and an increase in number of sites to ~100 as well as added Asia/Pacific region.

Changes to the planned analyses per the protocol were made in Apr and Jun 2021, following FDA feedback. Key changes pertained to: primary endpoint based on stratified log-rank test; DOR moved from key to other secondary endpoint removing it from multiplicity assessment; addition of 'time from prior ASCT to randomization subgroup analysis' for PFS, ORR and OS as well as imputation rules for this subgroup.

## Protocol deviations

Overall, a total of 154 major protocol deviations were identified during the study as of the data cutoff: 61 deviations related to study procedure or assessment (Table 27).

Table 27. Major Protocol Deviations

| Deviation Category              | MelphalanFlufenamide +Dexamethasone (N=246)   | Pomalidomide +Dexamethasone (N=249)   | Overall (N=495)   |
|---------------------------------|-----------------------------------------------|---------------------------------------|-------------------|
| StudyProcedureorAssessment      | 38 (15.4%)                                    | 23 (9.2%)                             | 61 (12.3%)        |
| Study Medication                | 21 (8.5%)                                     | 14 (5.6%)                             | 35 (7.1%)         |
| Other:GCP                       | 7 (2.8%)                                      | 12 (4.8%)                             | 19 (3.8%)         |
| Inclusion/ExclusionCriteria     | 6 (2.4%)                                      | 7 (2.8%)                              | 13 (2.6%)         |
| RandomizationProcedure          | 7 (2.8%)                                      | 2 (0.8%)                              | (%81) 6           |
| Excluded Concomitant Medication | 2 (0.8%)                                      | 6 (2.4%)                              | 8 (1.6%)          |
| Withdrawal Criteria             | 3 (1.2%)                                      | 1 (0.4%)                              | 4 (0.8%)          |
| Other:SourceDocumentation       | 2 (0.8%)                                      | 1 (0.4%)                              | 3 (0.6%)          |
| Infomed Consent                 | 2 (0.8%)                                      | 0                                     | 2 (0.4%)          |

<div style=\"page-break-after: always\"></div>

## Baseline data

## Demographics

Of the 495 patients in the FAS, the median age (years) was 68.0 years (Table 28). Approximately 36% of patients was &lt;65 years of age. There were slightly more male than female patients (56.4% vs 43.6%) and 90.1% of patients was white. Around 90% of patients had ECOG 0 or 1.

<div style=\"page-break-after: always\"></div>

Table 28. Demographics and Baseline Characteristics (FAS)

| Characteristic                             | Melflufen Deramethasone N=246   | Pomalidomide Dexamethasone N=249   | Overall N=495   |
|--------------------------------------------|---------------------------------|------------------------------------|-----------------|
| Age (years) a                              |                                 |                                    |                 |
| 11                                         | 246                             | 249                                | 495             |
| Mean (SD)                                  | 66.1 (8.98)                     | 66.5 (8.83)                        | 66.3 (8.89)     |
| Median                                     | 68.0                            | 68.0                               | 68.0            |
| Min, max                                   | 41,91                           | 39.87                              | 39.91           |
| Age category (years), n (%)                |                                 |                                    |                 |
| <65 years                                  | 96 (39.0%)                      | 85 (34.1%)                         | 181 (36.6%)     |
| 65 to <75 years                            | 113 (45.9%)                     | 125 (50.2%)                        | 238 (48.1%)     |
| ≥75 years                                  | 37 (15.0%)                      | 39 (15.7%)                         | 76 (15.4%)      |
| Sex, n (%)                                 |                                 |                                    |                 |
| Male                                       | 139 (56.5%)                     | 140 (56.2%)                        | 279 (56.4%)     |
| Female                                     | 107 (43.5%)                     | 109 (43.8%)                        | 216 (43.6%)     |
| Race, n (%)                                |                                 |                                    |                 |
| Asian                                      | 8 (3.3%)                        | 13 (5.2%)                          | 21 (4.2%)       |
| Black or African American                  | 4 (1.6%)                        | 4 (1.6%)                           | 8 (1.6%)        |
| White                                      | 224 (91.1%)                     | 222 (89.2%)                        | 446 (90.1%)     |
| Other                                      | 1 (0.4%)                        | 0                                  | 1 (0.2%)        |
| Unknown                                    | 9 (3.7%)                        | 9 (3.6%)                           | 18 (3.6%)       |
| Not Reported                               | 0                               | 1 (0.4%)                           | 1 (0.2%)        |
| Ethnicity, n (%)                           |                                 |                                    |                 |
| Hispanic or Latino                         | 8 (3.3%)                        | 5 (2.0%)                           | 13 (2.6%)       |
| Not Hispanic or Latino                     | 232 (94.3%)                     | 237 (95.2%)                        | 469 (94.7%)     |
| Not reported                               | 6 (2.4%)                        | 7 (2.8%)                           | 13 (2.6%)       |
| Baseline b ECOG Performance Status , n (%) |                                 |                                    |                 |
| 0                                          | 90 (36.6%)                      | 92 (36.9%)                         | 182 (36.8%)     |
| 1                                          | 130 (52.8%)                     | 136 (54.6%)                        | 266 (53.7%)     |
| 2                                          | 26 (10.6%)                      | 21 (8.4%)                          | 47 (9.5%)       |

ECOG = Eastem Cooperative Oncology Group; FAS = Full Analysis Set; Max = maximum; Min = minimum; SD = standard deviation

Age was calculated relative to the date of informed consent.

d For ECOG Performance Status: O -- Fully active, able to camy on all predisease performance without restriction; 1 - Restricted in physically strenuous activity but ambulatory and able to camry out work of a light or sedentary nature.

b Baseline was defined as the most recent assessment prior to administration of the first dose of study drug.

e.g., light housework, office work; 2 - Ambulatory and capable of all self-care but unable to carry out any work

activities. Up and about more than 50% of waking hours.

<div style=\"page-break-after: always\"></div>

## Disease Characteristics

The median time since initial diagnosis was close to 4 months in both arms. At study entry, most patients had ISS stage I (49.1%) or II (38%) and extramedullary disease was present in 12.5%. Bone lesions were present in slightly fewer patients in the meflufen+ dex arm (74.8%) compared to the pom+dex arm (82.7%). Other disease characteristics at study entry were generally consistent between treatment arms.

Table 29 Selected Myeloma Disease Characteristics at Study Entry and Baseline (FAS)

| Characteristic                                | Melflufen +Dexamethasone N=246   | Pomalidomide +Dexamethasone N=249   | Overall N=495     |
|-----------------------------------------------|----------------------------------|-------------------------------------|-------------------|
| Time since initial diagnosis, years a         |                                  |                                     |                   |
| N                                             | 246                              | 249                                 | 495               |
| Mean (SD)                                     | 4.88 (3.542)                     | 4.82 (3.424)                        | 4.85 (3.480)      |
| Median (Min, Max)                             | 3.98 (0.5, 26.3)                 | 3.88 (0.4, 25.2)                    | 3.93 (0.4, 26.3)  |
| ISS stage at study entry, n (%)               |                                  |                                     |                   |
| I                                             | 119 (48.4%)                      | 124 (49.8%)                         | 243 (49.1%)       |
| II                                            | 94 (38.2%)                       | 94 (37.8%)                          | 188 (38.0%)       |
| IⅡI                                           | 33 (13.4%)                       | 31 (12.4%)                          | 64 (12.9%)        |
| R-ISS stage of disease at study entry, n (%)  |                                  |                                     |                   |
| R-I                                           | 69 (28.0%)                       | 69 (27.7%)                          | 138 (27.9%)       |
| R-I                                           | 129 (52.4%)                      | 138 (55.4%)                         | 267 (53.9%)       |
| R-IⅢI                                         | 24 (9.8%)                        | 17 (6.8%)                           | 41 (8.3%)         |
| Unknown/missing                               | 24                               | 25                                  | 49                |
| Bone lesions present at study entry           |                                  |                                     |                   |
| Yes                                           | 184 (74.8%)                      | 206 (82.7%)                         | 390 (78.8%)       |
| No                                            | 62 (25.2%)                       | 43 (17.3%)                          | 105 (21.2%)       |
| Extramedullary disease present at study entry |                                  |                                     |                   |
| Yes                                           | 31 (12.6%)                       | 31 (12.4%)                          | 62 (12.5%)        |
| No                                            | 215 (87.4%)                      | 218 (87.6%)                         | 433 (87.5%)       |
| Type of measurable disease at Baseline b      |                                  |                                     |                   |
| SPEP and UPEP                                 | 48 (19.5%)                       | 57 (22.9%)                          | 105 (21.2%)       |
| SPEP only                                     | 140 (56.9%)                      | 128 (51.4%)                         | 268 (54.1%)       |
| UPEP only                                     | 37 (15.0%)                       | 36 (14.5%)                          | 73 (14.7%)        |
| sFLC only                                     | 21 (8.5%)                        | 28 (11.2%)                          | 49 (9.9%)         |
| Baseline SPEP M-Spike (g/dL) b                |                                  |                                     |                   |
| n                                             | 245                              | 248                                 | 493               |
| Mean (SD)                                     | 18.35 (14.877)                   | 19.07 (16.495)                      | 18.71 (15.700)    |
| Median (Min, Max)                             | 17.00 (0.0, 71.0)                | 17.00 (0.0,68.8)                    | 17.00 (0.0, 71.0) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Characteristic                                            | Melflufen + Deramethasone N=246   | Pomalidomide +Deramethasone N=249   | Overall N=495   |
|-----------------------------------------------------------|-----------------------------------|-------------------------------------|-----------------|
| Baseline UPEP M-Spike (mg/day) b                          |                                   |                                     |                 |
| n                                                         | 241                               | 247                                 | 488             |
| Mean (SD)                                                 | 588.3 (1604.36)                   | 525.7 (1068.14)                     | 556.6 (1358.60) |
| Median (Min, Max)                                         | 70.0 (0, 17016)                   | 50.0 (0, 7991)                      | 60.0 (0, 17016) |
| Cytogenetic risk group based on FISH at shudy entry       |                                   |                                     |                 |
| High                                                      | 83 (33.7%6)                       | 86 (34.5%)                          | 169 (34.1%)     |
| Standard                                                  | 128 (52.0%)                       | 130 (52.296)                        | 258 (52.1%)     |
| Unknown                                                   | 35 (14.2%%)                       | 33 (13.3%6)                         | 68 (13.7%6)     |
| Patients with two or more high-risk abnormalities, n (%6) |                                   |                                     |                 |
|                                                           | 24 (9.8%)                         | 25 (10.0%)                          | 49 (9.996)      |
| No                                                        | 201 (81.7%)                       | 205 (82.396)                        | 406 (82.0%)     |
| Missing                                                   | 21                                | 19                                  | 40              |
| Patients with deletion 17p, n (%6)                        | 33 (13.496)                       | 37 (14.9%)                          | 70 (14.1%)      |
| Heavy-light chain combination at shudy entry              |                                   |                                     |                 |
| IgA-Kappa                                                 | 33 (13.4%6)                       | 29 (11.6%)                          | 62 (12.5%)      |
| IgA-Lambda                                                | 15 (6.1%)                         | 18 (7.2%)                           | 33 (6.796)      |
| IgA; IgG-Kappa                                            | 0                                 | 2 (0.8%)                            | 2 (0.4%)        |
| IgA; IgG; IgM-Kappa                                       | 1 (0.4%)                          | 0                                   | 1 (0.2%)        |
| IgA; IgG; IgM-Lambda                                      | 2 (0.8%6)                         | 0                                   | 2 (0.4%)        |
| IgA; IgM-Kappa                                            | 1 (0.4%6)                         | 0                                   | 1 (0.2%)        |
| IgA; IgM-Lambda                                           | 1 (0.4%)                          | 0                                   | 1 (0.2%)        |
| IgD-Kappa                                                 | 1 (0.4%)                          | 1 (0.4%)                            | 2 (0.4%)        |
| IgD-Lambda                                                | 1 (0.496)                         | 1 (0.4%)                            | 2 (0.4%)        |
| IgG-Biclonal                                              | 1 (0.4%)                          | 0                                   | 1 (0.2%)        |
| IgG-Kappa                                                 | 99 (40.2%)                        | (%t65) 86                           | 197 (39.8%)     |
| IgG-Lambda                                                | 48 (19.596)                       | 53 (21.3%6)                         | 101 (20.4%)     |
| IgG; IgE-Kappa                                            | 0                                 | 1 (0.4%)                            | 1 (0.2%)        |
| IgG; IgM-Kappa                                            | 1 (0.4%)                          | 0                                   | 1 (0.2%)        |
| IgM-Kappa                                                 | 4 (1.6%)                          | 1 (0.4%)                            | 5 (1.0%)        |
| IgM-Lambda                                                | 1 (0.4%)                          | 0                                   | 1 (0.2%)        |
| None-Kappa                                                | 22 (8.9%)                         | 25 (10.0%)                          | 47 (9.596)      |
| None-Lambda                                               | 15 (6.1%)                         | 20 (8.0%)                           | 35 (7.196)      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Characteristic                    | Melflufen +Deramethasone N=246   | Pomalidomide +Deramethasone N=249   | Overall N=495         |
|-----------------------------------|----------------------------------|-------------------------------------|-----------------------|
| Baseline Kappa/Lambda FLC ratio b |                                  |                                     |                       |
| N                                 | 245                              | 249                                 | 494                   |
| Mean (SD)                         | 270.804 (1186.2441)              | 185.769 (554.5585)                  | 227.942 (923.5617)    |
| Median (Min, Max)                 | 9.833 (0.00,14222.22)            | 6.02 (0.00, 5430.23)                | 8.03 (0.00, 14222.22) |

FAS=Full Analysis Set;FISH=fluorescence in si hybridization; FLC=free light chain; Ig=imumumoglobulin;

Max = maximum; Min = minimum; (R-jISS = (Revised-) International Staging System; SD = standard deviation;

sFLC =senum free light chain; SPEp=senum protein electrophoresis;UpEp =urine protein electrophoresis.

Note: The Multiple Myeloma History CRF at Diagnosis CRF and the Multiple Myeloma History CRF at Study Entry CRF were used where \"at Diaguosis\" and \"at Study Entry\"were indicated, respectively.

* Time since initial diaguosis was calculated relative to first dose of study drug.

- b Baseline labs were defimed as the most recent assessment prior to administation of the first dose of study dnug. Sowce: Table 14.1-8

## Prior treatment

The median number of prior regimens was 3.0 (Table 30). The most common prior regimens contained PIs and IMiDs (100%, each), alkylators (86.9%), mAbs (21.0%), and other (99.8%). Dexamethasone was counted as 'other' therapy and represents the majority of this category.

<div style=\"page-break-after: always\"></div>

Table 30. Prior treatment for MM (FAS)

<!-- image -->

| Characteristic                                                                         | Melflufen Deramethasone N=246                                                          | Pomalidomide + Deramethasone N=249                                                     | Overall N=495                                                                          |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Patients with at least 1 prior radiotherapy, n (%6)                                    | 60 (24.4%)                                                                             | 71 (28.5%6)                                                                            | 131 (26.5%)                                                                            |
| Patients with at least 1 prior autologous tansplant, n (%)                             | 125 (50.8%6)                                                                           | 120 (48.29)                                                                            | 245 (49.5%6)                                                                           |
| Mean (SD)                                                                              | 1.3 (0.46)                                                                             | 1.3 (0.47)                                                                             | 1.3 (0.47)                                                                             |
| Median (Min, Max)                                                                      | 1.0 (1, 2)                                                                             | 1.0 (1, 3)                                                                             | 1.0 (1, 3)                                                                             |
| Total number of prior autologous transplants per patient                               | Total number of prior autologous transplants per patient                               | Total number of prior autologous transplants per patient                               | Total number of prior autologous transplants per patient                               |
| 1                                                                                      | 88 (35.896)                                                                            | 86 (34.5%6)                                                                            | 174 (35.296)                                                                           |
| 2                                                                                      | 37 (15.0%6)                                                                            | 33 (13.3%6)                                                                            | 70 (14.1%)                                                                             |
| 3                                                                                      | 0                                                                                      | 1 (0.4%)                                                                               | 1 (0.2%)                                                                               |
| Time from autologous transplant to randomization,                                      | Time from autologous transplant to randomization,                                      | Time from autologous transplant to randomization,                                      | Time from autologous transplant to randomization,                                      |
| c5 years                                                                               | 91                                                                                     | 86                                                                                     | 177                                                                                    |
| 2.5 years                                                                              | 43                                                                                     | 35                                                                                     | 78                                                                                     |
| 2.5 to 5 years                                                                         | 48                                                                                     | 51                                                                                     | 99                                                                                     |
| >5 years                                                                               | tE                                                                                     | 34                                                                                     | 68                                                                                     |
| No autologous tansplant                                                                | 121                                                                                    | 129                                                                                    | 250                                                                                    |
| Time from front line transplant to relapse (years)                                     | Time from front line transplant to relapse (years)                                     | Time from front line transplant to relapse (years)                                     | Time from front line transplant to relapse (years)                                     |
|                                                                                        | 63                                                                                     | 64                                                                                     | 127                                                                                    |
| Mean (SD)                                                                              | 2.69 (2.660)                                                                           | 2.33 (1.815)                                                                           | 2.51 (2.272)                                                                           |
| Median (Min, Max)                                                                      | 1.89 (0.1, 15.0)                                                                       | 1.82 (0.1, 9.0)                                                                        | 1.85 (0.1, 15.0)                                                                       |
| cl year                                                                                | 13 (20.6%)                                                                             | 15 (23.4%6)                                                                            | 28 (22.0%6)                                                                            |
| 1 to ≤1.5 years                                                                        | 8 (12.796)                                                                             | 12 (18.8%)                                                                             | 20 (15.7%)                                                                             |
| 1.5 to 2 years                                                                         | 14 (22.296)                                                                            | 10 (15.6%)                                                                             | 24 (18.9%)                                                                             |
| >2 years                                                                               | 28 (44.4%)                                                                             | 27 (42.2%6)                                                                            | 55 (43.396)                                                                            |
| Patients with at least l prior allogeneic transplant, n (96)                           | 3 (1.2%6)                                                                              | 0                                                                                      | 3 (0.6%6)                                                                              |
| Number of prior regimens                                                               | Number of prior regimens                                                               | Number of prior regimens                                                               | Number of prior regimens                                                               |
| jnayed ad staungai roudgo raqumn (as) tea                                              | 2.8 (0.80)                                                                             | 2.7 (0.76)                                                                             | 2.8 (0.78)                                                                             |
| Median (Min, Max) number of prior regimens per patient                                 | 3.0 (2,4)                                                                              | 3.0 (2,4)                                                                              | 3.0 (2, 4)                                                                             |
| Total number of prior regimens per patient                                             | Total number of prior regimens per patient                                             | Total number of prior regimens per patient                                             | Total number of prior regimens per patient                                             |
| 2                                                                                      | 114 (46.3%)                                                                            | 111 (44.6%)                                                                            | 225 (45.5%)                                                                            |
| 3                                                                                      | 76 (30.9%6)                                                                            | 90 (36.1%6)                                                                            | 166 (33.5%)                                                                            |
| 4                                                                                      | 56 (22.8%6)                                                                            | 48 (19.3%)                                                                             | 104 (21.0%)                                                                            |
| q (96) n 'nau2ar 1oud auo 1sea[ 1e m Aderaqydnon2 Emup pazipiepneis o1 pasodxa slnened | q (96) n 'nau2ar 1oud auo 1sea[ 1e m Aderaqydnon2 Emup pazipiepneis o1 pasodxa slnened | q (96) n 'nau2ar 1oud auo 1sea[ 1e m Aderaqydnon2 Emup pazipiepneis o1 pasodxa slnened | q (96) n 'nau2ar 1oud auo 1sea[ 1e m Aderaqydnon2 Emup pazipiepneis o1 pasodxa slnened |
| Alkylators                                                                             | 217 (88.296)                                                                           | 213 (85.596)                                                                           | 430 (86.9%)                                                                            |
| Monoclonal antibodies                                                                  | 54 (22.0%6)                                                                            | 50 (20.1%6)                                                                            | 104 (21.0%)                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Characteristic                                                                               | Melflufen Deramethasone N=246                                                                | Pomalidomide Deramethasone N=249                                                             | Overall N=495                                                                                |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| IMiD                                                                                         | 246 (100%)                                                                                   | 249 (100%)                                                                                   | 495 (100%)                                                                                   |
| Id                                                                                           | 246 (100%)                                                                                   | 249 (100%)                                                                                   | 495 (100%)                                                                                   |
| Other\"                                                                                       | 246 (100%)                                                                                   | 248 (99.6%6)                                                                                 | 494 (99.8%)                                                                                  |
| Dexamethasone                                                                                | 243 (98.8%)                                                                                  | 245 (98.496)                                                                                 | 488 (98.6%)                                                                                  |
| Patients exposed to standardized drug group/therapy in most recent prior regimen, n (%6) b   | Patients exposed to standardized drug group/therapy in most recent prior regimen, n (%6) b   | Patients exposed to standardized drug group/therapy in most recent prior regimen, n (%6) b   | Patients exposed to standardized drug group/therapy in most recent prior regimen, n (%6) b   |
| Allkylators                                                                                  | 27 (11.0%)                                                                                   | 30 (12.0%)                                                                                   | 57 (11.5%)                                                                                   |
| Monoclonal antibodies                                                                        | 42 (17.1%)                                                                                   | 39 (15.7%)                                                                                   | 81 (16.4%)                                                                                   |
| IMiD                                                                                         | 215 (87.4%6)                                                                                 | 218 (87.696)                                                                                 | 433 (87.5%6)                                                                                 |
| Id                                                                                           | 95 (38.6%6)                                                                                  | 91 (36.596)                                                                                  | 186 (37.6%)                                                                                  |
| Others                                                                                       | 230 (93.5%6)                                                                                 | 231 (92.896)                                                                                 | 461 (93.1%)                                                                                  |
| Dexamethasone                                                                                | 216 (87.8%6)                                                                                 | 220 (88.496)                                                                                 | 436 (88.1%)                                                                                  |
| Patients refactory to standardized dnug group/therapy in at least 1 prior regimen, n (%) b   | Patients refactory to standardized dnug group/therapy in at least 1 prior regimen, n (%) b   | Patients refactory to standardized dnug group/therapy in at least 1 prior regimen, n (%) b   | Patients refactory to standardized dnug group/therapy in at least 1 prior regimen, n (%) b   |
| Allkylators                                                                                  | 78 (31.7%6)                                                                                  | 75 (30.1%)                                                                                   | 153 (30.9%)                                                                                  |
| Monoclonal antibodies                                                                        | 51 (20.7%6)                                                                                  | 49 (19.7%)                                                                                   | 100 (20.2%)                                                                                  |
| IMiD                                                                                         | 245 (99.6%6)                                                                                 | 249 (100%)                                                                                   | 494 (99.8%)                                                                                  |
| Id                                                                                           | 163 (66.3%)                                                                                  | 163 (65.596)                                                                                 | 326 (65.9%)                                                                                  |
| Other\"                                                                                       | 237 (96.3%)                                                                                  | 233 (93.696)                                                                                 | 470 (94.9%6)                                                                                 |
| Dexamethasone                                                                                | 226 (91.9%)                                                                                  | 225 (90.496)                                                                                 | 451 (91.1%)                                                                                  |
| Patients refactory to standardized dnug group/therapy in most recent prior regimen, n (%6) b | Patients refactory to standardized dnug group/therapy in most recent prior regimen, n (%6) b | Patients refactory to standardized dnug group/therapy in most recent prior regimen, n (%6) b | Patients refactory to standardized dnug group/therapy in most recent prior regimen, n (%6) b |
| Alkylators                                                                                   | 10 (4.1%6)                                                                                   | 13 (5.2%)                                                                                    | 23 (4.6%)                                                                                    |
| Monoclonal antibodies                                                                        | 41 (16.7%6)                                                                                  | 39 (15.7%)                                                                                   | 80 (16.2%6)                                                                                  |
| IMiD                                                                                         | 214 (87.0%)                                                                                  | 218 (87.696)                                                                                 | 432 (87.3%)                                                                                  |
| Id                                                                                           | 76 (30.9%6)                                                                                  | 72 (28.9%)                                                                                   | 148 (29.9%6)                                                                                 |
| Others                                                                                       | 216 (87.8%)                                                                                  | 214 (85.996)                                                                                 | 430 (86.9%6)                                                                                 |
| Dexamethasone                                                                                | 203 (82.5%)                                                                                  | 206 (82.796)                                                                                 | 409 (82.6%)                                                                                  |
| Best respouse for most recent prior regimen                                                  | Best respouse for most recent prior regimen                                                  | Best respouse for most recent prior regimen                                                  | Best respouse for most recent prior regimen                                                  |
| Stingent Complete Response                                                                   | 1 (0.4%)                                                                                     | 1 (0.4%)                                                                                     | 2 (0.4%6)                                                                                    |
| Complete Response                                                                            | 19 (7.7%)                                                                                    | 17 (6.8%6)                                                                                   | 36 (7.3%)                                                                                    |
| Very Good Partial Response                                                                   | 50 (20.3%6)                                                                                  | 54 (21.7%)                                                                                   | 104 (21.0%)                                                                                  |
| Partial Response                                                                             | 91 (37.0%)                                                                                   | 89 (35.7%6)                                                                                  | 180 (36.4%)                                                                                  |
| Minimal Response                                                                             | 18 (7.396)                                                                                   | 19 (7.6%)                                                                                    | 37 (7.596)                                                                                   |
| Stable Disease                                                                               | 35 (14.2%6)                                                                                  | 39 (15.7%)                                                                                   | 74 (14.9%)                                                                                   |
| Progressive Disease                                                                          | 27 (11.0%%)                                                                                  | 21 (8.4%)                                                                                    | 48 (9.796)                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Characteristic                                     | Melflufen + Deramethasone N=246   | Pomalidomide Deramethasone N=249   | Overall N=495   |
|----------------------------------------------------|-----------------------------------|------------------------------------|-----------------|
| Unknown                                            | 4 (1.6%6)                         | 7 (2.896)                          | 11 (2.296)      |
| Best response for second most recent prior regimen |                                   |                                    |                 |
| Suingent Complete Response                         | 2 (0.8%)                          | 4 (1.696)                          | 6 (1.2%)        |
| Complete Response                                  | 32 (13.0%)                        | 36 (14.5%6)                        | 68 (13.7%6)     |
| Very Good Partial Response                         | 71 (28.9%)                        | 76 (30.5%)                         | 147 (29.7%6)    |
| Partial Response                                   | 83 (33.7%6)                       | 80 (32.1%)                         | 163 (32.9%6)    |
| Minimal Response                                   | 13 (5.3%)                         | 11 (4.4%)                          | 24 (4.89)       |
| Stable Disease                                     | 30 (12.2%)                        | 24 (9.6%6)                         | 54 (10.9%)      |
| Progressive Disease                                | 8 (3.396)                         | 10 (4.0%)                          | 18 (3.6%6)      |
| Unknown                                            | 6 (2.49%6)                        | 7 (2.8%)                           | 13 (2.696)      |

FAS = Full Analysis Set; IMiD = immumomodulatory drug:; Max =maximum; Min = minimum; PI = proteasome inhibitor; SD = standard deviation.

- Front-line transplant occured within the first regimen of therapy from start of first dose of antimyeloma therapy prior to, or on the date of last dose of therapy within the first regimen.
* Dexamethasone was counted as an *other' therapy and represents the majority of this category.
- b At each level of summarization (Standardized Drug Group, Therapy), patients reporting more than one medication were counted only once.

## Refractory status

All 495 patients (100%) in the FAS were double-class exposed, defined as patients who had received an IMiD and PI, and 89 patients (18.0%) were triple-class exposed, defined as patients who had received an IMiD, a PI, and an anti-CD38 mAb (Table 31). Of the 89 patients who were triple class exposed, 69 patients (14%) were triple class refractory.

<div style=\"page-break-after: always\"></div>

Table 31. Refractory Status (FAS)

<!-- image -->

| Refractory Status                                                        | Melflufen + Deramethasone N=246 n (96)   | Pomalidomide + Deramethasone N=249 n (96)   | Overall N=495 n (96)   |
|--------------------------------------------------------------------------|------------------------------------------|---------------------------------------------|------------------------|
| Refractory to most recent prior regimen                                  | 245 (99.6%)                              | 247 (99.296)                                | 492 (99.496)           |
| Refractory to lenalidomide in last line                                  | 213 (86.6%6)                             | 217 (87.196)                                | 430 (86.996)           |
| Refractory to lenalidomide within 18 months of randomization by dose     | 245 (99.6%6)                             | 248 (99.6%6)                                | 493 (99.6%)            |
| Refactory to 25 mg                                                       | 159 (64.6%6)                             | 165 (66.396)                                | 324 (65.596)           |
| Reftactory to <25 mg                                                     | 81 (32.99)                               | 77 (30.9%)                                  | 158 (31.996)           |
| Refractory to dose unknown                                               | 5 (2.0%)                                 | 6 (2.49)                                    | 11 (2.2%)              |
| Refractory to prior alkylator                                            | 78 (31.7%6)                              | 75 (30.1%6)                                 | 153 (30.996)           |
| Refractory or intolerant to prior IMiD                                   | 245 (99.6%6)                             | 249 (100%)                                  | 494 (99.896)           |
| Reffactory to prior IMiD                                                 | 245 (99.6%6)                             | 249 (100%)                                  | 494 (99.896)           |
| Refractory or intolerant to prior PI                                     | 177 (72.0%%)                             | 172 (69.1%6)                                | 349 (70.596)           |
| Refiactory to prior PI                                                   | 163 (66.396)                             | 163 (65.596)                                | 326 (65.996)           |
| Refractory and/or intolerant to prior anti-CD38 mAb                      | 48 (19.596)                              | 39 (15.7%6)                                 | 87 (17.6%6)            |
| Refiactory to prior anti-CD38 mAb                                        | 48 (19.596)                              | 39 (15.796)                                 | 87 (17.6%6)            |
| Received an IMiD and PI (double-class exposed)                           | 246 (100%)                               | 249 (100%)                                  | 495 (100%%)            |
| Number of patients with double-class refactory disease                   | 162 (65.9%)                              | 163 (65.596)                                | 325 (65.796)           |
| Received am IMiD, PI, and amfi-CD38 mAb (triple-class exposed)           | 49 (19.996)                              | 40 (16.1%)                                  | 89 (18.0%)             |
| Number of patients with triple-class refractory disease                  | 39 (15.996)                              | 30 (12.0%)                                  | 69 (13.9%6)            |
| Patients refiactory to at least l component of most recent prior regimen | 245 (99.6%6)                             | 247 (99.29)                                 | 492 (99.496)           |

FAS=Full Analysis Set;IMiD=immumomodulatory drug:mAb=monoclonal anibody:PI=proteasome inhibitor.

*Number (%6) of subjects who are refiactory to lenalidomide 25 mg vs. lenalidomide &lt; 25 mg (10 mg or 15 mg) during last (most recent) line of prior therapy or administered within 18 months prior to randomization.

## Subsequent therapy

A total of 140 patients (56.9%) in the melflufen+dex group and 135 patients (54.2%) in the pom+dex group received subsequent therapy. In the melflufen+dex group, the most commonly received subsequent therapies were IMiDs (26.4%) and PIs (23.2%) followed by anti-CD38s (16.3%) and alkylators (8.1%; Table 32). In the pom+dex group, the most commonly received subsequent therapies were anti-CD38s (26.9%]) and PIs (26.1%) followed by alkylators (12.0%) and IMiDs (9.6%).

<div style=\"page-break-after: always\"></div>

## Table 32. Subsequent therapy (FAS)

FAS = Full Analysis Set; IMiD = immunomodulatory drug; PI = protease inhibitor.

<!-- image -->

|                        | Melflufen+Deramethasone N=246 n (96)   | Pomalidomide+Deramethasone N=249 n (96)   |
|------------------------|----------------------------------------|-------------------------------------------|
| Any subsequent therapy | 140 (56.9%)                            | 135 (54.2%6)                              |
| Alkylator              | 20 (8.1%)                              | 30 (12.0%)                                |
| Cyclophosphamide       | 17 (6.9%)                              | 15 (6.0%)                                 |
| Melphalan              |                                        | 10 (4.0%)                                 |
| Melflufen              | 0                                      | 1 (0.4%)                                  |
| Anti-CD38              | 40 (16.3%6)                            | 67 (26.996)                               |
|                        | 40 (16.3%)                             | 65 (26.1%)                                |
| Isahiximab             | 0                                      | 2 (0.8%6)                                 |
| IMiD                   | 65 (26.4%6)                            | 24 (9.6%)                                 |
| Pomalidomide           | 50 (20.3%6)                            | 4 (1.6%)                                  |
| Lenalidomide           | 12 (4.9%)                              | 15 (6.0%)                                 |
| Thalidomide            | 3 (1.2%)                               | 3 (1.2%)                                  |
| PI                     | 57 (23.2%6)                            | 65 (26.1%6)                               |
| Bortezomib             | 30 (12.2%6)                            | 38 (15.396)                               |
| Carfilzomib            | 21 (8.5%)                              | 24 (9.6%)                                 |
| Ixazomib               | 6 (2.4%)                               | 3 (1.2%)                                  |

## Numbers analysed

The first patient initiated study treatment in Jun 2017. Due to a slower than expected enrolment rate, the event rate in the study was lower than projected and, therefore, enrolment was extended and more patients were randomized to the study than originally planned.

In total of 495 patients were included in the FAS: 246 patients were randomized to the melflufen+dex group and 249 patients to pom + dex.

In total 454 patients were included in the PP analysis set.

In total 30 patients represented a post-hoc defined subgroup of patients aligning with the proposed target population of TCR patients after at least 3 prior lines of therapy.

## Outcomes and estimation

Data cut-off 3 Feb 2021

Primary endpoint - PFS

The primary endpoint PFS was met for the overall study population (FAS). The median IRC assessed PFS was 6.83 (95% CI 4.96, 8.54) in the meflufen + dex arm vs. 4.93 (95% CI 4.24, 5.72) in the pom + dex arm. The stratified HR was 0.792 (95% CI: 0.640, 0.981; p=0.0319).

## Subgroup analyses

A HR for PFS &gt;1 was observed for the subgroups of patients with prior ASCT, refractory to anti-CD38 mAb, EMD at baseline, age &lt;65, Creatinine clearance &lt;45 ml/min or ≥ 9 0 ml/min and ≥1.5x ULN LDH (data not shown).

## Sensitivity analyses

<div style=\"page-break-after: always\"></div>

## Key secondary endpoints

## ORR

Based on IRC assessment for the FAS, key secondary endpoint ORR was not met. In total 80 patients out of 246 in the melflufen+dex group had a best response of PR or better for an overall confirmed response rate of 32.5% (95% CI: 26.71%, 38.76%) and 67 out of 249 patients in the pomalidomide+dex group had an overall confirmed response rate of 26.9% (95% CI: 21.50%, 32.87%). This difference was not significant (stratified p=0.1422).

## OS

The other key secondary endpoint OS was also not met for the FAS and suggested a detriment for the melflufen arm. The results of the OS analysis in the FAS as assessed by the Investigator at the time of the data cutoff (03 Feb 2021) indicated that melflufen+dex did not lead to longer OS, as would have been expected by the superior PFS, as shown by the HRs and p-values for the comparison between the melflufen+dex group and pom+dex group (stratified log-rank p-value: p=0.4667 and HR of 1.104 [95% CI: 0.846, 1.441]). Median OS was 19.75 months (15.08, 25.56) for melflufen + dex vs. 25.00 months (18.14, 31.87) for pom + dex.

OS subgroup analysis - For multiple subgroups HR is above 1 suggesting a worse overall survival, including age &lt;65, 3 or 4 prior lines of therapy, creatinine clearance ≥ 90 mL/min, low BSA, presence of EMD, prior ASCT, not refractory to alkylator, refractory to antiCD38 mAb, females, BSA ≤ median, white race, ISS stage II or III, and standard or unknown risk status (Figure 9). For age&lt;65 and prior ASCT, the 95% CI excludes 1.

<div style=\"page-break-after: always\"></div>

Figure 9. OS Subgroup Analysis

<!-- image -->

## Main other secondary endpoints ( meflufen+dex vs. pom+dex )

DOR The IRC based median DOR for the FAS was 11.17 months (95% CI: 8.48, 17.48) in the melflufen+dex group and 11.07 months (95% CI: 7.62, 15.44) in the pom+dex group with a stratified HR of 1.061 (95% CI: 0.651, 1.728).

CBR The CBR (i.e., proportion of patients with best response of MR or better) based on IRC assessment was 49.6% (95% CI: 43.18%, 56.02%) vs. 41.0% (95% CI: 34.80%, 47.35%), respectively.

TTR The IRC based median TTR was 2.1 (min, max 0.9, 14.6) vs. 2.0 months (0.8, 9.4).

TTP The median TTP based on IRC assessment in the FAS was 7.16 months (95% CI: 5.59, 9.23) vs. 5.32 months (95% CI: 4.63, 6.67) with a stratified HR 0.800 (95% CI: 0.640, 1.000; p=0.0498).

DOCB The median DOCB was 9.23 months (95% CI: 7.46, 12.68) vs. 8.31 months (95% CI: 6.44, 10.38) with a stratified HR 0.895 [95% CI: 0.635, 1.261.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

Based on a DCO 03 Feb 2022 efficacy results for the 31 patients in Study OP-103 aligning with the TCR 3L+ population, suggest an ORR of 35.5% (95% CI: 19.2, 54.6), CR, VGPR and no sCR in 6 patients (19.4%), PR in n=5 (16.1%) and median DoR of 9.5 months (95% CI: 2.2, NE). Median PFS was 6.6 months (95% CI: 3.2, 9.4) and median OS was 18.1 months (95% CI: 7.1, 26.6).

The discrepancy between the PFS and OS results and the divergent results of the subgroup OS analyses prompted further exploratory analyses. A multivariable analysis was performed to explore any signals of effect modification for different subgroups  (age, ASCT, gender, creatinine clearance). A strong signal of effect modification was observed for the post-hoc defined subgroup of time-toprogression (TTP) post ASCT &lt;36 months vs no ASCT or TTP post ASCT ≥36 months (HR: 2.02 (95% CI: 1.26-3.25); multivariable Cox-model after stepwise selection based on Akaike Information Criteria). In response to Day 180 list of outstanding issues, main efficacy results of Study OP-103 were presented by time to progression post ASCT (Table 33). Results seem to improve with larger time since ASCT or with no prior ASCT vs. the ITT. Further, for the primary endpoint of PFS as well as for ORR and OS, the results for patients with a time-to-progression post ASCT of &lt;36 months consistently demonstrated reduced efficacy in this group. On the contrary, consistent results on efficacy in favour of melflufen were seen for the subgroup with no ASCT or prior ASCT and TTP ≥36 months ( Table 34 ).

Table 33. OS, PFS and ORR by time-to-progression post-ASCT in Study OP-103

| Time-to- progression post-ASCT   | OS (95% CI)       | OS (95% CI)       | OS (95% CI)       | PFS (95% CI)    | PFS (95% CI)   | PFS (95% CI)      | ORR (95% CI)      | ORR (95% CI)      | ORR (95% CI)       |
|----------------------------------|-------------------|-------------------|-------------------|-----------------|----------------|-------------------|-------------------|-------------------|--------------------|
|                                  | Mel os            | Pom OS            | HR                | Mel PFS         | Pom PFS        | HR                | Mel%              | Pom%              | OR                 |
| <1 year n=31 (Mel) n=32 (Pom)    | 13.1 (5.9, NE)    | 20.9 (18.1, NE)   | 2.18 (1.01, 4.73) | 4.4 (3.2, 6.9)  | 4.3 (3.3, 8.6) | 1.21 (0.69, 2.12) | 19.4 (7.5, 37.5)  | 25.0 (11.5, 43.4) | 0.72 (0.22, 2.38)  |
| 1-2 years n=47 (Mel) n=51 (Pom)  | 14.8 (10.2, NE)   | 30.1 (19.1, NE)   | 2.07 (1.13, 3.79) | 4.0 (3.5, 6.6)  | 5.6 (3.8, 8.5) | 1.20 (0.74, 1.94) | 17.0 /7.6, 30.8)  | 23.5 (12.8, 37.5) | 0.67 (0.25, 1.81)  |
| 2-3 years n=23 (Mel) n=18 (Pom)  | 19.7 (15.1, NE)   | 32.0 (30.9, NE)   | 1.27 (0.46, 3.53) | 4.9 (3.7, 12.4) | 6.9 (4.7, NE)  | 1.49 (0.70, 3.16) | 21.7 (7.5, 43.7)  | 44.4 (21.5, 69.2) | 0.35 (0.09, 1.35)  |
| <3 years n=101 (Mel) n=101 (Pom) | 15.6 (13.1- NE)   | 30.9 (20.2- NE)   | 1.86 (1.21- 2.85) | 4.3 (3.7, 5.3)  | 5.2 (4.3, 7.5) | 1.28 (0.92, 1.77) | 18.8 (11.7, 27.8) | 27.7 (19.3, 37.5) | 0.60 (0.31, 1.17)  |
| ≥3 years n=24 (Mel) n=19 (Pom)   | 35.0 (20.2, NE)   | 32.6 (NE, NE)     | 0.95 (0.33, 2.76) | 6.7 (4.2, NE)   | 6.0 (4.3, NE)  | 0.68 (0.31, 1.48) | 41.7 (22.1, 63.4) | 21.1 (6.1, 45.6)  | 2.68 (0.68, 10.53) |
| Non-ASCT n=121 (Mel) n=129 (Pom) | 21.6 (14.8, 31.8) | 16.5 (12.1, 26.6) | 0.78 (0.55, 1.12) | 9.3 (7.3, 12.2) | 4.6 (3.5, 6.5) | 0.59 (0.44, 0.79) | 42.1 (33.2, 51.5) | 27.1 (19.7, 35.7) | 1.96 (1.15, 3.32)  |
| LLI n=246 (Mel) n=249 (Pom)      | 19.7 (15.4, 26.0) | 25.0 (18.2, 32.0) | 1.09 (0.84, 1.41) | 6.8 (5.1,8.6)   | 4.9 (4.3, 5.9) | 0.77 (0.62, 0.95) | 32.5 (26.7, 38.8) | 26.9 (21.5, 32.9) | 1.31 (0.89, 1.93)  |

Abbreviations:ASCTAutologousstem-cell transplant;CIConfidenceinterval;HRHazardratio;ITTintent-to-treat;Mel Melflufen;NENotestimable; PomPomalidomide; OR Odds ratio; ORR Overall response rate; OS Overall survival; PFSProgression-free survival;TTPTime to progression. MedianvaluesareshowninmonthsforOSandPFs.

<div style=\"page-break-after: always\"></div>

Table 34. Efficacy results Study OP-103 based on time-toprogression &lt; or ≥36 months post -ASCT (DCO 3 feb 2022)

|                             | Melflufen           | Pomalidomide        |                          |
|-----------------------------|---------------------|---------------------|--------------------------|
| ITT                         | N=246               | N=249               |                          |
| Median PFS (95% CI), months | 6.83 (4.96-8.54)    | 4.93 (4.24-5.72)    | HR: 0.792 (0.640-0.981)* |
|                             |                     |                     | HR: 0.770 (0.625-0.949)  |
| Median OS (95% CI), months  | 20.24 (15.84-24.34) | 23.98 (19.06-28.71) | HR: 1.144 (0.912-1.434)* |
|                             |                     |                     | HR: 1.132 (0.905-1.416)  |
| ORR (95% CI),%              | 32.5 (26.7-38.8)    | 26.9 (21.5-32.9)    | P=0.1722                 |
| No ASCT or TTP>=36 months   | N=145               | N=148               |                          |
| Median PFS (95% CI)         | 9.26 (7.16-11.79)   | 4.63 (3.65-6.28)    | HR: 0.577 (0.438-0.760)  |
| Median OS (95% CI)          | 23.56 (18.86-27.96) | 19.84 (12.62-26.48) | HR: 0.833 (0.620-1.120)  |
| ORR (95% CI), %             | 42.1 (33.9-50.5)    | 26.4 (19.5-34.2)    | P=0.0046                 |
| ASCT and TTP<36 months      | 101                 | 101                 |                          |
| Median PFS (95% CI)         | 4.27 (3.68-5.06)    | 5.16 (4.27-7.39)    | HR: 1.277 (0.920-1.772)  |
| Median OS (95% CI)          | 15.72 (11.89-20.47) | 28.71 (20.17-34.07) | HR: 1.803 (1.274-2.551)  |
| ORR (95% CI), %             | 18.8 (11.7-27.8)    | 27.7 (19.3-37.5)    | P=0.1349                 |

*Stratified HR

Twelve patients in the melflufen arm of OP-103 were 3L+ TCR without recent ASCT target. ORR for this subgroup was 50%, median DOR 4.8 months, median PFS 5.4 months and median OS 18.1 months, but results should be interpreted with caution due to the very limited patient number.

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

The application has been changed from a conditional marketing authorization (CMA) to a full approval MAA for TCR patients with ≥3 prior treatment lines, as the clinical study report for confirmatory Study OP-103 has been presented in response to the LoQ. Clinical data in the newly proposed target population is derived from the single, pivotal trial OP-106 (HORIZON). This is a single arm study of melflufen in combination with dexamethasone (dex) in patients with RRMM who had received a minimum of 2 prior lines of therapy, including an IMiD and a PI, and were refractory to pomalidomide and/or an anti-CD38 mAb. Support is provided by data from the randomized controlled trial OP-103 that included patients (mostly) in an earlier line of treatment. According to the applicant, no additional confirmatory data is deemed necessary.

## Patient population

The population of interest changed several times during the trial. Given the evolving MM treatment landscape during the study, it was recognized that triple class refractory patients (TCR) patients had a high unmet medical need. With final protocol amendment 6 (after inclusion of 143 patients) the applicant considered the TCR patients (~76% study population) the main population of interest for this CMA application. The higher unmet medical need in TCR RRMM patients as compared to the initially proposed primary efficacy population is acknowledged and reassuringly, the objective of the study was met for the overall study population as well. Still, there is a potential that study integrity was affected

<div style=\"page-break-after: always\"></div>

as the primary efficacy population was modified several times during the trial (see discussion regarding sample size increase).

Another subgroup of interest was defined based on preliminary signals of efficacy, i.e. patients with extramedullary disease (EMD). These patients have a significantly worse prognosis than patients without any extramedullary involvement. However, given controversies surrounding the precise definition of EMD, absence of a rationale as to why melflufen + dex would be specifically efficacious in this subgroup of patients in comparison to other treatments and the absence of a pre-planned hypothesis testing, the EMD analysis will be considered exploratory.

Eligible patients had to have documented disease progression in need of treatment at time of screening which is adequately reflected in the indication.

Moreover, patients had to have measurable disease at baseline that was defined according to standard International Myeloma Working Group (IMWG) criteria, except for the serum M-protein levels. Allowed serum protein electrophoresis (SPEP) levels were slightly lower than standard criteria (0.5 instead of 1.0 g/dL). The number of patients that had measurable disease based on SPEP between 0.5-&lt;1 g/dL only were limited to ~5% (n=6/119). Hence the overall TCR study population is considered sufficiently representative of patients in need of treatment.

Efficacy in primary refractory patients is unknown, as these patients were excluded from the pivotal trial. This is reflected in section 5.1 of the SmPC.

## Endpoints

The efficacy endpoints are well-established endpoints for RRMM. All tumour response and progressiondependent endpoints were based on IMWG Uniform Response Criteria (IMWG-URC; Rajkumar et al., 2011). The primary efficacy endpoint ORR supported with an IRC-based sensitivity analysis is acceptable in the context of an uncontrolled trial. The applicant defined a minimal ORR threshold of 15% as clinically relevant treatment effect. Although the single arm design could be acceptable for the TCR population considering the initiation date of the study and absence of a standard of care at that time, recent approval of alternative treatment options emphasizes the need for contextualization of the efficacy data, in particular for patients that are TCR after relative few prior lines of therapy. Moreover, uncertainty remains with regard to the effect on time-dependent endpoints, PFS and OS, which cannot be reliably interpreted in an uncontrolled study.

PRO endpoints were added post-hoc after evaluation of the primary endpoint and considered exploratory only, also given the non-randomized study design and limited evaluable data (see below).

## Response definition

All response categories (including MR and SD) required 2 consecutive assessments. No minimal time between the 2 assessments was defined in the protocol, but only few patients had consecutive response assessments on the same day.

For ORR and DoR analysis, it appears that the start time of a confirmed partial response has been based on data from both scheduled and unscheduled visits. Considering the single-arm trial design, sensitivity analyses for DoR and ORR were requested, for which (confirmed) responses are derived using only scheduled visits. For the determination of a progression both scheduled and unscheduled visits should be used. Results of these additional analyses were generally consistent with the primary results.

When it was established that HORIZON study would be pivotal for this CMA, an Independent Review Committee (IRC) was included to perform an independent assessment of response, which is acknowledged.

<div style=\"page-break-after: always\"></div>

## Dose

The proposed 40 mg meflufen dose regimen with 28 day cycle length is in line with the regimen used in the pivotal trial and adequately selected based on dose finding study O-12-M1. Since melphalan exposures are higher in patients with low body weight and in patients with renal impairment, a lower starting dose of 30 mg is proposed for those patients. The once per week 40 mg low dose dex schedule is considered well established in MM treatment. The single arm design of the pivotal Phase 2 trial does not allow to isolate the contribution of the two components of the combination. However, melflufen monotherapy data is available from the supportive dose finding study and some information with regard to low dose dex monotherapy is available in literature. In the melflufen monotherapy cohort, ORR was only 7.7% and clinical benefit rate (CBR) 23.1%, compared to ORR 31.1% and CBR 48.1% for the melflufen + dex combination (study O-12-M1). A recent publication (APL-C-001-09 - ADMYRE) with low dose dex (40mg once weekly) as comparator in RRMM patients with a median of 4 lines of prior systemic therapy indicated an ORR of 1.2%. These data contribute to alleviate the concerns that the effect observed with melflufen in combination with low dose dex would mainly be driven by only one of the components.

## Other protocol deviations

A sample size increase was made in connection to the change to the study population of interest. The method of estimating the sample size was also changed, with the new sample size calculation based on precision around the estimate rather than the original pre-specified hypothesis. Details with regard to DSMC correspondence indicate that the conduct of the study (sample size and study population of interest) was substantially influenced by interim analysis results and B/R evaluation by the DSMC which is far beyond the scope of the planned futility purpose of the interim analysis. The conduct of study may not have fully complied with GCP requirements, but a GCP inspection is unlikely to change regulatory decision-making. A sensitivity analysis that was performed based on patients recruited after the protocol amendment provided reassurance that the results from the first group of patients prior to the amendment were not overly optimistic and were not increasing the effect compared with the second group.

## Supportive data

Confirmatory trial OP-103 investigated RRMM patients in an earlier treatment line, although some patients representative of the target population were included (see below). The comparator pomalidomide + dex is acceptable in this line of treatment, as is the primary endpoint PFS + key secondary endpoints ORR and OS.

Most patients in study O-12-M1 were in an earlier stage of treatment: 66.7% was double refractory (PI and IMiD) and ~15% was refractory to the mAb class. The proportion of TCR patients was only 6%. Although Study O-12-M1 confirms anti-tumour activity, it provides limited direct support for efficacy in the target population.

## Other considerations

Efficacy of melflufen as part of a myeloablative conditioning regimen prior to a stem cell transplant (similar to established use of melphalan) has not been investigated. This is adequately addressed in section 4.4 of the product information.

The effect of moderate to severe hepatic impairment (total bilirubin &gt;1.5 × ULN and any AST) on melphalan flufenamide and the metabolite melphalan PK is unknown. Based on PK and experience with melphalan it is agreed that no dose adjustment is necessary for patients with hepatic impairment, this is adequately reflected in the SmPC.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

In Study OP-106 , approximately 50% of the overall study population was younger than 65 years and almost 85% had an ECOG performance score of 0 to 1, suggesting a younger, less frail population than could have been expected for heavily pre-treated RRMM patients. This brings some uncertainty to the true effect size in clinical practice, although it is acknowledged that the decision to start treatment and the selection of treatment regimen is multifactorial. The patient characteristics have been adequately reflected in section 5.1 of the SmPC.

Patients had received a median of 5 (range 2-12) prior therapies. In total 119 patients were TCR, of which the majority, i.e.117 patients, were TCR with at least 3 prior lines. Approximately 16% of the TCR population was melphalan refractory and 1.7% was considered refractory to melphalan following high-dose melphalan.

The primary endpoint overall confirmed response rate (ORR) of partial response (PR) or better was 29.3% (95% CI: 22.32%, 37.08%; data cut-off 14 Jan 2020) for the overall study population. Exploratory updated results (data cut-off 12 Aug 2021) suggest an ORR of 33.8% (95% CI: 26.4%, 41.7%) and median DoR of 6.70 months (95% CI: 4.40, 8.11) for the overall population. In the TCR population with at least 3 prior lines (n=117), the ORR was 29.1% (95% CI: 21.0, 38.2) with a DOR of 6.97 months (95% CI: 3.88, 9.79; data cut-off 12 Aug 2021).

Although presented PRO data in Study OP-106 do not suggest an apparent deterioration in quality of life, no conclusions can be drawn given the limited number of patients with evaluable PRO data at Cycle 4 (n=27 for the TCR subgroup), the post-hoc definition of these endpoints and the single arm design.

No firm conclusions can be drawn regarding the presented OP-106 subgroup analyses for ORR, PFS and OS due to the lack of formal hypothesis testing, the single-arm design and small numbers of patients in each subgroup. Even so, response rates in (high dose) melphalan refractory patients seem to be substantially lower (ORR 12.5-16.7%) with shorter duration (~3 months) compared to prior melphalan exposed patients or the overall study population, this is adequately reflected in the SmPC.

Updated response rate and duration of response from OP-106 are considered clinically relevant for the TCR population. Response rates were in line with those observed for other products in the (TCR) RRMM (23-32%). Higher response rates were reported for the CAR-T cell therapy idecabtagene vicleucel (ORR ~67%)), which may considered to have a highly selected target population.

For pivotal study OP-106, uncertainty remains with regard to effect on time-dependent secondary endpoints, PFS and OS, which cannot be reliably interpreted in an uncontrolled study. Support can in principle be derived from PFS (primary endpoint) results from Study OP-103. Indeed, the primary endpoint PFS of the study was met with a HR of 0.79 and median PFS of 6.83 months (95% CI: 4.96, 8.54) with melflufen + dex vs. 4.93 months (95% CI: 4.24, 5.72) with pom + dex in the overall study population. Several sensitivity analyses were presented in response to Day 180 and 195 LoI, in which impact was investigated on the PFS results of an unplanned PFS re-analyses of 29 patients, an imbalance in randomised but not-treated patients between treatment arms and concerns regarding handling of these patients in the analysis. These sensitivity analyses confirmed internal validity of obtained PFS results. The response rate in OP-103 (ORR: 32.5%) was comparable to that observed in OP-106 whereas median DoR appeared somewhat longer (± 11 months vs 7 months) and comparable to the comparator arm pom + dex. Overall, the PFS results are considered reliable and clinically relevant.

In a press-release of 8   July 2021, the company presented top-line results from confirmatory Study OP103 indicating a potential detriment in OS observed for melflufen + dex compared to pom + dex. The

<div style=\"page-break-after: always\"></div>

FDA had requested a partial hold of all clinical studies with melflufen pending further investigation. In response to the first LoQ, the full clinical study report of Study OP-103 was presented. Results showed an OS HR for the overall study population of 1.104 (p=0.47). Updated median OS with one additional year of follow up indicated similar results, with a median OS of 20.24 months (15.84, 24.34) in the melflufen +dex arm vs. 23.98 months (19.06, 28.71) in the pom + dex arm, and a HR of 1.14 (95% CI: 0.912-1.434, nominal p=0.2438). Despite that Study OP-103 was not powered to demonstrate a difference in overall survival and the presence of an active comparator, the OS HR of 1.1 and KM curves in the OP-103 ITT population warranted further investigation. This was further supported by the large heterogeneity observed for OS among subgroups, especially age and prior ASCT. Based on a post-hoc defined cut-off, the subgroup of patients who progressed within 3 years after ASCT seemed to be the major contributor to the OS HR &gt;1 result and multivariable OS analysis also provided a strong signal that TTP after ASCT was an effect modifier. Stratified analyses that looked at PFS, ORR and OS results by time to progression after ASCT in years also showed a consistent signal of reduced efficacy in patients with TTP &lt;36 months. Interestingly, consistent results on efficacy in favour of melflufen were seen for the subgroup with no ASCT or prior ASCT and TTP ≥36 months. While these analyses were based on a post-hoc defined variable, there is the biological rationale that patients who progress early after ASCT, which requires high dose melphalan, might be less responsive to another alkylatorbased regimen. In addition, these patients may have an increased risk of myelotoxicity with loss of marrow reserve after recent transplantation. A clear toxicity signal was, however, not observed (see safety section and BR discussion). The cut-off of 36 months is based on the data in the trial and to some extent supported by expert data stating that the PFS cut-off for a transplant to be considered successful enough to consider a salvage ASCT is ≥36 months, although not the same situation as in the trial (EHA-ESMO guidelines, Dimopoulus et al. 2021). In addition, the treatment effect observed in the subgroup is larger than the all-randomised study population, providing additional support for the subgroup (EMA/CHMP/539146/2013; Guideline on the investigation of subgroups in confirmatory clinical trials ). Subgroup analysis of OP-106 also suggest a larger effect in patients with no ASCT or prior AS CT and TTP ≥36 months, however interpretation is hampered by the lack of a control arm.

Upon consultation, the SAG-O concluded that melflufen + low dose dex is associated with clinically relevant efficacy, with the exception of the subgroup of patients with relapse within 36 months following high-dose melphalan and autologous SCT. In addition, the SAG-O considered that although the exact effect size cannot be determined due to differences in disease and treatment characteristics, the results of study OP-103 obtained in patients of whom most had fewer lines of treatment than the OP-106 patients, are relevant for the target population in study OP-106 (see expert consultation below).

Overall, based on the available data and upon consultation of the SAG-O, it is considered that melflufen + low dose dex has been shown to be efficacious and from an efficacy perspective, the data can be considered comprehensive and support full approval. However, given the major concern on the benefit of melflufen + dex in patients with prior ASCT and TTP &lt;36 months in study OP-103 and the fact that a risk for shorter survival cannot be excluded for these patients within the 3L+ TCR population in study OP-106 due to the absence of a control group, this patient group should be excluded from the applied indication.

## Additional expert consultation

A SAG-Oncology was held on the 11 th  of May 2022. The SAG was consulted to reflect on the OS results from OP-103 and their clinical relevance for the applied target population.

## 1. On the interpretation of the OS results from the confirmatory OP-103 study:

<div style=\"page-break-after: always\"></div>

- a) The MM-003 study, the registrational study for the pomalidomide + low dose dexamethasone combination (pom+dex; n=302) vs high dose dexamethasone (dex; n=153), was performed in patients with relapsed/refractory multiple myeloma, who had received at least two prior treatment regimens. The results showed an OS HR of 0.53 ([2-sided 95% CI 0.37, 0.74], p-value &lt;0.001). Are the results of the MM-003 study relevant for the population studied in OP-103? Please elaborate.

The SAG discussed the population of the two trials (OP-106 and OP-103), the only partial overlap in regard to pretreatment (e.g. exclusion of prior treatment with pomalidomide + dexamethasone in OP103), prior lines of therapy etc., and the assumptions that are generally needed with any type of extrapolation between patients with different disease and treatment characteristics. It was also discussed that the type of sequence of development (single-arm trial in a more advanced population (OP-106) followed by a phase III trial in an earlier population (OP-103)) is not unusual in cancer drug development.

Notwithstanding these considerations, the SAG agreed that although extrapolations cannot be precise, the activity and efficacy observed in the randomized trial as well as in the single arm trial are of some relevance. The SAG assumed that the combination of melflufen + low-dose dexamethasone may have a superior efficacy to high dose dexamethasone alone, if a comparative study would have been performed similar to the MM003 trial. The efficacy observed in the OP-103 trial in terms of ORR and PFS is of relevance for the triple refractory target population in the OP-106 trial. However, there are some uncertainties regarding OS in the experimental arm, which was lower, but not statistically significantly lower, than in the comparative arm with pomalidomide + dexamethasone (pom + dex). There was also an imbalance in early exclusion of patients (18 vs 3). Furthermore, the SAG pointed out that patients with relapse within 36 months following high-dose melphalan and autologous SCT, do not benefit from melflufen + low-dose dexamethasone.

- b) Are there indications for absolute OS harm by the melflufen + low dose dexamethasone combination given the impact of the pom +dex on OS as shown in the registrational study? Please elaborate.

Given the active-controlled trial, and the considerable effect established for the control arm, the effect noted in terms of OS for melflufen + low dose dexamethasone versus pom +dex can still be considered of interest if compared to a hypothetical high dose dexamethasone arm, as done in the MM003 trial. Hence, efficacy also in terms of OS can reasonably be concluded for the melflufen + low dose dexamethasone, even if likely not to the same magnitude as for pom + dex. The possible magnitude for OS in the triple refractory target population (OP-106) as an end-stage treatment cannot finally be concluded in the lack of a randomized trial in this population. The estimated effect on OS for melflufen + low dose dexamethasone compared to pom+dex, and the lack of effect in the identified resistant subgroup, should be clearly communicated in order to allow informed benefit-risk decisions.

Concerning PFS, it should be noted that there are some doubts about the robustness of the estimates of treatment given the high number of early censoring and other considerations. The aspect of informative censoring should be further investigated. In any case, given the methodological weaknesses of the PFS analysis, the extrapolation between the two trial populations, the relatively small incremental effect, and the lack of corroborative results in terms of OS, strong 'superiority' claims in terms of PFS may be not be justified.

- c) Are there (biologically plausible) reasons that the harm (if any) could differ by age (e.g. upon ASCT or prior alkylating drug exposure) or would these concern the full age-range?

<div style=\"page-break-after: always\"></div>

The SAG agreed that the activity of melflufen + low dose dexamethasone is likely importantly reduced with prior exposure to alkylating agents and ASCT, based on pharmacodynamic considerations (resistance) and confirmation by data from the randomized trial (post-hoc subgroup analyses). These treatment characteristics are likely associated with age, but age in itself does not seem to be key factor. The likely lack of efficacy in this subgroup should be taken into account in benefit-risk considerations.

## 2. To what extent are the PFS and OS results from the OP-103 study relevant for the partially overlapping triple class refractory 3L+ multiple myeloma patient population that is applied for? Please elaborate.

The PFS and OS results from the OP-103 study are of some relevance for the applied indication in triple refractory patients based on extrapolations and reasonable assumptions that the effect is not expected to be qualitatively different between populations. Overall, it can be concluded that melflufen + low dose dexamethasone is associated with clinically relevant efficacy although likely at a magnitude that is not as high as for pom+dex, especially in patients with relapse within 36 months following high-dose melphalan and autologous SCT. Although efficacy is not disputed, the precise magnitude is difficult to assess also in view of the methodological limitations and uncertainties described above. One SAG member disagreed on the basis that the results in terms of PFS and OS are insufficient to establish efficacy.

The SAG agreed that although the landscape has changed in the target indication with multiple new agents having become available, resistance often develops eventually, and additional active agents and combinations are still useful to offer alternative treatment options during the course of the disease.

One SAG member also noted that from a clinical perspective, it is important to keep in mind that the safety data are not well documented in the target population (especially in the older population of &gt;80 years of age, a substantial proportion of patients with triple-class refractory disease currently), and that patients in the melflufen group had more toxicity, mainly myelosuppression requiring dose modifications, compared to the pomalidomide group.

## 2.6.7. Conclusions on the clinical efficacy

Clinical data in the target population (Triple-class refractory patients with ≥ 3 prior treatment lines, excluding patients with recent prior ASCT) is derived from the single arm trial OP-106 + supportive data in an earlier line from a randomized controlled trial OP-103. The pivotal Study OP-106 updated ORR and DOR are considered clinically relevant for the target population. These results are confirmed in OP-103. Support from OP-103 is also derived for time-dependent endpoint PFS. OS data indicate a potential detriment with a HR of 1.14 in the overall study population, which seems mostly driven by a lack of efficacy/reduced efficacy in patients with progression within 3 years after ASCT. In line with the SAG-O conclusion, these patients should therefore be excluded from treatment by restricting the indication as follows: For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years.

## 2.6.8. Clinical safety

## 2.6.8.1. Patient exposure

Safety data were available for a total of 495 patients (Safety population) from 5 clinical studies within RRMM setting. Besides study OP-106 which is the pivotal trial for the current application, safety data are available from  study O-12-M1 (Phase 1/2a single arm study in patients with relapsed and/or

<div style=\"page-break-after: always\"></div>

RRMM, completed), study OP-103 (Phase 3 RCT of melflufen in combination with dex compared with pom/dex in patients with RRMM after 2 to 4 lines of prior therapy, ongoing), study OP-104 (Phase 1/2a open label study to assess the safety and efficacy of melflufen and dex in combination with either bor or dara in patients with relapsed MM or RRMM, ongoing) and study OP-107 (Phase 2 multicenter PK study of melflufen in combination with dex in patients with RRMM and impaired renal function, ongoing). The Targeted Safety Population (TSP) includes all 422 patients who received a starting dose of melflufen 40 mg on Day 1 of all planned 28-day cycles in combination with dex, including patients who received this combination as part of a triplet regimen in Study OP-104 (Table 35).

Study OP-106 has a higher percentage of TCR patients (76%) than the ISS (6%, 16%, 0% and 24% for Studies O-12-M1, OP-103, OP-104 and OP-107 respectively), and of the 422 patients in the TSP 146 (34.6%) were classified as TCR. The data cutoff dates were 14 January 2020 for Study OP-106 and 31 Mar 2020 for the pooled safety analysis.

Table 35 Composition of the targeted safety population

| Treatment              | 0-12-M1 (N=75)   | OP-106 (N=157)   | OP-103 (N=195)   | OP-104 (N=43)   | OP-107 (N=25)   |   Total (N=495) |
|------------------------|------------------|------------------|------------------|-----------------|-----------------|-----------------|
| Melflufen40mg+dex*     | 16               | 156              | 195              |                 | 21              |             388 |
| Melflufen40mg+dex+bor  |                  |                  |                  | 7               |                 |               7 |
| Meiflufen40mg+dex+dara |                  |                  |                  | 27              |                 |              27 |
| npatientsincludedinTSp | 16               | 156              | 195              | 34              | 21              |             422 |

Abbreviations:bor=bortezomib;dara=daratumumab;dex=dexamethasone.

Datacutoffdate:31March2020.

<!-- image -->

Median duration of treatment at the time of data cutoff for the TSP was 17.9 weeks (range: 4-117 weeks), and the median number of completed treated cycles was 3.0 (range: 0-28). More than 50% of the patients (224 patients, 53.1%) received study drug in 4 cycles, nearly 25% of patients (102 patients, 24.2%) received study drug in 8 cycles, and approximately 10% of patients (44 patients, 10.4%) received study drug in 12 cycles. Overall, 144/422 (34.1%) of patients were on study drug for ≥6 months and 46/422 (10.9%) for ≥12 months at the time of DCO. Melflufen exposure was similar to that of overall study drug.

For study OP-106, the median duration of treatment was 16.71 weeks and the median number of cycles started was started was 3.0 (range 1-17). The majority of patients were dosed in Cycle 2 and Cycle 3 (84.1% and 64.3%, respectively). The number of patients dosed in each cycle decreased to less than half at Cycle 4 (47.8%); beginning at Cycle 11, &lt;10% of patients overall were dosed. Melflufen and dexamethasone exposure is shown in (Table 36). The relative dose intensity of melflufen was 84%. A total of 3.1% (cycle 7) to 18.7% (cycle 4) of patients received 30 mg melflufen whereas 3.6% (cycle 8) to 9.6% (cycle 5) received 20 mg melflufen. Overall, 45/157 (28.7%) of patients were on study drug for ≥6 months and 9/157 (5.7 %) for ≥12 months at the time of DCO.

A total of 26 (16.6%) and 118 (28.0%) of patients were still on treatment in study OP-106 (DCO: 14 January 2020) and in the TSP (DCO: 31 March 2020), respectively. Most patients discontinued treatment due to disease progression.

<div style=\"page-break-after: always\"></div>

Table 36 Extent of exposure to study cycle in study OP-106 (Safety analysis set)

|                                    | Triple-class refractory a (N=119)   | Triple-class refractory a (N=119)   | Overall (N=157)                    | Overall (N=157)                    |
|------------------------------------|-------------------------------------|-------------------------------------|------------------------------------|------------------------------------|
|                                    | Melflufen                           | Dex                                 | Melflufen                          | Dex                                |
| Treatment duration (weeks) b       | Treatment duration (weeks) b        | Treatment duration (weeks) b        | Treatment duration (weeks) b       | Treatment duration (weeks) b       |
| n                                  | 119                                 | 119                                 | 157                                | 157                                |
| Mean (SD)                          | 19.88 (16.538)                      | 18.70 (16.532)                      | 21.03 (17.274)                     | 19.95 (17.134)                     |
| Median (min, max)                  | 14.71 (4.1, 75.9)                   | 13.43 (1.1, 78.6)                   | 16.14 (4.1, 99.1)                  | 15.29 (1.1, 95.1)                  |
| Number of treatment cycles started | Number of treatment cycles started  | Number of treatment cycles started  | Number of treatment cycles started | Number of treatment cycles started |
| n                                  | 119                                 | 119                                 | 157                                | 157                                |
| Mean (SD)                          | 4.3 (3.53)                          | 4.3 (3.53)                          | 4.5 (3.53)                         | 4.3 (3.53)                         |
| Median (min, max)                  | 3.0 (1, 17)                         | 3.0 (1, 17)                         | 3.0 (1, 17)                        | 3.0 (1, 17)                        |
| Cumulative dose received (mg)      | Cumulative dose received (mg)       | Cumulative dose received (mg)       | Cumulative dose received (mg)      | Cumulative dose received (mg)      |
| n                                  | 119                                 | 119                                 | 157                                | 157                                |
| Mean (SD)                          | 156.8 (120.59)                      | 592.5 (511.07)                      | 161.8 (121.55)                     | 610.7 (506.49)                     |
| Median (min, max)                  | 120.0 (40, 680)                     | 480.0 (80, 2640)                    | 120.0 (40, 680)                    | 480.0 (40, 2640)                   |
| Relative dose intensity (%) c      | Relative dose intensity (%) c       | Relative dose intensity (%) c       | Relative dose intensity (%) c      | Relative dose intensity (%) c      |
| n                                  | 119                                 | 119                                 | 157                                | 157                                |
| Mean (SD)                          | 85.55 (15.617)                      | 98.21 (29.551)                      | 83.73 (16.517)                     | 97.61 (29.392)                     |
| Median (min, max)                  | 93.72 (43.9, 101.8)                 | 100.0 (47.3, 275.0)                 | 90.07 (30.3, 105.0)                | 100.0 (43.8, 275.0)                |

a  Triple-class refractory was defined as refractory or intolerant to at least one proteasome inhibitor, at least one immunomodulatory drug, and at least one anti-CD38 monoclonal antibody b   Defined as (date of last dose + 28 days - date of first dose + 1) divided by 7.

c  Defined as the ratio of the average dose administered per week to the prescribed dose (40 mg per cycle = 10 mg per week for melflufen and 160 mg per cycle for patients &lt;75, 80 mg per cycle for patients=75 for dexamethasone), expressed as a percent.

## 2.6.8.2. Adverse events

An overview of the treatment-emergent adverse events (TEAEs) in study OP-106 is shown in (Table 37). All patients had at least one TEAE and most patients had one melflufen treatment-related TEAE (94.9%). Grade 3 or 4 TEAEs occurred frequently (93.6%) and were mostly melflufen-related (89.8%). The number of fatal TEAEs was low (6.4%) and not considered treatment-related. Serious TEAEs occurred in almost half of the patients (49.0%) and half of these were considered treatment-related (23.6%). Most patients had dose modifications (80.9%) and 73.9% of melflufen.

Overall, 23.6% of patients had at least one TEAE leading to discontinuation of study drug, and 21.7% with at least one TEAE leading to discontinuation of melflufen and 15.9% leading to discontinuation of dexamethasone. Dose modifications and discontinuation rates for dexamethasone were 57.3% and 15.9%, respectively. Results for the TCR population were comparable to the FAS.

<div style=\"page-break-after: always\"></div>

Table 37 Overview of treatment-emergent adverse events (Safety analysis set study OP-106)

<!-- image -->

| Number of patients with:                                       | Triple-class Refractory-a (N=119) (%)   | Overall (N=157) n (%)   |
|----------------------------------------------------------------|-----------------------------------------|-------------------------|
| Atleast one TEAE                                               | 119 (100%)                              | 157 (100%)              |
| Atleast one treatment-related TEAE                             | 112 (94.1%)                             | 150 (95.5%)             |
| Atleast one melflufen-related TEAE                             | 111 (93.3%)                             | 149 (94.9%)             |
| TEAEs of CTCAE Grade 3:                                        |                                         |                         |
| Atleast one Grade3 TEAE                                        | 108 (90.8%)                             | 145 (92.4%)             |
| At least one treatment-related Grade 3 TEAE                    | 102 (85.7%)                             | 139 (88.5%)             |
| At least one melflufen-related Grade3TEAE                      | 102 (85.7%)                             | 139 ($8.5%)             |
| TEAEsofCTCAE Grade 4:                                          |                                         |                         |
| At least one Grade 4 TEAE                                      | 74 (62.2%)                              | 105 (66.9%)             |
| At least one treatment-related Grade 4 TEAE                    | 72 (60.5%)                              | 103 (65.6%)             |
| At leastonemelflufen-relatedGrade4TEAE                         | 72 (60.5%)                              | 103 (65.6%)             |
| TEAEsofCTCAEGrade3or4                                          |                                         |                         |
| At least one Grade 3 or4 TEAE                                  | 110 (92.4%)                             | 147 (93.6%)             |
| At least one treatment-related Grade 3 or 4 TEAE               | 104 (87.4%)                             | 141 (89.8%)             |
| At least one melflufen-related Grade 3 or 4 TEAE               | 104 (87.4%)                             | 141 (89.8%)             |
| Fatal TEAEs (CTCAE Grade 5):                                   |                                         |                         |
| Atleast one fatal (Grade 5) TEAE                               | 8 (6.7%)                                | 10 (6.4%)               |
| At least one treatment-related fatal (Grade 5) TEAE            | 0                                       | 0                       |
| Atleast one serious TEAE                                       | 61 (51.3%)                              | 77 (49.0%)              |
| At least one treatment-related serious TEAE                    | 29 (24.4%)                              | 37 (23.6%)              |
| Atleast one TEAE leading to dose modification of study drug    | 95 (79.8%)                              | 127 (80.9%)             |
| Atleast oneTEAE leading todose modificationof melflufen        | 86 (72.3%)                              | 116 (73.9%)             |
| At least oneTEAE leading to dose modification of dexamethasone | 69 (58.0%)                              | 90 (57.3%)              |
| Atleast one TEAE leading to dose reduction of study drug       | 40 (33.6%)                              | 60 (38.2%)              |
| AtleastoneTEAEleadingtodosereductionofmelflufen                | 28 (23.5%)                              | 42 (26.8%)              |
| At least oneTEAE leading to dose reduction of dexamethasone    | 16 (13.4%)                              | 23 (14.6%)              |
| Atleast one TEAE leading to dose delay of study drug           | 76 (63.9%)                              | 103 (65.6%)             |
| At least one TEAE leading to dose delay of melflufen           | 72 (60.5%)                              | 97 (61.8%)              |
| At least one TEAE leading to dose delay of dexamethasone       | 49 (41.2%)                              | 64 (40.8%)              |
| Atleast one TEAE leading to discontinuation of study drug      | 27 (22.7%)                              | 37 (23.6%)              |
| At least oneTEAE leading todiscontinuation of melflufen        | 26 (21.8%)                              | 34 (21.7%)              |
| At least one TEAE leading to discontinuation of dexamethasone  | 19 (16.0%)                              | 25 (15.9%)              |

AE = adverse event; CTCAE = Common Teminology Criteria for Adverse Events; TEAE = treamment-emergent adverse event

Notes:

·Treatment-emergent AEs were defined as AEs with onset date/time or increase in severity level after the initial dose of shudy drug and within 30 days after the last dose of study drug or initiation ofnew multiple myeloma therapy. whichever was sooner.

*Triple-class refractory was defined as refractory or intolerant to at least one proteasome inhibitor, at least one immumomodulatory drug, and at least one anti-CD38 monoclonal antibody.

Treatment-related was defined as related to either melflufen or dexamethasone.Similarly, study drug refers to either melflufen or dexamethasone.

## Common AEs

A summary of TEAEs occurring in ≥ 5% of patients overall by PT for study OP -106 and the TSP are presented in Table 38. For study OP-106, overall 85.4% of patients had a TEAEs in the SOC Blood and lymphatic system disorders, followed by General disorders and administration site conditions (74.5%), Gastrointestinal disorders (61.8%), Infections and infestations (58.0%), Musculoskeletal and connective tissue disorders (50.3%), and Respiratory, thoracic and mediastinal disorders (50.3%).

<div style=\"page-break-after: always\"></div>

Table 38 Treatment-emergent adverse events by preferred term reported in ≥ 5% of patients overall in study OP-106 (OP-106 safety analysis set and ISS TSP)

<!-- image -->

|                                    | Study 0P-106                          | Study 0P-106           | Pooled ISS Analysis     |
|------------------------------------|---------------------------------------|------------------------|-------------------------|
| Preferred Term                     | Triple-Class Refractory (N=119) n (%) | Overall (N=157) (%) uI | Total ISP (N=422) n (%) |
| Patientswith atleast1TEAE          | 119 (100)                             | 157 (100)              | 396 (93.8)              |
| Anaemiaa                           | 77 (64.7)                             | 111 (70.7)             | 261 (61.8)              |
| Thrombocytopeniaa                  | 65 (54.6)                             | 94 (59.9)              | 257 (60.9)              |
| Neutropeniaa                       | 61 (51.3)                             | 87 (55.4)              | 241 (57.1)              |
| Fatigue                            | 35 (29.4)                             | 46 (29.3)              | 88 (20.9)               |
| Nausea                             | 38 (31.9)                             | 50 (31.8)              | 87 (20.6)               |
| Asthenia                           | 28 (23.5)                             | 42 (26.8)              | 80 (19.0)               |
| Diarrhoea                          | 27 (22.7)                             | 42 (26.8)              | 79 (18.7)               |
| Platelet count decreased           | 31 (26.1)                             | 36 (22.9)              | 73 (17.3)               |
| Neutrophil count decreased         | 33 (27.7)                             | 41 (26.1)              | 67 (15.9)               |
| White blood cell count decreased   | 35 (29.4)                             | 44 (28.0)              | 65 (15.4)               |
| Pyrexia                            | 29 (24.4)                             | 38 (24.2)              | 64 (15.2)               |
| Upper respiratory tract infection? | 18 (15.1)                             | 25 (15.9)              | 63 (14.9)               |
| Cough                              | 19 (16.0)                             | 26 (16.6)              | 50 (11.8)               |
| Constipation                       | 19 (16.0)                             | 23 (14.6)              | 38 (9.0)                |
| Back pain                          | 11 (9.2)                              | 19 (12.1)              | 38 (9.0)                |
| Insomnia                           | 12 (10.1)                             | 18 (11.5)              | 37 (8.8)                |
| Pneumoniaa                         | 14 (11.8)                             | 20 (12.7)              | 37 (8.8)                |
| Dyspnoea                           | 13 (10.9)                             | 17 (10.8)              | 35 (8.3)                |
| Leukopeniaa                        | 9 (7.6)                               | 12 (7.6)               | 35 (8.3)                |
| Hypokalaemia                       | 15 (12.6)                             | 22 (14.0)              | 33 (7.8)                |
| Decreased appetite                 | 13 (10.9)                             | 22 (14.0)              | 33 (7.8)                |
| Arthralgia                         | 11 (9.2)                              | 16 (10.2)              | 32 (7.6)                |
| Oedema peripheral                  | 11 (9.2)                              | 22 (14.0)              | 31 (7.3)                |
| Vomiting                           | 19 (16.0)                             | 21 (13.4)              | 31 (7.3)                |
| Bone pain                          | 16 (13.4)                             | 20 (12.7)              | 29 (6.9)                |
| Headache                           | 17 (14.3)                             | 21 (13.4)              | 29 (6.9)                |
| Pain in extremity                  | 17 (14.3)                             | 20 (12.7)              | 27 (6.4)                |
| Dizziness                          | 8 (6.7)                               | 17 (10.8)              | 26 (6.2)                |
| Hypocalcaemia                      | 10 (8.4)                              | 16 (10.2)              | 25 (5.9)                |
| Hypomagnesaemia                    | 11 (9.2)                              | 15 (9.6)               | 22 (5.2)                |
| Contusionb                         | 10 (8.4%)                             | 15 (9.6%)              | 21 (5.0%)               |
| Epistaxisa                         | 12 (10.1)                             | 14 (8.9)               | 21 (5.0)                |
| Bronchitis                         | 6 (5.0)                               | 8 (5.1)                | 21 (5.0)                |
| Lymphopenia                        | 6 (5.0)                               | 8 (5.1)                | 19 (4.5)                |
| Respiratory tract infection        | 8 (6.7)                               | 10 (6.4)               | 18 (4.3)                |
| Blood creatinine increased         | 7 (5.9)                               | 9 (5.7)                | 18 (4.3)                |
| Dyspnoea exertional                | 11 (9.2)                              | 16 (10.2)              | 18 (4.3)                |
| Hyperglycaemia                     | 4 (3.4)                               | 8 (5.1)                | 17 (4.0)                |
| Abdominal pain                     | 5 (4.2)                               | 8 (5.1)                | 16 (3.8)                |
| Musculoskeletal chest pain         | 6 (5.0)                               | 10 (6.4)               | 15 (3.6)                |

<div style=\"page-break-after: always\"></div>

Table 30 Continued - Treatmentemergent adverse events by preferred term reported in ≥ 5% of patients overall in study OP-106 (OP-106 safety analysis set and ISS TSP)

|                      | Study 0P-106                          | Study 0P-106          | Pooled ISS Analysis     |
|----------------------|---------------------------------------|-----------------------|-------------------------|
| Preferred Term       | Triple-Class Refractory (N=119) n (%) | Overall (N=157) n (%) | Total ISP (N=422) n (%) |
| Myalgia              | 8 (6.7)                               | 9 (5.7)               | 15 (3.6)                |
| Hypophosphataemia    | 9 (7.6)                               | 13 (8.3)              | 15 (3.6)                |
| Febrile neutropenia  | 7 (5.9)                               | 10 (6.4)              | 14 (3.3)                |
| Musculoskeletal pain | 7 (5.9)                               | 8 (5.1)               | 12 (2.8)                |
| Tachycardia          | 7 (5.9)                               | 8 (5.1)               | 11 (2.6)                |
| Hypotension          | 7 (5.9)                               | 8 (5.1)               | 9 (2.1)                 |

PT = preferred term; TEAE = treatment-emergent adverse event; TSP = Targeted Safety Population.

Abbreviations: ISS =Integrated Summary of Safety;MedDRA =Medical Dictionary for Regulatory Activities;

Notes: Percentages were based on the number of patients in the specified population in each column (denominator).

Adverseeventswere coded topreferred term usingMedDRA,version19.0orlater.

- A TEAE was defined as an AE with an onset date/time or increase in severity level after the initial dose of study drug and within 28 days after the last dose of study drug or initiation of new multiple myeloma therapy. whicheverwassooner.

Preferred terms are sorted by descending frequency in the Pooled ISS Analysis column.

- The indicated terms are included in the discussion of adverse events of special interest (Section 2.5.5.2.9). grouped understandardized,customized,ormodifiedMedDRAqueries as describedin Module 2.7.4.1.1.3.4.2.
- and Skin and subcutaneous tissue disorders.

14 January 2020 for Study OP-106 and 31 March 2020 for the pooled ISS analysis.

The most commonly reported TEAEs were haematologic in nature, including anaemia (70.7%), thrombocytopenia (59.9%), and neutropenia (55.4%) in study OP-106. Other commonly reported haematologic TEAEs by PT included platelet count decreased (22.9%), neutrophil count decreased (26.1%), and white blood cell (WBC) count decreased (28.0%). The most common non-haematologic TEAEs were asthenia (26.8%), nausea (31.8%), diarrhoea (26.8%), fatigue (29.3%), pyrexia (24.2%), and upper respiratory tract infection (15.9%). Results for the TCR population were comparable to that of the FAS.

The overall profile of TEAEs was similar between patients in Study OP-106 and the TSP, the frequencies of AEs were generally higher in Study OP-106.

## AE with toxicity Grade 3 or 4

The most frequently reported (≥20% of patien ts overall) Grade 3 or 4 TEAEs by PT were of haematological nature: thrombocytopenia (56.7%) and neutropenia (52.9%), followed by anaemia (42.7%), white blood cell count decreased (26.1%), neutrophil count decreased (23.6%), and platelet count decreased (21.0%) (Table 39). The most common Grade 3 or 4 non-haematological TEAEs were pneumonia (10.2%) and hypophosphatemia (5.1%) for the overall population in study OP-106. Results of the TCR population were comparable to the FAS. In addition, comparable results were seen for the TSP with slightly lower frequencies reported.

<div style=\"page-break-after: always\"></div>

Table 39 Grade 3 or 4 Treatment-Emergent Adverse Events by Preferred Term Reported by at Least 5% of Patients Overall in Study OP-106 (OP-106 Safety Analysis Set and ISS Targeted Safety Population)

<!-- image -->

|                                         | Study OP-106                         | Study OP-106                         | Study OP-106                         | Study OP-106         | Study OP-106         | Study OP-106         | Pooled ISS Analysis    | Pooled ISS Analysis    | Pooled ISS Analysis    |
|-----------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|
|                                         | Triple-Class Refractory (N=119) n(%) | Triple-Class Refractory (N=119) n(%) | Triple-Class Refractory (N=119) n(%) | Overall (N=157) n(%) | Overall (N=157) n(%) | Overall (N=157) n(%) | Total TSP (N=422) n(%) | Total TSP (N=422) n(%) | Total TSP (N=422) n(%) |
| Preferred Term                          | Grade3                               | Grade4                               | Grade 3/4*                           | Grade3               | Grade4               | Grade3/4*            | Grade3                 | Grade4                 | Grade 3/4              |
| Patients with at least 1 Grade 3/4 TEAE | 34 (28.6)                            | 71 (59.7)                            | 110 (92.4)                           | 40 (25.5)            | 100 (63.7)           | 147 (93.6)           | 125 (29.6)             | 223 (52.8)             | 348 (82.5)             |
| Thrombocytopeniab                       | 22 (18.5)                            | 40 (33.6)                            | 62 (52.1)                            | 28 (17.8)            | 61 (38.9)            | 89 (56.7)            | 103 (24.4)             | 127 (30. 1)            | 230 (54.5)             |
| Neutropeniab                            | 26 (21.8)                            | 32 (26.9)                            | 58 (48.7)                            | 35 (22.3)            | 48 (30.6)            | 83 (52.9)            | 110 (26.1)             | 110 (26.1)             | 220 (52.1)             |
| Anaemiab                                | 54 (45.4)                            | 1 (0.8)                              | 55 (46.2)                            | 66 (42.0)            | 1 (0.6)              | 67 (42.7)            | 162 (38.4)             | 3 (0.7)                | 165 (39.1)             |
| Platelet coumt decreasedb               | 11 (9.2)                             | 18 (15.1)                            | 29 (24.4)                            | 12 (7.6)             | 21 (13.4)            | 33 (21.0)            | 25 (5.9)               | 40 (9.5)               | 65 (15.4)              |
| Neutrophil couut decreasedb             | 17 (14.3)                            | 12 (10.1)                            | 29 (24.4)                            | 22 (14.0)            | 15 (9.6)             | 37 (23.6)            | 38 (9.0)               | 22 (5.2)               | 60 (14.2)              |
| Whitebloodcellcoumt decreasedb          | 18 (15.1)                            | 14 (11.8)                            | 32 (26.9)                            | 21 (13.4)            | 20 (12.7)            | 41 (26.1)            | 26 (6.2)               | 25 (5.9)               | 51 (12.1)              |
| Pueumoniab                              | 11 (9.2)                             | 0                                    | 11 (9.2)                             | 14 (8.9)             | 2 (1.3)              | 16 (10.2)            | 25 (5.9)               | 3 (0.7)                | 28 (6.6)               |
| Leukopeniab                             | 3 (2.5)                              | 5 (4.2)                              | 8 (6.7)                              | 4 (2.5)              | 6 (3.8)              | 10 (6.4)             | 16 (3.8)               | 9 (2.1)                | 25 (5.9)               |
| Lymphopeniab                            | 4 (3.4)                              | 2 (1.7)                              | 6 (5.0)                              | 6 (3.8)              | 2 (1.3)              | 8 (5.1)              | 10 (2.4)               | 7 (1.7)                | 17 (4.0)               |
| Febrile neutropeniah                    | 5 (4.2)                              | 2 (1.7)                              | 7 (5.9)                              | 7 (4.5)              | 3 (1.9)              | 10 (6.4)             | 9 (2.1)                | 4 (0.9)                | 13 (3.1)               |
| Hypophosphataemia                       | 6 (5.0)                              | 0                                    | 6 (5.0)                              | 8 (5.1)              | 0                    | 8 (5.1)              | 9 (2.1)                | 0                      | 9 (2.1)                |

Notes: Percentages were based on the mumber of patients in the specified population in each columm (denominator).

Abbreviations: AE = adverse event, ISS = Integrated Summary of Safety, MedDRA = Medical Dictionary for Regulatory Activities; TEAE = treatment-emergent adverse event; TSP = Targeted Safety Population.

- A TEAE was defined as an AE with an onset date/time or increase in severity level after the initial dose of study dnug and within 28 days after the last dose of study drug or initiation of new mmtiple myeloma therapy, whichever was sooner.

Preferred tems are sorted by descending frequency in the Pooled ISS Analysis columm.

Adverse events were coded to preferred tenm using MedDRA, version 19.0 or later.

- Grade3or4mayincludepatientswithGrade5eventsif they alsohadGrade3or4events.
- The indicated tenms are included in the discussion of adverse events of specialinterest (Section 2.5.5.2.9), grouped umder standardized, customized, or modifed MedDRA

## Treatment-related AEs

Overall in study OP-106, 150 patients (95.5%) reported events that were considered by the Investigator to be treatment-related (i.e. related to any study drug) and 141 (89.8%) reported treatment-related AEs that were Grade 3 or Grade 4. A total of 149 patients (94.9%) reported events that were considered to be melflufen-related, 24.2% and 65.6% were Grade 3 or Grade 4, respectively (Table 40).

Most frequently reported melflufen-related AEs by PT were haematologic in nature and these were also the most frequently reported grade 3 or grade 4 events. Other frequently non-haematological treatment-related TEAEs were nausea, fatigue and diarrhoea. Few of these TEAEs were grade 3 and no grade 4 events occurred. Results for the TCR population were comparable to the FAS.

## Dexamethasone-related adverse events

Overall, 110 patients (70.1%) reported events that were considered by the Investigator to be dexamethasone-related; 31.8% and 9.6% reported dexamethasone-related TEAEs that were Grade 3 and Grade 4, respectively. Dexamethasone-related TEAEs were most often reported in the SOCs of General disorders and administration site conditions and Gastrointestinal disorders.

The results of the TSP were supportive to that of the FAS and did not reveal new events.

<div style=\"page-break-after: always\"></div>

Table 40 Treatment-emergent adverse events reported as melflufenrelated in ≥3% of patients overall by any grade and by maximum severity (Safety analysis set study OP-106)

<!-- image -->

| System Organ Class                                  | Triple-class Refractory b (N=119) n (%)   | Triple-class Refractory b (N=119) n (%)   | Triple-class Refractory b (N=119) n (%)   | Overall (N=157) (%) u   | Overall (N=157) (%) u   | Overall (N=157) (%) u   |
|-----------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------|-------------------------|-------------------------|
| Preferred Term                                      | Any Grade                                 | Grade3                                    | Grade4                                    | Any Grade               | Grade3                  | Grade 4                 |
| Patients with at least 1 melflufen-related TEAE     | 111 (93.3%)                               | 32 (26.9%6)                               | 72 (60.5%)                                | 149 (94.9%)             | 38 (24.2%)              | 103 (65.6%)             |
| Blood and lymphaticsystemdisorders                  | 96 (80.7%6)                               | 38 (31.996)                               | 47 (39.596)                               | 131 (83.4%)             | 44 (28.0%6)             | 70 (44.6%6)             |
| Anaemia                                             | 72 (60.5%)                                | 51 (42.9%)                                | 1 (0.8%)                                  | 104 (66.2%)             | 63 (40.1%)              | 1 (0.6%)                |
| Thrombocytopenia                                    | 63 (52.9%)                                | 22 (18.5%)                                | 38 (31.9%)                                | 92 (58.6%)              | 28 (17.8%)              | 59 (37.6%)              |
| Neuropenia                                          | 59 (49.6%)                                | 24 (20.2%)                                | 32 (26.9%)                                | 85 (54.1%)              | 33 (21.0%)              | 48 (30.6%)              |
| Febrile neutropenia                                 | 7 (5.9%)                                  | 5 (4.2%)                                  | 2 (1.7%)                                  | 10 (6.4%)               | 7 (4.5%)                | 3 (1.9%)                |
| Leukopenia                                          | 7 (5.9%)                                  | 1 (0.8%)                                  | 5 (4.2%)                                  | 9 (5.7%)                | 1 (0.6%)                | 6 (3.8%)                |
| Lymphopenia                                         | 5 (4.2%)                                  | 3 (2.5%)                                  | 2 (1.7%)                                  | 7 (4.5%)                | 5 (3.2%)                | 2 (1.3%)                |
| Gastrointestinal disorders                          | 45 (37.8%6)                               | 3 (2.5%)                                  | 0                                         | 62 (39.596)             | 3 (1.996)               | 0                       |
| Nalsea                                              | 29 (24.4%)                                | 1 (0.8%)                                  | 0                                         | 39 (24.8%)              | 1 (0.6%)                | 0                       |
| Diarhoea                                            | 13 (10.9%)                                | 0                                         | 0                                         | 20 (12.7%)              | 0                       | 0                       |
| Vomiting                                            | 13 (10.9%)                                | 0                                         | 0                                         | 14 (8.9%)               | 0                       | 0                       |
| Constipation                                        | 8 (6.7%)                                  | 0                                         | 0                                         | 8 (5.1%)                | 0                       | 0                       |
| General disorders and administration siteconditions | 41 (34.5%6)                               | 5 (4.29)                                  | 1 (0.8%6)                                 | 54 (34.496)             | 6 (3.8%6)               | 1 (0.6%)                |
| Fatigue                                             | 22 (18.5%)                                | 3 (2.5%)                                  | 0                                         | 27 (17.2%)              | 3 (1.9%)                | 0                       |
| Asthenia                                            | 11 (9.2%)                                 | 0                                         | 1 (0.8%)                                  | 14 (8.9%)               | 0                       | 1 (0.6%)                |
| Pyrexia                                             | 6 (5.0%)                                  | 1 (0.8%)                                  | 0                                         | 10 (6.4%)               | 2 (1.3%)                | 0                       |
| Inveshigations                                      | 43 (36.1%6)                               | 11 (9.2%)                                 | 27 (22.7%)                                | 54 (34.4%)              | 13 (8.3%6)              | 35 (22.3%6)             |
| White blood cell coumt decreased                    | 35 (29.4%)                                | 18 (15.1%)                                | 14 (11.8%)                                | 44 (28.0%)              | 21 (13.4%)              | 20 (12.7%)              |
| Neutrophil couwt decreased                          | 33 (27.7%)                                | 17 (14.3%)                                | 12 (10.1%)                                | 41 (26.1%)              | 22 (14.0%)              | 15 (9.6%)               |
| Platelet coumt decreased                            | 30 (25.2%)                                | 11 (9.2%)                                 | 18 (15.1%)                                | 34 (21.7%)              | 12 (7.6%)               | 21 (13.4%)              |
| Infections and infestations                         | 25 (21.0%6)                               | 13 (10.9%)                                | 0                                         | 31 (19.7%6)             | 14 (8.996)              | 0                       |
| Puetumonia                                          | 7 (5.9%)                                  | 7 (5.9%)                                  | 0                                         | 9 (5.7%)                | 8 (5.1%)                | 0                       |
| Upper respiratory tractinfection                    | 6 (5.0%)                                  | 1 (0.8%)                                  | 0                                         | 8 (5.1%)                | 2 (1.3%)                | 0                       |
| Metabolismandnutritiondisorders                     | 18 (15.1%6)                               | 2 (1.7%)                                  | 0                                         | 27 (17.2%)              | 5 (3.2%)                | 0                       |
| Decreased appetite                                  | 6 (5.0%)                                  | 0                                         | 0                                         | 10 (6.4%)               | 0                       | 0                       |
| Hypokalaemia                                        | 6 (5.0%)                                  | 0                                         | 0                                         | 8 (5.1%)                | 0                       | 0                       |
| Hypophosphataemia                                   | 3 (2.5%)                                  | 2 (1.7%)                                  | 0                                         | 6 (3.8%)                | 4 (2.5%)                | 0                       |
| Respiratory, thoracic and mediastinal disorders     | 17 (14.39)                                | 0                                         | 1 (0.8%6)                                 | 21 (13.496)             | 0                       | 1 (0.6%6)               |
| Cough                                               | 4 (3.4%)                                  | 0                                         | 0                                         | 6 (3.8%)                | 0                       | 0                       |
| Epistaxis                                           | 4 (3.4%)                                  | 0                                         | 1 (0.8%)                                  | 5 (3.2%)                | 0                       | 1 (0.6%)                |
| Nervous system disorders                            | 12 (10.1%6)                               | 0                                         | 0                                         | 18 (11.596)             | 0                       | 0                       |
| Dizziness                                           | 4 (3.4%)                                  | 0                                         | 0                                         | 8 (5.1%)                | 0                       | 0                       |
| Headache                                            | 5 (4.2%)                                  | 0                                         | 0                                         | 6 (3.8%)                | 0                       | 0                       |
| Slkin and subcutaneous tissue disorders             | 5 (4.2%6)                                 | 0                                         | 0                                         | 9 (5.796)               | 0                       | 0                       |
| Coutusion                                           | 3 (2.5%)                                  | 0                                         | 0                                         | 5 (3.2%)                | 0                       | 0                       |

· Treatment-emergent AEs with onset date/time or increase in severity level after the initial dose of study drug and within 30 days after the last dose of study drug or initiation

AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities,; PT = preferred tenm; SOC = system organ class; TEAE = treatment-emergent adverse event Notes:

At each level of summarization(any event,Grade3 or4, SOC,and PT),patients reporting more than oneincidence of each adverse event were coumted only once regardless of whether the TEAE was Grade 3 or 4.

Adverse events Were coded to preferred temm using MedDRA, version 19.1.

b Triple-class refactory was defined as refractory or intolerant to at least one proteasome inhibitor, at least one immunomodulatory drnug, and at least one anti-CD38 monoclonal antibody.

## 2.6.8.3. Serious adverse event/deaths/other significant events

## Deaths

A total of 176 patients (41.7%) died during the studies within the TSP; 12 patients (2.8%) died ≤30 days after the last dose of melflufen. Most deaths occurred &gt;30 days after the last dose of melflufen (38.9%) and for 122 of these 164 patients, the primary cause of death was reported as PD. A total of 23 patients (5.4%) had adverse event recorded as the primary cause of death, including 9 patients (2.1%) who died ≤30 days and 14 patients (3.3%) who died &gt;30 days after the last dose of melflufen. Twenty patients (11.4%) experienced at least 1 TEAE with an outcome reported as fatal ( Table 41 ).

<div style=\"page-break-after: always\"></div>

Six events were considered related to melflufen. These events included: Escherichia sepsis (related to melflufen and dex) and neutropenia (related to melflufen) in one patient, pneumonia (n=2; n=1 related to melflufen and dex, and n=1 related to melflufen) in study O-12-M1; sepsis (n=1 related to melflufen) in study OP-104; pneumonia influenzal (n=1 related to melfufen and dex) in study OP-106, and bacteraemia (n=1 related to melflufen and dex) in study O-12-M1.

Within study OP-106, 88 patients (56.1%) died during the study; most patients (n=76) died &gt;30 days after last dose and the primary cause of death for these patients was PD (n=68). Overall, 10 patients (6.4%) reported a TEAE with a fatal outcome. The TEAEs included cardiopulmonary failure, plasma cell myeloma, diffuse alveolar damage, acute kidney injury, general physical health deterioration, and plasma cell leukemia (1 patient each) and respiratory failure and general physical health deterioration (2 patients each); 1 patient with a fatal TEAE of general physical health deterioration also had fatal TEAEs of pneumonia, hypercalcemia, metabolic disorder, and pleural effusion. None of these were considered by the investigator to be related to melflufen.

Table 41 Treatment-emergent adverse events with a fatal outcome by preferred term by treatment regimen (Targeted safety population)

| Preferred Term                                    | Melflufen + Dex (N=168) n (%)   |   Melflufen + Bor +Dex (N=1) n (%) | Melflufen + Dara + Der (N=7) n (%)   | Total (N=176) n (%)   |
|---------------------------------------------------|---------------------------------|------------------------------------|--------------------------------------|-----------------------|
| Patients with at least 1 TEAEwith a fatal outcome | 19 (11.3)                       |                                  0 | 1 (14.3)                             | 20 (11.4)             |
| Escherichia sepsis                                | 2 (1.2)                         |                                  0 | 0                                    | 2 (1.1)               |
| Neutropenia                                       | 2 (1.2)                         |                                  0 | 0                                    | 2 (1.1)               |
| Pneumonia                                         | 2 (1.2)                         |                                  0 | 0                                    | 2 (1.1)               |
| Asthenia                                          | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Cardiopulmonaryfailure                            | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Diffusealveolardamage                             | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Disease progression                               | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| General physical healthdeterioration              | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Multiple organ dysfunction syndrome               | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Oesophageal carcinoma                             | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Plasma cell leukaemia                             | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Plasmacell myeloma                                | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Pneumonia influenzal                              | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Postproceduralcomplication                        | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Pulmonary embolism                                | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Renal failure                                     | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Respiratory failure                               | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |
| Sepsis                                            | 0                               |                                  0 | 1 (14.3)                             | 1 (0.6)               |
| Sudden cardiacdeath                               | 1 (0.6)                         |                                  0 | 0                                    | 1 (0.6)               |

TheTargetedSafetyPopulationincludes all patientswhoreceived a starting dose ofmelflufen40mg onDay1 ofevery planned 28-day cycle in combination with dex, including patients who received this combination as part ofa triplet regimen in Study OP-104.

Abbreviations:bor= bortezomib;dara= daratumumab; dex=dexamethasone;TEAE= treatment-emergent adverse event. Notes:Percentages were based on the number ofpatientswhodiedon study in theTargetedSafety Population in each column (denominator).

If a patient experienced more than 1 episode of a TEAE,then the patient was counted only once within apreferred term Preferred terms arereportedusingtheMedical DictionaryforRegulatoryActivitiesversion19.0orlater.

## Serious adverse events

Overall, 77 (49.0%) reported at least one serious TEAE ( Table 42 ). The most frequently reported events were pneumonia (8.9%), febrile neutropenia (5.1%), and thrombocytopenia, platelet count decreased, respiratory tract infection, acute kidney injury, general physical health deterioration, and hypercalcaemia (2.5% each). Pneumonia, febrile neutropenia, and thrombocytopenia and platelet count decreased were the most common treatment-related SAEs (any drug) as well as the most common melflufen-related SAEs. Overall, 20.4% of patients reported at least one serious melflufenrelated TEAE. Overall, 18 patients (11%) reported a Grade 3 SAE that was considered by the

<div style=\"page-break-after: always\"></div>

Investigator to be melflufen-related, and 13 patients (8%) reported a melflufen-related Grade 4 SAE. Results for the TCR were comparable to the FAS. The TSP did not reveal new signals.

Table 42 Treatmentemergent serious adverse events by PT in ≥2 patients overall in study OP -106 (OP-106 Safety analysis set and ISS TSP)

|                                                 | StudyOP-106                           | StudyOP-106                           | StudyOP-106          | StudyOP-106          | Pooled ISS Analysis    | Pooled ISS Analysis    |
|-------------------------------------------------|---------------------------------------|---------------------------------------|----------------------|----------------------|------------------------|------------------------|
| Preferred Term                                  | Triple-Class Refractory (N=119) n(%6) | Triple-Class Refractory (N=119) n(%6) | Overall (N=151) n(%) | Overall (N=151) n(%) | Total TSP (N=422) n(%) | Total TSP (N=422) n(%) |
|                                                 | All                                   | Related                               | AII                  | Related              | Al                     | Related                |
| Patients with at least 1 treatment-emergent SAE | 61 (51.3)                             | 29 (24.4)                             | 77 (49.0)            | 37 (23.6)            | 153 (36.3)             | 90 (21.3)              |
| Pneumomia                                       | 8 (6.7)                               | 7 (5.9)                               | 14 (8.9)             | 11 (7.0)             | 28 (6.6)               | 20 (4.7)               |
| Tarombocytopenia                                | 4 (3.4)                               | 4 (3.4)                               | 4 (2.5)              | 4 (2.5)              | 13 (3.1)               | 13 (3.1)               |
| Febrile neutropenia                             | 6 (5.0)                               | 6 (5.0)                               | 8 (5.1)              | 8 (5.1)              | 12 (2.8)               | 12 (2.8)               |
| Neutropenia                                     | 2 (1.7)                               | 2 (1.7)                               | 2 (1.3)              | 2 (1.3)              | 9 (2.1)                | (61）8                  |
| Platelet coumt decreased                        | 4 (3.4)                               | 4 (3.4)                               | 4 (2.5)              | 4 (2.5)              | 9 (2.1)                | 9 (2.1)                |
| Pyrexia                                         | 3 (2.5)                               | 2 (1.7)                               | (61)E                | 2 (1.3)              | 6 (1.4)                | 4 (0.9)                |
| Upper respiratory tract infection               | 0                                     | 0                                     | 2 (1.3)              | 1 (0.6)              | 6 (1.4)                | 3 (0.7)                |
| Respiratory tract infection                     | 4 (3.4)                               | 0                                     | 4 (2.5)              | 0                    | 5 (1.2)                | 1 (0.2)                |
| Acute kidney injury                             | 4 (3.4)                               | 0                                     | 4 (2.5)              | 0                    | 5 (1.2)                | 0                      |
| Bronchitis                                      | 2 (1.7)                               | 2 (1.7)                               | 2 (1.3)              | 2 (1.3)              | 4 (0.9)                | 3 (0.7)                |
| Sepsis                                          | 1 (0.8)                               | 1 (0.8)                               | 2 (1.3)              | 1 (0.6)              | 4 (0.9)                | 3 (0.7)                |
| Bone pain                                       | 2 (1.7)                               | 0                                     | (ED)                 | 0                    | 3 (0.7)                | 0                      |
| General physical health deterioration           | 4 (3.4)                               | 0                                     | 4 (2.5)              | 0                    | 3 (0.7)                | 1 (0.2)                |
| Influenza                                       | 2 (1.7)                               | 1 (0.8)                               | 2 (1.3)              | 1 (0.6)              | 3 (0.7)                | 1 (0.2)                |
| Closmidium difficile infection                  | 2 (1.7)                               | 1 (0.8)                               | 2 (1.3)              | 1 (0.6)              | 2 (0.5)                | 1 (0.2)                |
| Fenmr frachure                                  | 2 (1.7)                               | 0                                     | 2 (1.3)              | 0                    | 2 (0.5)                | 0                      |
| Viral upper respiratory tract infection         | 2 (1.7)                               | 1 (0.8)                               | 2 (1.3)              | 1 (0.6)              | 2 (0.5)                | 1 (0.2)                |
| Respiratory Failure                             | 0                                     | 0                                     | 2 (1.3)              | 0                    | 2 (0.5)                | 0                      |
| Soft tissue infection                           | 2 (1.7)                               | 1 (0.8)                               | 2 (1.3)              | 1 (0.6)              | 2 (0.5)                | 1 (0.2)                |
| Hypercalcaemia                                  | 4 (3.4)                               | 0                                     | 4 (2.5)              | 0                    | 2 (0.5)                | 0                      |
| Lower gastrointestinal haemonhage               | 1 (0.8)                               | 1 (0.8)                               | 2 (1.3)              | 1 (0.6)              | 2 (0.5)                | 1 (0.2)                |
| Squamous cell carcinoma                         | 1 (0.8)                               | 0                                     | 2 (1.3)              | 0                    | 2 (0.5)                | 0                      |
| Hypotension                                     | 2 (1.7)                               | 0                                     | 2 (1.3)              | 0                    | 1 (0.2)                | 0                      |
| Pleural effusion                                | 2 (1.7)                               | 0                                     | 2 (1.3)              | 0                    | 1 (0.2)                | 0                      |
| Dyspnoea                                        | 2 (1.7)                               | 0                                     | 2 (1.3)              | 0                    | 0                      | 0                      |

Notes: Percentages were based on the mumber of patients in the specifed population in each column (denominator).

Abbreviations: dex = dexamethasone: ISS = Imtegrated Summary of Safety, MedDRA =Medical Dictionary for Reguhtory Activties; PT = prefered termr' SAE = senious adverse event; TSp = Targeted Safety Population.

Note:PTs with fewer TEAEs in Study OP-106 as conpared to ISS is due to different definitions used for TEAEs in Study OP-106 and ISS,see Section 2.7.4.1.1.3.4.1.

0 (propue angan ap Aps oipalgpro qd issd aqonsau aAqpasses uarea-un eepup sem pr-ei that had a missing causality on the case report fom.

At each level of sumwarization (any event, system organ clhss, and preferred term), patients reporting more than 1 adverse event were counted only once.

Adverse events were coded to preferred term using MedDRA, version 19.0 orlater.

Preferred terus are sorted by descending frequency in the Pooled ISS Analysis \"All\" column.

## Other AEs of special interest (AESI)

An overall summary of AESIs for patients in study OP-106 and the TSP is shown in Table 43 .

- Thrombocytopenia and bleeding events

Overall, 81.5% of patients in study OP-106 experienced AESIs of thrombocytopenia (SMQ) during the study, and 76.4% had a Grade 3 or 4 event. Twenty-nine patients (18.5%) and 36 patients (22.9%) overall reported Grade 3 and Grade 4, respectively, thrombocytopenia at Cycle 1. SAEs of thrombocytopenia (PT) were reported in 2.5% of patients. Dose modifications of melflufen due to thrombocytopenia occurred in 42.0% of patients: 31.8% had a dose delay, 14.0% had a dose reduction, and 10.2% discontinued melflufen. Supportive therapy for thrombocytopenia (platelet transfusions) was administered in 43% of patients.

Overall, 28.0% of patients reported AESIs of bleeding events. Twenty-five patients (15.9%) reported a TEAE of Grade 3 or 4 thrombocytopenia and concomitant haemorrhage, and 2.5% reported Grade 3 or 4 thrombocytopenia and concomitant Grade 3 or 4 bleeding events which were resolved after appropriate treatment. Five patients reported serious TEAEs; 3 of these events (lower gastrointestinal haemorrhage, hemorrhoidal haemorrhage, and epistaxis) were considered to be melflufen-related. No patients reported PTs related to haemorrhage that resulted in dose modifications of melflufen.

<div style=\"page-break-after: always\"></div>

Table 43 Overall summary of adverse events of special interest (OP-106 Safety population and ISS Targeted safety population)

|                            | Study 0P-106                          | Study 0P-106          | Pooled ISS Analysis     |
|----------------------------|---------------------------------------|-----------------------|-------------------------|
| AESI                       | Triple-Class Refractory (N=119) n (%) | Overall (N=157) n (%) | Total ISP (N=422) n (%) |
| Thrombocytopenia           | 94 (79.0)                             | 128 (81.5)            | 326 (77.3)              |
| Bleeding events            | 31 (26.1)                             | 44 (28.0)             | 73 (17.3)               |
| CNS bleedings              | 0                                     | 1 (0.6)               | 1 (0.2)                 |
| Neutropenia                | 94 (79.0)                             | 129 (82.2)            | 323 (76.5)              |
| Infections                 | 69 (58.0)                             | 91 (58.0)             | 205 (48.6)              |
| Infective pneumonia        | 36 (30.3)                             | 48 (30.6)             | 90 (21.3)               |
| Infective pneumonia narrow | 15 (12.6)                             | 21 (13.4)             | 42 (10.0)               |
| Febrile neutropenia        | 7 (5.9)                               | 10 (6.4)              | 14 (3.3)                |
| Anaemia                    | 77 (64.7)                             | 111 (70.7)            | 262 (62.1)              |
| Second primarymalignancies | 5 (4.2)                               | 6 (3.8)               | 8 (1.9)                 |
| MDS/AML                    | 2 (1.7)                               | 2 (1.3)               | 3 (0.7)                 |

Notes: Percentages were based on the number of patients in the specified population in each column (denominator).

Abbreviations: AESI = adverse event of special interest; AML = acute myeloid leukaemia; ISS = Integrated Summary of Safety; MDS = myelodysplastic syndrome; MedDRA = Medical Dictionary for Regulatory Activities; SMQ = standardized MedDRA query; TSP = Targeted Safety Population.

AESIsweredefinedusingStandardizedormodifiedStandardized(broadscope)orCustomizedMedDRAqueries or multiplepreferred terms.

Broad SMQ, which includes respiratory tract infections among other terms.

- Neutropenia, infections, infective pneumonia, and febrile neutropenia

Overall, 82.2% of patients experienced AESIs of neutropenia (SMQ) during the study, and 79.0% had a Grade 3 or 4 event. A total of 30.6% and 20.4% overall reported Grade 3 and Grade 4, respectively, neutropenia at Cycle 1. SAEs of neutropenia (PT) were reported in 1.3% of patients. Dose modifications of melflufen due to neutropenia occurred in 21.7% of patients, mainly dose delay (19.1%). Discontinuations occurred in 3.2% of patients. Supportive therapy for neutropenia (neutrophil growth factors such as filgrastim and analogues) was administered in 68% of patients.

Just over half (58.0%) of patients in Study OP-106 overall reported AESIs of infections; 21.7% reported AESIs of infections that were Grade 3 or 4 and one grade 5 event occurred. Infective pn eumonia was reported in 30.6% of patients. Overall, 28 patients (17.8%) had infections resulting in dose modifications, mainly dose delays (n=22, 14%). A total of 29.9% of patients reported an AESI of infection and concomitant Grade 3 or 4 neutropenia; 11.5% reported a Grade 3 or 4 AESI of infection and concomitant Grade 3 or 4 neutropenia.

A total of 6.4% of patients experienced an AESI of febrile neutropenia; of these patients, 5.1% reported serious AESIs of febrile neutropenia that were all considered to be melflufen-related.

## · Anaemia

Overall, 70.7% of patients in Study OP-106 experienced an AESI of anaemia; 17.2% and 0.6% reported Grade 3 and Grade 4, respectively, anaemia at Cycle 1. Only one patient reported a SAEs of anaemia (PT); the event was considered to be melflufen-related. Dose modifications due to anaemia were seen in 12.1% of patients: 9.6% had a dose delay, 1.3% had a dose reduction, and 1.3% discontinued melflufen. Supportive therapy for anaemia (red blood cell transfusion) was given in 61% of patients.

<div style=\"page-break-after: always\"></div>

## · MDS/AML and other second primary malignancies (SMP)

Within the full ISS Safety Population (n=495), 2.6% had SPMs; 9 patients (1.8%) had at least 1 AESI of SPMs, and 4 patients were reported to have SPMs during the overall survival follow-up, but these were not reported as AEs. Six patients (1.2%) had MDS/AML; 4 had at least 1 AESI of MDS/AML, and 2 patients were reported to have MDS/AML during the overall survival follow-up, but these were not reported as AEs. All four adverse events of MDS/AML were considered possibly/probably related to melflufen.

Other SMPs occurring in seven patients (1.4%) included: cutaneous basal cell carcinoma (3 patients), cutaneous squamous cell carcinoma (2 patients), and cutaneous malignant melanoma (1 patient) and plasma cell leukaemia (1 patient). Three of these events occurred in the same patient: 1 event of cutaneous basal cell carcinoma and the events of cutaneous malignant melanoma and cutaneous squamous cell carcinoma. Other SMPs included in one patient were colon adenocarcinoma during the overall survival follow-up that was not reported as AE and oesophageal carcinoma. None of the other SMPs reported as AE was considered related to melflufen.

Within study OP-106, 4.5% (n=7) patients had SPMs; 2 patients (1.3%) had MDS/AML and 5 patients (3.2%) had other SPMs.

## · Other events

## Extravasation and infusion reactions:

Within the full Safety population (n=495) one SAE of grade 2 extravasation was reported (2nd dose of melflufen 40 mg IV), and was considered not related to melflufen.

Infusion-related complications: A nonserious TEAE of Grade 1 catheter site extravasation was reported one week after the first dose of melflufen 40 mg IV and considered not-related. Overall, there were 4 TEAEs of peripheral swelling, 3 events of localized oedema, one serious event of administration site extravasation and one event of infusion site irritation. Three events (localized oedema and peripheral swelling (n=2)) were considered possibly related to melflufen. In addition, 25 patients experienced 31 TEAEs that potentially may have been considered infusion reactions. Five out of the 13 infusion related reactions were considered related to melflufen.

## Cardiac disorders:

Overall, 22 patients (14.0%) reported TEAEs in the SOC of Cardiac disorders in study OP-106. Ten patients (6.4%) reported TEAEs that were considered by the Investigator to be treatment-related: tachycardia (n=5, 3.2%) and bradycardia, cardiac failure, cardiomyopathy, palpitations, and sinus tachycardia (n=1, 0.6% each). Based on the TSP, there were in total 49/491 (10.0%) patients with TEAEs belonging to the SOC Cardiac disorders. Three PTs occurred in more than 5 (1%) patients, tachycardia, palpitations, and sinus tachycardia, with the PT tachycardia being the most common (n=10, 2.0%). Twenty patients (4.1%) reported TEAEs that were considered by the Investigator to be treatment-related, mostly tachycardia (n=7, 1.4%). Most events were non-serious, five patients experienced fatal events of which two were considered treatment-related by the investigator.

Regarding AEs potentially related to QTc prolongation, 9 TEAEs in 9/149 (1.8%) patients were identified (standardised MedDRA Query Torsade de pointes/QT prolongation). The most common was syncope experienced by 4 patients. All events except 1 were considered not-related to melflufen.

<div style=\"page-break-after: always\"></div>

## 2.6.8.4. Laboratory findings

## Haematology

For most patients in study OP-106, baseline values for haematological parameters was grade 0 or 1. Overall, there were mean decreases from Baseline at EoT in most haematologic parameters. Shifts to worst post-baseline decreased platelet counts were grade 3 or 4 for 26.2% and 53.5%, respectively. Shifts to post-baseline decreased neutrophil counts were grade 3 and grade 4 for 41.4% and 40.1%, respectively. The median times to onset of first Grade 3 or 4 neutrophils and platelets were 16 days and 26 days in the overall population, respectively. Similar shifts were seen for lymphocyte and leukocyte (WBC) counts.

In keeping with the higher incidence of AESIs of thrombocytopenia, neutropenia, and anaemia, shifts from Grade 0 or 1 to Grade 3 or 4 in haematology test results for platelet and neutrophil counts and haemoglobin values were more frequent in the Study OP-106 overall population compared with the TSP. However, there were no new or unexpected laboratory signals (post-baseline haematology or serum chemistry abnormalities) observed in either population.

## Serum chemistry

Shifts to Grade 4 were rare and shifts to Grade 3 were uncommon for most parameters for patients in study OP-106 or the TSP. The most frequently reported shift from Grade 0, 1, 2, or 3 at Baseline to worst post-Baseline Grade 3 or 4 overall (&gt; 10% of all subjects) was a Grade 0 to 3 increase in urate (13.9%) in study OP-106. There were no clinically relevant shifts from Baseline to EoT in the serum chemistry parameters during the study.

## Vital signs

There were no clinically significant vital sign abnormalities nor were there clinically meaningful trends identified in observed values or changes in mean values at each visit from Baseline.

## Effect on ECG parameters

Except for a subset of patients in Study O-12-M1, ECG assessments were performed only at the Screening and End of Treatment visits. Therefore, no additional on treatment data are available. Within study OP-106, there were 3 patients with abnormal CS ECG interpretations post-Baseline of sinus tachycardia, sinus bradycardia, and R wave progression. The abnormal CS ECG of sinus tachycardia was reported as a TEAE (PT: tachycardia) that was considered by the Investigator to be unrelated to study drug; the other abnormal CS ECG interpretations were not reported as TEAEs. No clinically relevant changes in mean values from Baseline to EoT were observed for the QTcF interval or any other parameters based on study O-12-M1 (see section 3.3.2.). The TSP did not reveal new findings.

## 2.6.8.5. Safety in special populations

Selected AESIs (thrombocytopenia, neutropenia, febrile neutropenia, infections, infective pneumonia, anaemia, bleeding events and MDS/AML) were summarised per subgroup (age, sex, race, BMI and baseline CrCl) for study OP-106 and the TSP.

An analysis of safety data by subgroup did not identify clinically meaningful differences, although there were some imbalances in the incidence of certain AEs. For the TSP, an increased frequency ( ≥10% difference) in thrombocytopenia was shown for patients &lt;65 years old or ≥65 and ≤75 years ol d (76.7% and 81.6% respectively) compared to patients &gt; 75 years old (64.9%, n=57). The frequency of neutropenia was increased in male patients compared to female patients (84.0% vs 71.3%). An increased frequency of infections (50.1% vs. 33.3%), infective pneumonia (22.3% vs 10.0%) and

<div style=\"page-break-after: always\"></div>

anaemia (63.8% vs 43.3%) was seen in white versus non-white patients (n=30). Due to the requirement for patients to have a baseline CrCl ≥45 mL/min , limited patients with a baseline CrCl of &lt;45 mL/min (n=21) were treated with melflufen. Overall, more patients with a baseline CrCl of &lt;45 mL/min (85.7%) experienced an AE than patients with a baseline CrCl of ≥45 -60 mL/min (71.8%). In addition, more patients with a baseline CrCl of ≥45 -60 mL/min (24.7%, n=85 ) and ≥ 60 mL/min (20.6%, n=310) experienced infective pneumonia than patients with a baseline CrCl &lt;45 mL/min (14.3%).

The safety profile by age group and by specific MedDRA terms is shown below for study OP-106 (Table 44).

Table 44 AEs by age groups and MedDRA terms (Study OP-106)

| MedDRA Terms                                                                             | Age <65 (N=78)   | Age 65-74 (N=54)   | Age 75 - 84 (N=24)   | Age 85+ (N=1)   | Overall (N=157)   |
|------------------------------------------------------------------------------------------|------------------|--------------------|----------------------|-----------------|-------------------|
| Total AEs                                                                                | 78 (100%)        | 54 (100%)          | 24 (100%)            | 1(100%)         | 157 (100%)        |
| Serious AEs -Total                                                                       | 47 (60.3%)       | 23 (42.6%)         | 10 (41.7%)           |                 | 80 (51.0%)        |
| Serious AEs -Fatal                                                                       | 5 (6.4%)         | 5 (9.3%)           |                      |                 | 10 (6.4%)         |
| Serious AEs - Hospitalization/prolong existing hospitalization                           | 39 (50.0%)       | 15 (27.8%)         | 10 (41.7%)           |                 | 64 (40.8%)        |
| Serious AEs - Life-threatening                                                           | 5 (6.4%)         | 1 (1.9%)           |                      |                 | 6 (3.8%)          |
| Serious AEs - Other (medically significant)                                              | 4 (5.1%)         | 4 (7.4%)           | 1 (4.2%)             |                 | 9 (5.7%)          |
| AE leading to drop-outl1]                                                                | 23 (29.5%)       | 13 (24.1%)         | 6 (25.0%)            |                 | 42 (26.8%)        |
| SOC Psychiatric disorders                                                                | 18 (23.1%)       | 13 (24.1%)         | 5 (20.8%)            |                 | 36 (22.9%)        |
| SOC Nervous system disorders                                                             | 29 (37.2%)       | 18 (33.3%)         | 13 (54.2%)           | 1(100%)         | 61 (38.9%)        |
| SOC Injury,poisoning and procedural complications                                        | 10 (12.8%)       | 10 (18.5%)         | 7 (29.2%)            |                 | 27 (17.2%)        |
| SOC Cardiac disorders                                                                    | 15 (19.2%)       | 4 (7.4%)           | 4 (16.7%)            |                 | 23 (14.6%)        |
| SOC Vascular disorders                                                                   | 16 (20.5%)       | 8 (14.8%)          | 4 (16.7%)            | 1(100%)         | 29 (18.5%)        |
| SOCInfections andinfestations                                                            | 49 (62.8%)       | 27 (50.0%)         | 15 (62.5%)           |                 | 91 (58.0%)        |
| PT Anticholinergic syndrome                                                              |                  |                    |                      |                 | No patients       |
| PTQualityoflifedecreased                                                                 |                  |                    |                      |                 | No patients       |
| Sum of postural hypotension, fall, black outs, syncope, dizziness, ataxia, fractures [2] | 12 (15.4%)       | 11 (20.4%)         | 4 (16.7%)            | 1(100%)         | 28 (17.8%)        |
| Other AE appearing morefrequently in older patients: Infective pneumonia (SMQ)[3)        | 10 (12.8%)       | 6 (11.1%)          | 5 (20.8%)            |                 | 21 (13.4%)        |

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; SOC = System Organ Class; SMQ =Standardized MedDRA Query;CMQ =Customized MedDRA Query;PT=Preferred Term;HLGT=High Level GroupTerm;HLT=High Level Term Within each grouped term, patients reporting more than one term are counted only once.

AdverseeventswerecodedtopreferredtermusingMedDRA,version19.1.

[1l Action taken with study drug: DRUG WITHDRAWN'

[3] SMQ 'Infective pneumonia Narrow terms.

[2] CMQ, PT {'Orthostatic hypotension' 'Fall' 'Loss of consciousness' 'Syncope'Dizziness' 'Dizziness postural 'Vertigo' 'Ataxia'}, HLGT {'Fractures'], or HLT {Coordination and balance disturbances''Vertigos NEC'}.

[Data as of January 14th, 2020.

Program: \\\\EMA 2021\\prog\\tf\\subprogs\\tflpgm\\Q165-T1-ae-agegrp.sas, 2021-11-17 17:35.

## 2.6.8.6. Immunological events

N/A

## 2.6.8.7. Safety related to drug-drug interactions and other interactions

No specific clinical studies assessing the effects of other drugs or extrinsic factors on melflufen were submitted.

<div style=\"page-break-after: always\"></div>

## Overdose

The highest dose of melflufen tested in clinical studies was 130 mg in Study O-05-001 in patients with solid tumours. In Study O-12-M1 in patients with RRMM, 55 mg exceeded the MTD associated with reversible haematologic toxicity, and 40 mg every 28 days in combination with weekly dexamethasone was determined to be the recommended dose in patients with RRMM. Because no overdose of melflufen has been reported as of the data cutoff date for this SCS (31 March 2020), there are no available data on overdose. However, because melflufen is rapidly converted to melphalan, the label of melphalan is of interest also in the treatment with melflufen.

## 2.6.8.8. Discontinuation due to adverse events

Overall, 37 patients (23.6%) had at least one TEAE leading to permanent discontinuation of study drug and 34 patients (21.7%) had at least one TEAE leading to discontinuation of melflufen ( Error! Reference source not found. ).Treatment-emergent AEs leading to discontinuation of melflufen were most often reported in the SOC of Blood and lymphatic system disorders (12.1%). The most frequently reported TEAE leading to discontinuation of melflufen by PT was thrombocytopenia (10.2%). All other TEAEs leading to discontinuation of melflufen were reported by &lt;5% of patients.

## TEAEs leading to dose reduction

Overall, 38.2% of patients had a TEAE that led to dose reduction of study drug and 26.8% patients had a TEAE resulting in dose reduction of melflufen. By PT, the most commonly reported TEAEs resulting in dose reductions of melflufen were thrombocytopenia (14.0%) and platelet count decreased (8.3%).

## TEAEs leading to dose interruption

Overall, 65.6% of patients had a TEAE that led to dose delay of study drug and 61.8% patients had a TEAE resulting in dose delay of melflufen. By PT, the most commonly reported TEAEs resulting in dose reductions of melflufen were thrombocytopenia (31.8%), neutropenia (19.1%), platelet count decreased (11.5%), anaemia (9.6%) and neutrophil count decreased (9.6%).

## Study OP-103 - OCEAN

A total of 228 patients and 246 patients in the melflufen+dex and pomalidomide+dex groups, respectively, were dosed with study drug on Day 1 and were included in the Safety Analysis Set. The median duration of study drug treatment was longer for the melflufen+dex group compared with the pomalidomide+dex group (25.14 weeks vs 22.14 weeks). The median number of cycles started was 5.0 for both treatment groups.

A summary of TEAEs is shown in Table 45. All patients had at least one TEAE and most patients had one melflufen treatment-related TEAE (93.9%). Grade 3 or 4 TEAEs occurred frequently (89.5%) and were mostly melflufen-related (84.2%). The number of fatal TEAEs was 11.8% and only one event was not considered treatment-related. Serious TEAEs occurred in 41.7% of patients and half of these were considered treatment-related (18.4%). Most patients (78.1%) had events leading to dose modifications of melflufen. Overall, 26.3% of patients had at least one TEAE leading to discontinuation of melflufen and 15.9% leading to discontinuation of dexamethasone. Treatment-related grade 3 or 4 events as well as dose modifications, including discontinuations, were more common for melflufen than for pomalidomide. SAEs and fatal events were in the same order of magnitude.

<div style=\"page-break-after: always\"></div>

Table 45 Overview of treatment-emergent adverse events (Safety Analysis Set Study OP-103)

| Number of patients with:                                                           | Melflufen + Deramethasone N=228 n(%)   | Pomalidomide+ Deamethasone N=246 n(%)   |
|------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------|
| At least one TEAE                                                                  | 226 (99.1%)                            | 241 (98.0%)                             |
| At least one treatment-related TEAE                                                | 216 (94.7%)                            | 209 (85.0%)                             |
| At least one melflufen- or pomalidomide-related TEAE                               | 214 (93.9%)                            | 193 (78.5%)                             |
| TEAEs ofCTCAE Grade 3:                                                             |                                        |                                         |
| Atleast one Grade3 TEAE                                                            | 204 (89.5%)                            | 176 (71.5%)                             |
| At least oue treatment-related Grade 3TEAE                                         | 194 (85.1%)                            | 148 (60.2%)                             |
| At least one melflufen- or pomalidomide-related Grade 3 TEAE                       | 192 (84.2%)                            | 138 (56.1%)                             |
| TEAEs ofCTCAE Grade 4:                                                             |                                        |                                         |
| At least one Grade 4 TEAE                                                          | 125 (54.8%)                            | 68 (27.6%)                              |
| At least one treabment-related Grade 4 TEAE                                        | 118 (51.8%)                            | 58 (23.6%)                              |
| At least one melflufen- or pomalidonide-related Grade 4 TEAE                       | 118 (51.8%)                            | 56 (22.8%)                              |
| TEAEs ofCTCAE Grade 3 or4                                                          |                                        |                                         |
| At least one Grade 3 or 4 TEAE                                                     | 205 (89.9%)                            | 183 (74.4%)                             |
| At least one treabment-related Grade 3 or 4 TEAE                                   | 195 (85.5%)                            | 157 (63.8%)                             |
| At least one melflufen- or pomalidomide-related Grade 3 or 4 TEAE                  | 193 (84.6%)                            | 148 (60.2%)                             |
| Fatal TEAEs (CTCAE Grade 5):                                                       |                                        |                                         |
| At least one fatal (Grade 5) TEAE                                                  | 27 (11.8%)                             | 32 (13.0%)                              |
| At least one treabment-related fatal (Grade 5) TEAE                                | 1 (0.4%)                               | 4 (1.6%)                                |
| At least one SAE                                                                   | 95 (41.7%)                             | 113 (45.9%)                             |
| At least one treahment-related SAE                                                 | 42 (18.4%)                             | 52 (21.1%)                              |
| At least one TEAE leading to dose modification of stucdy dnug                      | 183 (80.3%)                            | 164 (66.7%)                             |
| At least one TEAE leading to dose modification of melflufen or pomalidomide        | 178 (78.1%)                            | 144 (58.5%)                             |
| At least one TEAE leading to dose modification of dexamethasone                    | 129 (56.6%)                            | 135 (54.9%)                             |
| At least one TEAE leading to dose reduction of study dnug                          | 115 (50.4%)                            | 66 (26.8%)                              |
| At least one TEAE leading to dosereduction of melflufen or pomalidomide            | 107 (46.9%)                            | 37 (15.0%)                              |
| At least one TEAE leading to dose reduction of dexamethasone                       | 28 (12.3%)                             | 43 (17.5%)                              |
| At least one TEAE leading to dose delay of study dnug                              | 153 (67.1%)                            | 112 (45.5%)                             |
| At least one TEAE leading to dose delay of melflufen or pomalidomide               | 137 (60.1%)                            | 109 (44.3%)                             |
| At least one TEAE leading to dose delay of dexamethasone                           | 96 (42.1%)                             | 74 (30.1%)                              |
| At least one TEAE leading to penmanent discontinuation of study dnug               | 60 (26.3%)                             | 56 (22.8%)                              |
| At least one TEAE leading to pemanent discontinuation of melflufen or pomalidomide | 60 (26.3%)                             | 54 (22.0%)                              |
| At least one TEAE leading to pemmanent discontinuation of dexamethasone            | 46 (20.2%)                             | 55 (22.4%)                              |

·TEAEswere defned asAEswith onset datetime orincreaseinseveritylevelafer theinital dose of study drugand within30days aterthelast dose f study drug or initiation of new multiple myeloma therapy, whichever was sooner. Adiverse events were gaded per NCI-CTCAE v4.03.

AE = adverse event; CTCAE = Conmon Teminology Criteria for Adverse Events; NCI = National Cancer Instirute; TEAE = treatment-emergent adverse event. Notes:

·Treatment-related was defined as related possibly related probably related, or missingrelation to melflufen, pomalidouide, or dexamethasone.Similarly, study dugrefers to melflufen, pomalidomide, or dexamethasone.

·Dose modifications were defined as an action taken value of dose reduced dose held or permanent discontinuation.

The most commonly reported TEAEs for melflufen+dexamethasone were haematologic in nature, including thrombocytopenia (70.2%), anaemia (66.7%), and neutropenia (60.1%) (Table 46). The most common non-haematologic TEAEs were pyrexia (14.5%), asthenia and fatigue (each 14.0%), diarrhoea (13.6%), nausea (13.2%), and upper respiratory tract infection (12.7%).

<div style=\"page-break-after: always\"></div>

Table 46 Treatmentemergent adverse events in ≥5 % of patients in the melflufen+dexamethasone or pomalidomide+dexamethasone group by PT (Safety Analysis Set Study OP-103)

| System Organ Class Preferred Term*                | Melflufen+ Dexamethasone N=228 n (%)   | Pomalidomide+ Deramethasone N=246 (96）u   |
|---------------------------------------------------|----------------------------------------|-------------------------------------------|
| Number of patients with at least 1 TEAE           | 226 (99.196)                           | 241 (98.0%6)                              |
| Bloodand lymphaticsystem disorders                | 200 (87.7%6)                           | 159 (64.6%)                               |
| Neutropenia                                       | 137 (60.1%)                            | 113 (45.9%)                               |
| Ansemia                                           | 152 (66.7%)                            | 92 (37.4%)                                |
| Thrombocytopenia                                  | 160 (70.2%)                            | 48 (19.5%)                                |
| Leukopenia                                        | 24 (10.5%)                             | 11 (4.5%)                                 |
| Infections and infestations                       | 114 (50.0%6)                           | 137 (55.7%6)                              |
| Upper respiratory tact infection                  | 29 (12.7%)                             | 25 (10.2%)                                |
| Pneumonia                                         | 20 (8.8%)                              | 32 (13.0%)                                |
| Bronchitis                                        | 13 (5.7%)                              | 26 (10.6%)                                |
| Urinary tract infection                           | 11 (4.8%)                              | 16 (6.5%)                                 |
| Respiratory tract infection                       | 7 (3.1%)                               | 14 (5.7%)                                 |
| Generaldisorders and adninistrationsiteconditions | 94 (41.2%)                             | 107 (43.5%)                               |
| Fatigue                                           | 32 (14.0%)                             | 41 (16.7%)                                |
| Asthenia                                          | 32 (14.0%)                             | 28 (11.4%)                                |
| Pyrexia                                           | 33 (14.5%)                             | 16 (6.5%%)                                |
| Oedema peripheral                                 | 11 (4.8%)                              | 21 (8.5%)                                 |
| Investigations                                    | 86 (37.796)                            | 74 (30.196)                               |
| Neutrophil coumt decreased                        | 30 (13.2%)                             | 27 (11.0%)                                |
| Platelet coumt decreased                          | 40 (17.5%)                             | 11 (4.5%)                                 |
| White blood cell couwt decreased                  | 22 (9.6%)                              | 6 (2.4%)                                  |
| SARS-CoV-2 test positive                          | 13 (5.7%)                              | 12 (4.9%)                                 |
| Musculoslkeletalandconnectivetissuedisorders      | 74 (32.5%6)                            | 73 (29.7%6)                               |
| Back pain                                         | 17 (7.5%)                              | 24 (9.8%)                                 |
| Bone pain                                         | 17 (7.5%)                              | 12 (4.9%)                                 |
| Anhralgia                                         | 14 (6.1%)                              | 5 (2.0%)                                  |
| Gastrointestinal disorders                        | 75 (32.9%6)                            | 70 (28.596)                               |
| Diahoea                                           | 31 (13.6%)                             | 21 (8.5%)                                 |
| Nausea                                            | 30 (13.2%)                             | 17 (6.9%)                                 |
| Constipation                                      | 16 (7.0%)                              | 29 (11.8%)                                |
| Respiratory, thoracic and mediastinal disorders   | 54 (23.7%6)                            | 53 (21.596)                               |
| Dyspuoea                                          | 21 (9.2%)                              | 24 (9.8%)                                 |
| Cough                                             | 18 (7.9%)                              | 19 (7.7%)                                 |
| Nervous system disorders                          | 41 (18.0%)                             | 58 (23.6%6)                               |
| Dizziness                                         | 8 (3.5%)                               | 16 (6.5%)                                 |
| Psychiatric disorders                             | 37(16.2%6)                             | 39 (15.9%6)                               |
| Insomnia                                          | 19 (8.3%)                              | 21 (8.5%)                                 |

SARS-CoV-2 = severe acute respiratory syndrome coronavinus 2; TEAE = treatment-emergent adverse event. Notes:

AE = adverse event; MedDRA = Medical Dictionary for Regulatory Activities; PT = prefered termy

· TEAEs were defined as adverse events with onset date/time or increase in severity level afier the initial dose of study drug and within 30 days afier the last dose of study drug or initiation of new multiple myeloma therapy, whichever was sooner.

*AEs were coded to a lower-level term and presented by the linked prefered tem and primary system organ class using MedDRA, version 23.0.

·At each level of summarization(system organ class and preferred tem). patients reporting more than one AE were counted only once.

Haematological events were also the most frequently reported ≥Grade 3 events in both treatment arms and higher for melflufen arm (79.4% vs 52.0% for melflufen + dexamethasone and pomalidomide + dexamethasone, respectively) (Table 47). The percentage of patients who had at least one Grade 3 non-hematological TEAE was similar for the melflufen+dex group compared with the pomalidomide+dex group (32.5% vs 32.9%) and the percentage of patients who had at least one Grade 4 non-hematological TEAE was slightly lower in the melflufen+dex group compared with the pomalidomide+dex group (2.2% vs 6.1%).

<div style=\"page-break-after: always\"></div>

Table 47 Incidence of treatment-emergent adverse events by maximum severity (grade 3 or 4) in ≥5% of patients in the melflufen+dex or pomalidomide+dex arm by PT (Safety analysis set Study OP103)

<!-- image -->

Activitier; NCI = National Cancer Institute; PT = preferred temmr TEAF = tesment-smergent sdverre svont.

AE = sdvere evnt: CTCAF= Common Terminology Criteria for Adoree Evontr: MedDRA = Medicl Dictonry for Regulktory

Noter:

- At esch lovel of summriztion (yutem organ cla snd prefoned temm), patienis roporting more thsn ons incidenee of esch AF were coumted cnly onco by mxinmm soverity.
- ·TEAEs wre dofned ss AEs with coret date/timo orincronso in sovwrity levol affor he initial dos of study dng and wihin 30 days affer the last dore of study dnug orinitistion ofnew mmltiple myolomy thonpy, whichevor was soonor.
- Advere swents wee gsded per NCI-CTCAE v4.03.
- Ofnoto. in Table 14.3.1-3.1, TEAEg wwre only couted once bard on mxinmm sowwrity, including Gnde 3. Gnde 4, or Gnde 5 (fstal) TEAE; howovr, in Tablo 14.3.1-4, TEAE wre cnlycoumted onco bsred on mxin wverity, including only Gnde 3 or Grde 4. Therefore, the toblmmberof Grde 3 or Gnde 4 TEAEsis regreronntive ofall Grde 3 and Gnde 4 TEAEs, ineopecive of whether tho cueut rosulted in a Grde5 TEAE.
- Sun wep nfio mpfs fruud pue muet poueord poxul eq lq paluenend pue mun ponef-remof e o1 popos sram spens aapy. ModDRA, wwrsion 23.0.

Haematological events were also the most commonly treatment-related events ( Table 48 ).

<div style=\"page-break-after: always\"></div>

Table 48 Melflufen- or pomalidomiderelated adverse events in ≥5% of patients by any grade and maximum severity of grade 3 or 4 (Safety Analysis Set Study OP-103).

<!-- image -->

| System Organ Class                                               | Melflufen+Dexamethasone (N=228) n(%)   | Melflufen+Dexamethasone (N=228) n(%)   | Melflufen+Dexamethasone (N=228) n(%)   | Pomalidomide+Dexamethasone (N=240) (96）u   | Pomalidomide+Dexamethasone (N=240) (96）u   | Pomalidomide+Dexamethasone (N=240) (96）u   |
|------------------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Preferred Tenm a                                                 | Any Grade                              | Grade3                                 | Grade4                                 | Any Grade                                  | Grade3                                     | Grade 4                                    |
| Patients with at least 1 melflufen- or pomalidomide-relhted TEAE | 214 (93.9%)                            | 75 (32.9%%)                            | 117 (51.3%)                            | 193 (78.5%)                                | 91 (37.0%)                                 | 54 (22.0%)                                 |
| Blood and lymphatic system disorders                             | 193 (84.6%6)                           | 78 (34.296)                            | 96 (42.196)                            | 138 (56.1%6)                               | 71 (28.996)                                | 42 (17.1%6)                                |
| Neutropenia                                                      | 134 (58.8%)                            | 65 (28.5%)                             | 57 (25.0%)                             | 106 (43.1%)                                | 62 (25.2%)                                 | 34 (13.8%)                                 |
| Thrombocytopenia                                                 | 157 (68.9%)                            | 70 (30.7%)                             | 68 (29.8%)                             | 39 (15.9%)                                 | 13 (5.3%)                                  | 9 (3.7%)                                   |
| Amaemia                                                          | 132 (57.9%)                            | 82 (36.0%%)                            | 5 (2.2%)                               | 58 (23.6%)                                 | 23 (9.3%)                                  | 2 (0.8%)                                   |
| Leukopenia                                                       | 23 (10.1%)                             | 12 (5.3%)                              | 2 (0.9%)                               | 10 (4.1%)                                  | 5 (2.0%)                                   | 1 (0.4%)                                   |
| Investigations                                                   | 62 (27.296)                            | 19 (8.396)                             | 26 (11.4%6)                            | 37 (15.0%6)                                | 21 (8.546)                                 | 6 (2.4%6)                                  |
| Neutrophil count decreased                                       | 28 (12.3%)                             | 17 (7.5%)                              | 9 (3.9%)                               | 25 (10.2%)                                 | 16 (6.5%)                                  | 6 (2.4%)                                   |
| Platelet coumt decrensed                                         | 39 (17.1%)                             | 17 (7.5%)                              | 15 (6.6%)                              | 9 (3.7%)                                   | 5 (2.0%)                                   | 0                                          |
| White blood cell count decreased                                 | 21 (9.2%)                              | 6 (2.6%)                               | 7 (3.1%)                               | 6 (2.4%)                                   | 2 (0.8%)                                   | 0                                          |
| Infections and infestations                                      | 40 (17.596)                            | 14 (6.1%6)                             | 1 (0.4%)                               | 46 (18.7%6)                                | 17 (6.996)                                 | 3 (1.2%)                                   |
| Pneumonia                                                        | 8 (3.5%)                               | 5 (2.2%)                               | 0                                      | 13 (5.3%)                                  | 7 (2.8%)                                   | 0                                          |
| Geueral disorders and administration site conditions             | 39 (17.196)                            | 4 (1.8%)                               | 0                                      | 42 (17.1%)                                 | 8 (3.3%)                                   | 1(0.4%6)                                   |
| Fatigue                                                          | 20 (8.8%)                              | 0                                      | 0                                      | 22 (8.9%)                                  | 2 (0.8%)                                   | 1 (0.4%)                                   |
| Asthenia                                                         | 15 (6.6%)                              | 2 (0.9%)                               | 0                                      | 13 (5.3%)                                  | 5 (2.0%)                                   | 0                                          |
| Gastroiutestinal disorders                                       | 38 (16.796)                            | 2 (0.9%)                               | 0                                      | 26 (10.6%6)                                | 2 (0.8%6)                                  | 1(0.4%)                                    |
| Nausea                                                           | 24 (10.5%)                             | 1 (0.4%)                               | 0                                      | 6 (2.4%)                                   | 0                                          | 0                                          |
| Dianhoea                                                         | 12 (5.3%)                              | 1 (0.4%)                               | 0                                      | 10 (4.1%)                                  | 0                                          | 0                                          |
| Constipation                                                     | 4 (1.8%)                               | 0                                      | 0                                      | 14 (5.7%)                                  | 0                                          | 0                                          |

Notes:

·At each level of summarization (Grade 3 or 4, SOC, and PT), patients reporting more than one incidence of each AE were couted only once by maximum severity regardless of whether the TEAE was Grade 3 or4.

· TEAEs were defned as AEs with onset date/time or increase in severity level afer the initial dose of study drug and within 30 days after the last dose ofstudy drug or initiation of new multiple myeloua therapy, whichever was sooner.

- *AEs were coded to a lower-level term and presented by the linked PT and primary SOC using MedDRA, version 23.0.

## AEs by prior ASCT status

While the overall AE profile was similar in transplanted and non-transplanted melflufen+dex treated patients, hematologic AEs were reported more frequently in transplanted patients compared to patients with no prior ASCT, mostly due to thrombocytopenia (92.0% vs 81.9%) and anemia (71.4% vs 62.9%) ( Table 49 ). Further, there is a trend towards higher frequencies of AEs leading to dose modifications and discontinuations among patients with prior ASCT compared to patients without prior ASCT for melflufen+dex. This difference is driven by the SOC Blood and lymphatic system disorders, primarily the PT thrombocytopenia (59.8% vs 40.5% respectively, in patients with and without prior ASCT). On the other hand, fatal AEs and SAEs were comparable.

No major differences in frequencies of AESIs depending on transplant status were seen for patients treated with pomalidomide+dex, although fatal AEs were less frequently observed in patients with prior ASCT.

<div style=\"page-break-after: always\"></div>

Table 49 Overview of AEs by ASCT status (Safety Analysis Set Study OP-103)

|                                                                         | Prior ASCT=Yes   | Prior ASCT=Yes    | Prior ASCT =No   | Prior ASCT =No    |
|-------------------------------------------------------------------------|------------------|-------------------|------------------|-------------------|
|                                                                         | Mellufen +Dex    | Pomalidonide +Dex | Melflufen +Dex   | Ponalidonide +Dex |
| Nunber ofpatientswith                                                   | (N=112)          | (N=118)           | (N=116)          | (N=128)           |
| at leastoneAE                                                           | 111 (99.1%)      | 115 (97.5%)       | 115 (99.1%)      | 126 (98.4%)       |
| atleastoneseriousAE                                                     | 43 (38.4%)       | 57 (48.3%)        | 52 (44.8%)       | 56 (43.8%)        |
| atleastonefatalAE                                                       | 14 (12.5%)       | 10 (8.5%)         | 13 (11.2%)       | 22 (17.2%)        |
| at least one AEleading todose modification of melflufen or pomalidomide | 94 (83.9%)       | 70 (59.3%)        | 84 (72.4%)       | 74 (57.8%)        |
| atleastoneAEleadingtopermanent discontinuationofstudydrug               | 34 (30.4%)       | 19 (16.1%)        | 26 (22.4%)       | 35 (27.3%)        |

Abbreviations: AE = adverse event; ASCT = autologous stem cell transplantation; Dex = dexamethasone. Notes:

- AEs were defined as adverse events with onset date/time or increase in severity level after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new multiple myeloma therapy. whichever is sooner.
- ·Dose modifications included dose reduction, dose delay, or permanent discontinuation.
- ·Study drug includes melflufen, pomalidomide, and dexamethasone.

When comparing AESI for mel+dex arm in patients with ASCT and TTP&lt;36 months (n=91) versus patients with no ASCT or TTP ≥36 months, the main difference was an increase in grade 3/4 thrombocytopenia (85.7% vs 70.1%), whereas median treatment duration was shorter (16 vs 35.1 weeks).

## SAEs and deaths

A total of 106 patients (46.5%) in the melflufen+dex group and 106 patients (43.1%) in the pomalidomide+dex group died during the study. Most of these patients (83 patients [36.4%] in the melflufen+dex group and 73 patients [29.7%]) died &gt;30 days after last dose. The primary cause of death for patients in both treatment groups who died &gt;30 days after last dose was PD (53 patients [23.2%] in the melflufen+dex group and 46 patients [18.7%] in the pomalidomide+dex group). A total of 12 patients (5.3%) in the melflufen+dex group and 8 patients (3.3%) in the pomalidomide+dex group died within 60 days after the first dose. The primary causes of death within 60 days after the first dose for both treatment groups were PD (6 patients [2.6%] in the melflufen+dex group and 2 patients [0.8%] in the pomalidomide+dex group) and AE (6 patients [2.6%] in the melflufen+dex group and 5 patients [2.0%] in the pomalidomide+dex group); 1 additional patient (0.4%) in the pomalidomide+dex group died due to 'other' (pulmonary edema).

A total of 27 patients (11.8%) in the melflufen+dex group and 32 patients (13.0%) had a TEAE reported with a fatal outcome ( Table 50 ). All of the fatal TEAEs in the melflufen+dex group were considered by the Investigator to be unrelated to melflufen, with the exception of pancytopenia and cardiac failure acute in one patient, which were considered possibly related. All of the fatal TEAEs in the pomalidomide+dex group were considered by the Investigator to be unrelated to pomalidomide+dex, with the exception of COVID-19 pneumonia, myelodisplastic syndrome in one patient each, and pneumonia in two patients, which were considered possibly related. Most TEAEs with a fatal outcome occurred within 30 days of last dose of melflufen and pomalidomide, respectively.

<div style=\"page-break-after: always\"></div>

Table 50 Fatal treatment-emergent adverse event, by system organ class and preferred term (Safety Analysis Set Study OP-103)

<!-- image -->

| System Organ Class Preferred Term *                                 | Melflufen+ Dexamethasone (N=228)   | Melflufen+ Dexamethasone (N=228)   | Melflufen+ Dexamethasone (N=228)   | Pomalidomide+ Deramethasone (N=246)   | Pomalidomide+ Deramethasone (N=246)   | Pomalidomide+ Deramethasone (N=246)   |
|---------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| System Organ Class Preferred Term *                                 | (96)                               | Events                             | Related (%）                        | AlI n (%)                             | Events                                | Related n (%)                         |
| Number ofpatients with fatal (Grade 5) TEAEs                        | 27 (11.8%)                         | 31                                 | 1 (0.4%6)                          | 32 (13.0%6)                           | 33                                    | 4 (1.6%)                              |
| Infections and infestations                                         | 12 (5.3%)                          | 12                                 | 0                                  | 13 (5.396)                            | 13                                    | 3 (1.2%6)                             |
| COVID-19 pneumonia                                                  | 7 (3.1%)                           | 7                                  | 0                                  | 4 (1.6%)                              | 4                                     | 1 (0.4%)                              |
| Pneumonia                                                           | 3 (1.3%)                           | 3                                  | 0                                  | 4 (1.6%)                              | 4                                     | 2 (0.8%)                              |
| Septic shock                                                        | 0                                  | 0                                  | 0                                  | 2 (0.8%)                              | 2                                     | 0                                     |
| Urinary tract infection                                             | 2 (0.9%)                           | 2                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Escherichia sepsis                                                  | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Lower respiratory tract infection                                   | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Sepsis                                                              | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              |                                       | 0                                     |
| General disorders and administration siteconditions                 | 3 (1.3%)                           | 3                                  | 0                                  | 9 (3.796)                             | 9                                     | 0                                     |
| Multiple organ dysfunction syndrome                                 | 2 (0.9%)                           | 2                                  | 0                                  | 2 (0.8%)                              | 2                                     | 0                                     |
| General physical health deterioration                               | 0                                  | 0                                  | 0                                  | 3 (1.2%)                              | 3                                     | 0                                     |
| Sudden cardiac death                                                | 0                                  | 0                                  |                                    | 2 (0.8%)                              | 2                                     | 0                                     |
| Asthenia                                                            | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Death                                                               | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Sudden death                                                        | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              |                                       | 0                                     |
| Respiratory, thoracic and mediastinal disorders                     | 3 (1.3%)                           | 3                                  | 0                                  | 4 (1.6%6)                             | 4                                     | 0                                     |
| Respiatory failure                                                  | 2 (0.9%)                           | 2                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Pleuwral effusion                                                   | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Pulmonary embolism                                                  | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Pulmonary oedema                                                    | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Respiratory anrest                                                  | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Cardiac disorders                                                   | 2 (0.9%)                           | 2                                  | 1 (0.4%6)                          | 2 (0.8%6)                             | 2                                     | 0                                     |
| Cardiac arrest                                                      | 1 (0.4%)                           | 1                                  | 0                                  | 2 (0.8%)                              | 2                                     | 0                                     |
| Cardiac failure acute                                               | 1 (0.4%)                           | 1                                  | 1 (0.4%)                           | 0                                     | 0                                     | 0                                     |
| Renal and urinary disorders                                         | 2 (0.9%)                           | 2                                  | 0                                  | 2 (0.8%6)                             | 2                                     | 0                                     |
| Renal failure                                                       | 2 (0.9%)                           | 2                                  | 0                                  | 2 (0.8%)                              | 2                                     | 0                                     |
| Injury, poisoning and procedural complicatious                      | 2 (0.9%6)                          | 2                                  | 0                                  | 1 (0.496)                             | 1                                     | 0                                     |
| Craniocerebral injury                                               |                                    | 0                                  | 0                                  | 1 (0.4%)                              | ■                                     | 0                                     |
| Post procedural complication                                        | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Subduralhaematoma                                                   | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Nervous system disorders                                            | 2 (0.996)                          | 2                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Brain oedema                                                        | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Cerebral haemonhage                                                 | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Cerebrovascular insuffciency                                        | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | 1                                     | 0                                     |
| Blood and lymphatic system disorders                                | 2 (0.996)                          | 2                                  | 1 (0.4%6)                          | 0                                     | 0                                     | 0                                     |
| Neutropenia                                                         | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Pancytopenia                                                        | 1 (0.4%)                           | 1                                  | 1 (0.4%)                           | 0                                     | 0                                     | 0                                     |
| Gastrointestinal disorders                                          | 2 (0.9%6)                          | 2                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Abdominal mass                                                      | 2 (0.9%)                           | 2                                  | 0                                  | 0                                     | 0                                     | 0                                     |
| Neoplasms benign, maliguant and unspecified (incl cysts and polyps) | 1(0.4%)                            | 1                                  | 0                                  | 1(0.4%)                               | 1                                     | 1 (0.4%)                              |
| Myelodysplastic syndrome                                            | 0                                  | 0                                  | 0                                  | 1 (0.4%)                              | ■                                     | 1 (0.4%)                              |
| Oesophageal carcinoma                                               | 1 (0.4%)                           | 1                                  | 0                                  | 0                                     | 0                                     | 0                                     |

Note:

AE = advero owent; MedDRA = Medical Dictionsry for Regulatory Activifior:; TEAE = tostment-omorgent advereo event.

· TEAEs were dofined as AEs with onret date/time or increase in severity lovol afterthe initisl dose of study drug and within 30 daysafter the last dose of study drug orinitistion ofnew multiple myeloms therapy, whichewer war rooner.

*AEs woro coded to profomed tonm using MedDRA, vorsion 23.0.

· Treatment-rolated was defined srelated to molfufen, pomslidomide, or dexamotharone.

A summary of SAEs and related SAEs reported in ≥2 patients in either treatment group by all PTs is presented in Table 51. Frequencies of overall patients with one SAE or one treatment-related SAE were comparable between treatment arms. Infections were the most common SAEs in both treatment arms. In the melflufen+dex group, the most frequently reported SAEs by PT were pneumonia (5.7% vs 8.5% in pomalidomide+dex group), thrombocytopenia (3.9% vs. 1.2% in pomalidomide+dex arm), and anemia (3.1% vs 2.0% in pomalidomide+dex group). SAEs in the MedDRA SOC Blood and lymphatic system disorders were more common in the melflufen + dexamethasone arm (9.2%) than in the pomalidomide + dexamethasone arm (4.5%).

<div style=\"page-break-after: always\"></div>

Table 51 SAEs and related SAEs reported in ≥2 patients by PT either treatment group (Safety Analysis Set Study OP-103)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 51 Continued: SAEs and related SAEs reported in ≥2 patients by PT either treatment group (Safety Analysis Set Study OP-103)

<!-- image -->

| Systen Organ Class Prefered Tem *                                   | Melflufen+Dexainethasone (N=228) n (%)   | Melflufen+Dexainethasone (N=228) n (%)   | Pomalidomide+Dexamethasone (N=246) n (%)   | Pomalidomide+Dexamethasone (N=246) n (%)   |
|---------------------------------------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------------|--------------------------------------------|
| Systen Organ Class Prefered Tem *                                   | AII                                      | Related                                  | AIl                                        | Related                                    |
| Respiratory failure                                                 | 4 (1.8%)                                 | 0                                        | (%) &                                      | 1 (0.4%)                                   |
| Chronic obshuctive pulmonary disease                                | 1 (0.4%)                                 | 0                                        | 3 (1.2%)                                   | 0                                          |
| Injury, poisoning and procedural complieations                      | 10 (4.4%)                                | 1 (0.4%)                                 | 12 (4.9%)                                  | 0                                          |
| Femuw fiacture                                                      | 1 (0.4%)                                 | 0                                        | 2 (0.8%)                                   | 0                                          |
| Hip fracture                                                        | 1 (0.4%)                                 | 0                                        | 2 (0.8%)                                   | 0                                          |
| Humerus frachure                                                    | 1 (0.4%)                                 | 0                                        | 2 (0.8%)                                   | 0                                          |
| Femoral neck frachure                                               | 2 (0.9%)                                 | 0                                        | 0                                          | 0                                          |
| Stemal fiachue                                                      | 2 (0.9%)                                 | 0                                        | 0                                          | 0                                          |
| Gastrointestinal disorders                                          | 9 (3.9%)                                 | 2 (0.9%)                                 | 7 (2.8%)                                   | 3 (1.2%)                                   |
| Dianhoea                                                            | 2 (0.9%)                                 | 1 (0.4%)                                 | 1 (0.4%)                                   | 1 (0.4%)                                   |
| Abdominal mass                                                      | 2 (0.9%)                                 | 0                                        | 0                                          | 0                                          |
| Renaland urinary disorders                                          | 4 (1.8%)                                 | 1 (0.4%)                                 | 12 (4.9%)                                  | 0                                          |
| Renal failure                                                       | 2 (0.9%)                                 | 0                                        | 6 (2.4%)                                   | 0                                          |
| Acute kidney injuy                                                  | 2 (0.9%)                                 | 0                                        | 5 (2.0%)                                   | 0                                          |
| Musculoskeletaland comnective tissue disorders                      | 7 (3.1%)                                 | 0                                        | 8 (3.3%)                                   | 1 (0.4%)                                   |
| Bone pain                                                           | 1 (0.4%)                                 | 0                                        | 2 (0.8%)                                   | 1 (0.4%)                                   |
| Pathological fracture                                               | 2 (0.9%)                                 | 0                                        | 1 (0.4%)                                   | 0                                          |
| Spinal pain                                                         | 0                                        | 0                                        | 2 (0.8%)                                   | 0                                          |
| Investigations                                                      | 5 (2.2%)                                 | 4 (1.8%)                                 | 3 (1.2%)                                   | 3 (1.2%)                                   |
| Platelet coumt decreased                                            | 4 (1.8%)                                 | 4 (1.8%)                                 | 0                                          | 0                                          |
| Nervoussystem disorders                                             | 6 (2.6%)                                 | 0                                        | 8 (3.3%)                                   | 0                                          |
| Spinal cord compression                                             | 0                                        | 0                                        | 3 (1.2%)                                   | 0                                          |
| Transientischaemic attack                                           | 2 (0.9%)                                 | 0                                        | 1 (0.4%)                                   | 0                                          |
| Metabolism and nutrition disorders                                  | 2 (0.9%)                                 | 1 (0.4%)                                 | 8 (3.3%)                                   | 1 (0.4%)                                   |
| Hypercalcaemia                                                      | 0                                        | 0                                        | 4 (1.6%)                                   | 0                                          |
| Neoplasms benign, maliguant and unspecified (incl eysts and polyps) | 2 (0.9%)                                 | 1 (0.4%)                                 | 5 (2.0%)                                   | 2 (0.8%)                                   |
| Basal cell carcinoma                                                | 0                                        | 0                                        | 2 (0.8%)                                   | 1 (0.4%)                                   |
| Vascular disorders                                                  | 1 (0.4%)                                 | 1 (0.4%)                                 | 5 (2.0%)                                   | 2 (0.8%)                                   |
| Deep vein thrombosis                                                | 0                                        | 0                                        | 2 (0.8%)                                   | 2 (0.8%)                                   |

Abbreviations: AE aciverse event; MedDRA Medical Dictionary for Regulatory Activities; PT prefered temm TEAE teammentemergent adverse event. Notes:

study dnug or initiation of new mmltiple myeloma therapy, whichever was sooner.

·TEAEs with onset date/time orincrease in severity level after the initial dose ofstudy dnug and within30 days affer the last dose of

·Study dnug refers to either melflufen, pomalidomide, or dexamethasone.

## AEs of special interest

The AESIs thrombocytopenia, anaemia, and neutropenia frequently occurred in both treatment arms (Table 52). Overall, the frequencies of these AESIs were higher in the melflufen + dexamethasone arm, as were AESIs of haemorrhage although few patients experienced a grade 3 haemorrhage in combination with thrombocytopenia (any grade). AESIs of infection, especially grade 3 or 4, were less common in the melflufen + dexamethasone arm.

<div style=\"page-break-after: always\"></div>

Table 52 Overview of treatment-emergent adverse events of special interest (Safety Analysis Set OP103)

|                                                                                                | Meltfen+ Dexamethasone (N=228)   | Meltfen+ Dexamethasone (N=228)   | Pomalidomide + Dexanethasone (N=246)   | Pomalidomide + Dexanethasone (N=246)   | Overall (N=474)   | Overall (N=474)   |
|------------------------------------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------------|----------------------------------------|-------------------|-------------------|
|                                                                                                | n()                              | Events                           | n (0)                                  | Events                                 | n (/)             | Erents            |
| Atleast one TEAE ofAnaemia                                                                     | 153 (67.1%)                      | 474                              | 93 (37.8%)                             | 211                                    | 246 (51.9%)       | 685               |
| AtlenstoneTEAEofNeutropenia                                                                    | 161 (70.6%)                      | 928                              | 135 (54.9%)                            | 478                                    | 296 (62.4%)       | 1406              |
| AtleastoneTEAEofgrade3or4Neutopenia                                                            | 147 (64.5%)                      | 663                              | 121 (49.2%)                            | 338                                    | 268 (56.5%)       | 1001              |
| Atleast oneTEAE ofInfection                                                                    | 114 (50.0%))                     | 231                              | 137 (55.7%)                            | 281                                    | 251(53.0%)        | 512               |
| Atleast oneTEAE ofgrade3or4 Infection                                                          | 30 (13.2%)                       | 45                               | 53 (21.5%)                             | 71                                     | 83 (17.5%)        | 116               |
| Atlenst one TEAE of Infechonand corcommiant 29 (12.7%) gnde3 or4Neutropenin                    |                                  | 41                               | 37 (15.0%)                             | 50                                     | 66 (13.9%)        | 16                |
| AtlenstoneTEAEofInfectionandconcomitant gnde 4 Neutropenia                                     | 6(2.6)                           | 8                                | 12 (4.9%)                              | 14                                     | 18 (3.8%)         | 22                |
| AtlenstoneTEAEofgrade3or4Infection and concomitantgrade3or4Neutropenia                         | 7 (3.1%)                         | 8                                | 16 (6.5%)                              | 19                                     | 23 (4.9%)         | 27                |
| Atleast oneTEAE of Thrombocytoperia                                                            | 198 (86.8%)                      | 1056                             | 58 (23.6%)                             | 168                                    | 256 (54.0%)       | 1224              |
| Atlenst one TEAEof gade3 or4                                                                   | 174 (76.3%)                      | 713                              | 31 (12.6%)                             | 64                                     | 205 (43.2%)       | 777               |
| Throubocylopenia Atlenst oneTEAEofgrade3or4Haemonhnge2(0.9%) and concounitant Thrombocyiopenia |                                  | 3                                | 0                                      | 0                                      | 2(0.4%)           | 3                 |

Abbreviations: TEAE trentuent-emergent advese event.

- Second primary malignancies and myelodysplastic syndromes

Three and six patients in the melflufen+dex (1.3%) and pomalidomide+dex (2.4%) groups, respectively, reported an AESI of SPM and 1 patient in each treatment group (0.4%) reported a TEAE of MDS. 1 patient had an AESI of SPM leading to permanent discontinuation of melflufen and 1 patient each had an AESI of SPM and an AESI of MDS leading to permanent discontinuation of pomalidomide.

- Other AESIs: thromboembolism, hemorrhagic central nervous system vascular conditions, peripheral neuropathy, and tachyarrhythmias

Overall, 8.3% and 8.9% of patients reported at least 1 TEAE of thromboembolism (SMQ), 0.9% and 0.4% of patients reported at least 1 TEAE of Haemorrhagic central nervous system vascular conditions (SMQ), 3.1% and 3.3% of patients reported at least 1 TEAE of Peripheral neuropathy (SMQ) narrow, and 3.1% and 4.9% of patients reported at least 1 TEAE of Tachyarrhythmias (including supraventricular and ventricular tachyarrhythmias) (SMQ) narrow in the melflufen+dex and pomalidomide+dex groups, respectively.

## 2.6.8.9. Post marketing experience

Post-authorization safety information received by Oncopeptides for the period of 26 Feb 2021 to 27 August 2021 has been summarized in 2 Periodic Adverse Drug Experience Reports (PADERs) which have been submitted to the FDA. No new safety signals have been identified based on these data.

## 2.6.9. Discussion on clinical safety

## Safety database

Safety data of melflufen were available for 495 patients (Safety population) from 5 clinical studies in the RRMM setting; 422 patients received the recommended starting dose of melflufen 40 mg on Day 1 of a 28-day cycle in combination with dexamethasone (Targeted safety population (TSP), 34 patients received melflufen as part of a triple combination treatment). The updated safety database used for the SmPC excluded patients receiving melflufen as part of a triplet regimen and included patients using

<div style=\"page-break-after: always\"></div>

the single agent (15-55 mg). This resulted in a safety database of 491 patients from 4 clinical studies. Main data are derived from study OP-103 (n=228, 46%) and OP-106 (n=157, 32%). This safety population was used for description of the safety profile in the SmPC, which is acceptable. No new safety signals were identified. The safety discussion below is mainly based on study OP-106 and OP103.

There are several important limitations to the safety database:

1) With a median treatment duration of 17 weeks and a median number of 3-4 treatment cycles in the pivotal study OP-106 and the TSP, long-term safety data is limited. Twenty-six (16.6%) and 118 (28.0%) patients were still on treatment in study OP-106 (DCO: 14 January 2020) and in the TSP (DCO: 31 March 2020), respectively. A total of 45/157 (28.7%) and 144/422 (34.1%) were on study drug for ≥6 months in study OP -106 and for the TSP, respectively. Based on the updated total safety database including all patients from study OP-103 in an earlier setting of RRMM, treatment duration was slightly higher with a median treatment duration of 20 weeks and median number of cycles of 4.

2) The pivotal study lacks a control arm, making it difficult to distinguish the events related to melflufen from those related to dexamethasone, the underlying disease and/or previous treatment received. Results from the phase 3 RCT OP-103 were submitted and provide some contextualization of the safety profile in this aspect (see further below).

Importantly, uncertainties on long-term safety, less frequently occurring AEs and attributability may be partly overcome by what is known for melphalan, which has been in clinical use as an antitumor agent for more than 60 years. All in all, the safety database is considered sufficient to assess the safety profile of melflufen in the heavily pretreated triple class refractory (TCR) target population with a dismal prognosis (estimated OS of a few months to less than 1 year) with support from the phase 3 RTC OP-103 in an earlier setting.

This safety evaluation focusses primarily on the pivotal study OP-106 (n=157) as this study population most accurately represents the applied TCR indication (76% of the study OP-106 population vs 35% of the TSP). All patients reported TEAEs and almost all patients reported adverse events understood to be related to melflufen. Most patients (93.6%) reported ≥ grade 3 TEAEs and 49.0% reported SAEs.

## Haematological events and consequences

Haematological events were the most frequently reported TEAEs; anaemia, thrombocytopenia, and neutropenia were each reported in over half of the patients. These events were also the most commonly reported ≥ grade 3 events, but SAEs were limited and highest for thrombocytopenia (2.5% by PT). These adverse events are expected based on the mechanism of action of melphalan.

Dose modifications of melflufen were common and about one-fifth of patients (21.7%) discontinued melflufen treatment due to TEAEs, indicating a non-negligible safety profile. Most frequently occurring TEAEs leading to dose modifications were haematologic in nature and included thrombocytopenia, platelet count decreased, neutropenia, neutrophil count decreased, and anaemia. Thrombocytopenia was the most common TEAE leading to discontinuation of melflufen (10.2%).

Haematological events were manageable with dose modifications and supportive treatments and regular monitoring of blood counts is required (section 4.2 and 4.4 SmPC). Patients with platelet count &lt;50 x 10 9 /L or baseline ANC count &lt;1 x 10 9 /L were excluded from the study and treatment in these patients is not recommended. Adequate information is provided in section 4.2 and 4.4 of the SmPC. Anaemia mostly resulted in dose delays. Treatment of anaemia is established clinical practice and it is agreed that no additional dose recommendations are included in section 4.2, in addition to the statement in section 4.4 on regular monitoring and treatment of anaemia.

<div style=\"page-break-after: always\"></div>

Thrombocytopenia may lead to serious bleeding events. A total of 16% in study OP-106 had a grade 3 or 4 thrombocytopenia (including platelet count decreased) and concomitant haemorrhage, most of these bleedings were grade 1 or 2. Overall frequency of bleeding events was 28.0%. There were no melflufen dose modifications due to haemorrhages. An appropriate warning for the risk of bleeding is included in the SmPC (section 4.4). The most common bleedings (PT Epistaxis and PT Haematoma) have been added to the ADR table in section 4.8 of the SmPC.

Neutropenia can lead to infections and 29.9% of patients reported an AESI of infection and concomitant Grade 3 or 4 neutropenia; 11% reported a ≥ grade 3 infection and concomitant ≥ grade 3 neutropenia. Overall, over half of the patients reported AESIs of infections, and infective pneumonia was the most commonly reported event. Pneumonia was also the most commonly reported SAE (7.0%). Infections rarely resulted in discontinuation of melflufen (2.5%), and were managed by dose delays and antimicrobial treatment. The increased risk of infections is of relevance in the target population prone to infections due to the underlying disease and use of immunosuppressive treatments. Three patients in the TSP experienced infections with fatal outcome concomitantly with Grade 3 or 4 neutropenia and a statement on the risk of fatal infections has been added to SmPC 4.8. An appropriate warning for the risk of infections is included in the SmPC (section 4.4). In addition, a recommendation for prophylactic concomitant treatment with antimicrobials is included (section 4.2 and 4.4 SmPC).

Febrile neutropenia is another potentially serious consequence of neutropenia for the patient and a frequently occurring SAE (5.1%). Supportive treatment with haematopoietic growth factors was allowed in the study and is recommended in section 4.4. SmPC. Febrile neutropenia is included in section 4.8 SmPC. In addition, based on the myelosuppressive action of melphalan, leukopenia cannot be excluded as an ADR and is included in the ADR table in section 4.8 of the SmPC, as well as lymphopenia.

## Non-haematological events

Non-haematological TEAEs frequently reported with melflufen were asthenia, nausea, diarrhoea, fatigue, pyrexia, and upper respiratory tract infection (range 15.9% to 31.8%). Gastrointestinal events were mostly grade 1 or 2 and well known for melphalan. A recommendation for prophylactic concomitant use of anti-emetics is included (section 4.2 SmPC). Asthenia and fatigue were mostly grade 1 or 2 and known adverse events for treatments of MM. A high percentage (40%-60%) was considered treatment-related and asthenia and fatigue are included in section 4.8. Other commonly reported adverse events included in section 4.8 are hypokalaemia, decreased appetite, headache, dizziness, cough, dyspnoe and dyspnoe exe rtional. This is acceptable. No ≥ grade 3 events were reported for these TEAEs. Although frequently reported, constipation (14.6%; melflufen-related 5.1%) is not included as ADR, as it may be a complication of the use of (prophylactic) anti-emetics. In addition, there is no plausible biologic mechanism and constipation is also a known side effect of dexamethasone.

Furthermore, the risk of secondary primary malignancies (SPMs) was identified as an AESI. Within the overall safety population, 6 patients reported AMD/MDS and 7 patients had at least one ASEI of other SPM. The risk of SPMs is a known risk of MM treatments. A warning is included in section 4.4; SPMs are also added to section 4.8 SmPC.

Melflufen was not associated with QTc prolongation, although limited data are available, and is not a known risk for melphalan. However, in vitro data showed an effect of melflufen on hERG channel. Cardiac events were infrequent in study OP-106, but some were considered melflufen-related. Cardiac disorders, though rare, are included in the melphalan SmPC, though the mechanism of action is unknown. Data from the TSP confirm that event rates in the SOC Cardiac disorders were low and there were no signals for melflufen-related TEAEs associated with QTc prolongation. Some uncertainty

<div style=\"page-break-after: always\"></div>

remains as patients at high risk of cardiovascular disease were excluded and the number of elderly patients (&gt;75 age) is limited. Nevertheless it is agreed that no information on cardiac toxicity needs to be included in the SmPC.

Melphalan in combination with amongst others dexamethasone has been associated with an increased risk of thromboembolic complications (see SmPC Melphalan). Pulmonary embolism and deep vein thrombosis have been added to section 4.8 and an appropriate warning is included in section 4.4 for melflufen. Thrombosis prophylaxis was not warranted in the melflufen studies and it is agreed that there is no need for a statement in section 4.2. In the safety population (N=491) used for the proposed SmPC, 142 (29%) patients received concomitant ATT for a median time of 431 days (range 1-6942). A statement on anti-thrombotic prophylaxis in high-risk patients has been added in section 4.4 and is acceptable.

Several TEAEs (such as hypocalcaemia, hypomagnesemia, epistaxis, hypophosphatemia, tachycardia, hypotension) were reported with higher frequencies in study OP-106 compared to the pooled safety analysis. Not all of them could be straightforward substantiated by the severity and progression of the disease. The applicant reasonably argued that there was no evidence that these events were related to melflufen/melphalan and/or were likely related to underlying conditions. The risk of bleedings, including epistaxis has been now included in the SmPC.

## Deaths

A total of 88 patients (56.1%) died within study OP-106, mostly due to PD. Ten patients (6.4%) reported a TEAE with a fatal outcome and none was considered related to melflufen. Within the TSP, 176 (41.7%) died during the studies and 11.4% experienced at least 1 TEAE with an outcome reported as fatal. Six events were considered related to melflufen, all in the SOC Infections and Infestations. Four grade 5 events of infections in 3 patients occurred concomitantly with Grade 3 or 4 neutropenia. Though infections are not uncommon in this heavily treated population and the contribution of melflufen may be difficult to assess, septic shock is known for melphalan (SmPC) and has been added to the ADR table in section 4.8.

## Laboratory findings

Laboratory findings were dominated by changes in haematological parameters, and shifts to worst post-baseline grade 3 or 4 in haematological parameters were common. Shifts to grade 3 or 4 in serum chemistry were uncommon, the most frequently reported shift was a Grade 0 to 3 increase in urate (13.9%) in study OP-106. Hyperuricaemia has been added as ADR to section 4.8 of the SmPC. There were no other new or unexpected laboratory signals.

## Drug-drug interactions

No specific clinical studies assessing the effects of other drugs or extrinsic factors on melflufen were submitted which is acceptable. Given the mechanism of action of melflufen, drug-drug interactions by competition for drug metabolic enzymes or any other interactions are unlikely. There are also no relevant interactions known for melphalan that need to be included, except for a statement on the use attenuated live vaccines for which a warning is included in section 4.4.

## Adverse events of special interest by intrinsic/extrinsic factors

An analysis of AESIs (thrombocytopenia, neutropenia, febrile neutropenia, infections, infective pneumonia, anaemia, bleeding events and MDS/AML) by age, sex, race, BMI, and baseline CrCl did not identify clinically meaningful interactions. Further, the small number of patients included in some of the subgroups makes it difficult to draw conclusions. In general, there were no specific concerns based on the summary of specific adverse events presented by age category. Though the frequency of AEs in the SOC Nervous system disorder was higher in patients 75-84 years (54% vs 33-37%), there were no

<div style=\"page-break-after: always\"></div>

signs for an increase in a specific AE. The number of patients aged &gt;75 years was limited (n=57; 15.9%), but comparable to that in other clinical studies in the RRMM setting. Given a median time since diagnosis of 6 years and a median age of 65 years, these patients may not represent the general MM population, as the median age at diagnosis in the general population is around 72 years. In addition, 16% had ECOG score of 2, therefore, the current safety profile may be an underestimation of that in clinical practice. Few patients with a baseline CrCl of &lt;45 mL/min (n=21) were treated with melflufen, making it difficult to draw conclusions. Nevertheless, current data indicate an increase in exposure and potential for increase in AEs with reduced renal clearance and a recommendation for close monitoring has been added to section 4.4. A renal impairment study is ongoing and part of the RMP, which will provide more information.

## Overdose

There are no reports on overdose of melflufen, the highest dose used in combination with dexamethasone was 55 mg (study-O-12-M). It is reasonable to assume that melflufen is not associated with withdrawal or rebound effects, or a risk of drug abuse, in line with what is known for melphalan. No formal studies on the effects of melflufen on the ability to drive or operate machinery have been performed, which is acceptable. Overall, information included in section 4.7 and 4.9 of the SmPC is acceptable.

## Pregnancy, breast feeding and embryo-foetal toxicity

There are no data of pregnant women exposed to melflufen, nor data regarding the secretion of melflufen in human milk or its effects on the breastfed infant or on milk production. As with any other alkylating anticancer agents, melflufen is expected to induce embryo-foetal toxicity including malformations and has an impact on fertility. Adequate statements are included in section 4.6 of the SmPC.

## Post-marketing data

Post-marketing safety data from the USA did not raise new safety signals.

## Supportive safety data from Study OP-103

Additional comparative safety data was submitted from study OP-103 which was the confirmatory study in the context of the initially proposed CMA. This study enrolled patients in an earlier stage of disease (2-4 prior lines of treatment and refractory to both the last line and to lenalidomide), of which 228 patients were treated with melflufen + dexamethasone at the proposed dosing regimen and 246 subjects were treated with pomalidomide + dexamethasone. Treatment duration with melflufen was somewhat longer than for study OP-106 (median 25 weeks and median 5 cycles started), whereas the comparison arm allows contextualization of the safety profile. Safety data, though observed in an earlier treatment setting, support the safety profile of the combination observed in study OP-106, being mainly characterized by haematological and GI events. For the subgroup in study OP-103 that met the criteria of the proposed indication (n=30), frequencies of AEs were somewhat lower than observed in study OP-106. However, the potential detrimental effect observed for OS remains of major concern. Data show that the overall tolerability of melflufen + dexamethasone is lower than for pomalidomide + dexamethasone, as shown by higher frequencies of treatment-related grade 3/4 events and dose modifications (including discontinuations). On the other hand, frequencies of SAEs and fatal events were in the same order of magnitude, and it is considered unlikely that the OS detriment can be explained by a direct toxicological effect of melflufen. As OS subgroup analyses indicated a differential effect based on prior ASCT (detriment in patients with prior ACT), this was further explored as discussed in the efficacy section. Further, safety data were presented by prior ASCT. These data showed that patients with a prior ASCT more frequently reported haematological events compared to patients without a prior ASCT in the melflufen + dexamethasone arm. The

<div style=\"page-break-after: always\"></div>

explanation of the applicant that pretreatment with high dose of melphalan (200 mg/m 2 ) negatively affects a patient's hematopoietic reserve and therefore these patients may be less likely to tolerate subsequent treatments that induce cytopenia and are more prone to develop haematological toxicity, appears reasonable. This resulted in higher frequencies of drug discontinuations, though SAEs and fatal AEs were comparable for patients with and without prior ASCT. An analysis in the updated total safety data supports the finding that especially thrombocytopenia is observed more frequently in patients with prior ASCT with progression within 36 months whereas treatment duration was shorter. Although myelotoxicity is increased, it is unlikely that this entirely explains the lower survival rate also taking into that no increase in fatal AEs was observed. Given the signal of reduced efficacy throughout efficacy endpoints, the indication should exclude patients who have a TTP &lt;36 months post-ASCT (see efficacy discussion).

Based on the final data from study OP-103 submitted as part of the list of questions, the applicant requested a full MA instead of a CMA. From a safety perspective, the data can be considered comprehensive and potentially enable a full MA. Study OP-103 did not identify new safety signals to be included in section 4.8. The proposal of the applicant to update frequencies in section 4.8 based on the updated total safety database of 491 patients, including study OP-103, is considered acceptable. Though frequencies of some AEs were classified into a lower category and study OP-103 largely reflects an earlier setting of RRMM, the safety profile may be considered more accurate based on a larger number of RRMM patients.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 2.6.10. Conclusions on the clinical safety

The safety profile of melflufen appears non-negligible, although generally manageable with adequate monitoring and dose adjustment or discontinuation. The most important safety concerns are the haematological toxicities and the possible serious clinical consequences of infections and bleeds. These are understood to be related to the mechanism of action and well known for the active substance melphalan.

Relevant safety information and recommendations are presented in the SmPC. Also, the safety profile has been considered sufficiently characterized based on study OP-106 encompassing the target population and supported by comparative safety data from OP-103 in an earlier setting of RRMM. Safety data are therefore considered comprehensive potentially enabling a full MA. Additional safety data are expected on patients with severe renal impairment (see RMP).

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

Table 53

Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                   |
|------------------------------|----------------------------------------------|
| Missing information          | Use in patients with severe renal impairment |

## 2.7.2. Pharmacovigilance plan

<div style=\"page-break-after: always\"></div>

Table 54: Summary table of additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                         | Summary of objectives                                                                                                                                                                                                                   | Safety concerns addressed                                      | Milestones                                                                                                               | Due dates                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                        | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                           | Category 3 - Required additional pharmacovigilance activities  | Category 3 - Required additional pharmacovigilance activities                                                            | Category 3 - Required additional pharmacovigilance activities                   |
| OP-107 (BRIDGE) A Phase 2 study of the pharmacokinetics of melphalan during treatment with melflufen and dexamethasone in patients with relapsed- refractory multiple myeloma and impaired renal function Terminated | - Evaluate the relationship between renal function and pharmacokinetic parameters for melphalan during treatment with melflufen - Assess the safety and tolerability of melflufen in patients with moderate and severe renal impairment | Use in patients with severe renal impairment (eGFR <45 mL/min) | Start of enrolment End of recruitment Last patient last visit Clinical study report Supplemen- tal clinical study report | Link to protocol 17/09//2018 29/06/2021 22/12/2021 17/12/2021 Estimated Q2 2022 |

## 2.7.3. Risk minimisation measures

Table 55: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                               | Risk minimisation measures                                                                                                                                                                                               | Pharmacovigilance activities                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients with severe renal impairment | Routine risk minimisation measures: • SmPC section 4.2 stating that there are insufficient data in patients with eGFR <30 mL/min/1.73m 2 to support a dose recommendation. Additional risk minimisation measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: Study OP-107 (BRIDGE) A Phase 2 study of the pharmacokinetics of melphalan during treatment with melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma and impaired renal function Supplemental clinical study report estimated Q2 2022 |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 0.5 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

<div style=\"page-break-after: always\"></div>

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation

## 3.1.2. Available therapies and unmet medical need

Current treatment strategies in relapsed/refractory (RR) MM patients include glucocorticoids (dexamethasone, prednisolone, methylprednisolone), chemotherapy, proteasome inhibitors (PIs; e.g. bortezomib, carfilzomib and ixazomib), immunomodulatory drugs (IMiDs; e.g. thalidomide, lenalidomide and pomalidomide), monoclonal antibodies (mAbs; e.g. daratumumab, isatuximab and elotuzumab) and the histone deacetylase inhibitor panobinostat.

Patients who have become refractory to all 3 major treatment classes (PIs, IMiDs and anti-CD38 mAbs) are referred to as triple-class refractory (TCR). Since first line therapy in newly diagnosed MM patients often represents a combination of 2 of these treatment classes, patients could already be TCR after second line therapy.

Blenrep (belantamab mafodotin) received a CMA in a TCR population after at least four prior therapies and recently, anti-BCMA CAR-T cell therapy Abecma (idecabtagene vicleucel) is recently approved in the same target population. Nexpovio (selinexor), a Selective Inhibitor of Nuclear Export (SINE) compound, was recently approved in a penta-refractory population. Although patients with relapsed disease can achieve responses to subsequent anti-myeloma regimens, the duration of response typically decreases with successive relapses until resistant disease develops. While the advent of novel treatment regimens has translated into improvements in outcomes, the disease is ultimately fatal. Triple or higher class refractory patients have an estimated overall survival of a few months to less than one year. The impact of the recently approved products on OS is yet unknown due to the single

<div style=\"page-break-after: always\"></div>

arm trial design of registration studies. Therapies with new mechanisms of action to overcome drug resistance, also including patients pre-treated with daratumumab, remain an unmet medical need.

Melphalan flufenamide is a lipophilic derivative of melphalan designed/aimed to enhance cell penetration and thus obtain higher intracellular concentrations than melphalan. Melphalan is formed from melphalan flufenamide upon intracellular hydrolysis by peptidases and is considered the main active substance of melflufen. Cross-linking of DNA is probably the most important factor for the cytotoxic effect. Melphalan itself is licensed for the treatment of multiple myeloma. In theory, this would allow treatment in TCR patients as well. In clinical treatment guidelines, melphalan is recommended only in first line. In patients eligible for autologous stem cell transplantation (ASCT) it is used as part of the conditioning regimen, whereas in patients in-eligible for ASCT, melphalan could be used in combination with daratumumab, bortezomib and prednisone.

## 3.1.3. Main clinical studies

The proposed posology is 40 mg of intravenous (IV) melflufen on Day 1 of each 28-day cycle and 40 mg (or 20 mg in patients ≥ 75 years) of oral (PO) dexamethasone (dex) on Days 1, 8, 15, and 22. This regimen is supported by the dose-finding Phase 1/2a Study O-12-M1 in RRMM after 2 or more prior treatment lines (ORR 31.3%, n=45).

Main clinical data is derived from Phase 2 study OP-106 (HORIZON), a single arm study of melflufen in combination with dexamethason at the proposed dose in patients with RRMM who had received a minimum of 2 prior lines of therapy, including an IMiD and a PI, and who were refractory to pomalidomide and/or an anti-CD38 mAb. The TCR target population was defined as the study population of interest during the study after several protocol amendments.

In total 157 patients were included in Study OP-106 and treatment at the proposed dose continued until disease progression (PD), unacceptable toxicity, or the patient/treating physician decided that it was not in the patient's best interest to continue.

In the overall study population (n=157) and TCR study population (n=119, of which n=117 with at least 3 prior treatment lines, and n=52  3L+ with a TTP ≥ 36 months after ASCT, median age was 65 years. Patients had received a median of 5 (range 2-12) prior therapies, i.e. were penta-exposed. Median treatment duration was 17 weeks at the time of data cut-off (DCO).

The primary endpoint was ORR (sCR + CR + VGPR + PR) and key secondary endpoint duration of response (DOR). Main other secondary endpoints were progression free survival (PFS), overall survival (OS). The primary endpoint, ORR, was to be considered met if the lower bound of the 95% confidence interval for actual ORR among TCR patients was higher than 15%.

Supportive data is derived from Phase 3 Study OP-103 (OCEAN). This study with confirmatory intent compared the efficacy of melflufen + dexamethasone (dex) vs. pomalidomide (pom) + dex in patients with a (mostly) earlier line RRMM. Enrolled patients had documented disease progression with measurable disease, had received 2-4 prior lines of therapy, including lenalidomide and a PI, and were refractory to both the last line of therapy and to lenalidomide administered within 18 months prior to randomization. In total 31 patients were TCR patients with at least 3 prior lines. In total 145 patients had no prior ASCT or TTP ≥ 36 months after ASCT.

The primary endpoint was PFS and key secondary endpoints ORR and OS (both planned to be alphacontrolled).

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

## Study OP-106

The primary endpoint ORR based on Investigator (Inv) assessment in the overall study population was 29.3% (95% CI: 22.32%, 37.08%). Comparable results were obtained per Independent Review Committee (IRC). The median DoR was 5.5 months (95% CI: 3.9, 7.6) based on Inv and 6.7 months (95% CI: 4.2, 8.1) based on IRC assessment. Exploratory updated results (data cut-off 12 Aug 2021) suggest an ORR of 33.8% (95% CI: 26.4%, 41.7%) and median DoR of 6.70 months (95% CI: 4.40, 8.11) for the overall population.

Median Inv based PFS was 4.24 months (95% CI: 3.42, 4.86) and comparable results were seen per IRC. Median OS was 11.63 months (95% CI: 9.30, 15.41).

For the new proposed TCR target population with at least 3 prior lines (n=117), ORR was 29.1% (95% CI: 21.0, 38.2) and DOR of 6.97 months (95% CI: 3.88, 9.79; updated data cut-off 12 Aug 2021).

Median PFS was 3.94 months (95% CI: 3.02, 4.63) and comparable for Inv and IRC assessment. Median OS was 11.24 months (95% CI: 7.66, 13.17).

Median PFS remained unchanged in the updated analysis, median OS decreased to 10.12 months (7.20; 12.29).

OP-106 results for this 3L+ TCR population with TTP ≥ 36 months after ASCT or no ASCT (n=52) indicate an ORR of 28.8% (95% CI: 17.1, 43.1) with median DOR of 7.6 months (95% CI: 3.0, 12.3).

## Study OP-103

The primary endpoint median IRC assessed PFS was 6.83 (95% CI 4.96, 8.54) in the meflufen + dex arm vs. 4.93 (95% CI 4.24, 5.72) in the pom + dex arm. The stratified HR was 0.792 (95% CI: 0.640, 0.981; p=0.0319). The sensitivity analyses were in line with results from the primary PFS analysis.

Efficacy results for the 31 3L+ TCR patients, suggest an ORR of 40% (95% CI: 22.7, 59.4) and median DoR of 14.3 months (95% CI: 4.1, NE).

In patients (independent of treatment line) with TTP ≥ 36 months after ASCT or no ASCT (n=145), ORR was 42.1% (95% CI: 33.9, 50.5) for melflufen + dex vs. 26.4% (19.5, 34.2) with pom+dex, median PFS was 9.26 months (95% CI: 7.16, 11.79) vs. 4.63 (3.65, 6.28) with pom + dex, and median OS was 23.56 months (95% CI: 18.86, 27.96) vs. 19.84 (12.62, 26.48) with pom+dex.

## 3.3. Uncertainties and limitations about favourable effects

-Both key secondary endpoints ORR and OS for confirmatory Study OP-103 were not met. Although ORR was numerically in favour of the melflufen arm (32.5% vs. 26.9%. stratified p=0.1422), an OS HR of 1.104 (nominal p-value = 0.47) was observed for melflufen + dex compared to pom + dex. Median OS was 19.75 months (15.08, 25.56) for the melflufen + dex arm vs. 25.00 months (18.14, 31.87) with pom + dex. This was maintained with an OS update after one additional year of follow-up: median OS 20.24 months (15.84, 24.34) vs. 23.98 months (19.06, 28.71), with a HR of 1.14 (95% CI: 0.912-1.434, nominal p=0.2438). OS subgroup analyses showed large heterogeneity among several subgroups, especially age and prior ASCT. The results from post-hoc analyses indicate that the subgroup of patients with disease progression within 36 months after ASCT showed reduced efficacy; median OS was 15.72 months (11.89, 20.47) in the mel + dex arm vs 28.71 months (20.17, 34.07) in the pom +dex arm. Lower efficacy was consistently observed for all efficacy endpoints.

<div style=\"page-break-after: always\"></div>

-The single arm design of the pivotal Phase 2 trial OP-106 does not allow to isolate the contribution of the two components of the combination. Nevertheless, melflufen monotherapy data from Study O-12-M1 showed an ORR of only 7.7% and a recent publication (APL-C-001-09 - ADMYRE) with low dose dex (40mg once weekly) as comparator in RRMM patients with a median of 4 lines of prior systemic therapy indicated an ORR of 1.2%. These data contribute to alleviate the concerns that the effect observed with melflufen in combination with low dose dex would mainly be driven by only one of the components.

-There are no interpretable quality of life data. PRO endpoints were added post-hoc in this single arm trial and only a limited number of patients had evaluable data.

-The study population was younger and less frail than could have been expected for heavily pretreated RRMM patients. This brings some uncertainty to the true effect size in clinical practice, although it is acknowledged that the decision to start treatment and the selection of treatment regimen is multifactorial. The age categories and ECOG PS are adequately reflected in section 5.1 of the SmPC.

-Efficacy in primary refractory patients is unknown, as these patients were excluded from the pivotal trial. This is reflected in section 5.1 of the SmPC.

## 3.4. Unfavourable effects

Haematological events were the most frequently reported TEAEs, mainly anaemia, thrombocytopenia and neutropenia which were reported in 55.4% (neutropenia) to 70.7% (anaemia) of the patients in study OP-106 (n=157). These were also the most commonly reported ≥ grade 3 events, with incidences of roughly 50%. Haematological AEs are expected based on the mechanism of action of melphalan. The events were manageable with dose modifications and supportive treatment. Thrombocytopenia was the most common adverse event leading to discontinuation of melflufen (10.2%). A total of 16% in study OP-106 had a grade 3 or 4 thrombocytopenia (including platelet count decreased) and concomitant haemorrhage, most of these bleedings were grade 1 or 2. Overall frequency of bleeding events was 28.0%. About one third (29.9%) of patients had an infection and concomitant Grade 3 or 4 neutropenia (including neutrophil count decreased); 11% reported a ≥ grade 3 infection and concomitant ≥ grade 3 neutropenia. Overall, 58% of patients reported infections, mostly infective pneumonia, and frequently ≥ grade 3 events. Infections were in general manageable with anti-infective treatment and dose modifications.

Non-haematological TEAEs frequently (&gt; 15%) reported with melflufen were asthenia, nausea, diarrhoea, fatigue, pyrexia, and upper respiratory tract infection. These events were mostly grade 1 or 2. Gastrointestinal events are well known for melphalan.

Overall, grade 3/4 TEAEs were reported in 93.6% of patients and SAEs were reported in 49.0% of patients. Pneumonia (8.9%) and febrile neutropenia (5.1%) were the most frequently reported SAEs. In the overall population, 56.1% of patients died during the study OP-106 and 8% died within 30 days after last study drug. Most deaths were due to progressive disease, fatal TEAE rate was 6.4% in study OP-106. Within the targeted safety population (TSP, n=422 melflufen 40 mg in combination with dexamethasone), fatal TEAE rate was 11.4% and 6/20 patients reported fatal TEAEs in the SOC Infections and infestations. Four grade 5 events of infections in 3 patients occurred concomitantly with Grade 3 or 4 neutropenia.

MDS/AML was reported in six patients (1.2%) in the TSP, four of these were reported as TEAEs and considered possibly/probably related to melflufen. Other SMPs occurred in 7 patients.

Overall, 21.7% reported a TEAE leading to discontinuation of melflufen. Melflufen dose reductions were observed in 26.8% of patients and 61.8% had a dose delay of melflufen.

<div style=\"page-break-after: always\"></div>

The safety profile in the TCR population was comparable to that of the overall population in study OP106.

Supportive safety data were derived from the RCT OP-103 in an earlier treatment setting, with a median treatment duration of 25 weeks for melflufen +dexamethasone. Safety data support the safety profile of the combination as observed in study OP-106, being mainly characterized by haematological and GI events and no new safety events were identified. In addition, post-marketing safety data from the USA over the period of 26 Feb 2021 - 27 Aug 2021 did not raise new safety signals.

An updated safety database with a slightly different composition consisting of 491 patients treated with melflufen as single agent or in combination with dexamethasone was used for the safety profile in the SmPC. The safety profile is in line with the initial data and no new safety signals were identified.

## 3.5. Uncertainties and limitations about unfavourable effects

One of the main uncertainties in relation to the safety database is the lack of a control arm, making it difficult to distinguish the events attributable to melflufen, the underlying disease and concomitant/previous treatment received. It is of help that the safety profile of melphalan is well known, considering clinical use as an antitumor agent for more than 60 years. Nevertheless, presented frequencies for melflufen should be interpreted as rough estimates.

The risk of bleeding and infections is of particular importance in a patient population prone to these risks.

The median duration of exposure in the pivotal study and the TSP is 17 weeks, and slightly longer with updated data (20 weeks), therefore long term safety data is limited. This is of relevance for AEs that might occur after long-term exposure, like secondary primary malignances. This risk is, however, well known based on the long-standing use of melphalan and no additional risk minimization measures are needed.  This is addressed in the RMP based on what is known for melphalan.

Overall, within the safety database 422 patients received the recommended dose in combination with dexamethasone. With the understanding that the selection of type of treatment regimen is multifactorial, the observed safety profile may not be fully representative for clinical practice given the inclusion of a less frail patient population and a limited number of patients &gt;75 age.

Higher melphalan exposures were associated with an increased incidence of grade 3 and 4 haematologic AEs. Thrombocytopenia was a major reason for premature discontinuation of melflufen treatment. As patients with low body weight have higher melphalan exposure, a lower starting dose of 30 mg melfufen is proposed for subjects with body-weight &lt; 60 kg. This is considered acceptable

The safety profile with regard to the selected AESIs appeared comparable within various subgroups studied to the overall safety profile and did not reveal major differences, however, the small numbers in some subgroups prevent firm conclusions.

Only few patients with renal impairment were included, a study in patients with renal impairment is ongoing (OP-107) and part of the RMP. Interim analysis for patients with moderate renal impairment with eGFR 30-45 mL/min/1.73 m2 showed on average 30% higher melphalan exposure compared to patiens with normal renal function. Discontinuation of melphalan treatment due to TEAE was lower in Cohort 1b (30 mg starting dose) 20% compared to 46.7% in Cohort 1a (40 mg starting dose). Therefore, the reduced starting dose for subject with eGFR 30-45 mL/min/1.73 m2 is considered acceptable. Treatment of subjects with severe renal impairment is not recommended. This has adequately described in the SmPC.

<div style=\"page-break-after: always\"></div>

There appears to be no direct toxicological signal of melflufen that explains the observed OS detriment in study OP-103. Patients with a prior ASCT and TTP ≤ 36 months appear to have lower tolerability for melflufen resulting in higher frequencies of drug discontinuations. However, SAEs and fatal AEs were comparable for melflufen-treated patients with and without prior ASCT. It is unlikely that the difference in tolerability is the main cause of OS detriment/the lower survival rate in this subgroup.

## 3.6. Effects Table

Patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody (Study OP-106, data cut-off: 14 Jan 2020).

| Effect                 | Short Description                                                                           | Unit               | Melflufen + dex                                                                                                                    | Control            | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Refere nces        |
|------------------------|---------------------------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Favourable Effects     | Favourable Effects                                                                          | Favourable Effects | Favourable Effects                                                                                                                 | Favourable Effects | Favourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Favourable Effects |
| ORR (95% CI) Inv based | Proportion of patients for whom the best overall confirmed response is sCR, CR, VGPR or PR. | %                  | Overall study population 29.3% (22.3, 37.1) 3L+ TCR population with TTP ≥36 months after ASCT or no ASCT (n=52) 28.8% (17.1, 43.1) | N/A                | No control arm Sensitivity analysis based on IRC assessment showed similar results. Supported by OP-103 results. In patients (independent of treatment line) with TTP ≥36 months after ASCT or no ASCT (n=145), ORR was 42.1% (95% CI: 33.9, 50.5) for melflufen + dex vs. 26.4% (19.5, 34.2) with pom+dex, median PFS was 9.26 months (95% CI: 7.16, 11.79) vs. 4.63 (3.65, 6.28) with pom + dex, and median OS was 23.56 months (95% CI: 18.86, 27.96) vs. 19.84 (12.62, 26.48) with pom+dex. | CSR                |

<div style=\"page-break-after: always\"></div>

| Effect                        | Short Description                                                                                                                                                                     | Unit                  | Melflufen + dex                                                                                                                           | Control               | Uncertainties/ Strength of evidence                                                                                                                                                                                                       | Refere nces           |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Median DoR (95% CI) Inv based | Time between first documentation of a confirmed response to first evidence of confirmed disease progression or death due to any cause defined for patients who achieved PR or better. | Months                | Overall study population 5.5 months (3.9, 7.6) 3L+ TCR population with TTP ≥36 months after ASCT or no ASCT (n=52) 7.6 months (3.0, 12.3) | N/A                   | IRC based assessment: 6.7 months IRC based assessment: 5.5 months                                                                                                                                                                         | CSR                   |
| Unfavourable Effects*         | Unfavourable Effects*                                                                                                                                                                 | Unfavourable Effects* | Unfavourable Effects*                                                                                                                     | Unfavourable Effects* | Unfavourable Effects*                                                                                                                                                                                                                     | Unfavourable Effects* |
| Thromboc ytopenia             | Incidence of thrombocytope nia Grade 3-4                                                                                                                                              | %                     | 59.9 56.7                                                                                                                                 |                       | Discontinuations: 10.1% Concomitant bleedings mostly grade 1 or 2 Uncertainties: role of disease progression, concomitant and previous treatments, and incidence of events leading to bleeds. Supported safety data from study OP-103; no |                       |
| Neutrope nia                  | Incidence of neutropenia Grade 3-4                                                                                                                                                    | %                     | 55.4 52.9                                                                                                                                 |                       | Concomitant infections partly ≥grade 3 Uncertainties: role of disease progression, concomitant and previous treatments, and incidence of events leading to infections.                                                                    |                       |
| Anaemia                       | Incidence of anaemia Grade 3-4                                                                                                                                                        | %                     | 70.7 42.7                                                                                                                                 |                       | new safety signals Uncertainties: role of disease progression, concomitant and previous treatments. Supported safety data from study OP-103; no                                                                                           |                       |

<div style=\"page-break-after: always\"></div>

| Effect                     | Short Description                                            | Unit   | Melflufen + dex   | Control   | Uncertainties/ Strength of evidence                                                                                                    | Refere nces   |
|----------------------------|--------------------------------------------------------------|--------|-------------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Infections                 | Incidence of infections Grade 3-4                            | %      | 58.0 21.7         |           | 11.5% grade 3/4 AESI of infection and concomitant grade 3/4 neutropenia Supported safety data from study OP-103; no new safety signals |               |
| GI events                  | Nausea Diarrhoea Vomiting                                    | %      | 31.8 26.8 13.4    |           | Mostly grade 1 or 2 Supported safety data from study OP-103; no new safety signals                                                     |               |
| Deaths                     | Incidence of deaths Incidence of death <30 days last dose of | %      | 56.1 8            |           | Mostly due to PD; 6.4% TEAE with fatal outcome                                                                                         |               |
| Discontin uation due to AE | Incidence of discontinuation any drug Discontinuation        | %      | 23.6 21.7         |           |                                                                                                                                        |               |

Abbreviations: CI= confidence interval, CR= complete response, CSR= clinical study report, DoR= duration of response, Inv= investigator, IRC= independent review committee, N/A= not applicable, ORR= overall response rate, OS= overall survival, PR= partial response, sCR= stringent complete response, TCR= triple class refractory, VGPR= very good partial response, AESI=adverse event of special interest

Notes:* Based on the overall study population OP-106

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

A full approval is requested for TCR patients with ≥ 3 prior treatment lines, with a contra-indication for the subgroup of patients with TTP &lt;36 months after ASCT. Clinical data in the target population is derived from single arm trial OP-106 + supportive data in an earlier line from randomized controlled trial OP-103.

Given the poor prognosis of heavily pre-treated RRMM patients whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 mAb after 3 prior treatment lines, the antitumour activity of meflufen + dex (updated ORR of 29.1%) might be considered of clinical relevance, in combination with the observed DoR close to 7 months. Response rates are in line with those observed for other products in RRMM (23-32%). Higher response rates were reported for the recently approved CAR-T cell therapy idecabtagene vicleucel (ORR ~67%).

For pivotal study OP-106, uncertainty remains with regard to the effect on time-dependent endpoints, PFS and OS, which cannot be reliably interpreted in a single uncontrolled study.

Support can be derived from PFS (primary endpoint) results from Study OP-103. Indeed, the primary endpoint PFS of the study was met with a HR of 0.79 and median PFS of 6.83 months with melflufen + dex vs. 4.93 months with pom + dex in the overall study population. Several sensitivity analyses (a.o.

<div style=\"page-break-after: always\"></div>

due to concerns regarding handling of randomised but not-treated patients) confirmed internal validity of obtained PFS results. Despite the active comparator and the fact that study OP-103 was not powered to demonstrate a difference in overall survival, the updated OS HR of 1.14 and KM curves in the OP-103 ITT population warranted further investigation. Based on a post-hoc defined cut-off, the subgroup of patients who progressed within 3 years after ASCT seemed to be the major contributor to the OS result and multivariable OS analysis also provided a strong signal that TTP after ASCT was an effect modifier. Interestingly, consistent results on efficacy in favour of melflufen were seen for the subgroup with no ASCT or prior ASCT and TTP ≥ 36 months. While these analyses were based on a post-hoc defined variable, there is the biological rationale that patients who progress early after ASCT, which requires high dose melphalan, might be less responsive to another alkylator based regimen. In addition, these patients may have an increased risk of myelotoxicity with loss of marrow reserve after recent transplantation. The cut-off of 36 months is to some extent supported by expert data stating that the PFS cut-off for a transplant to be considered successful enough to consider a salvage ASCT is ≥ 36 months, although not the same situation as in the trial (EHA-ESMO guidelines, Dimopoulus et al. 2021). In addition, the treatment effect observed in the subgroup is larger than the all-randomised study population, providing additional support for the subgroup (EMA/CHMP/539146/2013; Guideline on the investigation of subgroups in confirmatory clinical trials). Subgroup analysis of OP-106 also suggest a larger effect in patients with no ASCT or prior ASCT and TTP ≥ 36 months, however interpretation is hampered by the lack of a control arm. the exact effect size cannot be determined due to differences in disease and treatment characteristics,

Upon consultation, the SAG-O concluded that melflufen + low dose dex is associated with clinically relevant efficacy, with the exception of the subgroup of patients with relapse within 36 months following high-dose melphalan and autologous SCT. In addition, the SAG-O considered that although the results of study OP-103 obtained in patients of whom most had fewer lines of treatment than the OP-106 patients, are relevant for the target population in study OP-106 (see expert consultation below).

Overall, based on the available data and upon consultation of the SAG-O, it is considered that melflufen + low dose dex has been shown to be efficacious and data can be considered comprehensive. However, given the major concern on the benefit of melflufen + dex in patients with prior ASCT and TTP &lt;36 months in study OP-103 and the fact that a risk for shorter survival cannot be excluded for these patients within the 3L+ TCR population in study OP-106 due to the absence of a control group, this patient group should be excluded from the applied indication.

The safety profile is dominated by haematological adverse events of which thrombocytopenia and neutropenia are the most important as they carry potentially severe clinical consequences in patients prone to bleeding events and infections. Fatal events of infections concomitant with neutropenia have been reported. The relative contribution of melflufen to these events is difficult to detangle from concomitant treatment with dexamethasone, disease progression and previous treatments. Nonhaematological adverse events were mostly grade 1 or 2. Most frequently occurring SAEs were pneumonia and febrile neutropenia. Although the toxicity of melflufen is in line with what may be expected from a drug product with melphalan as the active substance in a setting where patients are heavily pre-treated and can be considered generally manageable with adequate monitoring and dose adjustment or discontinuation, it is not negligible and relevant safety information and recommendations are presented in the SmPC. The overall impact of the safety profile on the quality of life could not be adequately assessed within this study. Melflufen offers a different mechanism of action compared to other products used in clinical practice in the TCR population and thus a somewhat different safety profile. The safety profile as observed in the OP-106 study is supported by the results from the phase 3 OP-103 and safety data are therefore considered comprehensive. Although there

<div style=\"page-break-after: always\"></div>

appears no indication of a direct toxicological effect of melflufen, it is less tolerated in patients with ACST ≤ 36 months.

## 3.7.2. Balance of benefits and risks

The benefit risk balance in the restricted indication is considered positive.

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall benefit/risk balance of Pepaxti is positive.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Pepaxti is not similar to Blenrep, Darzalex, Farydak, Imnovid, Kyprolis, Ninlaro, Abecma and Carvykti within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Pepaxti is favourable in the following indication:

Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Other conditions and requirements of the marketing authorisation

## · Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.